,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,856012,3715,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11111328,3715,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,357,2,1,,11111329,3715,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
3,361,1,2,,856012,3715,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
4,364,1,3,,856012,3715,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
5,368,2,3,,856012,3715,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
6,371,1,1,,856012,3715,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
7,373,1,4,,856012,3715,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
8,374,2,3,,856012,3715,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
9,375,2,3,,856012,3715,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
10,377,1,3,,10321568,3715,Active,42741659.0,5243.0,,,MDR-1,Other,,
11,388,1,2,,14720379,3715,Active,1203982.0,3248.0,,,"Compound Screen Assay, Human HPGD",Screening,,
12,410,1,5,,11111328,3715,Inconclusive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
13,410,1,5,,11111329,3715,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
14,410,1,5,,11113361,3715,Inconclusive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
15,411,2,1,,856012,3715,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
16,411,2,1,,11111328,3715,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
17,411,2,1,,11111329,3715,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
18,411,2,1,,11113361,3715,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
19,421,1,3,,17389851,3715,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
20,422,1,5,,856012,3715,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
21,422,1,5,,17405253,3715,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
22,425,3,2,,856012,3715,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
23,426,1,2,,17389851,3715,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
24,427,1,1,,17389851,3715,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
25,429,1,5,,856012,3715,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
26,429,1,5,,856012,3715,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
27,429,1,5,,17405253,3715,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
28,429,1,5,,17405253,3715,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
29,430,2,4,,856012,3715,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
30,431,2,4,,856012,3715,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
31,432,2,4,,856012,3715,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
32,433,1,1,,17389851,3715,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
33,434,1,2,,17389851,3715,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
34,435,1,2,,17389851,3715,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
35,436,2,1,,856012,3715,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
36,436,2,1,,17405253,3715,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
37,438,1,4,,856012,3715,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
38,440,3,3,,856012,3715,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
39,441,3,3,,856012,3715,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
40,444,1,1,,856012,3715,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
41,444,1,1,,11111328,3715,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
42,444,1,1,,11111329,3715,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
43,445,3,1,,11111328,3715,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
44,445,3,1,,11111329,3715,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
45,445,3,1,,11113361,3715,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
46,445,3,1,,17389851,3715,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
47,446,1,1,,856012,3715,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
48,446,1,1,,11111328,3715,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
49,446,1,1,,11111329,3715,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
50,447,1,1,,11111328,3715,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
51,447,1,1,,11111329,3715,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
52,447,1,1,,11113361,3715,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
53,448,1,2,,11111328,3715,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
54,448,1,2,,11111329,3715,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
55,448,1,2,,11113361,3715,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
56,449,1,5,,856012,3715,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
57,450,1,2,,856012,3715,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
58,450,1,2,,11111328,3715,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
59,450,1,2,,11111329,3715,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
60,450,1,2,,11113361,3715,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
61,451,1,2,,11111328,3715,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
62,451,1,2,,11111329,3715,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
63,451,1,2,,11113361,3715,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
64,453,2,2,,856012,3715,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
65,454,1,7,,856012,3715,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
66,455,1,7,,856012,3715,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
67,456,1,7,,856012,3715,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
68,457,1,7,,856012,3715,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
69,460,2,2,,856012,3715,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
70,483,1,6,,856012,3715,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
71,485,1,8,,856012,3715,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
72,487,1,2,,856012,3715,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
73,488,2,1,,856012,3715,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
74,501,2,2,,856012,3715,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
75,518,2,6,,856012,3715,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
76,521,2,5,,856012,3715,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
77,522,1,2,,856012,3715,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
78,524,1,3,,856012,3715,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
79,525,1,3,,856012,3715,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
80,526,1,1,,11111328,3715,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
81,526,1,1,,11111329,3715,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
82,526,1,1,,11113361,3715,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
83,527,3,1,,856012,3715,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
84,528,1,4,,856012,3715,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
85,529,1,4,,856012,3715,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
86,530,1,1,,11111328,3715,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
87,530,1,1,,11111329,3715,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
88,530,1,1,,11113361,3715,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
89,530,1,1,,17389851,3715,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
90,538,2,2,,856012,3715,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
91,539,1,2,,856012,3715,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
92,540,1,1,,17389851,3715,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
93,541,1,1,,17389851,3715,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
94,542,1,1,,17389851,3715,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
95,543,1,1,,17389851,3715,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
96,544,2,1,,17389851,3715,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
97,545,1,1,,17389851,3715,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
98,546,1,1,,17389851,3715,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
99,547,1,4,,17405253,3715,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
100,552,1,3,,856012,3715,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
101,555,1,2,,856012,3715,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
102,556,1,3,,856012,3715,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
103,559,2,2,,856012,3715,Inactive,147728.0,,,,RNA polymerase,Screening,,
104,560,1,2,,856012,3715,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
105,561,1,3,,856012,3715,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
106,565,1,4,,856012,3715,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
107,567,1,4,,856012,3715,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
108,568,1,7,,856012,3715,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
109,568,1,7,,856012,3715,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
110,570,1,4,,856012,3715,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
111,571,1,4,,856012,3715,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
112,572,1,5,,856012,3715,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
113,573,1,4,,856012,3715,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
114,574,1,3,,856012,3715,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
115,575,1,4,,856012,3715,Inactive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
116,576,1,2,,856012,3715,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
117,577,1,1,,856012,3715,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
118,580,1,5,,856012,3715,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
119,581,2,2,,856012,3715,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
120,583,2,6,,856012,3715,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
121,584,1,3,,11111328,3715,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
122,584,1,3,,11111329,3715,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
123,584,1,3,,11113361,3715,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
124,584,1,3,,17389851,3715,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
125,585,1,4,,11111328,3715,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
126,585,1,4,,11111329,3715,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
127,585,1,4,,11113361,3715,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
128,585,1,4,,17389851,3715,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
129,587,1,5,,856012,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
130,587,1,5,,11111328,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
131,587,1,5,,11111329,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
132,588,1,4,,856012,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
133,588,1,4,,11111328,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
134,588,1,4,,11111329,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
135,589,1,3,,856012,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
136,589,1,3,,11111328,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
137,589,1,3,,11111329,3715,Active,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
138,590,1,3,,856012,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
139,590,1,3,,11111328,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
140,590,1,3,,11111329,3715,Active,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
141,591,1,4,,856012,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
142,591,1,4,,11111328,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
143,591,1,4,,11111329,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
144,592,1,6,,856012,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
145,592,1,6,,11111328,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
146,592,1,6,,11111329,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
147,593,1,4,,856012,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
148,593,1,4,,11111328,3715,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
149,593,1,4,,11111329,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
150,594,1,4,,856012,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
151,594,1,4,,11111328,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
152,594,1,4,,11111329,3715,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
153,595,1,3,,11111328,3715,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
154,595,1,3,,11111329,3715,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
155,595,1,3,,11113361,3715,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
156,595,1,3,,17389851,3715,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
157,596,1,2,,11111328,3715,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
158,596,1,2,,11111329,3715,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
159,596,1,2,,11113361,3715,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
160,596,1,2,,17389851,3715,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
161,597,1,3,,856012,3715,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
162,597,1,3,,11111328,3715,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
163,597,1,3,,11111329,3715,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
164,597,1,3,,11113361,3715,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
165,598,1,4,,856012,3715,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
166,601,1,4,,856012,3715,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
167,602,1,4,,856012,3715,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
168,603,1,2,,11111328,3715,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
169,603,1,2,,11111329,3715,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
170,603,1,2,,11113361,3715,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
171,603,1,2,,17389851,3715,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
172,604,1,3,,856012,3715,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
173,605,1,2,,11111328,3715,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
174,605,1,2,,11111329,3715,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
175,605,1,2,,11113361,3715,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
176,605,1,2,,17389851,3715,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
177,606,1,3,,856012,3715,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
178,606,1,3,,856012,3715,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
179,607,1,3,,11111328,3715,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
180,607,1,3,,11111329,3715,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
181,607,1,3,,11113361,3715,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
182,609,1,2,,856012,3715,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
183,614,1,6,,856012,3715,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
184,615,1,6,,856012,3715,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
185,618,2,6,,856012,3715,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
186,620,2,5,,856012,3715,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
187,622,1,2,,856012,3715,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
188,623,1,3,,856012,3715,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
189,624,1,2,,856012,3715,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
190,625,1,2,,856012,3715,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
191,626,1,3,,856012,3715,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
192,628,2,4,,856012,3715,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
193,629,1,3,,856012,3715,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
194,630,1,1,,856012,3715,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
195,631,1,4,,856012,3715,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
196,631,1,4,,856012,3715,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
197,633,1,3,,856012,3715,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
198,636,1,4,,856012,3715,Inactive,,,,,Modulators of Post-Golgi Transport - 384-well pilot screen,Screening,,
199,637,1,4,,856012,3715,Inactive,,,,,Modulators of Post-Golgi Transport - 1536-well pilot screen,Screening,,
200,639,1,2,,856012,3715,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
201,641,1,4,,856012,3715,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
202,645,1,4,,856012,3715,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
203,648,1,3,,856012,3715,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
204,654,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
205,655,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
206,656,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
207,657,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
208,658,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
209,659,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
210,660,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
211,661,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
212,662,1,1,,11111328,3715,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
213,662,1,1,,11111329,3715,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
214,662,1,1,,11113361,3715,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
215,662,1,1,,17389851,3715,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
216,663,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
217,664,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
218,665,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
219,666,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
220,667,1,1,,17389851,3715,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
221,680,1,10,,856012,3715,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
222,684,1,12,,856012,3715,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
223,686,1,1,,856012,3715,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
224,687,1,17,,856012,3715,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
225,694,1,1,,17405253,3715,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
226,701,1,17,,856012,3715,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
227,708,1,4,,856012,3715,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
228,709,1,2,,856012,3715,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
229,719,1,3,,856012,3715,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
230,731,1,5,,856012,3715,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
231,731,1,5,,856012,3715,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
232,732,1,2,,17405253,3715,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
233,734,1,2,,856012,3715,Inactive,4505209.0,4322.0,,,Assay to identify inhibitors among the possible fluorescent artifacts from the primary HTS inhibition assay of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
234,741,1,4,,856012,3715,Inconclusive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance - Dose Response,Confirmatory,,
235,746,1,1,,856012,3715,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
236,750,1,3,,856012,3715,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
237,751,1,3,,856012,3715,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
238,757,1,4,,856012,3715,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
239,758,1,4,,856012,3715,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
240,759,1,4,,856012,3715,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
241,760,1,4,,856012,3715,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
242,761,1,4,,856012,3715,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
243,764,1,4,,856012,3715,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
244,770,1,1,,856012,3715,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
245,771,1,2,,856012,3715,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
246,772,1,2,,856012,3715,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
247,774,1,2,,856012,3715,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
248,775,1,3,,856012,3715,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
249,781,1,1,,856012,3715,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
250,782,1,2,,856012,3715,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
251,782,1,2,,856012,3715,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
252,784,1,4,,856012,3715,Inactive,55584151.0,2629.0,,,Primary Cell Based High Throughput Screening Assay for Enhancers of Beta-Glucosidase Activity,Screening,,
253,793,1,2,,856012,3715,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
254,795,1,1,,856012,3715,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
255,797,1,1,,856012,3715,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
256,798,2,12,,856012,3715,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
257,799,1,5,,856012,3715,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
258,800,2,11,,856012,3715,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
259,803,1,4,,856012,3715,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
260,804,1,3,,856012,3715,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
261,813,1,4,,856012,3715,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
262,817,1,1,,856012,3715,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
263,818,1,2,,856012,3715,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
264,827,1,2,,856012,3715,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
265,828,1,5,,856012,3715,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
266,834,1,3,,856012,3715,Inactive,,,,,C. albicans biofilm killing,Screening,,
267,841,1,1,,856012,3715,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
268,847,1,2,,856012,3715,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
269,861,1,1,,856012,3715,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
270,862,1,2,,856012,3715,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
271,868,1,3,,856012,3715,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
272,871,1,2,,856012,3715,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
273,873,1,13,,856012,3715,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
274,875,1,2,,11111329,3715,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
275,875,1,2,,11113361,3715,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
276,875,1,2,,17389851,3715,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
277,878,1,2,,856012,3715,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
278,879,1,2,,11113361,3715,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
279,879,1,2,,11113361,3715,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
280,880,2,1,,856012,3715,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
281,880,2,1,,856012,3715,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
282,880,2,1,,11111329,3715,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
283,880,2,1,,11111329,3715,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
284,880,2,1,,11113361,3715,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
285,880,2,1,,11113361,3715,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
286,880,2,1,,17389851,3715,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
287,880,2,1,,17389851,3715,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
288,880,2,1,,26747086,3715,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
289,880,2,1,,26747086,3715,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
290,880,2,1,,26751593,3715,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
291,880,2,1,,26751593,3715,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
292,880,2,1,,50104238,3715,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
293,880,2,1,,50104238,3715,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
294,881,2,2,,11111329,3715,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
295,881,2,2,,11113361,3715,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
296,881,2,2,,17389851,3715,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
297,881,2,2,,26751593,3715,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
298,883,1,3,,11111328,3715,Inconclusive,13699818.0,1559.0,39.8107,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
299,883,1,3,,11111329,3715,Inconclusive,13699818.0,1559.0,19.9526,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
300,883,1,3,,11113361,3715,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
301,884,1,2,,11111329,3715,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
302,884,1,2,,11113361,3715,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
303,884,1,2,,17389851,3715,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
304,885,1,2,,11111329,3715,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
305,885,1,2,,11113361,3715,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
306,885,1,2,,17389851,3715,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
307,886,1,2,,11111328,3715,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
308,886,1,2,,11111328,3715,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
309,886,1,2,,11111329,3715,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
310,886,1,2,,11111329,3715,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
311,886,1,2,,11113361,3715,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
312,886,1,2,,11113361,3715,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
313,886,1,2,,17389851,3715,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
314,886,1,2,,17389851,3715,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
315,887,1,2,,11111329,3715,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
316,887,1,2,,11113361,3715,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
317,887,1,2,,17389851,3715,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
318,889,1,3,,11111329,3715,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
319,889,1,3,,11113361,3715,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
320,889,1,3,,17389851,3715,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
321,891,1,2,,11111328,3715,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
322,891,1,2,,11111329,3715,Inconclusive,40805836.0,1565.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
323,891,1,2,,11113361,3715,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
324,892,1,2,,11111329,3715,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
325,892,1,2,,11113361,3715,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
326,892,1,2,,17389851,3715,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
327,893,1,2,,11111329,3715,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
328,893,1,2,,11111329,3715,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
329,893,1,2,,11113361,3715,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
330,893,1,2,,11113361,3715,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
331,893,1,2,,17389851,3715,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
332,893,1,2,,17389851,3715,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
333,894,2,1,,856012,3715,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
334,894,2,1,,11111329,3715,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
335,894,2,1,,11113361,3715,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
336,894,2,1,,17389851,3715,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
337,894,2,1,,26747086,3715,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
338,894,2,1,,26751593,3715,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
339,894,2,1,,50104238,3715,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
340,895,1,2,,11113361,3715,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
341,898,1,1,,856012,3715,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
342,899,1,2,,11111328,3715,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
343,899,1,2,,11111329,3715,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
344,899,1,2,,11113361,3715,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
345,900,1,3,,11111329,3715,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
346,900,1,3,,11113361,3715,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
347,900,1,3,,17389851,3715,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
348,901,1,2,,11111329,3715,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
349,901,1,2,,11113361,3715,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
350,902,1,2,,11111329,3715,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
351,902,1,2,,11113361,3715,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
352,902,1,2,,17389851,3715,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
353,910,1,2,,11113361,3715,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
354,912,1,2,,11111328,3715,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
355,912,1,2,,11111329,3715,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
356,912,1,2,,11113361,3715,Inconclusive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
357,912,1,2,,17389851,3715,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
358,914,1,3,,856012,3715,Inconclusive,32879895.0,3091.0,6.3096,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
359,914,1,3,,11111328,3715,Inconclusive,32879895.0,3091.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
360,914,1,3,,11111329,3715,Inconclusive,32879895.0,3091.0,6.3096,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
361,915,1,3,,856012,3715,Inconclusive,32879895.0,3091.0,6.3096,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
362,915,1,3,,11111328,3715,Inconclusive,32879895.0,3091.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
363,915,1,3,,11111329,3715,Inconclusive,32879895.0,3091.0,6.3096,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
364,917,1,3,,11113361,3715,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
365,918,1,3,,11113361,3715,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
366,920,1,2,,856012,3715,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
367,921,1,2,,17389851,3715,Inconclusive,,,12.5893,Potency,Cell Viability - LYMP2-001,Confirmatory,,
368,923,1,2,,11111329,3715,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
369,923,1,2,,11113361,3715,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
370,923,1,2,,17389851,3715,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
371,924,1,2,,11111329,3715,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
372,924,1,2,,11113361,3715,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
373,924,1,2,,17389851,3715,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
374,925,1,2,,11111328,3715,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
375,925,1,2,,11111329,3715,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
376,925,1,2,,17389851,3715,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
377,926,1,2,,11111328,3715,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
378,926,1,2,,11111329,3715,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
379,926,1,2,,11113361,3715,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
380,926,1,2,,17389851,3715,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
381,927,1,3,,11111329,3715,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
382,927,1,3,,11113361,3715,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
383,928,1,2,,11113361,3715,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
384,930,1,2,,11113361,3715,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
385,932,1,4,,856012,3715,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
386,938,1,2,,11111328,3715,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
387,938,1,2,,11111329,3715,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
388,938,1,2,,11113361,3715,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
389,938,1,2,,17389851,3715,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
390,940,1,2,,856012,3715,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
391,940,1,2,,17405253,3715,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
392,940,1,2,,26611783,3715,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
393,943,1,2,,11113361,3715,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
394,944,1,2,,11113361,3715,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
395,945,1,4,,11113361,3715,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
396,946,1,2,,17389851,3715,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
397,947,1,2,,17389851,3715,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
398,948,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
399,950,1,1,,856012,3715,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
400,951,1,1,,856012,3715,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
401,952,1,1,,856012,3715,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
402,954,1,2,,11113361,3715,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
403,955,1,2,,17389851,3715,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
404,957,1,2,,11113361,3715,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
405,958,1,2,,11113361,3715,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
406,959,1,4,,11113361,3715,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
407,960,1,2,,17389851,3715,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
408,961,1,2,,17389851,3715,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
409,962,1,2,,17389851,3715,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
410,963,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
411,964,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
412,965,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
413,966,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
414,967,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
415,968,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
416,969,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
417,970,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
418,971,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
419,972,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
420,973,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
421,974,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
422,975,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
423,976,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
424,977,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
425,978,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
426,979,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
427,980,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
428,981,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
429,982,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
430,983,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
431,984,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
432,985,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
433,986,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
434,987,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
435,988,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
436,989,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
437,992,1,3,,11113361,3715,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
438,993,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
439,994,1,2,,17389851,3715,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
440,995,1,2,,11111329,3715,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
441,995,1,2,,11113361,3715,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
442,995,1,2,,17389851,3715,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
443,997,1,2,,11113361,3715,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
444,998,1,2,,11113361,3715,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
445,999,1,1,,46487914,3715,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor Using a Diverse Compound Set,Screening,,
446,1001,2,2,,856012,3715,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
447,1004,1,1,,46487914,3715,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression Using a Diverse Compound Set,Screening,,
448,1006,1,6,,856012,3715,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
449,1007,1,1,,856012,3715,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
450,1008,1,2,,856012,3715,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
451,1009,1,2,,856012,3715,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
452,1012,1,4,,856012,3715,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
453,1016,1,4,,856012,3715,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
454,1018,2,5,,856012,3715,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
455,1019,1,4,,856012,3715,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
456,1020,1,5,,856012,3715,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
457,1021,1,1,,856012,3715,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
458,1022,1,1,,856012,3715,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
459,1027,1,3,,856012,3715,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
460,1030,2,1,,856012,3715,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
461,1030,2,1,,11111329,3715,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
462,1030,2,1,,11113361,3715,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
463,1030,2,1,,17389851,3715,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
464,1030,2,1,,26747086,3715,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
465,1030,2,1,,26751593,3715,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
466,1030,2,1,,50104238,3715,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
467,1032,1,2,,856012,3715,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
468,1032,1,2,,856012,3715,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
469,1040,1,2,,856012,3715,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
470,1046,1,6,,856012,3715,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
471,1048,1,1,,856012,3715,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
472,1048,1,1,,856012,3715,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
473,1049,1,1,,856012,3715,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
474,1049,1,1,,856012,3715,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
475,1051,1,1,,856012,3715,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
476,1051,1,1,,856012,3715,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
477,1063,1,1,,856012,3715,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
478,1066,1,2,,856012,3715,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
479,1085,1,1,,856012,3715,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
480,1135,1,3,,856012,3715,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
481,1136,1,3,,856012,3715,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
482,1189,1,5,,48413899,3715,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
483,1194,1,3,,48413899,3715,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
484,1203,1,3,,856012,3715,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
485,1208,1,3,,48413899,3715,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
486,1209,2,2,,856012,3715,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
487,1214,1,4,,856012,3715,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
488,1216,1,5,,856012,3715,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
489,1217,1,4,,856012,3715,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
490,1220,2,2,,856012,3715,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
491,1222,1,6,,856012,3715,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
492,1229,1,3,,856012,3715,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
493,1235,1,2,,856012,3715,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
494,1236,1,1,,856012,3715,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
495,1239,1,3,,856012,3715,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
496,1239,1,3,,856012,3715,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
497,1242,1,1,,856012,3715,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
498,1251,1,1,,856012,3715,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
499,1273,1,1,,856012,3715,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
500,1274,1,2,,856012,3715,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
501,1276,1,1,,856012,3715,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
502,1285,1,1,,856012,3715,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
503,1296,1,1,,856012,3715,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
504,1304,1,2,,856012,3715,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
505,1321,1,2,,856012,3715,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
506,1325,1,2,,856012,3715,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
507,1326,1,4,,856012,3715,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
508,1332,1,1,,49698710,3715,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
509,1359,1,4,,856012,3715,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
510,1362,1,2,,856012,3715,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
511,1376,1,2,,856012,3715,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
512,1377,1,1,,856012,3715,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
513,1379,1,2,,856012,3715,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
514,1379,1,2,,11111329,3715,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
515,1379,1,2,,11113361,3715,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
516,1379,1,2,,26747086,3715,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
517,1379,1,2,,26751593,3715,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
518,1379,1,2,,50104238,3715,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
519,1381,1,1,,856012,3715,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
520,1385,2,2,,856012,3715,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
521,1415,1,2,,856012,3715,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
522,1415,1,2,,856012,3715,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
523,1416,1,2,,856012,3715,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
524,1422,1,1,,856012,3715,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
525,1422,1,1,,17405253,3715,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
526,1422,1,1,,26611783,3715,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
527,1423,1,2,,856012,3715,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
528,1423,1,2,,856012,3715,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
529,1424,1,1,,856012,3715,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
530,1430,1,1,,856012,3715,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
531,1434,2,3,,856012,3715,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
532,1434,2,3,,856012,3715,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
533,1439,1,1,,856012,3715,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
534,1439,1,1,,856012,3715,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
535,1440,1,1,,856012,3715,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
536,1440,1,1,,856012,3715,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
537,1441,1,1,,856012,3715,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
538,1441,1,1,,856012,3715,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
539,1443,1,3,,856012,3715,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
540,1445,1,1,,856012,3715,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
541,1446,1,3,,856012,3715,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
542,1448,1,3,,856012,3715,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
543,1452,1,1,,856012,3715,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
544,1452,1,1,,11111329,3715,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
545,1452,1,1,,11113361,3715,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
546,1452,1,1,,17389851,3715,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
547,1452,1,1,,26751593,3715,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
548,1454,1,1,,856012,3715,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
549,1454,1,1,,11111329,3715,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
550,1454,1,1,,11113361,3715,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
551,1454,1,1,,26747086,3715,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
552,1454,1,1,,50104238,3715,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
553,1456,1,1,,856012,3715,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
554,1457,1,1,,856012,3715,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
555,1457,1,1,,11111329,3715,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
556,1457,1,1,,11113361,3715,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
557,1457,1,1,,17389851,3715,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
558,1457,1,1,,26747086,3715,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
559,1457,1,1,,26751593,3715,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
560,1457,1,1,,50104238,3715,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
561,1458,1,1,,856012,3715,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
562,1458,1,1,,11111329,3715,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
563,1458,1,1,,17389851,3715,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
564,1458,1,1,,26747086,3715,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
565,1458,1,1,,50104238,3715,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
566,1459,1,1,,50104238,3715,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
567,1460,1,3,,856012,3715,Inconclusive,92096784.0,4137.0,19.9526,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
568,1460,1,3,,11113361,3715,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
569,1460,1,3,,26747086,3715,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
570,1460,1,3,,26751593,3715,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
571,1460,1,3,,50104238,3715,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
572,1461,1,2,,856012,3715,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
573,1461,1,2,,50104238,3715,Inconclusive,46395496.0,387129.0,1.5849,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
574,1463,1,1,,856012,3715,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
575,1463,1,1,,11113361,3715,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
576,1463,1,1,,26747086,3715,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
577,1463,1,1,,26751593,3715,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
578,1463,1,1,,50104238,3715,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
579,1465,1,1,,856012,3715,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
580,1466,1,2,,856012,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
581,1467,1,3,,856012,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
582,1467,1,3,,11111329,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
583,1467,1,3,,11113361,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
584,1467,1,3,,26747086,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
585,1467,1,3,,26751593,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
586,1467,1,3,,50104238,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
587,1468,1,1,,856012,3715,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
588,1468,1,1,,11113361,3715,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
589,1468,1,1,,26747086,3715,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
590,1468,1,1,,26751593,3715,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
591,1468,1,1,,50104238,3715,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
592,1469,1,1,,856012,3715,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
593,1469,1,1,,11111329,3715,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
594,1469,1,1,,11113361,3715,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
595,1469,1,1,,17389851,3715,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
596,1469,1,1,,26747086,3715,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
597,1469,1,1,,26751593,3715,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
598,1469,1,1,,50104238,3715,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
599,1469,1,1,,50126367,3715,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
600,1471,2,1,,11111328,3715,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
601,1471,2,1,,11111329,3715,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
602,1471,2,1,,11113361,3715,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
603,1471,2,1,,17389851,3715,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
604,1471,2,1,,26747086,3715,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
605,1471,2,1,,26751593,3715,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
606,1476,2,1,,856012,3715,Inconclusive,281307097.0,,39.8107,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
607,1476,2,1,,11111329,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
608,1476,2,1,,11113361,3715,Inconclusive,281307097.0,,39.8107,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
609,1476,2,1,,17389851,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
610,1476,2,1,,26747086,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
611,1476,2,1,,26751593,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
612,1476,2,1,,50104238,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
613,1477,1,1,,856012,3715,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
614,1477,1,1,,11111329,3715,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
615,1477,1,1,,11113361,3715,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
616,1477,1,1,,17389851,3715,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
617,1477,1,1,,26747086,3715,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
618,1477,1,1,,26751593,3715,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
619,1477,1,1,,50104238,3715,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
620,1478,2,1,,856012,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
621,1478,2,1,,11111329,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
622,1478,2,1,,11113361,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
623,1478,2,1,,17389851,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
624,1478,2,1,,26747086,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
625,1478,2,1,,26751593,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
626,1478,2,1,,50104238,3715,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
627,1479,1,2,,856012,3715,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
628,1479,1,2,,11111329,3715,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
629,1479,1,2,,11113361,3715,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
630,1479,1,2,,17389851,3715,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
631,1479,1,2,,26747086,3715,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
632,1479,1,2,,26751593,3715,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
633,1479,1,2,,50104238,3715,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
634,1479,1,2,,50126367,3715,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
635,1481,1,2,,856012,3715,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
636,1486,1,3,,856012,3715,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
637,1487,1,1,,856012,3715,Inconclusive,27436948.0,4000.0,11.2202,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
638,1487,1,1,,11111329,3715,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
639,1487,1,1,,50104238,3715,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
640,1490,2,1,,856012,3715,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
641,1490,2,1,,11111329,3715,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
642,1490,2,1,,11113361,3715,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
643,1490,2,1,,26747086,3715,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
644,1490,2,1,,26751593,3715,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
645,1496,1,4,,856012,3715,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
646,1496,1,4,,856012,3715,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
647,1509,1,2,,856012,3715,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
648,1510,1,3,,856012,3715,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
649,1511,1,3,,856012,3715,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
650,1515,1,2,,856012,3715,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
651,1519,1,3,,11111329,3715,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
652,1519,1,3,,11113361,3715,Inconclusive,,,2.8184,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
653,1519,1,3,,26747086,3715,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
654,1519,1,3,,50104238,3715,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
655,1527,1,3,,856012,3715,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
656,1529,1,1,,856012,3715,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
657,1530,1,1,,856012,3715,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
658,1531,1,1,,856012,3715,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
659,1532,1,1,,856012,3715,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
660,1554,1,1,,856012,3715,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
661,1556,1,4,,856012,3715,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
662,1565,2,2,,856012,3715,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
663,1566,2,3,,856012,3715,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
664,1578,3,2,,856012,3715,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
665,1580,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
666,1581,1,1,,8149387,3715,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
667,1582,1,1,,8149387,3715,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
668,1583,1,1,,8149387,3715,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
669,1584,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
670,1585,1,1,,8149387,3715,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
671,1586,1,1,,8149387,3715,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
672,1587,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
673,1588,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
674,1589,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
675,1590,1,1,,8149387,3715,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
676,1593,1,1,,8149387,3715,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
677,1594,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
678,1595,1,1,,8149387,3715,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
679,1596,1,1,,8149387,3715,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
680,1597,1,1,,8149387,3715,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
681,1598,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
682,1599,1,1,,8149387,3715,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
683,1600,1,1,,8149387,3715,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
684,1601,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
685,1602,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
686,1603,1,1,,8149387,3715,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
687,1604,1,1,,8149387,3715,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
688,1605,1,1,,8149387,3715,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
689,1606,1,1,,8149387,3715,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
690,1607,1,1,,8149387,3715,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
691,1608,1,1,,8149387,3715,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
692,1609,1,1,,8149387,3715,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
693,1610,1,1,,8149387,3715,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
694,1611,1,1,,8149387,3715,Unspecified,,,,,Screen for compounds that induce the human heat shock transcriptional response (HSEluc),Other,,
695,1612,1,1,,8149387,3715,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
696,1613,1,1,,8149387,3715,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
697,1614,1,1,,8149387,3715,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
698,1616,1,1,,8149387,3715,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
699,1619,1,2,,856012,3715,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
700,1621,1,2,,856012,3715,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
701,1626,1,2,,856012,3715,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
702,1631,3,1,,856012,3715,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
703,1634,3,1,,856012,3715,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
704,1654,2,2,,856012,3715,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
705,1656,2,2,,856012,3715,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
706,1662,1,2,,856012,3715,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
707,1663,1,2,,856012,3715,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
708,1665,2,2,,856012,3715,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
709,1672,1,3,,856012,3715,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
710,1688,1,1,,856012,3715,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
711,1700,1,2,,856012,3715,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
712,1705,1,2,,50104238,3715,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
713,1706,1,2,,856012,3715,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
714,1707,1,3,,50104238,3715,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
715,1708,1,3,,50104238,3715,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
716,1721,1,2,,856012,3715,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
717,1722,1,2,,856012,3715,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
718,1766,1,1,,856012,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
719,1766,1,1,,856012,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
720,1766,1,1,,11111329,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
721,1766,1,1,,11111329,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
722,1766,1,1,,11113361,3715,Inactive,18860839.0,4221.0,31.6228,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
723,1766,1,1,,11113361,3715,Inactive,56550039.0,4297.0,31.6228,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
724,1766,1,1,,26747086,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
725,1766,1,1,,26747086,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
726,1766,1,1,,26751593,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
727,1766,1,1,,26751593,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
728,1766,1,1,,50104238,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
729,1766,1,1,,50104238,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
730,1768,1,1,,856012,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
731,1768,1,1,,856012,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
732,1768,1,1,,11111329,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
733,1768,1,1,,11111329,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
734,1768,1,1,,11113361,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
735,1768,1,1,,11113361,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
736,1768,1,1,,26747086,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
737,1768,1,1,,26747086,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
738,1768,1,1,,26751593,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
739,1768,1,1,,26751593,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
740,1768,1,1,,50104238,3715,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
741,1768,1,1,,50104238,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
742,1775,1,2,,856012,3715,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
743,1776,1,2,,856012,3715,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
744,1777,3,2,,856012,3715,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
745,1778,3,3,,856012,3715,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
746,1779,2,2,,856012,3715,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
747,1789,1,2,,856012,3715,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
748,1800,1,2,,856012,3715,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
749,1811,3,2,,46393715,3715,Active,67464376.0,,,,Experimentally measured binding affinity data derived from PDB,Other,15854652.0,
750,1813,1,2,,856012,3715,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
751,1814,1,2,,856012,3715,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
752,1815,1,1,,50104238,3715,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
753,1816,1,1,,50104238,3715,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
754,1817,2,2,,856012,3715,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
755,1822,1,3,,856012,3715,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
756,1825,1,1,,856012,3715,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
757,1828,2,1,,50104238,3715,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
758,1832,2,1,,856012,3715,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
759,1845,1,2,,856012,3715,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
760,1850,2,1,,856012,3715,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
761,1850,2,1,,56422212,3715,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
762,1851,1,2,,11111329,3715,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
763,1851,1,2,,11113361,3715,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
764,1851,1,2,1.0,11111329,3715,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
765,1851,1,2,1.0,11113361,3715,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
766,1851,1,2,2.0,11111329,3715,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
767,1851,1,2,2.0,11113361,3715,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
768,1851,1,2,3.0,11111329,3715,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
769,1851,1,2,3.0,11113361,3715,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
770,1851,1,2,4.0,11111329,3715,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
771,1851,1,2,4.0,11113361,3715,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
772,1851,1,2,5.0,11111329,3715,Inconclusive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
773,1851,1,2,5.0,11113361,3715,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
774,1861,2,1,,856012,3715,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
775,1862,1,4,,856012,3715,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
776,1863,2,1,,856012,3715,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
777,1863,2,1,,56422212,3715,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
778,1865,1,1,,856012,3715,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
779,1865,1,1,,11111329,3715,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
780,1865,1,1,,11113361,3715,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
781,1865,1,1,,26747086,3715,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
782,1865,1,1,,26751593,3715,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
783,1865,1,1,,50104238,3715,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
784,1867,1,4,,856012,3715,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
785,1868,1,4,,856012,3715,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
786,1870,1,4,,856012,3715,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
787,1873,1,4,,856012,3715,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
788,1875,2,1,,856012,3715,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
789,1876,1,1,,50104238,3715,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
790,1877,1,1,,50104238,3715,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
791,1882,1,1,,50104238,3715,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
792,1883,1,1,,50104238,3715,Inconclusive,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
793,1885,2,1,,856012,3715,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
794,1886,1,1,,50104238,3715,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
795,1887,1,4,,856012,3715,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
796,1899,1,3,,56422212,3715,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
797,1903,2,3,,856012,3715,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
798,1903,2,3,,56422212,3715,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
799,1906,1,3,,56422212,3715,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
800,1910,1,2,,856012,3715,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
801,1947,1,2,,56422212,3715,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
802,1948,1,1,,11111329,3715,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
803,1948,1,1,,11113361,3715,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
804,1948,1,1,,17389851,3715,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
805,1948,1,1,,26747086,3715,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
806,1948,1,1,,26751593,3715,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
807,1948,1,1,,50104238,3715,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
808,1950,1,3,,56422212,3715,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
809,1956,1,1,,856012,3715,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
810,1961,2,2,,856012,3715,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
811,1962,1,2,,56422212,3715,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
812,1967,1,1,,85231093,3715,Inconclusive,4505907.0,5376.0,84.9214,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
813,1974,1,2,,56422212,3715,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
814,1979,1,1,,856012,3715,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
815,1984,1,3,,856012,3715,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
816,1986,1,2,,856012,3715,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
817,1987,1,2,,56422212,3715,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
818,2006,3,2,,856012,3715,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
819,2006,3,2,,856012,3715,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
820,2006,3,2,,856012,3715,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
821,2012,3,2,,856012,3715,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
822,2013,2,2,,856012,3715,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
823,2014,3,2,,856012,3715,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
824,2016,1,3,,56422212,3715,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
825,2023,1,3,,56422212,3715,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
826,2025,1,3,,56422212,3715,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
827,2029,1,3,,56422212,3715,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
828,2052,2,1,,56422212,3715,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
829,2057,1,2,,56422212,3715,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
830,2058,3,2,,856012,3715,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
831,2063,1,2,,85209660,3715,Active,,,,,Ligands of peptide (Class A) GPCRs,Other,,
832,2064,1,2,,85209660,3715,Active,,,,,Ligands of prostanoid (Class A) GPCRs,Other,,
833,2066,1,4,,56422212,3715,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
834,2071,2,2,,856012,3715,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
835,2073,2,3,,856012,3715,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
836,2073,2,3,,856012,3715,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
837,2094,1,2,,856012,3715,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
838,2094,1,2,,856012,3715,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
839,2094,1,2,,856012,3715,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
840,2097,1,2,,856012,3715,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
841,2098,1,1,,856012,3715,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
842,2099,1,1,,856012,3715,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
843,2099,1,1,,56422212,3715,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
844,2100,1,1,,856012,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
845,2101,1,1,,856012,3715,Inconclusive,496369.0,2629.0,0.631,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
846,2101,1,1,,11111329,3715,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
847,2101,1,1,,11113361,3715,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
848,2101,1,1,,17389851,3715,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
849,2101,1,1,,26747086,3715,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
850,2101,1,1,,26751593,3715,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
851,2101,1,1,,50104238,3715,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
852,2107,1,1,,856012,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
853,2107,1,1,,11111329,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
854,2107,1,1,,11113361,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
855,2107,1,1,,17389851,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
856,2107,1,1,,26747086,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
857,2107,1,1,,26751593,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
858,2107,1,1,,50104238,3715,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
859,2112,1,1,,856012,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
860,2112,1,1,,11111329,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
861,2112,1,1,,11113361,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
862,2112,1,1,,17389851,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
863,2112,1,1,,26747086,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
864,2112,1,1,,26751593,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
865,2112,1,1,,50104238,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
866,2120,1,1,,17389851,3715,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
867,2129,1,2,,56422212,3715,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
868,2130,1,3,,56422212,3715,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
869,2147,1,1,,856012,3715,Inconclusive,221046486.0,,10.0,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
870,2147,1,1,,11111329,3715,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
871,2147,1,1,,11113361,3715,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
872,2147,1,1,,26747086,3715,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
873,2147,1,1,,50104238,3715,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
874,2156,2,2,,856012,3715,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
875,2174,1,3,,56422212,3715,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
876,2177,1,3,,56422212,3715,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
877,2205,1,1,,856012,3715,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
878,2216,1,3,,856012,3715,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
879,2221,1,2,,856012,3715,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
880,2227,1,2,,856012,3715,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
881,2234,1,2,,56422212,3715,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
882,2235,1,2,,56422212,3715,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
883,2237,1,2,,856012,3715,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
884,2239,1,2,,856012,3715,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
885,2240,1,1,,85787264,3715,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
886,2241,1,1,,85787264,3715,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
887,2242,1,1,,856012,3715,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
888,2247,1,2,,856012,3715,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
889,2275,1,1,,85787264,3715,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
890,2280,2,3,,56422212,3715,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
891,2288,1,1,,856012,3715,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
892,2289,1,1,,856012,3715,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
893,2300,1,3,,56422212,3715,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
894,2313,1,1,,85787264,3715,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
895,2314,1,2,,856012,3715,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
896,2314,1,2,,856012,3715,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
897,2315,1,2,,856012,3715,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
898,2315,1,2,,856012,3715,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
899,2316,1,1,,85787264,3715,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
900,2322,1,1,,85787264,3715,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
901,2323,1,1,,50104238,3715,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
902,2326,1,1,,856012,3715,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
903,2326,1,1,,50104238,3715,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
904,2330,1,1,,85787264,3715,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
905,2353,1,3,,50104238,3715,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
906,2364,1,2,,50104238,3715,Inactive,4557365.0,641.0,,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
907,2380,1,2,,856012,3715,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
908,2391,1,1,,56422212,3715,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
909,2417,1,1,,856012,3715,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
910,2435,1,2,,56422212,3715,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
911,2445,1,2,,56422212,3715,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
912,2451,1,2,,856012,3715,Inconclusive,122920737.0,,17.7407,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
913,2451,1,2,,11111329,3715,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
914,2451,1,2,,11113361,3715,Inconclusive,122920737.0,,35.3973,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
915,2451,1,2,,26747086,3715,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
916,2451,1,2,,26751593,3715,Inconclusive,122920737.0,,22.3342,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
917,2451,1,2,,50104238,3715,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
918,2462,1,1,,56422212,3715,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
919,2462,1,1,,56422212,3715,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
920,2472,1,2,,856012,3715,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
921,2472,1,2,,11111329,3715,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
922,2472,1,2,,11113361,3715,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
923,2472,1,2,,26747086,3715,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
924,2472,1,2,,26751593,3715,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
925,2517,2,1,,856012,3715,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
926,2517,2,1,,11111329,3715,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
927,2517,2,1,,11113361,3715,Inactive,6980812.0,,1.9953,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
928,2517,2,1,,17389851,3715,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
929,2517,2,1,,26747086,3715,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
930,2517,2,1,,26751593,3715,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
931,2517,2,1,,50104238,3715,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
932,2517,2,1,,124886861,3715,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
933,2520,1,4,,856012,3715,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
934,2521,1,3,,856012,3715,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
935,2523,1,1,,856012,3715,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
936,2524,1,2,,856012,3715,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
937,2528,1,2,,856012,3715,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
938,2528,1,2,,11111329,3715,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
939,2528,1,2,,11113361,3715,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
940,2528,1,2,,26747086,3715,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
941,2528,1,2,,26751593,3715,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
942,2528,1,2,,50104238,3715,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
943,2540,1,2,,856012,3715,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
944,2544,1,2,,856012,3715,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
945,2546,1,1,,856012,3715,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
946,2546,1,1,,11111329,3715,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
947,2546,1,1,,11113361,3715,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
948,2546,1,1,,17389851,3715,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
949,2546,1,1,,26747086,3715,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
950,2546,1,1,,26751593,3715,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
951,2549,1,1,,856012,3715,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
952,2549,1,1,,11111329,3715,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
953,2549,1,1,,11113361,3715,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
954,2549,1,1,,17389851,3715,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
955,2549,1,1,,26747086,3715,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
956,2549,1,1,,26751593,3715,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
957,2549,1,1,,50104238,3715,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
958,2550,1,3,,856012,3715,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
959,2551,1,1,,856012,3715,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
960,2551,1,1,,11111329,3715,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
961,2551,1,1,,11113361,3715,Inconclusive,188536040.0,19885.0,12.5893,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
962,2551,1,1,,17389851,3715,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
963,2551,1,1,,26747086,3715,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
964,2551,1,1,,26751593,3715,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
965,2553,1,2,,856012,3715,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
966,2557,1,3,,56422212,3715,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
967,2563,1,1,,856012,3715,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
968,2599,1,2,,856012,3715,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
969,2606,1,2,,56422212,3715,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
970,2629,1,1,,56422212,3715,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
971,2642,1,2,,856012,3715,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
972,2648,1,2,,856012,3715,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
973,2650,2,1,,56422212,3715,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
974,2660,1,1,,90340917,3715,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
975,2661,1,1,,56422212,3715,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
976,2662,2,1,,856012,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
977,2662,2,1,,85231093,3715,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
978,2666,1,1,,90340917,3715,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
979,2667,1,1,,90340917,3715,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
980,2668,1,1,,90340917,3715,Inconclusive,4826730.0,2475.0,4.6451,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
981,2674,1,1,,856012,3715,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
982,2675,1,1,,856012,3715,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
983,2675,1,1,,50104238,3715,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
984,2676,1,2,,856012,3715,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
985,2685,1,1,,856012,3715,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
986,2690,1,2,,56422212,3715,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
987,2706,1,1,,856012,3715,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
988,2716,1,1,,56422212,3715,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
989,2717,1,2,,56422212,3715,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
990,2718,1,1,,56422212,3715,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
991,2732,1,1,,856012,3715,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
992,2732,1,1,,17405253,3715,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
993,2751,2,2,,56422212,3715,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
994,2774,1,3,,92304242,3715,Inactive,,,,,LOPAC Circadian Assay,Screening,,
995,2796,1,4,,56422212,3715,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
996,2797,1,2,,56422212,3715,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
997,2805,2,2,,856012,3715,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
998,2806,2,2,,856012,3715,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
999,2825,1,2,,856012,3715,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
1000,3620,8,1,,103163840,3715,Unspecified,,,25.0,ID50,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Confirmatory,1433212.0,
1001,6710,6,7,,103163840,3715,Active,126407.0,240.0,7.0,IC50,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Confirmatory,9057869.0,
1002,6746,3,7,,103163840,3715,Unspecified,,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,Other,2491889.0,
1003,6793,9,2,,103163840,3715,Unspecified,,,100.0,IC50,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,Confirmatory,,
1004,6808,9,5,,103163840,3715,Unspecified,729945.0,25290.0,250.0,IC50,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Confirmatory,,
1005,6820,11,1,,103163840,3715,Unspecified,,,3700.0,IC50,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,Confirmatory,8254620.0,
1006,6860,9,1,,103163840,3715,Unspecified,,,100.0,IC50,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,Confirmatory,2115586.0,
1007,6861,6,7,,103163840,3715,Active,729945.0,25290.0,12.0,IC50,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Confirmatory,9057869.0,
1008,6870,9,5,,103163840,3715,Unspecified,729945.0,25290.0,20.0,IC50,Inhibition of 5-lipoxygenase in rat RBL-1 cells,Confirmatory,2319562.0,
1009,7062,9,1,,103163840,3715,Unspecified,,,25.0,IC50,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,Confirmatory,1507204.0,
1010,7074,9,2,,103163840,3715,Unspecified,,,100.0,IC50,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),Confirmatory,,
1011,7077,9,3,,103163840,3715,Unspecified,,,250.0,IC50,Tested for its inhibitory activity against 5-lipoxygenase,Confirmatory,,
1012,7103,3,6,,103163840,3715,Unspecified,,,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,Other,2104936.0,
1013,7132,6,3,,103163840,3715,Inconclusive,,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,Other,9484493.0,
1014,7779,3,3,,103163840,3715,Unspecified,,,,,Oral bioavailability in human,Other,11784135.0,
1015,7812,3,3,,103163840,3715,Unspecified,,,,,In vitro rate of absorption observed as Caco-2 permeability in humans,Other,11784135.0,
1016,7974,3,4,,103163840,3715,Unspecified,,,,,Metabolic stability observed at 30 min after administration in human liver microsomes,Other,11784135.0,
1017,12191,4,3,,103163840,3715,Inconclusive,,,,,Plasma concentration at 2 hr in rats was evaluated; Not available,Other,,
1018,19006,4,3,,103163840,3715,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
1019,19262,5,1,,103163840,3715,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
1020,22293,4,4,,103163840,3715,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
1021,23265,3,4,,103163840,3715,Unspecified,,,,,Partition coefficient (logD7.4),Other,2118185.0,
1022,23469,3,4,,103163840,3715,Inconclusive,,,,,Partition coefficient (logP),Other,,
1023,23672,3,3,,103163840,3715,Unspecified,,,,,Partition coefficient (logP),Other,7381857.0,
1024,24142,3,3,,103163840,3715,Unspecified,,,,,Gastric toxicity of the compound.,Other,11101350.0,
1025,24263,5,2,,103163840,3715,Unspecified,,,,,"Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of N,N-diethylglycolamide ester hydrolysis",Other,3820215.0,
1026,24265,3,4,,103163840,3715,Unspecified,,,,,Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of methyl ester hydrolysis,Other,3820215.0,
1027,25584,3,3,,103163840,3715,Unspecified,,,,,Dissociation constant (pKa),Other,2118185.0,
1028,26304,4,4,,103163840,3715,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
1029,29359,3,3,,103163840,3715,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
1030,29811,4,3,,103163840,3715,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
1031,34329,9,2,,103163840,3715,Active,,,5.0,IC50,Inhibition of Aldose reductase (AR),Confirmatory,11356107.0,
1032,34481,3,7,,103163840,3715,Unspecified,,,,,Percentage inhibition of Aldose Reductase (AR) at a concentration of 15 ug/mL,Other,11356107.0,
1033,34484,3,7,,103163840,3715,Unspecified,,,,,Percentage inhibition of Aldose Reductase (AR) at a concentration of 5 ug/mL,Other,11356107.0,
1034,34486,3,7,,103163840,3715,Unspecified,,,,,Percentage inhibition of Aldose Reductase (AR) at a concentration of 5 ug/mL; Experiment 2,Other,11356107.0,
1035,34782,9,2,,103163840,3715,Active,,,6.0,IC50,In vitro inhibition of rabbit lens aldose reductase.,Confirmatory,3097317.0,
1036,34786,4,7,,103163840,3715,Unspecified,,,,,In vitro inhibition of rabbit lens aldose reductase at 10e-4 M.,Other,3097317.0,
1037,34788,3,7,,103163840,3715,Unspecified,,,,,In vitro inhibition of rabbit lens aldose reductase at 10e-5 M.,Other,3097317.0,
1038,34789,3,7,,103163840,3715,Unspecified,,,,,In vitro inhibition of rabbit lens aldose reductase at 10e-6 M.,Other,3097317.0,
1039,41896,3,7,,103163840,3715,Unspecified,,,,,Beta-blocking activity measured by applying the stepwise linear discriminate analysis; Inactive,Other,,
1040,42828,6,2,,103163840,3715,Unspecified,,,30.0,IC50,In vitro inhibition of human recombinant IL-1-beta-induced breakdown of bovine cartilage in a cartilage organ culture assay,Confirmatory,7932530.0,
1041,42836,6,3,,103163840,3715,Unspecified,,,30.0,IC50,In vitro ability to inhibit cartilage breakdown by using 1L-1beta stimulated bovine nasal cartilage assay,Confirmatory,,
1042,43581,3,7,,103163840,3715,Unspecified,,,,,Inhibition of beta-lactamase at 100 uM,Other,14521410.0,
1043,46852,9,2,,103163840,3715,Active,,,5.8,IC50,IC50 against recombinant human Prostaglandin G/H synthase 2,Confirmatory,10197959.0,
1044,46853,9,2,,103163840,3715,Active,,,5.8,IC50,Inhibition of recombinant human prostaglandin G/H synthase 2 (COX-2),Confirmatory,10197960.0,
1045,46859,3,7,,103163840,3715,Unspecified,,,,,In vitro activity at a concentration of 10 uM against Prostaglandin G/H synthase 2,Other,10579834.0,
1046,46861,9,1,,103163840,3715,Active,,,0.0064,IC50,IC50 value was determined against Prostaglandin G/H synthase 2 of J7744A.1 cell lines.,Confirmatory,10197959.0,
1047,46862,9,1,,103163840,3715,Active,,,0.0064,IC50,IC50 value against Prostaglandin G/H synthase 2 of murine J774A.1 cell line,Confirmatory,10197960.0,
1048,49194,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated for percent inhibition of carrageenan induced rat paw edema at 0.005 mmol/kg,Other,14741253.0,
1049,49321,7,3,,103163840,3715,Unspecified,,,20.0,Ki,Evaluated for binding affinity against recombinant human central cannabinoid receptor 1,Confirmatory,,
1050,49849,7,3,,103163840,3715,Unspecified,,,20.0,Ki,Evaluated for binding affinity against recombinant human peripheral cannabinoid receptor 2,Confirmatory,,
1051,52139,6,2,,103163840,3715,Active,,,0.011000000000000001,IC50,Inhibitory activity against prostaglandin biosynthesis in stimulated chondrocyte cell culture,Confirmatory,3263504.0,
1052,52790,3,7,,103163840,3715,Unspecified,,,,,Inhibition of chymotrypsin at 250 uM,Other,14521410.0,
1053,54358,9,2,,103163840,3715,Active,,,0.5,IC50,Tested for inhibition of cyclooxygenase (ARBC) in calcium-stimulated rat basophilic leukemia cells(RBL-1),Confirmatory,,
1054,54534,9,2,,103163840,3715,Active,,,0.018000000000000002,IC50,In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-1,Confirmatory,,
1055,54536,9,1,,103163840,3715,Active,,,0.2,IC50,In vitro inhibitory potency against U-937 microsomal COX-1,Confirmatory,10576684.0,
1056,54540,9,1,,103163840,3715,Active,,,0.018000000000000002,IC50,In vitro inhibitory potency against human COX-1 in stably transfected chinese hamster ovary (CHO) cells,Confirmatory,10576684.0,
1057,54545,9,2,,103163840,3715,Active,,,0.02,IC50,Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes.,Confirmatory,10576685.0,
1058,54557,9,2,,103163840,3715,Active,,,0.026000000000000002,IC50,In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-2,Confirmatory,,
1059,54559,9,2,,103163840,3715,Active,,,0.5,IC50,In vitro inhibitory potency against human COX-2 (HWB COX-2) by whole blood assay,Confirmatory,10576684.0,
1060,54560,9,1,,103163840,3715,Active,,,0.026000000000000002,IC50,In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells,Confirmatory,10576684.0,
1061,54711,9,3,,103163840,3715,Active,,,0.5,IC50,Inhibitory potency against PGE-2 production in the human whole blood (HWB COX-2) assay,Confirmatory,10576685.0,
1062,54712,9,1,,103163840,3715,Active,,,0.026000000000000002,IC50,Inhibition of PGE-2 production in CHO cells expressing human COX-2.,Confirmatory,10576685.0,
1063,55271,7,2,,103163840,3715,Unspecified,,,100.0,IC50,Concentration required to inhibit human Cytosolic phospholipase A2,Confirmatory,11229777.0,
1064,62810,3,4,,103163840,3715,Unspecified,,,,,Antagonist activity was measured by maximum urine osmolality with a dose of 100 ug/kg peptide after pretreatment with indomethacin in dog,Other,3397986.0,
1065,63427,5,2,,103163840,3715,Unspecified,,,,,Antagonist activity was measured by maximum urine flow with a dose of 100 ug/kg peptide,Other,3397986.0,
1066,74199,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity evaluated as Minimum effective oral dose that inhibits dextran UV erythema in guinea pig,Other,3965711.0,
1067,74200,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity measured as effect on ultraviolet induced erythema in guinea pigs,Other,6982340.0,
1068,75982,6,2,,103163840,3715,Inconclusive,,,,,Inhibition of CCl4 induced lipid peroxidation (LPO) of guinea pig hepatic microsomes at 300 uM concentration; NT=Not tested,Other,9484493.0,
1069,76665,6,2,,103163840,3715,Unspecified,,,,,Antipyretic activity on peroral administration against LPS-induced fever in guinea pig.,Other,6607354.0,
1070,77205,3,3,,103163840,3715,Unspecified,,,,,"Tested for effect on the production of Lipoxygenase (LO) metabolite, 5,12-diHETE in guinea pig peritoneal polymorphonuclear neutrophils at 30 uM concentration",Other,3114493.0,
1071,77209,3,3,,103163840,3715,Unspecified,,,,,"Tested for effect on the production of Lipoxygenase (LO) metabolite, 5-HETE in guinea pig peritoneal polymorphonuclear neutrophils at 30 uM concentration",Other,3114493.0,
1072,77213,3,3,,103163840,3715,Unspecified,,,,,"Tested for effect on the production of cyclooxygenase (COX) metabolite, PGE-2 (prostaglandin E2) of arachidonic acid in guinea pig peritoneal polymorphonuclear neutrophils at 30 uM concentration",Other,3114493.0,
1073,77217,3,3,,103163840,3715,Unspecified,,,,,"Tested for effect on the production of cyclooxygenase (COX) metabolite, PGF2-alpha (prostaglandin F2-alpha) of arachidonic acid in guinea pig peritoneal polymorphonuclear neutrophils at 30 uM concentration",Other,3114493.0,
1074,77220,3,3,,103163840,3715,Unspecified,,,,,"Tested for effect on the production of cyclooxygenase (COX) metabolite, TXB2 of arachidonic acid in guinea pig peritoneal polymorphonuclear neutrophils at 30 uM concentration",Other,3114493.0,
1075,77237,6,3,,103163840,3715,Unspecified,,,,,Inhibition of Collagen-induced Thromboxane (TXB2) in guinea pig whole blood ex vivo after 1 hr of 10 mg/kg oral administration of compound.,Other,3656356.0,
1076,77483,3,4,,103163840,3715,Unspecified,,,,,Inhibition of Collagen-induced serum Thromboxane (TXB2) in guinea pig whole blood ex vivo after 10 mg/kg oral administration of compound.,Other,3656356.0,
1077,77819,3,4,,103163840,3715,Unspecified,,,,,Inhibition of Collagen-induced Thromboxane (TXB2) generation in guinea pig whole blood ex vivo by oral 10 mg/kg administration of test compound.,Other,3656356.0,
1078,78477,3,4,,103163840,3715,Unspecified,,,,,Ability to bind to guinea pig atrial homogenate,Other,7381857.0,
1079,91154,8,2,,103163840,3715,Inactive,,,,,Compound is evaluated for inhibitory effect on the generation of Leukotriene B4 (LTB4) from human neutrophils; Not active,Other,3118023.0,
1080,91334,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity against TXB2 generation at 100 uM concentration,Other,7629818.0,
1081,91335,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity against elastase release by human neutrophils,Other,7629818.0,
1082,91480,3,8,,103163840,3715,Unspecified,,,,,Ability to bind to human serum albumin (HSA),Other,7381857.0,
1083,91481,4,7,,103163840,3715,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
1084,92236,6,2,,103163840,3715,Active,,,0.8,IC50,Inhibition of adenosine diphosphate (ADP) induced human platelet aggregation,Confirmatory,3133477.0,
1085,92237,6,2,,103163840,3715,Active,,,0.7,IC50,Inhibition of adenosine diphosphate (ADP) induced serotonin secretion,Confirmatory,3133477.0,
1086,92239,6,2,,103163840,3715,Active,,,1.0,IC50,Inhibition of arachidonic acid (AA) induced human platelet aggregation,Confirmatory,3133477.0,
1087,92240,6,2,,103163840,3715,Active,,,1.0,IC50,Inhibition of arachidonic acid (AA) induced serotonin secretion,Confirmatory,3133477.0,
1088,92677,6,2,,103163840,3715,Active,,,4.0,IC50,In vitro inhibition of arachidonic acid induced platelet aggregation of human platelet-rich plasma,Confirmatory,3097316.0,
1089,93426,3,3,,103163840,3715,Unspecified,,,,,In vitro inhibition of human platelet aggregation induced by 10 uM ADP after incubation at 100 uM,Other,11020281.0,
1090,93591,5,3,,103163840,3715,Inconclusive,,,,,In vitro methemoglobin Induction at 10e-4 M in lysed human red blood cells; Not tested,Other,2319562.0,
1091,93812,8,1,,103163840,3715,Unspecified,,,30.0,ID50,Compound was evaluated for the inhibition of IL-1 beta converting enzyme biosynthesis.,Confirmatory,1433212.0,
1092,106806,3,8,,103163840,3715,Unspecified,,,,,Inhibition of malate dehydrogenase (MDH) at 400 uM,Other,14521410.0,
1093,107291,3,3,,103163840,3715,Unspecified,,,,,Analgesic activity in mice by mouse phenylquinone writhing assay relative to aspirin.,Other,3097317.0,
1094,110863,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity against mouse uM/cm**2 (control=7.0),Other,15081016.0,
1095,112434,4,2,,103163840,3715,Unspecified,,,,,"Inhibition of TPA-induced inflammatory ear edema in mice(compound was applied 30 min before TPA (1 mg),Ear thickness was determined 6 hr after TPA treatment)",Other,7473540.0,
1096,112732,5,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity, administered ip at 150 uM/kg dose was determined against carrageenan-induced mice paw edema model",Other,15203134.0,
1097,113098,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity in mice by phenyl quinone-induced writhing assay with respect to aspirin.,Other,3572970.0,
1098,113300,6,2,,103163840,3715,Unspecified,,,,,Dose required for the inhibition of phenylquinone-induced writhing in male mice,Other,3491210.0,
1099,114054,6,2,,103163840,3715,Unspecified,,,,,Oral analgesic activity was determined in mice by the acetylcholine-induced abdominal constriction assay upon ip administration of acetylcholine bromide 20 min following oral administration,Other,6436487.0,
1100,114055,6,2,,103163840,3715,Unspecified,,,,,Oral analgesic activity was determined in mice by the acetylcholine-induced abdominal constriction assay upon ip administration of acetylcholine bromide 5 hours following oral administration,Other,6436487.0,
1101,114287,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against CPE in mice following peroral administration of 10 mg/kg,Other,1560442.0,
1102,114342,6,2,,103163840,3715,Unspecified,,,,,Effective dose by mouse phenyl-p-benzoquinone writhing (PQW)assay after peroral administration; 0.23-0.53,Other,3875725.0,
1103,114543,6,2,,103163840,3715,Unspecified,,,,,Tested for inhibitory activity after administration of compound at 50 mg/kg perorally using AcOH writhing method; 1.5-6.5,Other,6977035.0,
1104,115240,3,3,,103163840,3715,Unspecified,,,,,Inhibition of phenylbenzoquinone writhing in mice was tested at the dose of 3 mg/kg for 4 hr,Other,3669013.0,
1105,115376,3,4,,103163840,3715,Unspecified,,,,,Inhibitory activity against carrageenan induced mouse paw edema in mice.,Other,1560442.0,
1106,115378,3,3,,103163840,3715,Unspecified,,,,,"Inhibitory against carrageenan induced paw edema in mice at 12 mg/kg, sc dose after 3h",Other,7057427.0,
1107,115379,3,3,,103163840,3715,Unspecified,,,,,"Inhibitory against carrageenan induced paw edema in mice at 12 mg/kg, sc dose after 5 hr",Other,7057427.0,
1108,115720,3,4,,103163840,3715,Unspecified,,,,,The compound was evaluated for inhibition of edema induced by PGE at 2 micro/mL,Other,1560442.0,
1109,115722,3,4,,103163840,3715,Unspecified,,,,,The compound was evaluated for inhibition of edema induced by arachidonic acid at 1 mg/mL,Other,1560442.0,
1110,115723,3,4,,103163840,3715,Unspecified,,,,,The compound was evaluated for inhibition of edema induced by bradykinin at 100 micro g/mL,Other,1560442.0,
1111,115726,3,4,,103163840,3715,Unspecified,,,,,The compound was evaluated for inhibition of edema induced by histamine at 10 mg/mL,Other,1560442.0,
1112,115727,3,4,,103163840,3715,Unspecified,,,,,The compound was evaluated for inhibition of edema induced by serotonin at 250 micro g/mL,Other,1560442.0,
1113,116672,3,3,,103163840,3715,Unspecified,,,,,Analgesic activity was measured by phenylquinone writhing test in male Swiss albino mice at dose of 12 mg/Kg sc after 3h,Other,7097725.0,
1114,116673,3,3,,103163840,3715,Unspecified,,,,,Analgesic activity was measured by phenylquinone writhing test in male Swiss albino mice at dose of 12 mg/Kg sc after 5 hr,Other,7097725.0,
1115,116723,6,2,,103163840,3715,Unspecified,,,,,Acute toxicity as LD50 value was determined in mice administered orally,Other,6218302.0,
1116,116838,3,3,,103163840,3715,Unspecified,,,,,Antirheumatic effect was determined in mice after combined treatment of TAS-202 (30 mg/kg/day) and indomethacin (1 mg/kg/day) at day 14,Other,11844686.0,
1117,116839,3,3,,103163840,3715,Unspecified,,,,,Antirheumatic effect was determined in mice after oral administration of a dose of 1 mg/kg/day at day 14,Other,11844686.0,
1118,117413,3,4,,103163840,3715,Unspecified,,,,,Gastric ulcerogenic activity at a dose of 10 mg/kg,Other,1560442.0,
1119,117726,3,3,,103163840,3715,Unspecified,,,,,Percent uM/cm**2,Other,15081016.0,
1120,118143,5,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity, administered ip at 150 uM/kg dose was determined against carrageenan-induced mice paw edema model",Other,15203134.0,
1121,123498,3,3,,103163840,3715,Unspecified,,,,,Inhibition of phenylbenzoquinone writhing in mice was tested at the dose of 3 mg/kg for 1 hr,Other,3669013.0,
1122,123499,3,3,,103163840,3715,Unspecified,,,,,Inhibition of phenylbenzoquinone writhing in mice was tested at the dose of 3 mg/kg for 2 hr,Other,3669013.0,
1123,123810,3,3,,103163840,3715,Unspecified,,,,,Inhibition of phenylquinone -induced writhing in male mice by p.o. administration 20 min prior to i.p. phenylquinone (relative to aspirin).,Other,3491210.0,
1124,123872,3,4,,103163840,3715,Unspecified,,,,,Gastric ulcerogenic activity at a dose of 10 mg/kg: 8 mice were considered for the test,Other,1560442.0,
1125,124002,3,4,,103163840,3715,Unspecified,,,,,Intestinal ulcerogenic activity at a dose of 10 mg/kg; 8 mice were considered for the test,Other,1560442.0,
1126,124988,3,3,,103163840,3715,Unspecified,,,,,Inhibition of phenylbenzoquinone writhing in mice was tested at the dose of 3 mg/kg for 1 hr,Other,3669013.0,
1127,124989,3,3,,103163840,3715,Unspecified,,,,,Inhibition of phenylbenzoquinone writhing in mice was tested at the dose of 3 mg/kg for 2 hr,Other,3669013.0,
1128,124990,3,3,,103163840,3715,Unspecified,,,,,Inhibition of phenylbenzoquinone writhing in mice was tested at the dose of 3 mg/kg for 4 hr,Other,3669013.0,
1129,127503,6,2,,103163840,3715,Active,,,0.3,IC50,Inhibition of human PGE-2 production.,Confirmatory,1995900.0,
1130,128036,6,2,,103163840,3715,Unspecified,,,,,Compound was tested for antianalgesic activity in mice after perorally administered at 1 hr,Other,3669013.0,
1131,128182,6,2,,103163840,3715,Unspecified,,,,,Compound was tested for hyperalgesia activity in mice after perorally administered at 1 hr,Other,3669013.0,
1132,128487,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity was assessed from the ability to inhibit phenylquinone-induced writhing in mouse,Other,2724294.0,
1133,128860,3,3,,103163840,3715,Unspecified,,,,,Acute toxicity was evaluated as number of mice died (tested = 7) after 72nd hour when 12 mg/kg is administered intraperitoneally,Other,6606043.0,
1134,128861,3,3,,103163840,3715,Unspecified,,,,,Acute toxicity was evaluated as number of mice died (tested = 7) after 72nd hour when 15 mg/kg is administered intraperitoneally,Other,6606043.0,
1135,128862,3,3,,103163840,3715,Unspecified,,,,,Acute toxicity was evaluated as number of mice died (tested = 7) after 72nd hour when 75 mg/kg is administered intraperitoneally,Other,6606043.0,
1136,128863,3,3,,103163840,3715,Unspecified,,,,,Acute toxicity was evaluated as number of mice died (tested = 7) after 72nd hour when 8 mg/kg is administered intraperitoneally,Other,6606043.0,
1137,128868,3,3,,103163840,3715,Unspecified,,,,,Percentage acute toxicity after 12 mg/kg administered intraperitoneally to rats,Other,6606043.0,
1138,128871,3,3,,103163840,3715,Unspecified,,,,,Percentage acute toxicity after 15 mg/kg administered intraperitoneally to rats,Other,6606043.0,
1139,128881,3,3,,103163840,3715,Unspecified,,,,,Percentage acute toxicity after 75 mg/kg administered intraperitoneally to rats,Other,6606043.0,
1140,128882,3,3,,103163840,3715,Unspecified,,,,,Percentage acute toxicity after 8 mg/kg administered intraperitoneally to rats,Other,6606043.0,
1141,128886,3,3,,103163840,3715,Unspecified,,,,,Percent analgesia in phenylquinone writhing assay at 0.3 mg/kg,Other,6972450.0,
1142,128887,3,3,,103163840,3715,Unspecified,,,,,Percent analgesia in phenylquinone writhing assay at 1 mg/kg,Other,6972450.0,
1143,128890,3,3,,103163840,3715,Unspecified,,,,,Percent analgesia in phenylquinone writhing assay at 3 mg/kg,Other,6972450.0,
1144,129290,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was assessed from the ability to inhibit cotton pellet granuloma in mice,Other,2724294.0,
1145,130472,6,2,,103163840,3715,Unspecified,,,,,Carrageenan-induced edema was determined value for oral administration,Other,6218302.0,
1146,130718,4,2,,103163840,3715,Unspecified,,,,,In vivo inhibitory activity against A-23187 ear edema at a dose of 100 ug/ear,Other,1507204.0,
1147,130719,4,2,,103163840,3715,Unspecified,,,,,In vivo inhibitory activity against arachidonic acid(AA) ear edema at a dose of 100 ug/ear,Other,1507204.0,
1148,130878,6,2,,103163840,3715,Unspecified,,,,,Inhibition against writhing induced by Phenylbenzoquinone in male swiss albino mice,Other,3263504.0,
1149,131339,6,2,,103163840,3715,Unspecified,,,,,Dose giving one-half of average maximal [40%] response in carrageenan assay,Other,6972450.0,
1150,131340,6,2,,103163840,3715,Unspecified,,,,,Dose giving one-half of average maximal [40%] response in phenylquinone writhing assay,Other,6972450.0,
1151,131592,4,2,,103163840,3715,Unspecified,,,,,Tested for ability to inhibit the topical inflammatory response in the topical mouse ear(TME) model,Other,2308140.0,
1152,131689,6,2,,103163840,3715,Unspecified,,,,,Effective dose for analgesic activity in mice,Other,6982340.0,
1153,131935,3,3,,103163840,3715,Unspecified,,,,,Tested for its antiinflammatory activity in the A-23187 (calcium ionophore) ear edema model.,Other,,
1154,131937,3,3,,103163840,3715,Unspecified,,,,,Tested for its antiinflammatory activity in the arachidonic acid(AA) induced ear edema model,Other,,
1155,131939,4,3,,103163840,3715,Inconclusive,,,,,Tested for its antiinflammatory activity in the contact sensitive (CS) ear edema model; ND: not determined,Other,,
1156,131941,4,3,,103163840,3715,Inconclusive,,,,,Tested for its antiinflammatory activity in the tetradecanoyl phorbol acetate induced ear edema model (TPA Ear); ND: not determined,Other,,
1157,132250,4,2,,103163840,3715,Unspecified,,,,,Effective dose to inhibit 50% of mouse arachidonic acid induced ear edema assay,Other,2104936.0,
1158,132251,5,2,,103163840,3715,Unspecified,,,,,Inhibition of arachidonic acid oedema in mouse ear.,Other,8568814.0,
1159,132669,6,2,,103163840,3715,Unspecified,,,10.0,IC50,In vitro inhibition of electrically stimulated contractions of isolated mouse vas deferens.,Confirmatory,1732519.0,
1160,132689,6,2,,103163840,3715,Active,,,0.5,IC50,Inhibitory activity against PG synthesis was measured in mouse brain microsomes.,Confirmatory,1732519.0,
1161,133223,3,3,,103163840,3715,Unspecified,,,,,Percentage inhibition of the mouse arachidonic acid induced ear edema assay (AA) at a dose of 100 ug/ear,Other,2104936.0,
1162,134423,7,2,,103163840,3715,Unspecified,,,,,Compound was evaluated for the toxicity in mice,Other,6972450.0,
1163,134578,6,2,,103163840,3715,Unspecified,,,,,Lethal dose evaluated in NPP assay,Other,6972450.0,
1164,134741,6,2,,103163840,3715,Unspecified,,,,,Lethal dose in mice determined by Litchfield and Wilcoxon methods after peroral administration.,Other,6965727.0,
1165,134755,6,2,,103163840,3715,Unspecified,,,,,The compound was tested for acute toxicity in mice after oral administration,Other,2299620.0,
1166,134761,6,2,,103163840,3715,Unspecified,,,,,Toxic activity is expressed as LD50 values,Other,6606043.0,
1167,135221,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity against carrageenan induced paw edema at a oral dose of 10 mg/kg in mouse 3 hours after carrageenan administration,Other,9703468.0,
1168,135276,3,3,,103163840,3715,Unspecified,,,,,Neurotoxic dose that causes minimal recognizable neurotoxicity in 50% of animals tested,Other,6972450.0,
1169,136446,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated for the percent reduction of carrageenan induced edema in mice at dose of 0.3 mg/kg,Other,6972450.0,
1170,136448,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated for the percent reduction of carrageenan induced edema in mice at dose of 1.0 mg/kg,Other,6972450.0,
1171,136457,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated for the percent reduction of carrageenan induced edema in mice at dose of 3.0 mg/kg,Other,6972450.0,
1172,138456,3,3,,103163840,3715,Unspecified,,,,,In vivo inhibitory activity in a phorbol myristyl acetate (PMA) ear edema model at a dose of 100 ug/ear,Other,1507204.0,
1173,138594,4,2,,103163840,3715,Unspecified,,,,,Inhibition of arachidonic acid induced mouse ear edema at 30 ug/ear,Other,8254620.0,
1174,138596,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity against carrageenan induced paw edema at a oral dose of 10 mg/kg in mouse 5 hours after carrageenan administration,Other,9703468.0,
1175,139179,3,3,,103163840,3715,Unspecified,,,,,Therapeutic index was expressed as LD50/ED50 carragreenin model,Other,6606043.0,
1176,155359,6,2,,103163840,3715,Active,,,0.1,IC50,Inhibitory activity to inhibit Inophore-induced arachidonic acid metabolism (inhibition of PGE-2 formation) in rat,Confirmatory,2547071.0,
1177,155902,8,1,,103163840,3715,Unspecified,,,1000.0,ID50,Compound was evaluated for the inhibition of PLA2.,Confirmatory,1433212.0,
1178,158620,6,4,,103163840,3715,Unspecified,,,1000.0,IC50,Inhibitory activity against phospholipase A2 of Croatalus adamanteus,Confirmatory,1507204.0,
1179,159080,9,3,,103163840,3715,Unspecified,,,250.0,IC50,Tested for its inhibitory activity against Phospholipase A2 (PLA2),Confirmatory,,
1180,159248,10,5,,103163840,3715,Unspecified,129416.0,29526.0,250.0,IC50,Inhibitory activity against polymorphonuclear cell phospholipase-A2 in rat,Confirmatory,,
1181,160262,3,7,,103163840,3715,Unspecified,,,,,Inhibition of Prostaglandin G/H synthase 2 (COX-2) in human whole blood at 10 uM,Other,12877584.0,
1182,160264,3,6,,103163840,3715,Unspecified,,,,,In vitro inhibition of human Prostaglandin G/H synthase 2 (expressed in sf9 insect cells using baculovirus) enzyme at a concentration of 10 M,Other,12954051.0,
1183,160266,3,7,,103163840,3715,Unspecified,,,,,In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 (COX-2) at 10 uM expressed in sf-9 cells infected with baculovirus,Other,15026050.0,
1184,160400,3,7,,103163840,3715,Unspecified,,,,,In vitro percent inhibition of prostaglandin G/H synthase 2 (COX-2) in human whole blood at 1 uM,Other,12877584.0,
1185,160431,3,7,,103163840,3715,Unspecified,,,,,Percentage of inhibition of Prostaglandin G/H synthase 2 activity in human whole blood(HWB) at 1 uM,Other,11462976.0,
1186,160432,3,7,,103163840,3715,Unspecified,,,,,Percentage of inhibition of Prostaglandin G/H synthase 2 activity in human whole blood(HWB) at 10 uM,Other,11462976.0,
1187,160556,6,2,,103163840,3715,Active,,,0.1,IC50,Compound is evaluated for inhibitory effect on the generation of Prostaglandin E2 (PGE2) from rat synovial cells,Confirmatory,3118023.0,
1188,160567,7,2,,103163840,3715,Active,,,0.21,IC50,Inhibition concentration against Prostaglandin G/H synthase 2,Confirmatory,11965379.0,
1189,160597,8,5,,103163840,3715,Active,548484.0,29527.0,0.01,IC50,Inhibition of Prostaglandin G/H synthase 2,Confirmatory,,
1190,160598,7,3,,103163840,3715,Active,,,0.01,IC50,In vitro inhibition of Prostaglandin G/H synthase 2,Confirmatory,,
1191,160599,9,2,,103163840,3715,Active,,,0.22,IC50,In vitro inhibitory concentration against rat Prostaglandin G/H synthase 2,Confirmatory,11591502.0,
1192,160706,9,1,,103163840,3715,Active,,,1.8,IC50,In vitro inhibition of Prostaglandin G/H synthase in BSV cell line.,Confirmatory,2104936.0,
1193,160707,9,2,,103163840,3715,Active,,,1.0,IC50,Inhibition of prostaglandin G/H synthase obtained from bovine seminal vesicles.,Confirmatory,6436487.0,
1194,160710,9,2,,103163840,3715,Active,,,0.43,IC50,Inhibitory activity against Prostaglandin G/H synthase (bovine seminal vesicles),Confirmatory,1507204.0,
1195,160714,5,4,,103163840,3715,Unspecified,,,1584890.0,IC50,Ability to inhibit Prostaglandin G/H synthase was evaluated in vitro using bovine seminal vesicle preparations.,Confirmatory,2118185.0,
1196,160715,8,1,,103163840,3715,Active,,,0.43,ID50,Compound was evaluated for the inhibition of Prostaglandin G/H synthase,Confirmatory,1433212.0,
1197,160716,3,7,,103163840,3715,Unspecified,,,,,Inhibition of Prostaglandin G/H synthase from bovine seminal vesicle at 20 uM concentration,Other,2319562.0,
1198,160721,9,1,,103163840,3715,Active,,,0.01,IC50,In vitro inhibitory activity against cyclooxygenase of human platelets was determined,Confirmatory,3104589.0,
1199,160737,9,5,,103163840,3715,Active,3914304.0,443460.0,2.4,IC50,Inhibitory activity against Prostaglandin G/H synthase 2 obtained from sheep placenta,Confirmatory,9484493.0,
1200,160863,7,3,,103163840,3715,Active,,,0.02,IC50,Inhibition of PGE-2 production in 3T3 (murine fibroblast) cell culture.,Confirmatory,8568814.0,
1201,160886,9,2,,103163840,3715,Active,,,1.1,IC50,Evaluated for the inhibition of prostaglandin synthetase obtained from bovine seminal vesicles at the dose of 4.0 mg/kg (p.o.),Confirmatory,6802974.0,
1202,160887,9,2,,103163840,3715,Active,,,1.1,IC50,Inhibition of PG synthetase activity obtained from bovine seminal vesicles,Confirmatory,6481768.0,
1203,160888,9,2,,103163840,3715,Active,,,1.0,IC50,Tested for Prostaglandin synthetase inhibition in Bovine seminal vesicle microsomes using Beckman liquid scintillation counter at 10 e-5 M,Confirmatory,6965727.0,
1204,160895,9,5,,103163840,3715,Active,3914301.0,282023.0,1.8,IC50,Tested for its inhibitory activity against PGS (prostaglandin synthetase).,Confirmatory,,
1205,160895,9,5,,103163840,3715,Active,166897622.0,282022.0,1.8,IC50,Tested for its inhibitory activity against PGS (prostaglandin synthetase).,Confirmatory,,
1206,160899,9,2,,103163840,3715,Active,,,0.5,IC50,Concentration required to inhibit 50% activity of prostaglandin synthetase was determined in vitro in mouse brain microsomes,Confirmatory,1900533.0,
1207,160906,9,2,,103163840,3715,Active,,,1.8,IC50,Inhibition of prostaglandin synthetase in rat renal medulla,Confirmatory,1995900.0,
1208,160907,8,2,,103163840,3715,Active,,,1.2,IC50,Inhibition of prostaglandin synthetase in sheep seminal vesicle,Confirmatory,1995900.0,
1209,160908,9,5,,103163840,3715,Active,3914304.0,443460.0,17.2,IC50,Inhibition of ovine seminal vesicle prostaglandin synthetase,Confirmatory,,
1210,160908,9,5,,103163840,3715,Active,754286265.0,443551.0,17.2,IC50,Inhibition of ovine seminal vesicle prostaglandin synthetase,Confirmatory,,
1211,161005,9,1,,103163840,3715,Active,,,0.5,IC50,Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line,Confirmatory,2115586.0,
1212,161014,9,2,,103163840,3715,Active,,,0.1,IC50,In vitro inhibitory activity against polymorphonuclear leukocyte Prostaglandin G/H synthase,Confirmatory,2502629.0,
1213,161163,9,5,,103163840,3715,Active,3914304.0,443460.0,0.3,IC50,Inhibition of Prostaglandin G/H synthase of ram seminal vesicle microsomes,Confirmatory,3488405.0,
1214,161163,9,5,,103163840,3715,Active,754286265.0,443551.0,0.3,IC50,Inhibition of Prostaglandin G/H synthase of ram seminal vesicle microsomes,Confirmatory,3488405.0,
1215,161166,10,1,,103163840,3715,Active,,,0.8,IC50,Inhibition of Prostaglandin G/H synthase activity in sheep seminal vesicle was determined,Confirmatory,8254620.0,
1216,161184,9,5,,103163840,3715,Active,3914304.0,443460.0,0.15,IC50,Inhibition of ram seminal vesicle Cyclooxygenase,Confirmatory,3930740.0,
1217,161184,9,5,,103163840,3715,Active,754286265.0,443551.0,0.15,IC50,Inhibition of ram seminal vesicle Cyclooxygenase,Confirmatory,3930740.0,
1218,161308,9,2,,103163840,3715,Active,,,0.2,IC50,Inhibitory activity against Prostaglandin G/H synthase,Confirmatory,2115589.0,
1219,161325,3,7,,103163840,3715,Unspecified,,,,,In vitro activity at a concentration of 10 uM against Prostaglandin G/H synthase 1,Other,10579834.0,
1220,161327,9,2,,103163840,3715,Active,,,0.19,IC50,"Biochemical index for Prostaglandin G/H synthase 1 measured as, thromboxane 2 (TXB2) levels following blood coagulation",Confirmatory,10937738.0,
1221,161334,9,3,,103163840,3715,Active,,,0.1,IC50,In vitro inhibitory activity against constitutive form of human recombinant Prostaglandin G/H synthase 1,Confirmatory,,
1222,161335,9,2,,103163840,3715,Active,,,0.1,IC50,In vitro inhibition of prostaglandin G/H synthase 1.,Confirmatory,7473585.0,
1223,161343,9,5,,103163840,3715,Active,317373262.0,5742.0,0.039,IC50,Inhibition of PGE-2 production in arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 1,Confirmatory,,
1224,161470,9,2,,103163840,3715,Active,,,0.1,IC50,Concentration required to inhibit human prostaglandin G/H synthase 1 (COX-1) by 50%,Confirmatory,9171873.0,
1225,161471,9,1,,103163840,3715,Active,,,0.0082,IC50,IC50 against Prostaglandin G/H synthase 1 from human platelet rich plasma,Confirmatory,10197959.0,
1226,161472,9,1,,103163840,3715,Active,,,0.0082,IC50,IC50 value against Prostaglandin G/H synthase 1 of human platelet rich plasma,Confirmatory,10197960.0,
1227,161480,9,1,,103163840,3715,Active,,,0.002,IC50,In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells,Confirmatory,12877584.0,
1228,161483,9,2,,103163840,3715,Active,,,0.1,IC50,In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 1.,Confirmatory,8627608.0,
1229,161484,9,2,,103163840,3715,Active,,,0.2,IC50,In vitro inhibitory activity against human whole blood Prostaglandin G/H synthase 1,Confirmatory,10406640.0,
1230,161485,9,2,,103163840,3715,Active,,,0.02,IC50,In vitro inhibitory activity against human whole cells Prostaglandin G/H synthase 1,Confirmatory,10406640.0,
1231,161490,9,1,,103163840,3715,Active,,,0.15,IC50,In vitro inhibitory activity towards human platelet recombinant Prostaglandin G/H synthase 1,Confirmatory,11738574.0,
1232,161493,9,5,,103163840,3715,Active,317373262.0,5742.0,0.16,IC50,Inhibition of Prostaglandin G/H synthase 1 in human whole blood (HWB) assay,Confirmatory,10397507.0,
1233,161496,9,2,,103163840,3715,Active,,,0.012,IC50,Inhibition activity against recombinant human Prostaglandin G/H synthase 1,Confirmatory,9057869.0,
1234,161499,9,1,,103163840,3715,Active,,,0.003,IC50,Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma,Confirmatory,11462976.0,
1235,161501,9,1,,103163840,3715,Active,,,0.02,IC50,Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid,Confirmatory,9873621.0,
1236,161503,6,3,,103163840,3715,Active,,,0.003,IC50,Inhibition of arachidonic acid induced TXB2 generation in isolated human platelets (Prostaglandin G/H synthase 1 cell assay),Confirmatory,11906281.0,
1237,161596,6,2,,103163840,3715,Active,,,0.25,IC50,In vitro inhibitory activity on platelet aggregation induced by arachidonic acid (AA),Confirmatory,11212091.0,
1238,161604,6,2,,103163840,3715,Active,,,1.8,IC50,Tested for in vitro inhibition of collagen-induced aggregation of human platelets,Confirmatory,7359523.0,
1239,161609,3,3,,103163840,3715,Unspecified,,,,,Effect on the synthesis of Thromboxane A2 at dose of 20 uM,Other,2970551.0,
1240,161610,3,3,,103163840,3715,Unspecified,,,,,Effect on the synthesis of metabolites of arachidonic acid in human platelets,Other,2970551.0,
1241,161653,9,2,,103163840,3715,Active,,,0.1,IC50,Inhibitory activity against Prostaglandin G/H synthase 1,Confirmatory,10956225.0,
1242,161654,9,2,,103163840,3715,Active,,,0.25,IC50,Inhibitory activity against prostaglandin G/H synthase 1,Confirmatory,10649977.0,
1243,161656,9,2,,103163840,3715,Active,,,0.2,IC50,Inhibitory activity against Prostaglandin G/H synthase 1 in human whole blood,Confirmatory,10465547.0,
1244,161659,9,2,,103163840,3715,Active,,,0.11,IC50,Inhibitory activity against recombinant human prostaglandin G/H synthase 1,Confirmatory,14980665.0,
1245,161660,9,5,,103163840,3715,Active,317373262.0,5742.0,0.15,IC50,Inhibition of human Prostaglandin G/H synthase 1,Confirmatory,11906292.0,
1246,161667,9,1,,103163840,3715,Active,,,12.4,IC50,Inhibitory concentration against human recombinant Prostaglandin G/H synthase 1 cloned and expressed in baculovirus (Sf9),Confirmatory,11392547.0,
1247,161671,6,3,,103163840,3715,Active,,,0.23,IC50,Inhibitory effect on Prostaglandin G/H synthase 1 activity was evaluated in human whole blood as TXB2 production,Confirmatory,11906281.0,
1248,161672,9,2,,103163840,3715,Active,,,0.19,IC50,Inhibitory potency against Prostaglandin G/H synthase 1 in human whole blood assay,Confirmatory,14980665.0,
1249,161674,9,2,,103163840,3715,Active,,,0.2,IC50,Tested for inhibition against Prostaglandin G/H synthase 1,Confirmatory,7966148.0,
1250,161676,9,2,,103163840,3715,Active,,,0.018000000000000002,IC50,Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 1 in chinese hamster ovary (CHO) cells,Confirmatory,,
1251,161740,3,3,,103163840,3715,Unspecified,,,,,The synthesis of cyclooxygenase or lipoxygenase derived products (HHT and HETE) in human washed platelets at dose of 20 uM,Other,2970551.0,
1252,161986,3,7,,103163840,3715,Unspecified,,,,,Percentage of inhibition of Prostaglandin G/H synthase 1 activity in human whole blood (HWB) at 1 uM,Other,11462976.0,
1253,161987,3,7,,103163840,3715,Unspecified,,,,,Percentage of inhibition of Prostaglandin G/H synthase 1 activity in human whole blood (HWB) at 10 uM,Other,11462976.0,
1254,161994,9,3,,103163840,3715,Active,,,0.9,IC50,In vitro inhibitory activity against inducible form of human recombinant Prostaglandin G/H synthase 1,Confirmatory,,
1255,162009,8,5,,103163840,3715,Active,3914292.0,24693.0,0.006,IC50,Inhibition of Prostaglandin G/H synthase 1 using whole cell assay,Confirmatory,,
1256,162010,7,3,,103163840,3715,Active,,,0.006,IC50,In vitro inhibition of Prostaglandin G/H synthase 1,Confirmatory,,
1257,162011,9,2,,103163840,3715,Active,,,0.19,IC50,In vitro inhibitory concentration against rat prostaglandin G/H synthase 1,Confirmatory,11591502.0,
1258,162015,10,1,,103163840,3715,Active,754286265.0,443551.0,0.0122,IC50,IC50 against ovine Prostaglandin G/H synthase 1,Confirmatory,10197959.0,
1259,162016,10,5,,103163840,3715,Active,754286265.0,443551.0,0.0122,IC50,IC50 value against ovine Prostaglandin G/H synthase 1,Confirmatory,10197960.0,
1260,162019,10,5,,103163840,3715,Active,754286265.0,443551.0,0.05,IC50,In vitro inhibitory activity against ovine Prostaglandin G/H synthase 1 (44 nM) using [14C]AA (50 uM) was determined,Confirmatory,10956194.0,
1261,162020,10,5,,103163840,3715,Active,754286265.0,443551.0,0.067,IC50,In vitro inhibitory activity against prostaglandin G/H synthase 1 from the microsomal fraction of ram seminal vesicles,Confirmatory,15026050.0,
1262,162141,8,5,,103163840,3715,Active,754286265.0,443551.0,0.05,IC50,Inhibition concentration against Prostaglandin G/H synthase 1,Confirmatory,11965379.0,
1263,162145,10,5,,103163840,3715,Active,754286265.0,443551.0,1.7,IC50,Inhibitory activity against Prostaglandin G/H synthase 1 isolated from ram (sheep) seminal vesicle,Confirmatory,9484493.0,
1264,162151,10,1,,103163840,3715,Active,754286265.0,443551.0,0.31,IC50,Tested for inhibitory activity against Prostaglandin G/H synthase 1 from ovine,Confirmatory,7562922.0,
1265,162156,3,11,,103163840,3715,Unspecified,754286265.0,443551.0,,,In vitro inhibitory activity against prostaglandin G/H synthase 1 (COX-1) from the microsomal fraction of ram seminal vesicles at 10 uM concentration,Other,15026050.0,
1266,162177,9,5,,103163840,3715,Active,754286265.0,443551.0,0.067,IC50,In vitro inhibition against Prostaglandin G/H synthase 1 from ram seminal vesicles,Confirmatory,12954051.0,
1267,162306,3,9,,103163840,3715,Unspecified,754286265.0,443551.0,,,In vitro inhibition of Prostaglandin G/H synthase 1 (from ram seminal vesicles) at a concentration of 10 M,Other,12954051.0,
1268,162339,9,2,,103163840,3715,Active,,,0.41,IC50,"Biochemical index for Prostaglandin G/H synthase 2 measured as, PGE-2 levels in lipopolysaccharide (LPS)-challenged human whole blood",Confirmatory,10937738.0,
1269,162346,9,2,,103163840,3715,Active,,,0.9,IC50,In vitro inhibition of prostaglandin G/H synthase 2 (COX-2).,Confirmatory,7473585.0,
1270,162474,9,5,,103163840,3715,Active,3915797.0,5743.0,0.049,IC50,Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2,Confirmatory,,
1271,162481,9,2,,103163840,3715,Active,,,0.9,IC50,Concentration required to inhibit human Prostaglandin G/H synthase 2 (COX-2) by 50%,Confirmatory,9171873.0,
1272,162483,9,1,,103163840,3715,Active,,,0.026000000000000002,IC50,In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2,Confirmatory,9873621.0,
1273,162484,9,2,,103163840,3715,Active,,,7.8,IC50,In vitro inhibition against human Prostaglandin G/H synthase 2,Confirmatory,12954051.0,
1274,162488,9,2,,103163840,3715,Active,,,0.75,IC50,In vitro inhibitory activity against human Prostaglandin G/H synthase 2 (66 nM) using [14C]AA (50 uM) was determined,Confirmatory,10956194.0,
1275,162489,9,1,,103163840,3715,Active,,,0.009000000000000001,IC50,In vitro inhibitory activity against human Prostaglandin G/H synthase 2 (COX-2) in 143982 cells,Confirmatory,12877584.0,
1276,162492,9,2,,103163840,3715,Active,,,0.9,IC50,In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2,Confirmatory,8627608.0,
1277,162493,9,1,,103163840,3715,Active,,,7.81,IC50,In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus,Confirmatory,15026050.0,
1278,162494,9,5,,103163840,3715,Active,3915797.0,5743.0,0.5,IC50,In vitro inhibitory activity against human whole blood Prostaglandin G/H synthase 2,Confirmatory,10406640.0,
1279,162495,9,2,,103163840,3715,Active,,,0.03,IC50,In vitro inhibitory activity against human whole cells (CHO) Prostaglandin G/H synthase 2,Confirmatory,10406640.0,
1280,162501,9,2,,103163840,3715,Active,,,2.4,IC50,In vitro inhibitory activity towards human recombinant Prostaglandin G/H synthase 2 enzyme,Confirmatory,11738574.0,
1281,162505,4,7,,103163840,3715,Active,,,0.2,IC50,Inhibition of Prostaglandin G/H synthase 2 in CHO whole cell assay,Confirmatory,10397507.0,
1282,162506,9,5,,103163840,3715,Active,3915797.0,5743.0,0.5,IC50,Inhibition of Prostaglandin G/H synthase 2 in human whole blood (HWB) assay,Confirmatory,10397507.0,
1283,162630,7,2,,103163840,3715,Active,,,0.64,IC50,In vitro percent inhibition of Prostaglandin G/H synthase 2 (COX-2) in human whole blood was determined,Confirmatory,12877584.0,
1284,162631,9,3,,103163840,3715,Active,,,0.46,IC50,In vivo ability to inhibit Prostaglandin G/H synthase 2 in human whole blood assay,Confirmatory,,
1285,162632,9,2,,103163840,3715,Active,,,0.56,IC50,Inhibition activity against recombinant human Prostaglandin G/H synthase 2,Confirmatory,9057869.0,
1286,162635,6,4,,103163840,3715,Active,,,0.0059,IC50,Inhibition of PGE-2 generation in LPS-stimulated human monocytes (Prostaglandin G/H synthase 2 cell assay),Confirmatory,11906281.0,
1287,162636,9,1,,103163840,3715,Active,,,0.009000000000000001,IC50,Inhibition of Prostaglandin G/H synthase 2 in 143.98.2 from human osteosarcoma cells,Confirmatory,11462976.0,
1288,162637,9,2,,103163840,3715,Active,,,0.5,IC50,Inhibition of Prostaglandin G/H synthase 2 was measured by the inhibition of PGE-2 produced by lipopolysaccharide-challenged HWB,Confirmatory,9873621.0,
1289,162643,9,2,,103163840,3715,Active,,,0.9,IC50,Inhibitory activity against Prostaglandin G/H synthase 2,Confirmatory,10956225.0,
1290,162644,9,2,,103163840,3715,Active,,,0.22,IC50,Inhibitory activity against prostaglandin G/H synthase 2,Confirmatory,10649977.0,
1291,162646,9,5,,103163840,3715,Active,3915797.0,5743.0,0.4,IC50,Inhibition of Prostaglandin G/H synthase 2 in human whole blood,Confirmatory,10465547.0,
1292,162650,9,2,,103163840,3715,Active,,,0.73,IC50,Inhibitory activity against recombinant human Prostaglandin G/H synthase 2,Confirmatory,14980665.0,
1293,162651,9,5,,103163840,3715,Active,3915797.0,5743.0,2.38,IC50,Inhibition of human Prostaglandin G/H synthase 2,Confirmatory,11906292.0,
1294,162658,7,1,,103163840,3715,Active,,,0.03,IC50,Inhibitory concentration against human recombinant Prostaglandin G/H synthase 2 cloned and expressed in baculovirus (Sf9),Confirmatory,11392547.0,
1295,162662,6,3,,103163840,3715,Active,,,0.63,IC50,Inhibitory effect on Prostaglandin G/H synthase 2 activity was evaluated in human whole blood as LPS-induced PGE-2 generation,Confirmatory,11906281.0,
1296,162663,9,3,,103163840,3715,Active,,,0.44,IC50,Inhibitory potency against cyclooxygenase-2 in human whole blood assay,Confirmatory,14980665.0,
1297,162665,9,2,,103163840,3715,Active,,,1.2,IC50,Tested for inhibition against Prostaglandin G/H synthase 2,Confirmatory,7966148.0,
1298,162666,9,2,,103163840,3715,Unspecified,,,180.0,IC50,Tested for inhibitory activity against Prostaglandin G/H synthase 2 from human,Confirmatory,7562922.0,
1299,162668,9,2,,103163840,3715,Active,,,0.026000000000000002,IC50,Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 2 in chinese hamster ovary (CHO) cells,Confirmatory,,
1300,165495,3,4,,103163840,3715,Unspecified,,,,,"In vitro of platelet aggregation of citreated rabbit platelet-rich plasma, induced by arachidonic acid at 200 uM",Other,11738562.0,
1301,165496,3,4,,103163840,3715,Unspecified,,,,,"In vitro of platelet aggregation of citreated rabbit platelet-rich plasma, induced by collagen at 5 uM; value expressed as slope",Other,11738562.0,
1302,166601,3,3,,103163840,3715,Unspecified,,,,,In vitro percent inhibition of platelet aggregation in citreated rabbit platelet-rich plasma induced by arachidonic acid at 200 uM,Other,11738562.0,
1303,166603,3,3,,103163840,3715,Unspecified,,,,,In vitro platelet aggregation of citreated rabbit platelet-rich plasma induced by collagen at 5 ug/mL,Other,11738562.0,
1304,168049,3,3,,103163840,3715,Unspecified,,,,,Ability of compound to cause gastric ulcerogenicity was determined in rats at 5 mg/kg when administered daily once,Other,14761182.0,
1305,168746,6,2,,103163840,3715,Unspecified,,,,,"Analgesic activity in acetic acid writhing test, activity is expressed as ED50 values",Other,6606043.0,
1306,168892,3,4,,103163840,3715,Unspecified,,,,,"Analgesic activity evaluated by measuring % analgesic effect, after oral administration of 1.0 mg/kg in acetic acid writhing test",Other,6606043.0,
1307,168893,3,4,,103163840,3715,Unspecified,,,,,"Analgesic activity evaluated by measuring % analgesic effect, after oral administration of 120 mg/kg in acetic acid writhing test",Other,6606043.0,
1308,168894,3,4,,103163840,3715,Unspecified,,,,,"Analgesic activity evaluated by measuring % analgesic effect, after oral administration of 3.0 mg/kg in acetic acid writhing test",Other,6606043.0,
1309,169230,3,3,,103163840,3715,Unspecified,,,,,In vivo oral activity by air pouch assay on Sprague-Dawley rats at dose 2 mg/kg administered intragastrically in a volume of 5 mL/kg 2 hr prior to injection.,Other,8627608.0,
1310,169240,4,2,,103163840,3715,Unspecified,,,,,Incidence of melena defecation was recorded 24 hrs of last treatment given once daily for 4 days; Positive,Other,15203134.0,
1311,169634,3,3,,103163840,3715,Unspecified,,,,,Compound is evaluated for gastric ulceration in rats at a dose of 10 mg/kg(5/12),Other,3118023.0,
1312,169639,3,3,,103163840,3715,Inconclusive,,,,,Compound is evaluated for gastric ulceration in rats at a dose of 100 mg/kg; Not tested,Other,3118023.0,
1313,169642,3,3,,103163840,3715,Unspecified,,,,,Compound is evaluated for gastric ulceration in rats at a dose of 3 mg/kg(1/6),Other,3118023.0,
1314,169646,3,3,,103163840,3715,Unspecified,,,,,Compound is evaluated for gastric ulceration in rats at a dose of 30 mg/kg(7/12),Other,3118023.0,
1315,170138,3,3,,103163840,3715,Unspecified,,,,,Inhibition of carrageenan-induced inflammation of rat paw relative to phenylbutazone.,Other,3097317.0,
1316,170140,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for its analgesic activity by Randall-Selitto test in comparison with that of Aspirine,Other,6609233.0,
1317,170141,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for its antipyretic activity by antipyresis effect in comparison with that of Aspirin.,Other,6609233.0,
1318,170722,3,3,,103163840,3715,Unspecified,,,,,Percent changes of hind paw edema and severity scores compared to control animals at 0.7 micro mol/kg/day,Other,7359519.0,
1319,170862,3,3,,103163840,3715,Unspecified,,,,,Percent changes of hind paw edema and severity scores compared to control animals at 1.4 micro mol/kg/day,Other,7359519.0,
1320,170866,3,3,,103163840,3715,Unspecified,,,,,Percent changes of hind paw edema and severity scores compared to control animals at 2.8 micro mol/kg/day,Other,7359519.0,
1321,170869,3,3,,103163840,3715,Unspecified,,,,,Percent changes of hind paw edema and severity scores compared to control animals at 7.0 micro mol/kg/day,Other,7359519.0,
1322,170951,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated for its antiinflammatory activity by adjuvant-induced polyarthritis test in rats at a dosage of 1 mg/kg administered orally,Other,6609233.0,
1323,171178,3,3,,103163840,3715,Unspecified,,,,,Body weight change after once daily administration at 84 uM/kg for 4 days in rats was determined,Other,15203134.0,
1324,171209,3,3,,103163840,3715,Unspecified,,,,,Persent change of the antiinflammatory activity in the 5-h Evans Blue-Carrageenan induced pleural effusion assay at the dose of 4.0 mg/kg (p.o.),Other,6802974.0,
1325,171540,2,4,,103163840,3715,Unspecified,,,,,Cartilage space narrowing was measured radiographically after 42 days initial immunization with type II collagen in rats at a dose of 200 mg/kg,Other,,
1326,171711,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory effect at a dose of 100 umol/kg administered orally in the carrageenan-induced rat pleurisy assay (10e6 Cells/cavity),Other,11738562.0,
1327,172361,5,2,,103163840,3715,Active,,,,,Gain in the body weight of rat was measured at 2.8 micro mol/kg/day. (+ means significant body weight),Other,7359519.0,
1328,172364,5,2,,103163840,3715,Active,,,,,Gain in the body weight of rat was measured at 7.0 micro mol/kg/day. (+ means significant body weight),Other,7359519.0,
1329,172570,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was evaluated by carrageenan induced rat paw edema volume was determined.,Other,7731014.0,
1330,172635,3,4,,103163840,3715,Unspecified,,,,,Analgesic activity was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 12 hr.,Other,3669013.0,
1331,172636,3,4,,103163840,3715,Unspecified,,,,,Analgesic activity was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 1 hr.,Other,3669013.0,
1332,172637,3,4,,103163840,3715,Unspecified,,,,,Analgesic activity was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 24 hr.,Other,3669013.0,
1333,172638,3,4,,103163840,3715,Unspecified,,,,,Analgesic activity was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 4 hr.,Other,3669013.0,
1334,172640,3,4,,103163840,3715,Unspecified,,,,,Analgesic activity was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 8 hr.,Other,3669013.0,
1335,172647,3,4,,103163840,3715,Unspecified,,,,,Analgesic activity in rats by acetic acid writhing test at a dose of 0.017 mmol/kg,Other,12565932.0,
1336,172651,3,3,,103163840,3715,Unspecified,,,,,Animals with Hyperemia in Carrageenan-induced paw edema test at a dose of 5 mg/kg perorally in rats,Other,11597401.0,
1337,172777,3,3,,103163840,3715,Unspecified,,,,,Animals with Ulcers in Carrageenan-induced paw edema test at a dose of 5 mg/kg perorally in rats,Other,11597401.0,
1338,172889,3,3,,103163840,3715,Unspecified,,,,,Percent change in avg. volume of pleural fluid at a dose of 0.16 mg/kg and 5-h response is evaluated by Evans blue-carrageenan induced pleural effusion assay,Other,6436487.0,
1339,172892,3,3,,103163840,3715,Unspecified,,,,,Percent change in average volume of pleural fluid at a dose of 4.0 mg/kg and 5-h response by Evans blue-carrageenan induced pleural effusion assay.,Other,6436487.0,
1340,173209,3,3,,103163840,3715,Unspecified,,,,,Gastrointestinal tolerability was evaluated in rats and amount blood loss was reported.,Other,6608000.0,
1341,173359,3,3,,103163840,3715,Unspecified,,,,,Hypolipidemic action at 500 uM/kg was determined as reduction in low density lipoprotein in rat plasma,Other,15203134.0,
1342,173360,3,3,,103163840,3715,Unspecified,,,,,Hypolipidemic action at 500 uM/kg was determined as reduction in total cholesterol in rat plasma,Other,15203134.0,
1343,173361,3,4,,103163840,3715,Unspecified,,,,,Hypolipidemic action at 500 uM/kg was determined as reduction in triglycerides in rat plasma,Other,15203134.0,
1344,173577,3,3,,103163840,3715,Unspecified,,,,,Dose required to prevent lesion formation in gastric mucosa of unanesthetized rats upon subcutaneous administration.,Other,9873468.0,
1345,173702,5,2,,103163840,3715,Inactive,,,,,Percent decrease in serum haemoglobin evaluated in a developing adjuvant arthritis model rats; No significant effect,Other,1995900.0,
1346,173977,3,3,,103163840,3715,Unspecified,,,,,Dose that inhibits paw swelling by 25% compared with control in carrgeenin rat paw edema assay,Other,7359519.0,
1347,174079,3,5,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was measured as inhibition of carrageenan-induced paw edema in male rats at 4 mg/kg dose,Other,1404232.0,
1348,174428,5,1,,103163840,3715,Unspecified,,,,,Plasma drug level was measured in rat yeast induced hyperalgesia assay in presence of indomethacin at a dose of 10 mg/kg for 12 hr.,Other,3669013.0,
1349,174429,5,1,,103163840,3715,Unspecified,,,,,Plasma drug level was measured in rat yeast induced hyperalgesia assay in presence of indomethacin at a dose of 10 mg/kg for 1 hr.,Other,3669013.0,
1350,174431,5,1,,103163840,3715,Unspecified,,,,,Plasma drug level was measured in rat yeast induced hyperalgesia assay in presence of indomethacin at a dose of 10 mg/kg for 24 hr.,Other,3669013.0,
1351,174432,5,1,,103163840,3715,Unspecified,,,,,Plasma drug level was measured in rat yeast induced hyperalgesia assay in presence of indomethacin at a dose of 10 mg/kg for 4 hr.,Other,3669013.0,
1352,174433,5,1,,103163840,3715,Unspecified,,,,,Plasma drug level was measured in rat yeast induced hyperalgesia assay in presence of indomethacin at a dose of 10 mg/kg for 8 hr.,Other,3669013.0,
1353,174679,3,4,,103163840,3715,Unspecified,,,,,"Percentage of [51Cr]- secreted in feces was determined by fecal drug-induced bleeding method in rat at 100 mg/kg, bid for 5 days",Other,12877584.0,
1354,176212,6,2,,103163840,3715,Unspecified,,,,,Effective dose was determined in vivo in male lewis rats by rat adjuvant-induced arthritis assay,Other,9135032.0,
1355,176213,6,2,,103163840,3715,Unspecified,,,,,Effective dose was determined in vivo in male Dawley rats by rat carrageenan-induced foot pad edema assay,Other,9135032.0,
1356,176214,6,2,,103163840,3715,Unspecified,,,,,Effective dose was determined in vivo in male Dawley rats by rat carrageenan-induced hyperalgesia assay,Other,9135032.0,
1357,176240,6,2,,103163840,3715,Unspecified,,,,,Inhibitory effect for increase in plasma prostaglandin E2 (PGE2) level after arachidonic acid (AA) injection into COX-1 non-lipopolysaccharide-treated rats,Other,10821716.0,
1358,176241,7,2,,103163840,3715,Unspecified,,,,,Inhibitory effect for increase in plasma prostaglandin E2 (PGE2) level after arachidonic acid (AA) injection into COX-2 lipopolysaccharide-treated rats,Other,10821716.0,
1359,176243,6,2,,103163840,3715,Unspecified,,,,,Inhibitory effect for increase in plasma prostaglandin E2 (PGE2) level after arachidonic acid (AA) injection intoCOX-1 non-lipopolysaccharide-treated rats,Other,10821716.0,
1360,176342,6,2,,103163840,3715,Unspecified,,,,,Compound was tested in vivo for its efficacy in the rat paw edema assay,Other,10397507.0,
1361,176343,6,2,,103163840,3715,Unspecified,,,,,Compound was tested in vivo for its efficacy in the rat pyresis assay,Other,10397507.0,
1362,176481,9,1,,103163840,3715,Unspecified,,,,,Chronic gastrointestinal erosive activity in male rats by the oral administration was determined.,Other,3491210.0,
1363,176482,6,2,,103163840,3715,Unspecified,,,,,Inhibition of adjuvant-induced polyarthritis in rat following p.o. administration.,Other,7332706.0,
1364,176483,6,2,,103163840,3715,Unspecified,,,,,Compound administered perorally for inhibition of carrageenan induced paw edema after 3h in rat,Other,7332706.0,
1365,176984,6,2,,103163840,3715,Unspecified,,,,,In vivo antiinflammatory activity by the Carrageenan-induced rat paw edema assay.,Other,8523403.0,
1366,176985,6,2,,103163840,3715,Unspecified,,,,,In vivo antiinflammatory activity by the Carrageenan-induced rat paw hyperalgesia assay.,Other,8523403.0,
1367,176996,6,2,,103163840,3715,Unspecified,,,,,In vivo antiinflammatory activity by rat carrageenan-induced paw edema assay,Other,12565932.0,
1368,177015,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity assessed by inhibition of carrageenan-induced edema in rats at a dose of 15 mg/kg,Other,2724294.0,
1369,177016,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was determined by inhibition of carrageenan-induced edema in rat paw with respect to phenylbutazone,Other,3572970.0,
1370,177018,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was evaluated in rat carrageenan foot edema assay in experiment 1,Other,3118023.0,
1371,177019,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was evaluated in rat carrageenan foot edema assay in experiment 2,Other,3118023.0,
1372,177023,2,4,,103163840,3715,Unspecified,,,,,Compound was evaluated for inhibition of paw edema in rat,Other,,
1373,177026,2,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in vivo for its activity in the rat paw edema assay.,Other,,
1374,177034,5,1,,103163840,3715,Unspecified,,,,,Compound was tested for its oral antiinflammatory activity in the rat carrageenan paw edema assay (CAR),Other,,
1375,177037,3,3,,103163840,3715,Unspecified,,,,,Dose required for 30% inhibition of adjuvant-induced arthritis,Other,10821716.0,
1376,177038,3,3,,103163840,3715,Unspecified,,,,,Dose required for 30% inhibition of carrageenan-induced edema,Other,10821716.0,
1377,177071,6,2,,103163840,3715,Unspecified,,,,,Compound was evaluated for efficacy in rat paw edema assay upon oral administration,Other,9873621.0,
1378,177073,6,2,,103163840,3715,Unspecified,,,,,Efficacy in rat pyresis assay upon oral administration,Other,9873621.0,
1379,177075,6,2,,103163840,3715,Unspecified,,,,,Compound was evaluated for highest non-ulcerogenic dose (less than 50% ulcer incidence),Other,6502598.0,
1380,177102,6,2,,103163840,3715,Unspecified,,,,,ED50 was measured by CFE assay method.,Other,10197960.0,
1381,177103,6,2,,103163840,3715,Unspecified,,,,,ED50 was measured by hyperalgesia assay method.,Other,10197960.0,
1382,177134,6,2,,103163840,3715,Unspecified,,,,,In vivo antipyretic activity by endotoxin-induced rat pyresis assay.,Other,8523403.0,
1383,177150,6,2,,103163840,3715,Unspecified,,,,,In vivo effective concentration of compound in rat adjuvant arthritis,Other,10465547.0,
1384,177151,6,2,,103163840,3715,Unspecified,,,,,In vivo effective concentration of compound in rat hyperalgesia,Other,10465547.0,
1385,177152,6,2,,103163840,3715,Unspecified,,,,,In vivo effective concentration of compound in rat paw edema,Other,10465547.0,
1386,177153,6,2,,103163840,3715,Unspecified,,,,,In vivo effective concentration of compound in rat pyresis,Other,10465547.0,
1387,177164,8,1,,103163840,3715,Active,,,0.84,ED50,In vivo effective dose required for antiinflammatory activity in rat adjuvant arthritis model,Confirmatory,7562922.0,
1388,177221,3,3,,103163840,3715,Unspecified,,,,,In vivo inhibition of carrageenan-induced air pouch in rats,Other,10649977.0,
1389,177223,3,3,,103163840,3715,Unspecified,,,,,Inhibition of carrageenan paw edema in rats,Other,10649977.0,
1390,177289,7,2,,103163840,3715,Unspecified,,,,,Effect in rat pleural Carrageenan test (exudate volume),Other,2970549.0,
1391,177291,5,2,,103163840,3715,Inactive,,,,,Effect in rat pleural Carrageenan test (exudate white blood cells (WBC)); No significant effect at 28 umol/kg (Not active),Other,2970549.0,
1392,177358,6,2,,103163840,3715,Unspecified,,,,,In vivo inhibition of adjuvant arthritis in rats,Other,10649977.0,
1393,177361,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity was evaluated in an adjuvant arthritis (subchronic inflammation) test, after administering compound orally in rats.",Other,6608000.0,
1394,177368,3,3,,103163840,3715,Unspecified,,,,,ED50 measured by CFE assay,Other,10197959.0,
1395,177369,3,3,,103163840,3715,Unspecified,,,,,ED50 measured by hyperalgesia assay,Other,10197959.0,
1396,177372,5,2,,103163840,3715,Inactive,,,,,Effective dose of compound for 40% inhibition of rat dermal reverse passive Arthus reaction (RPAR) on peroral administration; No significant inhibition at 56 umol/kg (Inactive),Other,2970549.0,
1397,177375,4,3,,103163840,3715,Inactive,,,,,Inhibition of dermal RPAR in rats following p.o. administration; Not significant.,Other,6827539.0,
1398,177511,6,2,,103163840,3715,Unspecified,,,,,In vivo inhibition of carrageenan-induced hyperalgesia in rats,Other,10649977.0,
1399,177520,6,2,,103163840,3715,Unspecified,,,,,In vivo inhibition of pyresis in rats,Other,10649977.0,
1400,177523,6,2,,103163840,3715,Unspecified,,,,,In vivo inhibitory activity against adjuvant induced arthritis in the rat.,Other,10956225.0,
1401,177532,9,1,,103163840,3715,Unspecified,,,,,In vivo inhibitory activity against carrageenan induced paw edema in the rat.,Other,10956225.0,
1402,177545,6,2,,103163840,3715,Unspecified,,,,,Ability to inhibit Carrageenan-induced paw edema in rat administered perorally,Other,6607999.0,
1403,177548,6,2,,103163840,3715,Unspecified,,,,,Ability to inhibit gastric irritation in rat administered perorally,Other,6607999.0,
1404,177550,6,2,,103163840,3715,Unspecified,,,,,Ability to inhibit phenylquinone induced writhing in rat administered perorally,Other,6607999.0,
1405,177761,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity measured as acetic acid writhing in rats,Other,6982340.0,
1406,177762,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity measured as silver nitrate induced arthritic pain in rats,Other,6982340.0,
1407,177770,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity against AcOH writhing after po administration.,Other,7205873.0,
1408,177772,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity on peroral administration against Bradykinin induced pain in rat paw,Other,6607354.0,
1409,177780,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity was determined by measuring the dose required to inhibit acetic acid induced writhing,Other,2299620.0,
1410,177781,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity was evaluated in the rat flection pain test,Other,3118023.0,
1411,177808,5,3,,103163840,3715,Unspecified,,,,,Compound was evaluated in vivo for its activity in the rat pyresis assay.,Other,,
1412,177810,5,3,,103163840,3715,Unspecified,,,,,Compound was evaluated in vivo for potency against rat paw edema model,Other,,
1413,177889,6,2,,103163840,3715,Unspecified,,,,,Inhibition of carrageenan edema in adrenalectomized rats was determined after peroral administration,Other,7131493.0,
1414,177890,6,2,,103163840,3715,Unspecified,,,,,Inhibition of carrageenan edema in normal rats was determined after peroral administration,Other,7131493.0,
1415,177891,6,2,,103163840,3715,Unspecified,,,,,Inhibition of carrageenan edema in rats was determined after peroral administration of 100 mg/kg,Other,7131493.0,
1416,178033,6,2,,103163840,3715,Unspecified,,,,,Effective dose for antiinflammatory activity in carrageenan paw edema assay in rats after oral administration,Other,6982340.0,
1417,178230,5,2,,103163840,3715,Inactive,,,,,Inhibition of pleural reverse passive Arthus reactions (RPAR) in rat (exudate volume); No significant inhibition at 56 umol/kg (Inactive),Other,2970549.0,
1418,178232,5,2,,103163840,3715,Inactive,,,,,Inhibition of pleural reverse passive Arthus reactions (exudate white blood cells (WBC)); No significant inhibition at 56 umol/kg (Inactive),Other,2970549.0,
1419,178373,6,2,,103163840,3715,Unspecified,,,,,Effective dose against analgesic activity (peroral administration),Other,6965727.0,
1420,178375,6,2,,103163840,3715,Unspecified,,,,,Effective dose against carrageenan edema(peroral administration),Other,6965727.0,
1421,178376,6,2,,103163840,3715,Unspecified,,,,,Effective dose against gastroulcerogenic activity (peroral administration),Other,6965727.0,
1422,178378,6,2,,103163840,3715,Unspecified,,,,,Effective dose against nystatin edema(peroral administration),Other,6965727.0,
1423,178471,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity evaluated as Minimum effective oral dose that inhibits bradykinin paw edema in rat,Other,3965711.0,
1424,178472,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity evaluated as Minimum effective oral dose that inhibits carrageenan paw edema in rat,Other,3965711.0,
1425,178473,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity evaluated as Minimum effective oral dose that inhibits dextran paw edema in rat,Other,3965711.0,
1426,178489,6,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in carrageenan model, activity is expressed as ED50 values",Other,6606043.0,
1427,178491,4,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in the rat foot edema at the dose of 1.0-10 mg/kg po,Other,2113951.0,
1428,178493,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against adjuvant induced arthritis in male charles river rats,Other,8151626.0,
1429,178496,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity on peroral administration in rat determined by Randall-Slelitto test,Other,6607354.0,
1430,178497,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was assessed from the ability to inhibit adjuvant-induced arthritis in rats,Other,2724294.0,
1431,178498,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity by using Rat adjuvant arthritis assay,Other,12392741.0,
1432,178593,6,2,,103163840,3715,Unspecified,,,,,Effective dose determined against rat adjuvant arthritis after peroral administration,Other,3875725.0,
1433,178641,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity by using Rat hyperalgesia assay,Other,12392741.0,
1434,178643,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity by using Rat paw edema assay,Other,12392741.0,
1435,178644,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity by using Rat pyresis assay,Other,12392741.0,
1436,178647,6,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity was evaluated in an carrageenan edema (acute inflammation) test, after administering compound orally in rats.",Other,6608000.0,
1437,178653,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was determined against rats carrageenan hind paw edema after oral administration,Other,2299620.0,
1438,178662,4,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using preventive method; Range is 0.2~0.3 (dose administered daily twice),Other,14761182.0,
1439,178668,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was determined to inhibit adjuvant-induced arthritis in rats with respect to naproxen,Other,3572970.0,
1440,178669,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was determined to inhibit cotton pellet granuloma in rats with respcet to Indomethacin,Other,3572970.0,
1441,178754,6,3,,103163840,3715,Unspecified,,,,,Inhibitory activity in the adjuvant induced arthritis model of chronic inflammation in rat,Other,9171873.0,
1442,178757,6,2,,103163840,3715,Unspecified,,,,,Effective dose was evaluated in the carrageenan induced model of para edema in the rat,Other,9171873.0,
1443,178776,5,2,,103163840,3715,Inactive,,,,,Reduction in exudate volume in rat pleural RPAR test; Nonactive.,Other,6827539.0,
1444,178777,7,2,,103163840,3715,Unspecified,,,,,Reduction in exudate volume in rat pleural carrageenan test.,Other,6827539.0,
1445,178845,6,2,,103163840,3715,Unspecified,,,,,Antipyretic activity measured as yeast induced fever assay in rats,Other,6982340.0,
1446,178908,5,2,,103163840,3715,Inactive,,,,,Reduction in leukocyte numbers in rat pleural RPAR exudate; Nonactive.,Other,6827539.0,
1447,178910,5,2,,103163840,3715,Inactive,,,,,Reduction in leukocyte numbers in rat pleural RPAR exudate; Nonactive.,Other,6827539.0,
1448,178915,6,2,,103163840,3715,Unspecified,,,,,Effective dose required for antiinflammatory activity by adjuvant arthritis assay tested in vivo,Other,10406640.0,
1449,178917,6,2,,103163840,3715,Unspecified,,,,,Effective dose required for antiinflammatory activity by pyresis assay tested in vivo,Other,10406640.0,
1450,178918,6,2,,103163840,3715,Unspecified,,,,,Effective dose required for antiinflammatory activity by rat paw edema assay tested in vivo,Other,10406640.0,
1451,178919,6,2,,103163840,3715,Unspecified,,,,,Effective dose required for antiinflammatory activity by rat paw hyperalgesia assay tested in vivo,Other,10406640.0,
1452,178934,4,2,,103163840,3715,Unspecified,,,,,Effective dose required for the inhibition of adjuvant arthritis in Sprague-Darley rats,Other,11206450.0,
1453,178986,6,2,,103163840,3715,Unspecified,,,,,Inhibition of the development of adjuvant-induced polyarthritis in rats was determined,Other,7131493.0,
1454,179010,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated for percentage recovery from femur weight in adjuvant-induced arthritic model of rat at a dose of 2 mg/kg,Other,12113803.0,
1455,179432,3,5,,103163840,3715,Unspecified,,,,,In vivo percent inhibition of carrageenan foot-pad edema (CFE) after peroral administration was determined.,Other,2115586.0,
1456,179444,3,4,,103163840,3715,Unspecified,,,,,In vivo percent inhibition of mycobacterium foot-pad edema (MFE) after peroral administration was determined.,Other,2115586.0,
1457,179451,7,2,,103163840,3715,Unspecified,,,,,Analgesic activity on peroral administration against Scald induced pain in rat paw,Other,6607354.0,
1458,179452,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity on peroral administration against scald induced pain in rat paw,Other,6607354.0,
1459,179509,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for percentage recovery from GAG in adjuvant-induced arthritic model of rat at a dose of 2 mg/kg,Other,12113803.0,
1460,179535,2,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in vivo for effect on gastrointestinal integrity(GI) in rats using [51Cr]- assay: causes lesions,Other,,
1461,179689,3,3,,103163840,3715,Unspecified,,,,,Percentage of gastric damage was measured in rats.,Other,10197959.0,
1462,179690,3,3,,103163840,3715,Unspecified,,,,,Acute gastric toxicity (single oral dose) in male fasted rats,Other,6436487.0,
1463,179746,6,3,,103163840,3715,Active,,,0.2,IC50,In vitro inhibition of prostaglandin synthesis was tested in rat,Confirmatory,7332706.0,
1464,180216,2,4,,103163840,3715,Unspecified,,,,,Erosions of tarsal bones measured radiographically after 42 days initial immunization with type II collagen in rats at a dose of 200 mg/kg,Other,,
1465,180296,6,2,,103163840,3715,Unspecified,,,60.0,IC50,Inhibitory activity to inhibit Inophore-induced arachidonic acid metabolism (inhibition of LTB4 formation) in rat,Confirmatory,2547071.0,
1466,180546,6,2,,103163840,3715,Unspecified,,,,,The compound was tested in vivo for activity against adjuvant-induced arthritis in rat after peroral administration,Other,11906292.0,
1467,180548,6,2,,103163840,3715,Unspecified,,,,,The compound was tested in vivo for activity against carrageenan induced paw edema in rat after peroral administration,Other,11906292.0,
1468,180549,6,2,,103163840,3715,Unspecified,,,,,The compound was tested in vivo for activity against yeast -induced hyperalgesia in rat after peroral administration,Other,11906292.0,
1469,180550,6,2,,103163840,3715,Unspecified,,,,,The compound was tested in vivo for activity against yeast -induced hyperthermia in rat after peroral administration,Other,11906292.0,
1470,180759,3,4,,103163840,3715,Unspecified,,,,,Exudate volume was determined after administration at a dose of 100 umol/kg in the carrageenan-induced rat pleurisy assay,Other,11738562.0,
1471,181152,8,1,,103163840,3715,Unspecified,,,,,Hemoglobin levels in the different assays ranged from 11.5-14.7 g/dl.,Other,10649977.0,
1472,181418,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity evaluated as Minimum effective oral dose that inhibits adjuvant arthritis in rats,Other,3965711.0,
1473,181446,4,3,,103163840,3715,Unspecified,,,,,Evaluated for the carrageenan-induced paw edema on 11-day after 3.16 mg/kg dose of peroral administration of the compound,Other,2115585.0,
1474,181451,4,3,,103163840,3715,Unspecified,,,,,Evaluated for the carrageenan-induced paw edema on 32-day after 3.16 mg/kg dose of peroral administration of the compound,Other,2115585.0,
1475,181534,6,2,,103163840,3715,Unspecified,,,100.0,IC50,Antiinflammatory activity was adjuvant arthritis model,Confirmatory,3104589.0,
1476,181536,6,2,,103163840,3715,Active,,,0.8,IC50,Antiinflammatory efficacy is measured by the percent inhibition of edema in carrageenan induced rats during the 3 week adjuvant arthritis test,Confirmatory,6502598.0,
1477,181586,3,3,,103163840,3715,Unspecified,,,,,Percent Edema variation in Carrageenan-induced paw edema test at a dose of 5 mg/kg perorally in rats after 120 min,Other,11597401.0,
1478,181587,3,3,,103163840,3715,Unspecified,,,,,Percent Edema variation in Carrageenan-induced paw edema test at a dose of 5 mg/kg perorally in rats after 180 min (p<0.01),Other,11597401.0,
1479,181588,3,3,,103163840,3715,Unspecified,,,,,Percent Edema variation in Carrageenan-induced paw edema test at a dose of 5 mg/kg perorally in rats after 60 min,Other,11597401.0,
1480,181831,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated in developing adjuvant arthritis model rats for its effect on paw edema.,Other,1995900.0,
1481,182009,2,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in vivo for the ability to inhibit inflammation caused by the introduction of carrageenan after oral administration using rat paw edema assay(assay performed at 30 mpk),Other,,
1482,182047,3,3,,103163840,3715,Unspecified,,,,,In vivo inhibition of contralateral paw swelling after oral treatment for 28 days (1 mg/kg od) was determined by adjuvabt arthritis in rat,Other,12877584.0,
1483,182282,3,3,,103163840,3715,Unspecified,,,,,Percent inhibition of cellular migration by the compound at a dose of 100 umol/kg was evaluated in the carrageenan-induced rat pleurisy assay,Other,11738562.0,
1484,182289,3,3,,103163840,3715,Unspecified,,,,,Percent inhibition of edema in carrageenan-induced rat paw edema was determined by comparing with vehicle control group when tested on 5 rats at peroral dose of 100 umol/Kg,Other,9871651.0,
1485,182298,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for its antiinflammatory activity by adjuvant-induced polyarthritis test in rats at a dosage of 1 mg/kg administered orally,Other,6609233.0,
1486,182301,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 12 hr.,Other,3669013.0,
1487,182302,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 1 hr.,Other,3669013.0,
1488,182303,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 24 hr.,Other,3669013.0,
1489,182304,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 4 hr.,Other,3669013.0,
1490,182306,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 8 hr.,Other,3669013.0,
1491,182609,6,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity on peroral administration against carrageenan paw edema,Other,6607354.0,
1492,182707,3,3,,103163840,3715,Unspecified,,,,,Compound was tested for the inhibition of rat reversed passive Arthus pleurisy after peroral administration of 10 mg/kg dose at 0.44 mL of exudate volume with 0.55 mL of control (injected intrapleurally),Other,1552506.0,
1493,182711,4,2,,103163840,3715,Unspecified,,,,,Compound was tested for the inhibition of rat reversed passive Arthus pleurisy after peroral administration of 10 mg/kg dose at 3.2*10e6 no of cells with 2.77*10e6 cells of control,Other,1552506.0,
1494,182780,6,2,,103163840,3715,Unspecified,,,,,Compound was tested in vivo for its efficacy in the model of carrageenan-induced hyperalgesia in rats,Other,10397507.0,
1495,182814,6,2,,103163840,3715,Unspecified,,,,,Gastric lesion activity on peroral administration in rat.,Other,6607354.0,
1496,182956,4,2,,103163840,3715,Unspecified,,,,,In vivo inhibitory dose in adjuvant-induced arthritis in rats,Other,9873621.0,
1497,182957,6,2,,103163840,3715,Unspecified,,,,,In vivo inhibitory dose in carrageenan-induced hyperalgesia in rats,Other,9873621.0,
1498,183012,3,3,,103163840,3715,Unspecified,,,,,Analgesic activity was determined using acetic acid writing test at a dose of 5 mg/kg perorally in rats. (p<0.01),Other,11597401.0,
1499,183014,6,2,,103163840,3715,Unspecified,,,,,Analgesic activity was determined as its ability to inhibit abdominal writhing after intraperitoneal administration of phenylbenzoquinone (PBQ) at dose of 15 mg/kg,Other,3488405.0,
1500,183034,3,3,,103163840,3715,Unspecified,,,,,Compound was tested for the inhibition of rat reversed passive Arthus pleurisy after peroral administration of 3 mg/kg dose at 0.59 mL of exudate volume with 0.55 mL of control (injected intrapleurally),Other,1552506.0,
1501,183037,4,2,,103163840,3715,Unspecified,,,,,Compound was tested for the inhibition of rat reversed passive Arthus pleurisy after peroral administration of 3 mg/kg dose at 4.01*10e6 no of cells with 2.77*10e6 cells of control,Other,1552506.0,
1502,183056,3,3,,103163840,3715,Unspecified,,,,,Inhibition against adjuvant-induced paw edema at a dose of 25 mg/kg in male Sprague-Dawley rats.,Other,3263504.0,
1503,183089,3,3,,103163840,3715,Unspecified,,,,,Inhibition of adjuvant-induced arthritis (AA) in SD rats upon peroral administration (BID) at 0.3 mg/kg/day,Other,15026065.0,
1504,183128,4,2,,103163840,3715,Unspecified,,,,,Inhibition of secondary paw swelling in rat adjuvant arthritis model,Other,9873604.0,
1505,183403,3,3,,103163840,3715,Unspecified,,,,,Inhibition of secondary paw swelling in rat adjuvant arthritis model at 1 mg/kg b.i.d.,Other,9873604.0,
1506,183501,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in vivo by carrageenan paw edema assay in rat at a dose of 10 mg/kg,Other,11591502.0,
1507,183642,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was evaluated by the inhibition of rat carrageenan foot edema (CFE) assay at the dose of 1 mg/kg,Other,3488405.0,
1508,183643,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was evaluated by the inhibition of rat carrageenan foot edema (CFE) assay at the dose of 10 mg/kg,Other,3488405.0,
1509,183644,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was evaluated by the inhibition of rat carrageenan foot edema (CFE) assay at the dose of 3 mg/kg,Other,3488405.0,
1510,183650,3,3,,103163840,3715,Unspecified,,,,,Inhibition of carrageenan-induced rat foot oedema following 3 mg/kg administration.,Other,14761182.0,
1511,183657,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was evaluated by carrageenan induced rat paw edema (6 rats/ dose) at peroral dose of 10 mg/kg by inhibition of Prostaglandin E2 (PGE2).,Other,7731014.0,
1512,183658,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was evaluated by carrageenan induced rat paw edema (6 rats/ dose) at peroral dose of 10 mg/kg by inhibition of leukotriene B4 (LTB4) synthesis.,Other,7731014.0,
1513,183671,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test at 0.0014 mM/kg (0.50 mg),Other,6502598.0,
1514,183700,6,3,,103163840,3715,Inconclusive,,,,,Evaluated in vivo for antiinflammatory activity at 30 mg/kg oral dose in the carrageenan-induced rat paw edema (male Wistar rat); Not determined,Other,12954051.0,
1515,183909,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity on carrageenan-induced paw edema in rats 3h after po administration of 0.5 mg/kg,Other,7205873.0,
1516,183912,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity on carrageenan-induced paw edema in rats 3h after po administration of 2 mg/kg,Other,7205873.0,
1517,183914,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity on carrageenan-induced paw edema in rats 3h after po administration of 5 mg/kg,Other,7205873.0,
1518,184061,3,3,,103163840,3715,Unspecified,,,,,Inhibitory effect of compound on carrageenan-induced rat paw edema administered p.o. at 10 mg/kg,Other,15081007.0,
1519,184144,3,3,,103163840,3715,Unspecified,,,,,Inhibition of carrageenan hind paw edema in rats after oral administration of a dose of 5 mg/kg,Other,2299620.0,
1520,184160,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for its antiinflammatory activity in the cotton pellet induced granuloma(CPG) in normal rats at the dose 3 mg/kg p.o.,Other,6609233.0,
1521,184174,3,3,,103163840,3715,Unspecified,,,,,In vivo anti-inflammatory activity determined by rat carrageenan paw edema method at 10 mg/kg perorally,Other,12877584.0,
1522,184175,3,3,,103163840,3715,Unspecified,,,,,In vivo anti-inflammatory activity against carrageenan-induced paw edema assay in rats at dose 0.11 mM/kg,Other,10206543.0,
1523,184187,4,3,,103163840,3715,Unspecified,,,,,In vivo effect on prostaglandin and leukotriene mediated production in rat pleural cavity was assessed by the inhibition of LTE4 in 5-lipoxygenase/ cyclooxygenase at dose 1.0 mg/kg,Other,2145433.0,
1524,184192,3,3,,103163840,3715,Unspecified,,,,,In vivo effect on prostaglandin and leukotriene mediated production in rat pleural cavity was assessed by the inhibition of cell influx in 5-lipoxygenase/ cyclooxygenase at dose 1.0 mg/kg,Other,2145433.0,
1525,184196,3,3,,103163840,3715,Unspecified,,,,,In vivo effect on prostaglandin and leukotriene mediated production in rat pleural cavity was assessed by the inhibition of fluid volume in 5-lipoxygenase/ cyclooxygenase at dose 1.0 mg/kg,Other,2145433.0,
1526,184310,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for the inhibition of adjuvant-induced arthritis model in rats at a dose of 1 mg/kg,Other,3118023.0,
1527,184311,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for the inhibition of adjuvant-induced arthritis model in rats at a dose of 3 mg/kg,Other,3118023.0,
1528,184499,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was assessed in carrageenan-induced rat paw edema(CIRPE) test after po administration,Other,7086815.0,
1529,184502,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was assessed in prophylactic adjuvant induced polyarthritis(AIP) test after po administration.,Other,7086815.0,
1530,184504,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was assessed in therapeutic adjuvant induced polyarthritis(AIP) test after po administration.,Other,7086815.0,
1531,184537,3,3,,103163840,3715,Unspecified,,,,,Mortality caused by the compound in rats after administration at 84 uM/kg for 4 days,Other,15203134.0,
1532,184600,6,2,,103163840,3715,Unspecified,,,,,Acute toxicity evaluated as oral lethal dose in rat; Range is 12-25,Other,3965711.0,
1533,184640,6,2,,103163840,3715,Unspecified,,,,,Lethal dose determined in rats when administered perorally,Other,6982340.0,
1534,184782,6,2,,103163840,3715,Unspecified,,,,,Median lethal dose using 10 rats per dose.,Other,6620298.0,
1535,184787,6,2,,103163840,3715,Unspecified,,,,,"Tested for percent inhibition of carrageenan paw edema in rat, administered orally at a dose of one tenth of oral lethal dose in mice",Other,6965727.0,
1536,184914,3,3,,103163840,3715,Unspecified,,,,,Percent inhibition of adjuvant-induced arthritis at 10 mg/kg po; no data,Other,10821716.0,
1537,184915,3,4,,103163840,3715,Unspecified,,,,,Percent inhibition of carrageenan-induced foot-pad edema at 30 mg/kg po; no data,Other,10821716.0,
1538,185017,3,3,,103163840,3715,Unspecified,,,,,Minimum effective dose against adjuvant arthritis on administration),Other,6965727.0,
1539,185018,3,3,,103163840,3715,Unspecified,,,,,Minimum effective dose against adjuvant arthritis on prophylactic dosing (peroral administration),Other,6965727.0,
1540,185019,3,3,,103163840,3715,Unspecified,,,,,Minimum effective dose against adjuvant arthritis on therapeutic dosing (peroral administration),Other,6965727.0,
1541,185020,3,3,,103163840,3715,Unspecified,,,,,Minimum effective dose is the lowest dose preventing any futher increase in body temperature,Other,6965727.0,
1542,185055,3,3,,103163840,3715,Unspecified,,,,,Nonnarcotic analgesic effect was determined after peroral administration in rats.,Other,7131493.0,
1543,185156,3,3,,103163840,3715,Unspecified,,,,,"Compound was tested for intestinal Ulcerogenic effect in rats, activity expressed as lesion length",Other,3086558.0,
1544,185238,3,3,,103163840,3715,Unspecified,,,,,Percent inhibition of pleural inflammation in carrageenan-induced rat model was determined by comparing with vehicle control group when tested on 10 rats at peroral dose of 100 umol/Kg,Other,9871651.0,
1545,185328,3,3,,103163840,3715,Unspecified,,,,,Lesion frequency measured in rats,Other,10197959.0,
1546,185333,3,3,,103163840,3715,Unspecified,,,,,"Compound was tested for intestinal Ulcerogenic effect in rats, activity expressed as lesion score",Other,3086558.0,
1547,185416,3,3,,103163840,3715,Unspecified,,,,,Percent inhibition was measured on untreated rat paw at different dosage forms,Other,1875355.0,
1548,185528,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rats, activity expressed as minimum ulcerogenic dose(MUD) for a period of 24 hr.",Other,6620298.0,
1549,185773,3,3,,103163840,3715,Unspecified,,,,,Percentage dose required to prevent lesion formation in gastric mucosa of unanesthetized rats upon intraperitoneal administration of 1 mg/kg dose in the HCl/ethanol-induced lesion model,Other,9873468.0,
1550,185774,3,3,,103163840,3715,Unspecified,,,,,Percentage dose required to prevent lesion formation in gastric mucosa of unanesthetized rats upon intraperitoneal administration of 10 mg/kg dose in the HCl/ethanol-induced lesion model,Other,9873468.0,
1551,185775,3,3,,103163840,3715,Unspecified,,,,,Percentage dose required to prevent lesion formation in gastric mucosa of unanesthetized rats upon intraperitoneal administration of 3 mg/kg dose in the HCl/ethanol-induced lesion model,Other,9873468.0,
1552,186127,3,3,,103163840,3715,Unspecified,,,,,"Radiographic change was judged in the area of the talus joint, using an arbitrary scoring system upon termination of the test (14 days dosing of 1 mg/kg) in a model of type II collagen arthritis in the rat.",Other,1995900.0,
1553,186277,3,3,,103163840,3715,Unspecified,,,,,"Radiographic change was judged in the area of the tarsus region, using an arbitrary scoring system upon termination of the test (14 days dosing of 1 mg/kg) in a model of type II collagen arthritis in the rat.",Other,1995900.0,
1554,186438,4,2,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 0.1 mg/kg at time interval- 0.5 hr,Other,8071938.0,
1555,186439,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 0.1 mg/kg at time interval- 1 hr,Other,8071938.0,
1556,186440,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 0.1 mg/kg at time interval- 2 hr,Other,8071938.0,
1557,186441,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 0.1 mg/kg at time interval- 3h,Other,8071938.0,
1558,186442,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 0.1 mg/kg at time interval- 4 hr,Other,8071938.0,
1559,186448,4,2,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 10 mg/kg at time interval- 0.5 hr,Other,8071938.0,
1560,186449,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 10 mg/kg at time interval- 1 hr,Other,8071938.0,
1561,186450,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 10 mg/kg at time interval- 2 hr,Other,8071938.0,
1562,186451,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 10 mg/kg at time interval- 3h,Other,8071938.0,
1563,186452,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 10 mg/kg at time interval- 4 hr,Other,8071938.0,
1564,186453,4,2,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 1 mg/kg at time interval- 0.5 hr,Other,8071938.0,
1565,186454,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 1 mg/kg at time interval- 1 hr,Other,8071938.0,
1566,186455,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 1 mg/kg at time interval- 2 hr,Other,8071938.0,
1567,186456,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 1 mg/kg at time interval- 3h,Other,8071938.0,
1568,186457,3,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of carrageenan-induced foot edema in rats at dose of 1 mg/kg at time interval- 4 hr,Other,8071938.0,
1569,186468,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema at dose of 1 mg/kg at time interval- 3h,Other,8071938.0,
1570,186469,4,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 0.1 mg/kg at time interval- 0.5 hr,Other,8071938.0,
1571,186470,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 0.1 mg/kg at time interval- 1 hr,Other,8071938.0,
1572,186471,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 0.1 mg/kg at time interval- 2 hr,Other,8071938.0,
1573,186586,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 0.1 mg/kg at time interval- 3h,Other,8071938.0,
1574,186587,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 0.1 mg/kg at time interval- 4 hr,Other,8071938.0,
1575,186593,4,3,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 10 mg/kg at time interval- 0.5 hr,Other,8071938.0,
1576,186594,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 10 mg/kg at time interval- 1 hr,Other,8071938.0,
1577,186595,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 10 mg/kg at time interval- 2 hr,Other,8071938.0,
1578,186596,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 10 mg/kg at time interval- 3h,Other,8071938.0,
1579,186597,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 10 mg/kg at time interval- 4 hr,Other,8071938.0,
1580,186598,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 1 mg/kg at time interval- 0.5 hr,Other,8071938.0,
1581,186599,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 1 mg/kg at time interval- 1 hr,Other,8071938.0,
1582,186600,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 1 mg/kg at time interval- 2 hr,Other,8071938.0,
1583,186601,3,4,,103163840,3715,Unspecified,,,,,Tested for acute anti-inflammatory activity of the antirat serum-induced edema in rats at dose of 1 mg/kg at time interval- 4 hr,Other,8071938.0,
1584,186888,2,4,,103163840,3715,Unspecified,,,,,Paw diameter measured with a micrometer caliper after 42 days initial immunization with type II collagen in rats at a dose of 200 mg/kg,Other,,
1585,187056,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for its antiinflammatory activity by adjuvant-induced polyarthritis test in rats at a dosage of 1 mg/kg administered orally,Other,6609233.0,
1586,187314,3,3,,103163840,3715,Unspecified,,,,,Relative Oral Anti inflammatory activity in the 5-h Evans Blue-Carrageenan pleural assay using indomethacin as reference compound,Other,6481768.0,
1587,187424,3,3,,103163840,3715,Unspecified,,,,,Reaction time in Hot plate test at a dose of 5 mg/kg perorally in rats after 120 min (p<0.01),Other,11597401.0,
1588,187425,3,3,,103163840,3715,Unspecified,,,,,Reaction time in Hot plate test at a dose of 5 mg/kg perorally in rats after 180 min (p<0.01),Other,11597401.0,
1589,187426,3,3,,103163840,3715,Unspecified,,,,,Reaction time in Hot plate test at a dose of 5 mg/kg perorally in rats after 60 min (p<0.01),Other,11597401.0,
1590,187727,3,3,,103163840,3715,Unspecified,,,,,Evaluated for the antiinflammatory activity in the 5-h Evans Blue-Carrageenan induced pleural effusion assay at the dose of 4.0 mg/kg (p.o.),Other,6802974.0,
1591,187729,3,3,,103163840,3715,Unspecified,,,,,Evaluated for the carrageenan-induced pleural volume in rats at a dose of 3.16 mg/kg after peroral administration.,Other,2115585.0,
1592,187756,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity evaluated by measuring % reduction of edema, 3h after oral administration of 1 mg/kg in carrageenan model",Other,6606043.0,
1593,187761,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity evaluated by measuring % reduction of edema, 3h after oral administration of 5 mg/kg in carrageenan model",Other,6606043.0,
1594,187762,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was assessed by the ability to improve the adjuvant induced arthritis in left secondary lesion in rats (volume change in the injected paw measured from day 9 to day 18),Other,3114493.0,
1595,187766,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was assessed by the ability to improve the adjuvant induced arthritis in right primary lesion in rats(volume change in the injected paw measured from day 0 to day 8),Other,3114493.0,
1596,187767,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was assessed by the ability to improve the adjuvant induced arthritis in right secondary lesion in rats (volume change in the injected paw measured from day 9 to day 18),Other,3114493.0,
1597,187770,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity was assessed improvement of adjuvant induced arthritis in rats, determined by joint mobility of the paw",Other,3114493.0,
1598,187906,3,4,,103163840,3715,Unspecified,,,,,Compound is evaluated for antiinflammatory activity using carrageenan-induced paw edema method in rat at a dose 10 mg/kg ip after 1 hr,Other,,
1599,187907,3,4,,103163840,3715,Unspecified,,,,,Compound is evaluated for antiinflammatory activity using carrageenan-induced paw edema method in rat at a dose 10 mg/kg ip after 2 hr,Other,,
1600,187908,3,4,,103163840,3715,Unspecified,,,,,Compound is evaluated for antiinflammatory activity using carrageenan-induced paw edema method in rat at a dose 10 mg/kg ip after 3h,Other,,
1601,188014,4,1,,103163840,3715,Unspecified,,,,,Evaluated for acute potency in pleural effusion assay,Other,6436487.0,
1602,188015,4,1,,103163840,3715,Unspecified,,,,,Evaluated for chronic potency in adjuvant arthritis assay,Other,6436487.0,
1603,188026,4,1,,103163840,3715,Unspecified,,,,,Pharmacological potency relative to indomethacin for prodrug candidate by adjuvant-induced arthritis assay,Other,2115589.0,
1604,188027,4,1,,103163840,3715,Unspecified,,,,,Pharmacological potency relative to indomethacin for prodrug candidate by intestinal toxicity assay.,Other,2115589.0,
1605,188038,4,1,,103163840,3715,Unspecified,,,,,Potency relative to phenylbutazone at 0.0014 mM/kg,Other,6502598.0,
1606,188068,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in the developed adjuvant arthritis assay at a dose of 0.3 mg/kg for the percent reduction of carrageenan induced edema (LHF) on 22nd day,Other,6972450.0,
1607,188069,4,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in the developed adjuvant arthritis assay at a dose of 0.3 mg/kg for the percent reduction of carrageenan induced edema (LHF) on 23rd day,Other,6972450.0,
1608,188070,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in the developed adjuvant arthritis assay at a dose of 1 mg/kg for the percent reduction of carrageenan induced edema (LHF) on 21nd day,Other,6972450.0,
1609,188071,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in the developed adjuvant arthritis assay at a dose of 1 mg/kg for the percent reduction of carrageenan induced edema (LHF) on 22nd day,Other,6972450.0,
1610,188072,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in the developed adjuvant arthritis assay at a dose of 1 mg/kg for the percent reduction of carrageenan induced edema (LHF) on 23rd day,Other,6972450.0,
1611,188080,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in the developed adjuvant arthritis assay at a dose of 3 mg/kg for the percent reduction of carrageenan induced edema (LHF) on 22nd day,Other,6972450.0,
1612,188081,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in the developed adjuvant arthritis assay at a dose of 3 mg/kg for the percent reduction of carrageenan induced edema (LHF) on 23rd day,Other,6972450.0,
1613,188207,3,4,,103163840,3715,Unspecified,,,,,Compound was evaluated in the developed adjuvant arthritis assay at a dose of 3 mg/kg for the percent reduction of carrageenan induced edema (LHF) on 21st day,Other,6972450.0,
1614,188746,3,3,,103163840,3715,Unspecified,,,,,Gastric toxicity in fasted rat at the dose of 16 mg/Kg (ig)(number of animals with damage/number of animals treated=6/6),Other,10956225.0,
1615,188751,3,3,,103163840,3715,Unspecified,,,,,Intestinal toxicity in fed rat at the dose of 16 mg/Kg (ig)(number of animals with damage/number of animals treated=6/6),Other,10956225.0,
1616,189094,3,3,,103163840,3715,Unspecified,,,,,Number of writhings in Acetic acid Writhing test at a dose of 5 mg/kg perorally in rats,Other,11597401.0,
1617,189211,3,3,,103163840,3715,Unspecified,,,,,Percent reduction of edema in rat on 23rd day after oral administration of 3 mg/kg in antiarthritis assay,Other,6606043.0,
1618,189411,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 12 hr.,Other,3669013.0,
1619,189412,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 1 hr.,Other,3669013.0,
1620,189413,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 24 hr.,Other,3669013.0,
1621,189414,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 4 hr.,Other,3669013.0,
1622,189416,3,3,,103163840,3715,Unspecified,,,,,Vocalization threshold value was measured in rat yeast induced hyperalgesia assay at a dose of 10 mg/kg for 8 hr.,Other,3669013.0,
1623,189614,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for percentage recovery from paw edema in adjuvant-induced arthritic model of rat at a dose of 2 mg/kg,Other,12113803.0,
1624,189983,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal tolerability was evaluated under acute conditions, in rats. The ulcerogenic dose was reported.",Other,6608000.0,
1625,189988,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal tolerability was evaluated under chronic conditions, in rats. The ulcerogenic dose was reported.",Other,6608000.0,
1626,189998,3,3,,103163840,3715,Unspecified,,,,,Dose which produced lesions in 50% of the treated animals,Other,7359519.0,
1627,190152,3,3,,103163840,3715,Unspecified,,,,,In vivo ulcerogenicity was determined after peroral administration in rat,Other,2115586.0,
1628,190154,3,3,,103163840,3715,Unspecified,,,,,Median ulcerogenic dose was determined at 30 mg/kg dose,Other,6606043.0,
1629,190163,3,3,,103163840,3715,Unspecified,,,,,The compound was tested for gastric ulcerogenicity in rats; ca. 8,Other,2299620.0,
1630,190164,3,3,,103163840,3715,Unspecified,,,,,The compound was tested in vivo for gastric ulcerogenic activity in rat after peroral administration,Other,11906292.0,
1631,190165,3,3,,103163840,3715,Unspecified,,,,,"Ulcerogenic dose that produced gastric lesions, ulcers and/or hemorrhage in 50% of the animals tested",Other,6972450.0,
1632,190168,3,3,,103163840,3715,Unspecified,,,,,compound was evaluated for the induction no of gastric ulcers in rats when administered perorally,Other,6982340.0,
1633,190173,3,3,,103163840,3715,Unspecified,,,,,Ulcer index at 30 mg/kg concentration,Other,6606043.0,
1634,190174,3,3,,103163840,3715,Unspecified,,,,,Ulcer index at 50 mg/kg concentration,Other,6606043.0,
1635,190175,3,3,,103163840,3715,Unspecified,,,,,Ulcer index at 5 mg/kg concentration,Other,6606043.0,
1636,190326,3,3,,103163840,3715,Unspecified,,,,,Potency in adjuvant-induced arthritis assay/ potency in intestinal toxicity assay.,Other,2115589.0,
1637,190359,3,3,,103163840,3715,Unspecified,,,,,"Compound was tested for intestinal Ulcerogenic effect in rats, activity expressed as ulcer incidence",Other,3086558.0,
1638,190366,3,3,,103163840,3715,Unspecified,,,,,Compound was tested for intestinal ulcerogenic effect in rats at a dose of 10 mg/kg,Other,3086558.0,
1639,190376,3,3,,103163840,3715,Unspecified,,,,,Concentration at which gastric damage will occur was determined in rat,Other,9135032.0,
1640,190426,4,3,,103163840,3715,Unspecified,,,,,32-day X-ray(0= normal to 10= maximum joint destruction) was determined.,Other,2115585.0,
1641,190509,3,3,,103163840,3715,Unspecified,,,,,Ulcerogenic activity administered once daily at 84 uM/kg for 4 days was determined as no of animals showing perforating ulcers,Other,15203134.0,
1642,190670,3,4,,103163840,3715,Unspecified,,,,,Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test.(animals with ulcers/animals in test) at 0.0014 mM/kg (0.50 mg),Other,6502598.0,
1643,190671,3,4,,103163840,3715,Unspecified,,,,,Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test.(animals with ulcers/animals in test) at 0.008 mM/kg (2.86 mg),Other,6502598.0,
1644,190695,3,4,,103163840,3715,Unspecified,,,,,Ulcerogenicity was measured in stomach during the 3 week adjuvant arthritis test.(animals with ulcers/animals in test) at 0.0014 mM/kg (0.50 mg),Other,6502598.0,
1645,190696,3,4,,103163840,3715,Unspecified,,,,,Ulcerogenicity was measured in stomach during the 3 week adjuvant arthritis test.(animals with ulcers/animals in test) at 0.008 mM/kg (2.86 mg),Other,6502598.0,
1646,192058,3,3,,103163840,3715,Unspecified,,,,,Compound was tested for reduction of streptococcal cell wall(SCW) in rats at a dose of 0.67 mg/kg,Other,9873452.0,
1647,192162,4,4,,103163840,3715,Active,,,,,Weight change of rat was determined; + = significant increase in weight change from control,Other,2115585.0,
1648,192169,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory efficacy is measured by the weight gain in rats during the 3 week adjuvant arthritis test at 0.0014 mM/kg (0.50 mg),Other,6502598.0,
1649,192178,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory efficacy is measured by the weight gain in rats during the 3 week adjuvant arthritis test at 0.008 mM/kg (2.86 mg),Other,6502598.0,
1650,192180,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory efficacy is measured by the weight gain in rats during the 3 week adjuvant arthritis test at 0.011 mM/kg (3.94 mg),Other,6502598.0,
1651,192291,3,3,,103163840,3715,Unspecified,,,,,Percent swelling was measured on untreated rat paw at different dosage forms,Other,1875355.0,
1652,192518,3,3,,103163840,3715,Unspecified,,,,,Percent inhibition of carrageenan induced rat paw edema 3 hr after a peroral administration of 0.5 mg/kg,Other,6977035.0,
1653,192519,3,3,,103163840,3715,Unspecified,,,,,Percent inhibition of carrageenan induced rat paw edema 3 hr after a peroral administration of 50 mg/kg,Other,6977035.0,
1654,192648,3,3,,103163840,3715,Unspecified,,,,,Dose required for Ulcerogenic effect,Other,10821716.0,
1655,192860,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity expressed as minimum effective dose was screened by using adjuvant-induced local hyperthermia in rats,Other,3118023.0,
1656,192889,3,3,,103163840,3715,Unspecified,,,,,Percentage of gastric damage was measured in rats.,Other,10197960.0,
1657,193127,3,3,,103163840,3715,Unspecified,,,,,inhibition of swelling in rat paw edema was measured at a dose of 0.7 micro mol/kg/day for days 14-25,Other,7359519.0,
1658,193129,3,3,,103163840,3715,Unspecified,,,,,inhibition of swelling in rat paw edema was measured at a dose of 1.4 micro mol/kg/day for days 14-25,Other,7359519.0,
1659,193133,3,3,,103163840,3715,Unspecified,,,,,inhibition of swelling in rat paw edema was measured at a dose of 2.8 micro mol/kg/day for days 14-25,Other,7359519.0,
1660,193136,3,3,,103163840,3715,Unspecified,,,,,inhibition of swelling in rat paw edema was measured at a dose of 7.0 micro mol/kg/day for days 14-25,Other,7359519.0,
1661,193141,3,3,,103163840,3715,Unspecified,,,,,Percentage inhibition of the prostaglandin synthesis was measured in rats.,Other,10197960.0,
1662,193232,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for edema density in adjuvant-induced arthritis model in rats at a dose of 1 mg/kg (Experiment # 1),Other,3118023.0,
1663,193234,3,3,,103163840,3715,Unspecified,,,,,Compound was evaluated for edema density in adjuvant-induced arthritis model in rats at a dose of 3 mg/kg (Experiment # 1),Other,3118023.0,
1664,193828,3,3,,103163840,3715,Unspecified,,,,,Evaluated for chronic intestinal toxicity (multiple oral dose) in rats,Other,6436487.0,
1665,193990,3,3,,103163840,3715,Unspecified,,,,,Lesion frequency was measured in rats.,Other,10197960.0,
1666,193992,4,3,,103163840,3715,Unspecified,,,,,Gastrointestinal tolerability was evaluated in rats and compound dose that causes lethality was reported.,Other,6608000.0,
1667,194098,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity was evaluated for the compound in rat adjuvant arthritis model and the percent of inhibition was determined at 1 mg/kg dose administered orally,Other,3104589.0,
1668,194136,3,3,,103163840,3715,Unspecified,,,,,Ability to inhibit Mycobacterium butyricum induced inflammatory hind paw edema in rats,Other,2118185.0,
1669,194775,3,3,,103163840,3715,Unspecified,,,,,Percentage inhibition of the prostaglandin synthesis was measured in rats.,Other,10197959.0,
1670,194778,3,3,,103163840,3715,Unspecified,,,,,Percent inhibition after administration at 2 mg/kg perorally using carrageenan induced rat paw edema method,Other,6977035.0,
1671,195801,3,3,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity against carrageenan-induced paw edema in female rats relative to phenylbutazone by p.o. administration.,Other,3491210.0,
1672,196176,3,3,,103163840,3715,Unspecified,,,,,Effect on non perforated ulcers(NPU) at the dose of 10 mg/kg.,Other,10649977.0,
1673,196179,3,3,,103163840,3715,Unspecified,,,,,Effect on perforated ulcers(PU) at the dose of 10 mg/kg.,Other,10649977.0,
1674,196724,3,3,,103163840,3715,Unspecified,,,,,In vivo antiinflammatory activity against edema formation in the noninjected(secondary) paw of the rat (after edema stimulation) at dose 2.0 mg/kg,Other,2145433.0,
1675,196726,3,3,,103163840,3715,Unspecified,,,,,In vivo antiinflammatory activity against edema formation in the noninjected(secondary) paw of the rat (before edema stimulation) at dose 2.0 mg/kg,Other,2145433.0,
1676,196876,3,3,,103163840,3715,Unspecified,,,,,Lengths of bleeding ulcer of drug-administered group,Other,10821716.0,
1677,196878,3,3,,103163840,3715,Unspecified,,,,,"Compound was evaluated for its gastroulcerogenic effect in rats at a peroral dose of 200 mg/kg, P<0.05.",Other,6609233.0,
1678,197596,4,2,,103163840,3715,Active,,,,,Lysozyme-conjugated prodrugs: in vitro stability at pH 5,Other,1560438.0,
1679,197598,4,2,,103163840,3715,Active,,,,,Lysozyme-conjugated prodrugs: in vitro stability at pH 7.4,Other,1560438.0,
1680,197600,4,2,,103163840,3715,Active,,,,,Lysozyme-conjugated prodrugs: in vitro stability in rat cortical homogenate at pH 5,Other,1560438.0,
1681,197602,4,2,,103163840,3715,Active,,,,,Lysozyme-conjugated prodrugs: in vitro stability in rat cortical homogenate at pH 7.4,Other,1560438.0,
1682,197726,4,2,,103163840,3715,Active,,,,,Lysozyme-conjugated prodrugs: in vitro stability in lysosomal lysate at pH 5,Other,1560438.0,
1683,197730,4,2,,103163840,3715,Active,,,,,Lysozyme-conjugated prodrugs: in vitro stability in buffered plasma at pH 7.4,Other,1560438.0,
1684,205268,4,7,,103163840,3715,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
1685,205269,3,7,,103163840,3715,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM,Other,2579237.0,
1686,209196,4,5,,103163840,3715,Unspecified,,,10.0,IC50,Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-23187,Confirmatory,11229777.0,
1687,209197,4,5,,103163840,3715,Active,,,0.0036,IC50,Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-23187,Confirmatory,11229777.0,
1688,209198,4,5,,103163840,3715,Unspecified,,,10.0,IC50,Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-23187,Confirmatory,11229777.0,
1689,209202,6,2,,103163840,3715,Unspecified,,,10.0,IC50,"Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4",Confirmatory,10737736.0,
1690,209204,6,2,,103163840,3715,Active,,,0.0036,IC50,"Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4",Confirmatory,10737736.0,
1691,209205,6,2,,103163840,3715,Unspecified,,,10.0,IC50,Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay,Confirmatory,10737736.0,
1692,210502,6,3,,103163840,3715,Active,,,0.1,IC50,Inhibitory activity to inhibit Inophore-induced arachidonic acid metabolism (inhibition of TXB2 formation) in rat,Confirmatory,2547071.0,
1693,212000,6,2,,103163840,3715,Unspecified,,,,,Peroral dose causing 50% death of the mice population,Other,11597401.0,
1694,212779,9,2,,103163840,3715,Unspecified,,,100.0,IC50,Inhibitory activity against thromboxane A2 synthetase,Confirmatory,3930740.0,
1695,213140,6,8,,103163840,3715,Active,3914301.0,282023.0,0.017,IC50,Inhibition of PGE-2 synthesis in bovine platelet suspension,Confirmatory,10794700.0,
1696,213140,6,8,,103163840,3715,Active,166897622.0,282022.0,0.017,IC50,Inhibition of PGE-2 synthesis in bovine platelet suspension,Confirmatory,10794700.0,
1697,213141,6,8,,103163840,3715,Unspecified,3914301.0,282023.0,,,Inhibition of PGE-2 synthesis in bovine platelet suspension,Other,10794700.0,
1698,213141,6,8,,103163840,3715,Unspecified,166897622.0,282022.0,,,Inhibition of PGE-2 synthesis in bovine platelet suspension,Other,10794700.0,
1699,220190,9,2,,103163840,3715,Active,,,0.5,IC50,Compound was evaluated for its inhibitory activity against CO(cyclooxygenase) in intact RBL-1 cell line assay,Confirmatory,,
1700,221973,6,2,,103163840,3715,Unspecified,,,100.0,IC50,In vitro effect on production of lipopolysaccharide (LPS) -induced IL1-beta in human THP-1 cells,Confirmatory,10821716.0,
1701,222769,6,2,,103163840,3715,Active,,,6.0,IC50,Inhibition of platelet aggregation induced by arachidonic acid(AA) in human platelet-rich plasma,Confirmatory,2966247.0,
1702,222778,8,2,,103163840,3715,Unspecified,,,,,In vitro inhibition of collagen-induced human platelet aggregation.,Other,6854582.0,
1703,222797,3,3,,103163840,3715,Unspecified,,,,,Relative activity (compared to acetylsalicylic acid) for in vitro inhibition of collagen-induced human platelet aggregation,Other,6854582.0,
1704,223074,6,2,,103163840,3715,Unspecified,,,10.0,IC50,Concentration required to inhibit production of LDH from whole blood stimulated with A-23187,Confirmatory,11229777.0,
1705,223075,6,2,,103163840,3715,Unspecified,,,10.0,IC50,Concentration required to inhibit production of LTB4 from whole blood stimulated with A-23187,Confirmatory,11229777.0,
1706,223076,6,2,,103163840,3715,Active,,,0.26,IC50,Concentration required to inhibit production of PGE-2 from whole blood stimulated with A-23187,Confirmatory,11229777.0,
1707,223077,6,2,,103163840,3715,Active,,,0.36,IC50,Concentration required to inhibit production of TXB2 from whole blood stimulated with A-23187,Confirmatory,11229777.0,
1708,223078,6,2,,103163840,3715,Unspecified,,,10.0,IC50,Concentration required to inhibit production of arachidonic acid from whole blood stimulated with A-23187,Confirmatory,11229777.0,
1709,223172,3,4,,103163840,3715,Unspecified,,,,,Percent reduction of edema in mice 3h after oral administration of 3 mg/kg in carrageenan model,Other,6606043.0,
1710,223721,3,3,,103163840,3715,Unspecified,,,,,Activity against arthritis on adjuvant-untreated paw in rats at 1 mg/kg by oral administration,Other,1469696.0,
1711,223739,6,1,,103163840,3715,Unspecified,,,,,The compound was tested for IL-1 generation on CMC-LPS air-pouch model at 3 mg/kg by oral administration,Other,1469696.0,
1712,223906,3,3,,103163840,3715,Unspecified,,,,,The compound was tested for Granuloma generation on CMC-LPS air-pouch model at 3 mg/kg by oral administration,Other,1469696.0,
1713,223907,4,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity dosed orally against D-adjuvant arthiritis in rat.,Other,1732553.0,
1714,224060,3,3,,103163840,3715,Unspecified,,,,,% inhibition against arthritis on adjuvant-untreated paw in rats at 1 mg/kg by oral administration,Other,1469696.0,
1715,224062,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against D-adjuvant arthiritis in injected rat paw at the dose of 1.0 mg/kg by oral administration,Other,1732553.0,
1716,224063,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against D-adjuvant arthiritis in injected rat paw at the dose of 2.5 mg/kg by oral administration,Other,1732553.0,
1717,224064,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against D-adjuvant arthiritis in uninjected rat paw at the dose of 1.0 mg/kg by oral administration,Other,1732553.0,
1718,224065,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against D-adjuvant arthiritis in uninjected rat paw at the dose of 50 mg/kg by oral administration,Other,1732553.0,
1719,224209,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity against Granuloma on CMC-LPS air-pouch model at 3 mg/kg by oral administration,Other,1469696.0,
1720,224212,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity against IL-1 on CMC-LPS air-pouch model at 3 mg/kg by oral administration,Other,1469696.0,
1721,224215,3,3,,103163840,3715,Unspecified,,,,,Inhibitory activity against PGE-2 on CMC-LPS air-pouch model at 3 mg/kg by oral administration,Other,1469696.0,
1722,224362,3,4,,103163840,3715,Unspecified,,,,,Intestinal ulcerogenic activity at a dose of 10 mg/kg,Other,1560442.0,
1723,225628,4,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity dosed orally against carrageenan induced rat paw edema(CPE),Other,1732553.0,
1724,227084,3,5,,103163840,3715,Unspecified,,,,,Relative binding affinity to 5-lipoxygenase and cyclooxygenase,Other,2115586.0,
1725,227272,6,1,,103163840,3715,Unspecified,,,,,The compound was tested for PGE-2 generation on CMC-LPS air-pouch model at 3 mg/kg by oral administration,Other,1469696.0,
1726,227554,3,4,,103163840,3715,Unspecified,,,,,Acute therapeutic index as ratio of potency in pleural effusion to that of potency in gastric toxicity assay,Other,6436487.0,
1727,228004,6,2,,103163840,3715,Unspecified,,,100.0,IC50,In vitro effect on production of calcium ionophore (A23187) -induced Leukotriene B4 (LTB4) in rat peritoneal cells,Confirmatory,10821716.0,
1728,228173,6,4,,103163840,3715,Active,548484.0,29527.0,0.0029,IC50,In vitro inhibitory effect on production of prostaglandin E2 (PGE2) in rat synovial cells.,Confirmatory,10821716.0,
1729,228173,6,4,,103163840,3715,Active,3914292.0,24693.0,0.0029,IC50,In vitro inhibitory effect on production of prostaglandin E2 (PGE2) in rat synovial cells.,Confirmatory,10821716.0,
1730,228468,3,3,,103163840,3715,Unspecified,,,,,Chronic therapeutic index as ratio of potency in adjuvant-induced arthritis assay to that of potency in intestinal toxicity assay,Other,6436487.0,
1731,229414,3,10,,103163840,3715,Unspecified,3915797.0,5743.0,,,Selectivity ratio for COX-1 over COX-2,Other,11906292.0,
1732,229414,3,10,,103163840,3715,Unspecified,317373262.0,5742.0,,,Selectivity ratio for COX-1 over COX-2,Other,11906292.0,
1733,229415,3,6,,103163840,3715,Unspecified,,,,,Selectivity ratio (COX-1/COX-2),Other,11906281.0,
1734,229532,4,3,,103163840,3715,Unspecified,,,,,Ratio of IC50 values at Cyclooxygenase-1 and Cyclooxygenase-2,Other,10406640.0,
1735,229902,3,10,,103163840,3715,Unspecified,3915797.0,5743.0,,,Relative binding to COX-1 and COX-2 (ratio of IC50),Other,10956225.0,
1736,229902,3,10,,103163840,3715,Unspecified,317373262.0,5742.0,,,Relative binding to COX-1 and COX-2 (ratio of IC50),Other,10956225.0,
1737,229958,3,7,,103163840,3715,Unspecified,,,,,IC50 ratio measured as the IC50 values of COX-1 to that of COX-2.,Other,7562922.0,
1738,230227,3,3,,103163840,3715,Unspecified,,,,,Inhibitory ratio at 1.0 mg/ear,Other,7473540.0,
1739,232223,3,10,,103163840,3715,Unspecified,3915797.0,5743.0,,,Selectivity for COX-1/COX-2 was determined,Other,,
1740,232223,3,10,,103163840,3715,Unspecified,317373262.0,5742.0,,,Selectivity for COX-1/COX-2 was determined,Other,,
1741,232419,3,6,,103163840,3715,Unspecified,,,,,Ratio of inhibition of COX-1 to COX-2,Other,10821716.0,
1742,232500,3,7,,103163840,3715,Unspecified,,,,,Selectivity ratio of COX-1/COX-2,Other,10649977.0,
1743,232623,3,10,,103163840,3715,Unspecified,3915797.0,5743.0,,,Relative inhibitory activity against COX-1 and COX-2,Other,10397507.0,
1744,232623,3,10,,103163840,3715,Unspecified,317373262.0,5742.0,,,Relative inhibitory activity against COX-1 and COX-2,Other,10397507.0,
1745,233584,3,7,,103163840,3715,Unspecified,,,,,Ratio of IC50 of COX-1 to COX-2.,Other,7473585.0,
1746,233634,3,7,,103163840,3715,Unspecified,,,,,Ratio of inhibitory concentration of COX-1 and COX-2 measured for their oral activity in an acute inflammation model,Other,8627608.0,
1747,233697,3,8,,103163840,3715,Unspecified,,,,,Selectivity ratio against COX-1 and COX-2 binding,Other,,
1748,233833,3,8,,103163840,3715,Unspecified,,,,,Selectivity (COX-1/COX-2) was determined,Other,,
1749,234761,3,10,,103163840,3715,Unspecified,3915797.0,5743.0,,,Ratio of inhibitory activity against COX-1 and COX-2,Other,10937738.0,
1750,234761,3,10,,103163840,3715,Unspecified,317373262.0,5742.0,,,Ratio of inhibitory activity against COX-1 and COX-2,Other,10937738.0,
1751,234944,3,10,,103163840,3715,Unspecified,3915797.0,5743.0,,,Ratio of IC50 for COX-1 and COX-2 binding inhibitors,Other,7966148.0,
1752,234944,3,10,,103163840,3715,Unspecified,317373262.0,5742.0,,,Ratio of IC50 for COX-1 and COX-2 binding inhibitors,Other,7966148.0,
1753,235405,3,3,,103163840,3715,Unspecified,,,,,Therapeutic ratio was determined for peroral administration,Other,6218302.0,
1754,235519,4,7,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50s from COX-1 and COX-2,Other,10956194.0,
1755,235767,3,3,,103163840,3715,Unspecified,,,,,Ratio of UD50 to that of ED50,Other,7359519.0,
1756,235831,3,3,,103163840,3715,Unspecified,,,,,Safety index is the ratio of UD50 to ED50 in carrageenan hind paw edema,Other,2299620.0,
1757,235863,3,7,,103163840,3715,Unspecified,,,,,In vitro selectivity against COX-1 to that of COX-2 was determined,Other,12954051.0,
1758,237416,3,4,,103163840,3715,Unspecified,,,,,Log D value against bovine serum albumin,Other,15267234.0,
1759,237474,3,3,,103163840,3715,Unspecified,,,,,Percentage of drug bound in bovine plasma albumin,Other,15267234.0,
1760,237685,4,3,,103163840,3715,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
1761,238375,10,1,,103163840,3715,Unspecified,2495010.0,19214.0,10.0,Ki,Binding affinity for mouse Prostanoid DP receptor,Confirmatory,15357992.0,
1762,238401,10,5,,103163840,3715,Unspecified,548475.0,19216.0,10.0,Ki,Binding affinity for mouse Prostanoid EP1 receptor,Confirmatory,15357992.0,
1763,238402,10,1,,103163840,3715,Unspecified,2495012.0,19217.0,10.0,Ki,Binding affinity for mouse Prostanoid EP2 receptor,Confirmatory,15357992.0,
1764,238403,10,1,,103163840,3715,Unspecified,266747.0,19218.0,10.0,Ki,Binding affinity for mouse Prostanoid EP3 receptor,Confirmatory,15357992.0,
1765,238404,10,1,,103163840,3715,Unspecified,417466.0,19219.0,10.0,Ki,Binding affinity for mouse Prostanoid EP4 receptor,Confirmatory,15357992.0,
1766,239780,3,9,,103163840,3715,Unspecified,113576.0,213.0,,,Percentage plasma protein binding towards human serum albumin,Other,15801837.0,
1767,239787,3,10,,103163840,3715,Unspecified,3914304.0,443460.0,,,Ratio of IC50 against COX-1 to that of COX-2,Other,15943479.0,
1768,239787,3,10,,103163840,3715,Unspecified,754286265.0,443551.0,,,Ratio of IC50 against COX-1 to that of COX-2,Other,15943479.0,
1769,239789,3,11,,103163840,3715,Unspecified,129900.0,19224.0,,,Ratio of IC50 of Prostaglandin G/H synthase 1 and Prostaglandin G/H synthase 2,Other,15857149.0,
1770,239789,3,11,,103163840,3715,Unspecified,548483.0,19225.0,,,Ratio of IC50 of Prostaglandin G/H synthase 1 and Prostaglandin G/H synthase 2,Other,15857149.0,
1771,239884,4,2,,103163840,3715,Unspecified,,,,,pKa value of the compound,Other,15267234.0,
1772,240795,9,5,,103163840,3715,Active,754286265.0,443551.0,0.1,IC50,In vitro inhibitory concentration against COX-1 enzyme,Confirmatory,15943479.0,
1773,240796,9,5,,103163840,3715,Active,3914304.0,443460.0,5.7,IC50,In vitro inhibitory concentration against COX-2 enzyme,Confirmatory,15943479.0,
1774,241074,10,1,,103163840,3715,Unspecified,2495010.0,19214.0,10.0,IC50,Inhibition of mouse Prostanoid DP receptor,Confirmatory,15357992.0,
1775,241917,10,1,,103163840,3715,Active,129900.0,19224.0,0.002,IC50,In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells,Confirmatory,15857149.0,
1776,241918,10,1,,103163840,3715,Active,548483.0,19225.0,0.009000000000000001,IC50,In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells,Confirmatory,15857149.0,
1777,243230,4,1,,103163840,3715,Unspecified,113576.0,213.0,15135600000.0,Ki,Binding affinity towards human serum albumin,Confirmatory,15801837.0,
1778,243647,3,8,,103163840,3715,Unspecified,,,,,In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive,Other,15369391.0,
1779,243653,3,7,,103163840,3715,Unspecified,548483.0,19225.0,,,Percentage inhibition of Prostaglandin G/H synthase 2 in murine J774 cells at 1 uM,Other,15857149.0,
1780,243659,3,7,,103163840,3715,Unspecified,548483.0,19225.0,,,Percentage inhibition of Prostaglandin G/H synthase 2 in murine J774 cells at 10 uM,Other,15857149.0,
1781,249066,6,2,,103163840,3715,Unspecified,,,,,In vivo antiinflammatory activity after 3 hr of oral administration was determined using rat carrageenan induced paw edema model,Other,15943479.0,
1782,249667,3,5,,103163840,3715,Active,,,,,Effect of compound (10 uM) on doxorubicin-induced cytotoxicity towards T98G cell line expressing multidrug resistance associated protein 1 (MRP-1); Active,Other,15715484.0,
1783,252988,3,3,,103163840,3715,Unspecified,,,,,Acute ulcerogenic activity is measured as gastric ulcer index upon administration at dose equivalent to 250 mg of aspirin/kg,Other,15943479.0,
1784,254389,9,5,,103163840,3715,Active,296439334.0,11251.0,8.0,Ki,Binding affinity towards human CRTH2 receptor expressed in CHO cells; range 25 nM to 8 uM,Confirmatory,16190744.0,
1785,254438,8,5,,103163840,3715,Active,296439334.0,11251.0,0.05,Ki,In vitro binding affinity (agonistic) towards human CRTH2 receptor expressed in CHO cells; range 15 to 25 nM,Confirmatory,16190744.0,
1786,255251,3,9,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibitory concentration against human cyclooxygenase-1 at 10 uM,Other,16190777.0,
1787,255261,3,9,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibitory concentration against human cyclooxygenase-2 at 10 uM concentration,Other,16190777.0,
1788,256340,3,4,,103163840,3715,Unspecified,,,,,Percent inhibition of carrageenan 2% (0.1 mL intradermal) induced paw edema at the i.p. dose of 0.01 m mol/kg in fisher 344 rats; n=5,Other,16190766.0,
1789,260543,3,3,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity against paw edema induced by carrageenan in fischer rat at 300 umol/kg, ip",Other,16309906.0,
1790,260546,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in rat at 84 umol/kg, sc",Other,16309906.0,
1791,260554,3,3,,103163840,3715,Unspecified,,,,,"Increase in paw weight in Fischer rats at 300 umol/kg, ip",Other,16309906.0,
1792,263719,3,12,,103163840,3715,Unspecified,1709856.0,5663.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 100 uM,Other,16455248.0,
1793,263719,3,12,,103163840,3715,Unspecified,1709858.0,5664.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 100 uM,Other,16455248.0,
1794,263719,3,12,,103163840,3715,Unspecified,12231037.0,23385.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 100 uM,Other,16455248.0,
1795,263719,3,12,,103163840,3715,Unspecified,37077707.0,51107.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 100 uM,Other,16455248.0,
1796,263719,3,12,,103163840,3715,Unspecified,37081820.0,55851.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 100 uM,Other,16455248.0,
1797,263719,3,12,,103163840,3715,Unspecified,61252592.0,83464.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 100 uM,Other,16455248.0,
1798,263722,3,6,,103163840,3715,Unspecified,,,,,Inhibition of beta amyloid protein 42 in HEK cell lines overexpressing APP695 at 100 uM,Other,16455248.0,
1799,263727,7,1,,103163840,3715,Active,,,,,"Drug level in mouse brain at 50 mg/kg, po",Other,16455248.0,
1800,263728,7,1,,103163840,3715,Unspecified,,,,,"Drug level in mouse plasma at 50 mg/kg, po",Other,16455248.0,
1801,263729,3,3,,103163840,3715,Unspecified,,,,,"Ratio of drug level in brain against plasma in mice at 50 mg/kg, po",Other,16455248.0,
1802,266763,4,1,,103163840,3715,Unspecified,,,,,Membrane retention in 70% silicon-30% IPM membrane,Other,16789751.0,
1803,266764,3,3,,103163840,3715,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane",Other,16789751.0,
1804,266765,6,1,,103163840,3715,Unspecified,,,,,Effective permeability coefficient in 70% silicon-30% IPM membrane,Other,16789751.0,
1805,266766,3,3,,103163840,3715,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,16789751.0,
1806,266771,6,1,,103163840,3715,Unspecified,,,,,Permeability in human skin,Other,16789751.0,
1807,271283,7,6,,103163840,3715,Active,317373262.0,5742.0,0.005,IC50,Inhibition of COX1 assessed as TBX2 production in human whole blood,Confirmatory,16814546.0,
1808,271284,7,6,,103163840,3715,Active,3915797.0,5743.0,0.036000000000000004,IC50,Inhibition of COX2 assessed as LPS-stimulated PGE2 production in human whole blood leukocyte,Confirmatory,16814546.0,
1809,271285,3,10,,103163840,3715,Unspecified,3915797.0,5743.0,,,"Selectivity index, IC50 for COX1/IC50 for COX2 in human whole blood",Other,16814546.0,
1810,271285,3,10,,103163840,3715,Unspecified,317373262.0,5742.0,,,"Selectivity index, IC50 for COX1/IC50 for COX2 in human whole blood",Other,16814546.0,
1811,271286,9,5,,103163840,3715,Active,754286265.0,443551.0,0.004,IC50,Inhibition of ovine COX1,Confirmatory,16814546.0,
1812,271287,9,5,,103163840,3715,Active,3914304.0,443460.0,0.34,IC50,Inhibition of ovine COX2,Confirmatory,16814546.0,
1813,271288,3,10,,103163840,3715,Unspecified,3914304.0,443460.0,,,"Selectivity index, IC50 for ovine COX1/IC50 for ovine COX2",Other,16814546.0,
1814,271288,3,10,,103163840,3715,Unspecified,754286265.0,443551.0,,,"Selectivity index, IC50 for ovine COX1/IC50 for ovine COX2",Other,16814546.0,
1815,274903,3,10,,103163840,3715,Unspecified,129900.0,19224.0,,,Activity at COX1 assessed as inhibition of arachidonic acid-induced PGE2 production in J774 cells at 100 uM,Other,17181159.0,
1816,274904,3,10,,103163840,3715,Unspecified,129900.0,19224.0,,,Activity at COX1 assessed as inhibition of arachidonic acid-induced PGE2 production in J774 cells at 10 uM,Other,17181159.0,
1817,274905,3,10,,103163840,3715,Unspecified,129900.0,19224.0,,,Activity at COX1 assessed as inhibition of arachidonic acid-induced PGE2 production in J774 cells,Other,17181159.0,
1818,274909,3,3,,103163840,3715,Active,,,,,Antiinflammatory activity in carrageenan-induced mouse paw edema,Other,17181159.0,
1819,274912,4,3,,103163840,3715,Unspecified,,,,,"Gastric damage in rat at 100 mg/kg, po by GI damage assay",Other,17181159.0,
1820,277214,3,4,,103163840,3715,Inactive,,,,,"Reduction of edema formation in rat reverse passive arthus model at 3 mg/kg, po",Other,17243660.0,
1821,284322,5,8,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 100 uM,Other,17079150.0,
1822,284323,5,8,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 100 uM,Other,17079150.0,
1823,284324,9,5,,103163840,3715,Active,754286265.0,443551.0,0.03,IC50,Inhibition of ovine COX1,Confirmatory,17079150.0,
1824,284325,9,5,,103163840,3715,Active,3914304.0,443460.0,7.7,IC50,Inhibition of ovine COX2,Confirmatory,17079150.0,
1825,284326,3,3,,103163840,3715,Active,,,,,"Effect on gastric damage in rat assessed as induction of gastric ulcer at 10 mg/kg, po after 5 hrs",Other,17079150.0,
1826,284327,3,3,,103163840,3715,Active,,,,,"Effect on gastric damage in rat assessed as induction of gastric ulcer at 30 mg/kg, po after 5 hrs",Other,17079150.0,
1827,284339,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity assessed as reduction of carrageenan-induced paw volume in Wistar rat at 10 mg/kg, ip after 3 hrs",Other,17079151.0,
1828,286231,9,5,,103163840,3715,Active,317373262.0,5742.0,0.036000000000000004,IC50,Inhibition of human platelet COX1 by EIA assay,Confirmatory,17378609.0,
1829,286751,3,9,,103163840,3715,Inconclusive,126398.0,547923.0,,,Inhibition of soybean lipoxygenase at 0.1 mM,Other,17444626.0,
1830,286752,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced Fischer 344 rat paw edema at 0.01 mmol/kg, ip",Other,17444626.0,
1831,287011,3,3,,103163840,3715,Unspecified,,,,,Inhibition of LPS-induced TNFalpha secretion in C57BL/6J mouse peritoneal macrophages at 10 uM after 24 hrs,Other,17461599.0,
1832,287076,4,2,,103163840,3715,Unspecified,,,,,Inhibition of TPA-induced inflammation in mouse assessed per ear by edema assay,Other,17480098.0,
1833,287089,6,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in ICR mouse assessed as inhibition of TPA-induced edema per ear applied topically 30 mins before TPA treatment,Other,17480100.0,
1834,287090,3,3,,103163840,3715,Unspecified,,,,,Inhibitory ratio of TPA-induced edema in presence of drug to TPA-induced edema in ICR mouse,Other,17480100.0,
1835,287142,3,3,,103163840,3715,Unspecified,,,,,"Toxicity assessed as ulcerogenic effect in Albino rat at 30 mg/kg, po twice a day after 3 days",Other,17052805.0,
1836,287233,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory effect on carrageenan-induced paw oedema Sprague-Dawley rat assessed as reduction of paw oedema at 10 mg/kg, ip",Other,17129641.0,
1837,287288,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Swiss albino mouse assessed as swelling thickness at 100 mg/kg, po after 90 mins",Other,17166724.0,
1838,287289,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Swiss albino mouse assessed as swelling thickness at 100 mg/kg, po after 180 mins",Other,17166724.0,
1839,287290,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Swiss albino mouse assessed as swelling thickness at 100 mg/kg, po after 270 mins",Other,17166724.0,
1840,287291,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Swiss albino mouse assessed as swelling thickness at 100 mg/kg, po after 360 mins",Other,17166724.0,
1841,287292,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Swiss albino mouse at 100 mg/kg, po after 90 mins relative to control",Other,17166724.0,
1842,287293,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Swiss albino mouse at 100 mg/kg, po after 180 mins relative to control",Other,17166724.0,
1843,287294,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Swiss albino mouse at 100 mg/kg, po after 270 mins relative to control",Other,17166724.0,
1844,287295,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Swiss albino mouse at 100 mg/kg, po after 360 mins relative to control",Other,17166724.0,
1845,287337,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Swiss albino mouse assessed as swelling thickness at 10 mg/kg, po after 90 mins",Other,17166724.0,
1846,287338,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Swiss albino mouse assessed as swelling thickness at 10 mg/kg, po after 180 mins",Other,17166724.0,
1847,287339,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Swiss albino mouse assessed as swelling thickness at 10 mg/kg, po after 270 mins",Other,17166724.0,
1848,287340,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Swiss albino mouse assessed as swelling thickness at 10 mg/kg, po after 360 mins",Other,17166724.0,
1849,287341,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Swiss albino mouse at 10 mg/kg, po after 90 mins relative to control",Other,17166724.0,
1850,287342,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Swiss albino mouse at 10 mg/kg, po after 180 mins relative to control",Other,17166724.0,
1851,287343,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Swiss albino mouse at 10 mg/kg, po after 270 mins relative to control",Other,17166724.0,
1852,287344,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Swiss albino mouse at 10 mg/kg, po after 360 mins relative to control",Other,17166724.0,
1853,287607,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar Albino rat assessed as inhibition of carrageenan-induced paw oedema at 5 mg/kg, ip after 1 hr",Other,17267228.0,
1854,287608,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar Albino rat assessed as inhibition of carrageenan-induced paw oedema at 5 mg/kg, ip after 2 hrs",Other,17267228.0,
1855,287609,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar Albino rat assessed as inhibition of carrageenan-induced paw oedema at 5 mg/kg, ip after 3 hrs",Other,17267228.0,
1856,287610,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar Albino rat assessed as inhibition of carrageenan-induced paw oedema at 5 mg/kg, ip after 4 hrs",Other,17267228.0,
1857,287611,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in Wistar Albino rat assessed as mean swelling paw volume at 5 mg/kg, ip after 1 hr",Other,17267228.0,
1858,287612,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in Wistar Albino rat assessed as mean swelling paw volume at 5 mg/kg, ip after 2 hrs",Other,17267228.0,
1859,287613,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in Wistar Albino rat assessed as mean swelling paw volume at 5 mg/kg, ip after 3 hrs",Other,17267228.0,
1860,287614,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in Wistar Albino rat assessed as mean swelling paw volume at 5 mg/kg, ip after 4 hrs",Other,17267228.0,
1861,288821,9,5,,103163840,3715,Active,754286265.0,443551.0,0.1,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,17509888.0,
1862,288822,9,5,,103163840,3715,Active,3914304.0,443460.0,5.7,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,17509888.0,
1863,288823,3,3,,103163840,3715,Unspecified,,,,,Selectivity index COX1 over COX2,Other,17509888.0,
1864,288824,7,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced rat paw edema in orally dosed rat after 3 hrs,Other,17509888.0,
1865,288829,3,3,,103163840,3715,Unspecified,,,,,"Gastric damage production in rat assessed as gastric ulcer index at 0.08 mmol/kg, po after 6 hrs",Other,17509888.0,
1866,289271,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced paw edema in Fisher 344 rat at 0.01 mol/kg, ip relative to control",Other,17604175.0,
1867,289291,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw oedema in Swiss Albino mouse assessed as swelling thickeness at 100 mg/kg, po after 90 mins",Other,17611112.0,
1868,289292,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw oedema in Swiss Albino mouse assessed as swelling thickeness at 100 mg/kg, po after 180 mins",Other,17611112.0,
1869,289293,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw oedema in Swiss Albino mouse assessed as swelling thickeness at 100 mg/kg, po after 270 mins",Other,17611112.0,
1870,289294,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw oedema in Swiss Albino mouse assessed as swelling thickeness at 100 mg/kg, po after 360 mins",Other,17611112.0,
1871,289295,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced hind paw oedema in Swiss Albino mouse at 100 mg/kg, po after 90 mins relative to control",Other,17611112.0,
1872,289296,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced hind paw oedema in Swiss Albino mouse at 100 mg/kg, po after 180 mins relative to control",Other,17611112.0,
1873,289297,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced hind paw oedema in Swiss Albino mouse at 100 mg/kg, po after 270 mins relative to control",Other,17611112.0,
1874,289298,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced hind paw oedema in Swiss Albino mouse at 100 mg/kg, po after 360 mins relative to control",Other,17611112.0,
1875,289300,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of acetic acid-induced capillary permeability in Swiss Albino mouse at 10 mg/kg, po",Other,17611112.0,
1876,293408,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister Albino rat assessed as inhibition of paw edema at 1.5 mg/kg, po after 3hrs",Other,17189665.0,
1877,295042,10,2,,103163840,3715,Active,,,5.6,IC50,Inhibition of COX1,Confirmatory,17346963.0,
1878,295043,10,2,,103163840,3715,Unspecified,,,77.1,IC50,Inhibition of COX2,Confirmatory,17346963.0,
1879,295044,10,6,,103163840,3715,Active,74752227.0,10170.0,14.0,IC50,Inhibition of 3alphaHSD,Confirmatory,17346963.0,
1880,295358,3,3,,103163840,3715,Unspecified,,,,,"Toxicity in arthritic Wistar rat assessed as gastric ulcerogenic response at 10 mg/kg, po",Other,17382550.0,
1881,295467,4,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced hind paw oedema at 35 mg/kg, po after 4 hrs",Other,17395469.0,
1882,295469,3,3,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in Swiss mouse assessed as inhibition of acetic-acid induced writhing at 35 mg/kg, po after 30 mins by Koster test",Other,17395469.0,
1883,295471,3,3,,103163840,3715,Unspecified,,,,,"Effect on thermal pain in Swiss mouse at 35 mg/kg, po after 1 hr by hot plate test",Other,17395469.0,
1884,295671,3,3,,103163840,3715,Unspecified,,,,,Antinociceptive activity in sc dosed Sprague-Dawley rat assessed as increase in latency time after 1 hr by hot plate method,Other,17408809.0,
1885,295677,3,3,,103163840,3715,Unspecified,,,,,Antinociceptive activity in sc dosed Sprague-Dawley rat assessed as increase in latency time after 2 hrs by hot plate method,Other,17408809.0,
1886,300444,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw oedema in mouse assessed as inhibition of swelling thickness at 10 mg/kg, po after 90 mins",Other,17587585.0,
1887,300447,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw oedema in mouse assessed as inhibition of swelling thickness at 10 mg/kg, po after 180 mins",Other,17587585.0,
1888,300450,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw oedema in mouse assessed as inhibition of swelling thickness at 10 mg/kg, po after 270 mins",Other,17587585.0,
1889,300453,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced hind paw oedema in mouse assessed as inhibition of swelling thickness at 10 mg/kg, po after 360 mins",Other,17587585.0,
1890,302058,9,1,,103163840,3715,Unspecified,,,,,Inhibition of IL1-beta induced MMP3 secretion in human articular chondrocytes at 100 ug/ml,Other,17889545.0,
1891,302758,4,2,,103163840,3715,Active,,,,,Solubility by shake flask method,Other,17929794.0,
1892,303030,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced paw edema rat model at 0.01 mmol/ml/kg,Other,17942306.0,
1893,303564,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 1 hr",Other,17964781.0,
1894,303565,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 2 hrs",Other,17964781.0,
1895,303566,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 3 hrs",Other,17964781.0,
1896,303567,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 4 hrs",Other,17964781.0,
1897,303568,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 6 hrs",Other,17964781.0,
1898,303569,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 24 hrs",Other,17964781.0,
1899,303570,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss Albino mouse assessed as number of acetic acid-induced writhing at 100 mg/kg, po after 1 hr relative to control",Other,17964781.0,
1900,303572,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss Albino mouse assessed as inhibition of acetic acid-induced writhing responses at 100 mg/kg, po after 1 hr",Other,17964781.0,
1901,303574,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against LPS-induced pyresis in Wistar rat assessed as change in rectal temperature at 100 mg/kg, po after 1 hr",Other,17964781.0,
1902,303575,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against LPS-induced pyresis in Wistar rat assessed as change in rectal temperature at 100 mg/kg, po after 2 hrs",Other,17964781.0,
1903,303576,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against LPS-induced pyresis in Wistar rat assessed as change in rectal temperature at 100 mg/kg, po after 3 hrs",Other,17964781.0,
1904,303577,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against LPS-induced pyresis in Wistar rat assessed as change in rectal temperature at 100 mg/kg, po after 4 hrs",Other,17964781.0,
1905,303578,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against LPS-induced pyresis in Wistar rat assessed as change in rectal temperature at 100 mg/kg, po after 5 hrs",Other,17964781.0,
1906,303579,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against LPS-induced pyresis in Wistar rat assessed as change in rectal temperature at 100 mg/kg, po after 6 hrs",Other,17964781.0,
1907,303580,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against LPS-induced pyresis in Wistar rat assessed as change in rectal temperature at 100 mg/kg, po after 7 hrs",Other,17964781.0,
1908,303591,3,3,,103163840,3715,Unspecified,,,,,"Antiarthritic activity against adjuvant-induced arthritis in Wistar rat assessed as inhibition of paw edema at 10 mg/kg, po on day 3",Other,17964781.0,
1909,303592,3,3,,103163840,3715,Unspecified,,,,,"Antiarthritic activity against adjuvant-induced arthritis in Wistar rat assessed as inhibition of paw edema at 10 mg/kg, po on day 8",Other,17964781.0,
1910,303593,3,3,,103163840,3715,Unspecified,,,,,"Antiarthritic activity against adjuvant-induced arthritis in Wistar rat assessed as inhibition of paw edema at 10 mg/kg, po on day 13",Other,17964781.0,
1911,303595,3,3,,103163840,3715,Unspecified,,,,,"Antiarthritic activity against adjuvant-induced arthritis in Wistar rat assessed as weight change at 10 mg/kg, po",Other,17964781.0,
1912,303596,3,3,,103163840,3715,Unspecified,,,,,"Toxicity in 24 hrs fasted Wistar rat assessed as ulcer index at 30 mg/kg, po after 6 hrs",Other,17964781.0,
1913,303599,3,3,,103163840,3715,Unspecified,,,,,"Toxicity in 24 hrs fasted Wistar rat assessed as ulcer index at 1 mg/kg, po after 14 days",Other,17964781.0,
1914,304223,9,5,,103163840,3715,Active,317373262.0,5742.0,0.5,IC50,Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production,Confirmatory,17994684.0,
1915,304224,9,5,,103163840,3715,Active,3915797.0,5743.0,0.7,IC50,Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production,Confirmatory,17994684.0,
1916,304225,4,3,,103163840,3715,Unspecified,,,,,Selectivity for human COX2 over human COX1,Other,17994684.0,
1917,304226,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against intrapouch dosed Sprague-Dawley rat carrageenan air-pouch model assessed as reduction of prostaglandin E2 at 45 umol/kg,Other,17994684.0,
1918,304228,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against Sprague-Dawley rat carrageenan air-pouch model assessed as reduction of prostaglandin E2 at 22.5 umol/kg, po",Other,17994684.0,
1919,304235,3,9,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 3 uM relative to control,Other,17994684.0,
1920,304236,3,9,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 1 uM relative to control,Other,17994684.0,
1921,304237,3,9,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 0.3 uM relative to control,Other,17994684.0,
1922,304238,3,9,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 0.1 uM relative to control,Other,17994684.0,
1923,304239,3,9,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 0.03 uM relative to control,Other,17994684.0,
1924,304240,3,9,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 0.1 uM relative to control,Other,17994684.0,
1925,304241,3,9,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 0.3 uM relative to control,Other,17994684.0,
1926,304242,3,9,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 1 uM relative to control,Other,17994684.0,
1927,304243,3,9,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 3 uM relative to control,Other,17994684.0,
1928,305968,6,2,,103163840,3715,Active,,,0.14,IC50,Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation,Confirmatory,17197180.0,
1929,305969,6,2,,103163840,3715,Unspecified,,,100.0,IC50,Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation,Confirmatory,17197180.0,
1930,305970,6,2,,103163840,3715,Unspecified,,,40.0,IC50,Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation,Confirmatory,17197180.0,
1931,305971,6,2,,103163840,3715,Unspecified,,,40.0,IC50,Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release,Confirmatory,17197180.0,
1932,309363,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear oedema at 0.3 umol/cm^2 after 6 hrs,Other,17768049.0,
1933,310931,3,4,,103163840,3715,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17300161.0,
1934,310932,3,6,,103163840,3715,Unspecified,,,,,Permeability across human Skin,Other,17300161.0,
1935,310933,3,4,,103163840,3715,Unspecified,,,,,Permeability across PAMPA membrane after 7 hrs,Other,17300161.0,
1936,311367,3,6,,103163840,3715,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
1937,312246,3,3,,103163840,3715,Unspecified,,,,,"Increase in body weight in acetic acid-induced chronic gastric ulcer Wistar rat at 2.0 mg/kg, po",Other,18072726.0,
1938,312248,3,3,,103163840,3715,Unspecified,,,,,"Effect on acetic acid-induced chronic gastric ulcer Wistar rat assessed as area of ulcer at 2.0 mg/kg, po",Other,18072726.0,
1939,313119,7,1,,103163840,3715,Active,,,,,Inhibition of mouse COX2 V349A mutant,Other,17341061.0,
1940,313120,12,1,,103163840,3715,Active,548483.0,19225.0,,IC50,Inhibition of mouse wild type COX2,Confirmatory,17341061.0,
1941,313121,7,1,,103163840,3715,Active,,,,,Inhibition of mouse COX2 V349L mutant,Other,17341061.0,
1942,313125,9,2,,103163840,3715,Active,,,0.01,IC50,Inhibition of COX2,Confirmatory,17341061.0,
1943,313126,9,2,,103163840,3715,Active,,,0.006,IC50,Inhibition of COX1,Confirmatory,17341061.0,
1944,313770,3,9,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 0.01 uM,Other,18061444.0,
1945,313771,3,9,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 10 uM,Other,18061444.0,
1946,313772,9,5,,103163840,3715,Active,3914304.0,443460.0,0.75,IC50,Inhibition of ovine COX2,Confirmatory,18061444.0,
1947,313773,9,5,,103163840,3715,Active,754286265.0,443551.0,0.05,IC50,Inhibition of ovine COX1,Confirmatory,18061444.0,
1948,313774,3,3,,103163840,3715,Unspecified,,,,,"Selectivity index, Ratio of IC50 for ovine COX2 to IC50 for ovine COX1",Other,18061444.0,
1949,314422,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in rat assessed as reversal of CFA-induced hyperalgesia at 3 mg/kg, po after 2 hrs",Other,18243692.0,
1950,314423,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in rat assessed as reversal of CFA-induced hyperalgesia at 3 mg/kg, po after 4 hrs",Other,18243692.0,
1951,315577,3,3,,103163840,3715,Unspecified,,,,,Inhibition of carrageenan-induced hind paw edema in rat assessed as decrease in paw volume at 10 mg/kg,Other,17993277.0,
1952,315578,3,3,,103163840,3715,Unspecified,,,,,"Inhibition of carrageenan-induced hind paw edema in rat assessed as decrease in paw volume at 10 mg/kg, po after 5 hrs",Other,17993277.0,
1953,315580,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against croton oil-induced ear edema in mouse at 0.5 mg/ear,Other,17993277.0,
1954,322002,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 10 mg/kg, po after 1 hr",Other,18158248.0,
1955,322003,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 10 mg/kg, po after 2 hrs",Other,18158248.0,
1956,322004,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 10 mg/kg, po after 3 hrs",Other,18158248.0,
1957,322005,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 10 mg/kg, po after 4 hrs",Other,18158248.0,
1958,322955,6,2,,103163840,3715,Unspecified,,,958.0,IC50,Inhibition of synthetic amyloid beta-42 oligomerization by ELISA,Confirmatory,17284452.0,
1959,322957,4,2,,103163840,3715,Unspecified,,,,,Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control,Other,17284452.0,
1960,322958,3,4,,103163840,3715,Inactive,,,,,Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control,Other,17284452.0,
1961,325066,9,5,,103163840,3715,Active,754286265.0,443551.0,7.9,Ki,Inhibition of ovine COX1 pre-incubated before addition of [1-14C]arachidonic acid,Confirmatory,17434872.0,
1962,326226,7,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced foot paw edema in rat,Other,18314945.0,
1963,326233,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity against sodium chloride-induced abdominal constriction in rat at 84 umol/kg, po after 30 mins",Other,18314945.0,
1964,326234,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity against sodium chloride-induced abdominal constriction in rat at 84 umol/kg, po after 60 mins",Other,18314945.0,
1965,326240,3,3,,103163840,3715,Unspecified,,,,,"Toxicity in rat assessed as ulcer index at 0.08 mmol/kg, po after 6 hrs",Other,18314945.0,
1966,328104,6,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against corton oil-induced ear edema in mouse,Other,18197604.0,
1967,328203,3,7,,103163840,3715,Unspecified,,,,,Inhibition of COX1 at 100 uM,Other,18363350.0,
1968,328204,3,7,,103163840,3715,Unspecified,,,,,Inhibition of COX2 at 100 uM,Other,18363350.0,
1969,328205,9,2,,103163840,3715,Active,,,0.1,IC50,Inhibition of COX1,Confirmatory,18363350.0,
1970,328206,9,2,,103163840,3715,Active,,,11.0,IC50,Inhibition of COX2,Confirmatory,18363350.0,
1971,328209,3,3,,103163840,3715,Active,,,,,"Induction of gastric ulcer formation in Sprague-Dawley rat at 10 mg/kg, po after 5 hrs",Other,18363350.0,
1972,328212,3,3,,103163840,3715,Active,,,,,"Analgesic activity in ICR mouse assessed as reduction in number of acetic acid-induced writhing at 10 mg/kg, po after 10 mins",Other,18363350.0,
1973,328898,7,1,,103163840,3715,Active,754286265.0,443551.0,,,Binding affinity to ovine COX1 at 1 uM to 25 uM,Other,17656360.0,
1974,332061,8,1,,103163840,3715,Active,,,0.838,ID50,Inhibition of TPA-induced inflammation in mouse assessed per ear by edema assay,Confirmatory,18439824.0,
1975,332233,4,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against ICR mouse assessed as inhibition of TPA-induced ear edema compound administered topically preincubated 30 mins before TPA challenge,Other,11858752.0,
1976,332234,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against ICR mouse assessed as inhibition ratio of TPA-induced ear edema at 1 mg/ear, topically preincubated 30 mins before TPA challenge relative to TPA",Other,11858752.0,
1977,332631,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Swiss mouse assessed as inhibition of 12-O-tetradecanoylphorbol acetate-induced ear edema at 0.5 mg/ear administered tropically,Other,7760072.0,
1978,335396,2,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 2 mg/kg, po",Other,,
1979,336476,3,7,,103163840,3715,Unspecified,,,,,Inhibition of COX2 at 6 uM by scintillation proximity assay,Other,12444669.0,
1980,336479,9,2,,103163840,3715,Active,,,3.9,IC50,Inhibition of COX1 by scintillation proximity assay,Confirmatory,12444669.0,
1981,337153,5,1,,103163840,3715,Unspecified,,,,,Inhibition of carrageenan-induced edema in po dosed Wistar rat paw,Other,1919590.0,
1982,337154,3,4,,103163840,3715,Active,,,,,"Inhibition of carrageenan-induced edema in Wistar rat paw at 5 mg/kg, po",Other,1919590.0,
1983,337404,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced Swiss mouse paw edema at 10 mg/kg, po",Other,14510620.0,
1984,337407,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced Swiss mouse ear edema assessed as reduction in ear swelling at 0.5 mg/ear topically after 4 hrs relative to control,Other,14510620.0,
1985,337675,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced Swiss mouse ear edema assessed as reduction in ear swelling at 0.25 mg/ear topically after 4 hrs relative to control,Other,14510620.0,
1986,338667,11,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Wistar rat peritoneal mast cells assessed as inhibition of concanavalin A-induced histamine release treated 10 mins before concanavalin A challenge measured after 30 mins,Other,2453615.0,
1987,338726,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against CF1 mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg administered 30 mins before carrageenan challenge measured after 3 hrs relative to control,Other,1800632.0,
1988,338729,4,5,,103163840,3715,Inconclusive,,,,,In vivo antineoplastic activity against mouse Ehrlich ascite carcinoma cells xenografted in CF1 mouse assessed as inhibition of tumor growth at 10 mg/kg after 9 days relative to control,Other,1800632.0,
1989,339127,3,4,,103163840,3715,Unspecified,,,,,Inhibition of ADP-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method,Other,8350094.0,
1990,339128,3,4,,103163840,3715,Unspecified,,,,,Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method,Other,8350094.0,
1991,339129,3,4,,103163840,3715,Unspecified,,,,,Inhibition of collagen-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method,Other,8350094.0,
1992,339130,3,4,,103163840,3715,Unspecified,,,,,Inhibition of platelet activity factor-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method,Other,8350094.0,
1993,345950,3,3,,103163840,3715,Active,,,,,"Inhibition of zymosan-induced peritonitis inflammation in BALB/c mouse assessed as blocking of neutrophil influx at 10 umol/kg, sc administered 30 mins after zymosan challenge measured after 2 hrs",Other,18983139.0,
1994,351265,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 1 hr of induction of inflammation relative to control",Other,18947903.0,
1995,351266,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 2 hrs of induction of inflammation relative to control",Other,18947903.0,
1996,351267,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 3 hrs of induction of inflammation relative to control",Other,18947903.0,
1997,351268,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 4 hrs of induction of inflammation relative to control",Other,18947903.0,
1998,351269,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 24 hrs of induction of inflammation relative to control",Other,18947903.0,
1999,351820,6,2,,103163840,3715,Unspecified,,,64.3,GI50,Growth inhibition of human NCI60 cells,Confirmatory,19398334.0,
2000,352495,9,5,,103163840,3715,Active,754286265.0,443551.0,0.1,IC50,Inhibition of ovine COX1 by enzyme immunoassay,Confirmatory,19419861.0,
2001,352496,9,5,,103163840,3715,Active,3914304.0,443460.0,5.7,IC50,Inhibition of ovine COX2 by enzyme immunoassay,Confirmatory,19419861.0,
2002,352499,3,3,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX2,Other,19419861.0,
2003,352502,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced rat inflammation model assessed as inhibition of paw edema at 11.7 umol/kg, po after 3 hrs",Other,19419861.0,
2004,355021,6,2,,103163840,3715,Unspecified,,,,,Inhibition of ram seminal vesicle cyclooxygenase pretreated 2 mins before arachidonate substrate addition,Other,8864236.0,
2005,355028,9,1,,103163840,3715,Active,,,0.56,IC50,Inhibition of prostaglandin synthesis in bovine seminal vesicle microsomes using [14C]arachidonic acid,Confirmatory,8786365.0,
2006,355094,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release at 100 uM by Ellman's method relative to control,Other,8988605.0,
2007,355097,6,2,,103163840,3715,Active,,,22.0,IC50,Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method,Confirmatory,8988605.0,
2008,355124,6,2,,103163840,3715,Active,,,0.21,IC50,Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method,Confirmatory,8988600.0,
2009,355225,3,3,,103163840,3715,Unspecified,,,,,Inhibition of cyclooxygenase assessed as rate of disappearance of dissolved oxygen at 2.4 uM relative to control,Other,9134748.0,
2010,356046,8,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema in Swiss mouse chronic dermatitis model assessed as inhibition of increase in ear weight,Other,12828487.0,
2011,356054,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced Swiss mouse paw edema assessed as inhibition of paw volume at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 1 hr relative to control",Other,12828487.0,
2012,356055,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced Swiss mouse paw edema assessed as inhibition of paw volume at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to control",Other,12828487.0,
2013,356056,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced Swiss mouse paw edema assessed as inhibition of paw volume at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs relative to control",Other,12828487.0,
2014,356058,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema Swiss mouse chronic dermatitis model assessed as inhibition of increase in ear weight at 0.5 mg/ear relative to control,Other,12828487.0,
2015,356060,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against Swiss mouse chronic dermatitis model assessed as inhibition of TPA-induced tissue myeloperoxidase activity at 0.5 mg/ear applied twice daily for 4 days measured after 6 hrs relative to control,Other,12828487.0,
2016,356318,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse assessed as inhibition of TPA-induced ear edema at 560 nmol,Other,12932134.0,
2017,356713,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema in mouse assessed inhibition of edema at 0.10 mg/ear,Other,11473412.0,
2018,356714,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema in mouse assessed inhibition of edema at 0.05 mg/ear,Other,11473412.0,
2019,356716,4,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema in mouse assessed inhibition of edema,Other,11473412.0,
2020,356717,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema in mouse assessed inhibition of edema at 0.50 mg/ear,Other,11473412.0,
2021,356718,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema in mouse assessed inhibition of edema at 1 mg/ear,Other,11473412.0,
2022,357286,4,5,,103163840,3715,Active,,,,,Inhibition of A23187-induced PGE2 formation in human polymorphonuclear leukocytes at 1 to 100 uM,Other,2822857.0,
2023,357287,4,5,,103163840,3715,Active,,,,,"Inhibition of A23187-induced 12-hydroxy-5,8,10-heptadecatrienoic acid formation in human polymorphonuclear leukocytes at 1 to 100 uM",Other,2822857.0,
2024,360928,9,5,,103163840,3715,Active,166897622.0,282022.0,1.3,IC50,Inhibition of bovine COX1-mediated prostaglandin biosynthesis using [1-14C]arachidonic acid,Confirmatory,11421736.0,
2025,364306,3,10,,103163840,3715,Unspecified,13432234.0,5468.0,,,Activity at PPARgamma in human Caco-2 cells assessed as luciferase activity at 50 uM relative to control,Other,18222570.0,
2026,364547,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip after 0.5 hrs",Other,18242782.0,
2027,364548,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip after 1 hrs",Other,18242782.0,
2028,364549,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip after 2 hrs",Other,18242782.0,
2029,364550,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip after 3 hrs",Other,18242782.0,
2030,364551,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip after 4 hrs",Other,18242782.0,
2031,364552,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip after 5 hrs",Other,18242782.0,
2032,365463,10,5,,103163840,3715,Active,296439301.0,4363.0,12.0,IC50,Inhibition of human MRP1 in human 2008 cells,Confirmatory,18707884.0,
2033,365464,10,5,,103163840,3715,Unspecified,308153583.0,1244.0,235.0,IC50,Inhibition of human MRP2 expressed in dog MDCK2 cells,Confirmatory,18707884.0,
2034,365465,7,1,,103163840,3715,Inactive,238054374.0,5243.0,,IC50,Inhibition of P-gp in human A2780 cells,Confirmatory,18707884.0,
2035,371494,3,3,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in Swiss mouse assessed as inhibition of acetic acid-induced writhing response at 10 mg/kg, po administered 1 hr before acetic acid challenge measured for 30 mins",Other,18045747.0,
2036,371495,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat at 10 mg/kg, po dose administered 1 hr before carrageenan challenge assessed after 3 hrs",Other,18045747.0,
2037,373867,6,3,,103163840,3715,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
2038,374106,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po after 1 hr",Other,18977557.0,
2039,374108,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po after 2 hrs",Other,18977557.0,
2040,374110,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po after 3 hrs",Other,18977557.0,
2041,374236,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po after 4 hrs",Other,18977557.0,
2042,376763,13,1,,103163840,3715,Active,,,0.1,IC50,Inhibition of COX1 from ram seminal vesicles by liquid scintillation counter,Confirmatory,15679320.0,
2043,376764,13,1,,103163840,3715,Active,,,0.6,IC50,Inhibition of sheep placental COX2 by liquid scintillation counter,Confirmatory,15679320.0,
2044,377009,9,5,,103163840,3715,Active,754286265.0,443551.0,1.4,IC50,Inhibition of ovine COX1,Confirmatory,16792405.0,
2045,377010,9,5,,103163840,3715,Active,3915797.0,5743.0,5.8,IC50,Inhibition of human recombinant COX2,Confirmatory,16792405.0,
2046,379443,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against Swiss mouse assessed as inhibition of TPA-induced edema at 0.5 mg/ear applied simultaneously with TPA measured after 4 hrs,Other,10217718.0,
2047,379574,4,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema in mouse,Other,17190444.0,
2048,379635,3,9,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of COX1 in ram seminal vesicle microsomes assessed as reduction of PGE2 formation at 5 uM,Other,10757731.0,
2049,379636,9,5,,103163840,3715,Active,754286265.0,443551.0,1.5,IC50,Inhibition of COX1 in ram seminal vesicle microsomes assessed as reduction of PGE2 formation,Confirmatory,10757731.0,
2050,380766,8,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against croton oil-induced ear edema in mouse,Other,16562861.0,
2051,381055,3,6,,103163840,3715,Inactive,,,,,Activation of PPARgamma transfected in human MCF7 cells at 100 to 300 uM after 48 hrs by luciferase reporter gene assay,Other,16643023.0,
2052,381056,10,5,,103163840,3715,Unspecified,13432234.0,5468.0,50.0,EC50,Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay,Confirmatory,16643023.0,
2053,381058,3,6,,103163840,3715,Inactive,,,,,Activation of PPARgamma transfected in human MDA-MB-231 cells at 100 to 300 uM after 48 hrs by luciferase reporter gene assay,Other,16643023.0,
2054,381196,3,4,,103163840,3715,Unspecified,,,,,Inhibition of cyclooxygenase in Wistar rat peritoneal leukocytes at 50 ug/mL,Other,10514305.0,
2055,381197,3,9,,103163840,3715,Unspecified,729945.0,25290.0,,,Inhibition of 5-lipoxygenase in Wistar rat peritoneal leukocytes at 50 ug/mL,Other,10514305.0,
2056,382809,8,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Sprague-Dawley rat cotton pellet-induced granuloma model,Other,17532544.0,
2057,382810,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcerogenic effect at 30 umol/kg, po for 3 days",Other,17532544.0,
2058,382811,6,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as protection against carrageenan-induced paw edema at 10 umol/kg, sc administered 1 hr prior to carrageenan challenge",Other,17532544.0,
2059,382813,9,5,,103163840,3715,Active,3915797.0,5743.0,2.63,IC50,Inhibition of human recombinant COX2,Confirmatory,17532544.0,
2060,382814,9,5,,103163840,3715,Active,317373262.0,5742.0,0.26,IC50,Inhibition of human platelet COX1,Confirmatory,17532544.0,
2061,382815,3,3,,103163840,3715,Unspecified,,,,,Selectivity for human recombinant COX2 over human platelet COX1,Other,17532544.0,
2062,383547,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced edema in Sprague-Dawley rat at 6 mg/kg, po",Other,17602797.0,
2063,384123,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po",Other,17689837.0,
2064,384264,6,3,,103163840,3715,Active,,,0.12,IC50,Inhibition of arachidonic acid-induced platelet aggregation in human blood after 3 mins by turbidimetric assay,Confirmatory,18407506.0,
2065,384265,6,3,,103163840,3715,Unspecified,,,100.0,IC50,Inhibition of collagen-induced platelet aggregation in human blood after 3 mins by turbidimetric assay,Confirmatory,18407506.0,
2066,384266,6,3,,103163840,3715,Active,,,0.4,IC50,Inhibition of thrombin-induced platelet aggregation in human blood after 3 mins by turbidimetric assay,Confirmatory,18407506.0,
2067,384267,6,3,,103163840,3715,Unspecified,,,100.0,IC50,Inhibition of U46619-induced platelet aggregation in human blood after 3 mins by turbidimetric assay,Confirmatory,18407506.0,
2068,384269,3,3,,103163840,3715,Unspecified,,,,,Inhibition of arachidonic acid-induced TxB2 formation in human platelet at 0.5 uM per 3 x 10'8 platelets by immunoassay,Other,18407506.0,
2069,384823,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in albino rat at 1.5 mg/kg, po, relative to control",Other,17804121.0,
2070,386844,6,2,,103163840,3715,Unspecified,,,,,Acute toxicity in ip dosed albino mouse after 24 hrs,Other,17959273.0,
2071,386845,6,2,,103163840,3715,Unspecified,,,,,Acute toxicity in po dosed albino mouse after 24 hrs,Other,17959273.0,
2072,386847,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as ulcerogenic effect at 10 mg/kg, po administered twice at 2 hrs interval after 4 hrs",Other,17959273.0,
2073,386848,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in albino mouse assessed as inhibition of acetic acid-induced writhing at 10 mg/kg, po",Other,17959273.0,
2074,386850,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of formalin-induced paw oedema volume at 10 mg/kg, po administered 30 mins before formalin challenge after 1 hr relative to control",Other,17959273.0,
2075,386852,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of formalin-induced paw oedema volume at 10 mg/kg, po administered 30 mins before formalin challenge after 2 hrs relative to control",Other,17959273.0,
2076,386854,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of formalin-induced paw oedema volume at 10 mg/kg, po administered 30 mins before formalin challenge after 3 hrs relative to control",Other,17959273.0,
2077,386856,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of formalin-induced paw oedema volume at 10 mg/kg, po administered 30 mins before formalin challenge after 4 hrs relative to control",Other,17959273.0,
2078,386858,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of formalin-induced paw oedema volume at 10 mg/kg, po administered 30 mins before formalin challenge after 5 hrs relative to control",Other,17959273.0,
2079,386952,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wister albino rat at 10 mg/kg, ip administered 1 hr before inflammation induction assessed after 4 hrs",Other,18242783.0,
2080,386954,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wister albino rat at 10 mg/kg, ip administered 1 hr before inflammation induction assessed after 1 hr",Other,18242783.0,
2081,386957,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wister albino rat at 10 mg/kg, ip administered 1 hr before inflammation induction assessed after 2 hrs",Other,18242783.0,
2082,386959,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wister albino rat at 10 mg/kg, ip administered 1 hr before inflammation induction assessed after 3 hrs",Other,18242783.0,
2083,387677,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced albino rat hind paw edema model assessed as edema rate at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 1 hr",Other,18783947.0,
2084,387679,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced albino rat hind paw edema model assessed as edema rate at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 2 hrs",Other,18783947.0,
2085,387682,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced albino rat hind paw edema model assessed as edema rate at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs",Other,18783947.0,
2086,387685,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced albino rat hind paw edema model assessed as edema rate at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs",Other,18783947.0,
2087,387967,3,4,,103163840,3715,Unspecified,,,,,Antiproliferative activity against human WI38 cells at 10 uM after 48 hrs relative to control,Other,18951802.0,
2088,387968,3,4,,103163840,3715,Unspecified,,,,,Antiproliferative activity against mouse RAW264.7 cells at 10 uM after 48 hrs relative to control,Other,18951802.0,
2089,389156,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced foot paw edema in rat at 0.01 mmol/kg, ip",Other,18819796.0,
2090,389443,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in ICR mouse at 4 mg/kg, ip administered 30 mins before carrageenan challenge assessed after 0.5 hrs",Other,18829331.0,
2091,389444,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in ICR mouse at 4 mg/kg, ip administered 30 mins before carrageenan challenge assessed after 1 hr",Other,18829331.0,
2092,389638,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in ICR mouse at 4 mg/kg, ip administered 30 mins before carrageenan challenge assessed after 2 hrs",Other,18829331.0,
2093,389639,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in ICR mouse at 4 mg/kg, ip administered 30 mins before carrageenan challenge assessed after 3 hrs",Other,18829331.0,
2094,389640,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in ICR mouse at 4 mg/kg, ip administered 30 mins before carrageenan challenge assessed after 4 hrs",Other,18829331.0,
2095,389641,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in ICR mouse at 4 mg/kg, ip administered 30 mins before carrageenan challenge assessed after 5 hrs",Other,18829331.0,
2096,392748,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip after 3.5 hrs",Other,19150597.0,
2097,393211,3,9,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 in LPS-stimulated human whole blood assessed as inhibition of PGE2 production at 10 uM by radioimmunoassay,Other,19200742.0,
2098,393213,3,10,,103163840,3715,Unspecified,548483.0,19225.0,,,Inhibition of COX2 in LPS-stimulated mouse J774 cells assessed as inhibition of PGE2 production by radioimmunoassay,Other,19200742.0,
2099,393214,3,10,,103163840,3715,Unspecified,266649.0,18126.0,,,Inhibition of iNOS in LPS-stimulated mouse J774 cells assessed as inhibition of nitric oxide generation at 10 uM,Other,19200742.0,
2100,393658,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wister albino rat assessed as inhibition of edema at 10 mg/kg, ip administered 1 hr prior to carrageenan challenge measured after 1 hr relative to control",Other,18455272.0,
2101,393659,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wister albino rat assessed as inhibition of edema at 10 mg/kg, ip administered 1 hr prior to carrageenan challenge measured after 2 hrs relative to control",Other,18455272.0,
2102,393660,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wister albino rat assessed as inhibition of edema at 10 mg/kg, ip administered 1 hr prior to carrageenan challenge measured after 3 hrs relative to control",Other,18455272.0,
2103,393661,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wister albino rat assessed as inhibition of edema at 10 mg/kg, ip administered 1 hr prior to carrageenan challenge measured after 4 hrs relative to control",Other,18455272.0,
2104,393846,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 hr",Other,18455273.0,
2105,393847,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, po administered 30 mins before carrageenan challenge measured after 2 hrs",Other,18455273.0,
2106,393848,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs",Other,18455273.0,
2107,393849,6,2,,103163840,3715,Unspecified,,,,,Toxicity in ip dosed albino mouse assessed as mortality after 24 hrs,Other,18455273.0,
2108,393850,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcer index at 10 mg/kg, po after 6 hrs",Other,18455273.0,
2109,393851,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcer index at 50 mg/kg, po after 6 hrs",Other,18455273.0,
2110,393852,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcer index at 100 mg/kg, po after 6 hrs",Other,18455273.0,
2111,396322,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Charles-Foster rat assessed as inhibition of carrageenan-induced paw oedema at 50 mg/kg, po measured before 1 hr and after 3 hrs of carrageenan challenge relative to control",Other,18063224.0,
2112,396325,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Charles-Foster rat assessed as inhibition of carrageenan-induced paw oedema at 5 mg/kg, po measured before 1 hr and after 3 hrs of carrageenan challenge relative to control",Other,18063224.0,
2113,396326,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Charles-Foster rat assessed as inhibition of carrageenan-induced paw oedema at 7.5 mg/kg, po measured before 1 hr and after 3 hrs of carrageenan challenge relative to control",Other,18063224.0,
2114,396327,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Charles-Foster rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, po measured before 1 hr and after 3 hrs of carrageenan challenge relative to control",Other,18063224.0,
2115,396331,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in mouse assessed as protection against phenylquinone-induced writhing at 5 mg/kg, po administered 1 hr before phenylquinone challenge measured for 5 mins relative to controll",Other,18063224.0,
2116,396332,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in mouse assessed as protection against phenylquinone-induced writhing at 7.5 mg/kg, po administered 1 hr before phenylquinone challenge measured for 5 mins relative to controll",Other,18063224.0,
2117,396333,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in mouse assessed as protection against phenylquinone-induced writhing at 10 mg/kg, po administered 1 hr before phenylquinone challenge measured for 5 mins relative to control",Other,18063224.0,
2118,396345,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against cotton pellets-induced inflammation in Wistar rat assessed as wet weight of granuloma at 5 mg/kg, po after 7 days",Other,18063443.0,
2119,396346,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against cotton pellets-induced inflammation in Wistar rat assessed as dry weight of granuloma at 5 mg/kg, po after 7 days",Other,18063443.0,
2120,396558,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against cotton pellets-induced inflammation in Wistar rat assessed as final weight of granuloma at 5 mg/kg, po after 7 days",Other,18063443.0,
2121,396562,6,2,,103163840,3715,Unspecified,,,,,Acute toxicity in po dosed mouse assessed as death within 7 days,Other,18063443.0,
2122,396564,3,3,,103163840,3715,Unspecified,,,,,Safety ratio for toxicity to antiinflammatory activity in po dosed mouse,Other,18063443.0,
2123,396638,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Laca mouse assessed as inhibition of arachidonic acid-induced ear oedema at 300 ug/ear,Other,18406013.0,
2124,396714,8,5,,103163840,3715,Active,317373262.0,5742.0,0.0282,IC50,Inhibition of human platelet COX1 assessed as effect on prostaglandin E2 production by ELISA,Confirmatory,19056264.0,
2125,396997,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw edema volume at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 4 hrs",Other,19056146.0,
2126,397001,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in fasted albino rat assessed ulcer index at 10 mg/kg, po administered for 3 days measured after 1 hr of last dose",Other,19056146.0,
2127,397003,6,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced inflammation in albino rat 6-day-old air pouch model assessed as inhibition of PGE2 level at 10 mg/kg, po administered prior to carrageenan challenge measured after 6 hrs",Other,19056146.0,
2128,397226,5,8,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 10 uM by enzyme immunoassay relative to control,Other,19084295.0,
2129,397227,3,9,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 10 uM by enzyme immunoassay relative to control,Other,19084295.0,
2130,397231,9,5,,103163840,3715,Active,3914304.0,443460.0,0.537,IC50,Inhibition of ovine COX2 by enzyme immunoassay,Confirmatory,19084295.0,
2131,397232,9,5,,103163840,3715,Active,754286265.0,443551.0,0.069,IC50,Inhibition of ovine COX1 by enzyme immunoassay,Confirmatory,19084295.0,
2132,399387,3,3,,103163840,3715,Unspecified,,,,,Antiplatelet activity in human whole blood assessed as inhibition of collagen-induced platelet aggregation at 100 ug/mL relative to control,Other,9461664.0,
2133,399388,3,4,,103163840,3715,Unspecified,,,,,Antiplatelet activity in human whole blood assessed as inhibition of ADP-induced platelet aggregation at 100 ug/mL relative to control,Other,9461664.0,
2134,399389,3,4,,103163840,3715,Unspecified,,,,,Antiplatelet activity in human whole blood assessed as inhibition of arachidonic acid-induced platelet aggregation at 100 ug/mL relative to control,Other,9461664.0,
2135,399390,3,4,,103163840,3715,Unspecified,,,,,Antiplatelet activity in human whole blood assessed as inhibition of ristocetin-induced platelet aggregation at 100 ug/mL relative to control,Other,9461664.0,
2136,399401,9,5,,103163840,3715,Active,166897622.0,282022.0,3.3,IC50,Inhibition of bovine seminal microsomal COX1 assessed as PGE2 production,Confirmatory,9461646.0,
2137,399402,7,6,,103163840,3715,Unspecified,3914304.0,443460.0,1710.0,IC50,Inhibition of sheep placental cotyledons COX2 assessed as PGE2 production,Confirmatory,9461646.0,
2138,399403,3,3,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for sheep placental cotyledons COX2 to IC50 for bovine seminal microsomal COX1,Other,9461646.0,
2139,399404,9,5,,103163840,3715,Unspecified,166897622.0,282022.0,,IC50,Inhibition of bovine seminal microsomal COX1 assessed as PGE2 production preincubated for 10 mins,Confirmatory,9461646.0,
2140,399405,10,5,,103163840,3715,Unspecified,3914304.0,443460.0,,IC50,Inhibition of sheep placental cotyledons COX2 assessed as PGE2 production preincubated for 10 mins,Confirmatory,9461646.0,
2141,399406,3,3,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for sheep placental cotyledons COX2 to IC50 for bovine seminal microsomal COX1 preincubated for 10 mins,Other,9461646.0,
2142,399411,11,2,,103163840,3715,Active,166897622.0,282022.0,1.1,IC50,Inhibition of bovine seminal vesicle microsomal COX1-mediated prostaglandin production,Confirmatory,9461647.0,
2143,400126,9,2,,103163840,3715,Active,,,1.2,IC50,Inhibition of COX1,Confirmatory,9544564.0,
2144,400235,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat at 5 mg/kg, po",Other,15043416.0,
2145,401492,3,3,,103163840,3715,Unspecified,,,,,Inhibition of PMA-induced ear edema in Swiss mouse at 3 mg/ear after 1 hr,Other,9051913.0,
2146,401493,3,3,,103163840,3715,Unspecified,,,,,Inhibition of PMA-induced ear edema in Swiss mouse at 3 mg/ear after 3 hrs,Other,9051913.0,
2147,401494,3,3,,103163840,3715,Unspecified,,,,,Inhibition of PMA-induced ear edema in Swiss mouse at 3 mg/ear after 5 hrs,Other,9051913.0,
2148,402402,9,2,,103163840,3715,Unspecified,,,165.0,IC50,Inhibition of COX2-catalyzed prostaglandin biosynthesis after 10 mins of preincubation,Confirmatory,9784154.0,
2149,402403,9,2,,103163840,3715,Active,,,1.4,IC50,Inhibition of COX1-catalyzed prostaglandin biosynthesis 10 mins of preincubation,Confirmatory,9784154.0,
2150,402404,3,3,,103163840,3715,Unspecified,,,,,Ratio of IC50 for COX2 to IC50 for COX1,Other,9784154.0,
2151,402987,6,3,,103163840,3715,Unspecified,,,,,Inhibition of compound 48/80-induced histamine release in Wistar rat peritoneal mast cells,Other,15270561.0,
2152,403340,11,1,,103163840,3715,Active,,,3.9,IC50,Inhibition of COX2,Confirmatory,16038536.0,
2153,403341,11,1,,103163840,3715,Active,,,0.01,IC50,Inhibition of COX1,Confirmatory,16038536.0,
2154,403345,3,7,,103163840,3715,Unspecified,,,,,Inhibition of COX1 at 0.01 mM,Other,16038536.0,
2155,403346,3,7,,103163840,3715,Unspecified,,,,,Inhibition of COX1 at 50 ug/mL,Other,16038536.0,
2156,403347,3,7,,103163840,3715,Unspecified,,,,,Inhibition of COX1 at 5 uM,Other,16038536.0,
2157,403351,3,7,,103163840,3715,Unspecified,,,,,Inhibition of COX1 at 0.1 mM,Other,16038536.0,
2158,403354,3,7,,103163840,3715,Unspecified,,,,,Inhibition of COX2 at 0.01 mM,Other,16038536.0,
2159,403356,3,7,,103163840,3715,Unspecified,,,,,Inhibition of COX1 at 20 uM,Other,16038536.0,
2160,404304,3,10,,103163840,3715,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
2161,404565,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced edema at 50 mg/kg, po after 2 hrs",Other,18502132.0,
2162,404566,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced edema at 50 mg/kg, po after 1 hr",Other,18502132.0,
2163,404567,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced edema at 50 mg/kg, po after 3 hrs",Other,18502132.0,
2164,404568,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced edema at 50 mg/kg, po after 4 hrs",Other,18502132.0,
2165,404569,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced edema at 50 mg/kg, po after 5 hrs",Other,18502132.0,
2166,404570,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced edema at 50 mg/kg, po after 6 hrs",Other,18502132.0,
2167,404571,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in Albino mouse at 50 mg/kg, po assessed as thermal stimuli reaction time change after 30 mins by hot plate method relative to basal level",Other,18502132.0,
2168,404573,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in Albino mouse at 50 mg/kg, po assessed as thermal stimuli reaction time change after 1 hr by hot plate method relative to basal level",Other,18502132.0,
2169,404575,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in Albino mouse at 50 mg/kg, po assessed as thermal stimuli reaction time change after 2 hrs by hot plate method relative to basal level",Other,18502132.0,
2170,404577,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity against visceral pain in Albino mouse assessed as acetic acid-induced writhing at 50 mg/kg, po after 30 mins",Other,18502132.0,
2171,408271,8,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced paw edema in sc dosed Albino rat assessed as inhibition of paw edema volume measured 4 hrs after carrageenan challenge,Other,18430576.0,
2172,408272,4,3,,103163840,3715,Unspecified,,,,,"Toxicity in Albino rat assessed as gastric-ulcerogenic effect at 30 uM/kg, po twice daily for 3 days",Other,18430576.0,
2173,408273,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in sc dosed Albino rat assessed as protection against carrageenan-induced paw edema measured 4 hrs after carrageenan challenge,Other,18430576.0,
2174,409534,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as ulcer index at 1 mg/kg, po after 14 days",Other,17945398.0,
2175,409536,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as ulcer index at 30 mg/kg, po after 6 hrs",Other,17945398.0,
2176,409537,3,3,,103163840,3715,Unspecified,,,,,"Antiarthritic activity in Freund's complete adjuvant challenged Albino rat model assessed as change in body weight at 10 mg/kg, po administered for 14 days daily once starting a day before adjuvant challenge",Other,17945398.0,
2177,409539,3,3,,103163840,3715,Unspecified,,,,,"Antiarthritic activity in Albino rat assessed as inhibition of Freund's complete adjuvant-induced paw volume at 10 mg/kg, po administered for 14 days daily once starting a day before adjuvant challenge measured on day 13",Other,17945398.0,
2178,409540,3,3,,103163840,3715,Unspecified,,,,,"Antiarthritic activity in Albino rat assessed as inhibition of Freund's complete adjuvant-induced paw volume at 10 mg/kg, po administered for 14 days daily once starting a day before adjuvant challenge measured on day 8",Other,17945398.0,
2179,409541,3,3,,103163840,3715,Unspecified,,,,,"Antiarthritic activity in Albino rat assessed as inhibition of Freund's complete adjuvant-induced paw volume at 10 mg/kg, po administered for 14 days daily once starting a day before adjuvant challenge measured on day 3",Other,17945398.0,
2180,409545,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity in Wistar rat assessed as change in LPS-induced rectal temperature at 10 mg/kg, po administered 30 mins before LPS challenge after 7 hrs",Other,17945398.0,
2181,409546,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity in Wistar rat assessed as change in LPS-induced rectal temperature at 10 mg/kg, po administered 30 mins before LPS challenge after 6 hrs",Other,17945398.0,
2182,409547,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity in Wistar rat assessed as change in LPS-induced rectal temperature at 10 mg/kg, po administered 30 mins before LPS challenge after 5 hrs",Other,17945398.0,
2183,409548,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity in Wistar rat assessed as change in LPS-induced rectal temperature at 10 mg/kg, po administered 30 mins before LPS challenge after 4 hrs",Other,17945398.0,
2184,409549,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity in Wistar rat assessed as change in LPS-induced rectal temperature at 10 mg/kg, po administered 30 mins before LPS challenge after 3 hrs",Other,17945398.0,
2185,409550,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity in Wistar rat assessed as change in LPS-induced rectal temperature at 10 mg/kg, po administered 30 mins before LPS challenge after 2 hrs",Other,17945398.0,
2186,409551,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity in Wistar rat assessed as change in LPS-induced rectal temperature at 10 mg/kg, po administered 30 mins before LPS challenge after 1 hr",Other,17945398.0,
2187,409559,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing at 10 mg/kg, po administered 60 mins before acetic acid challenge after 5 to 15 mins relative to control",Other,17945398.0,
2188,409562,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw edema volume at 10 mg/kg, po administered 60 mins before carrageenan challenge after 24 hrs relative to control",Other,17945398.0,
2189,409563,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw edema volume at 10 mg/kg, po administered 60 mins before carrageenan challenge after 6 hrs relative to control",Other,17945398.0,
2190,409564,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw edema volume at 10 mg/kg, po administered 60 mins before carrageenan challenge after 4 hrs relative to control",Other,17945398.0,
2191,409565,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw edema volume at 10 mg/kg, po administered 60 mins before carrageenan challenge after 3 hrs relative to control",Other,17945398.0,
2192,409566,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw edema volume at 10 mg/kg, po administered 60 mins before carrageenan challenge after 2 hrs relative to control",Other,17945398.0,
2193,409567,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw edema volume at 10 mg/kg, po administered 60 mins before carrageenan challenge after 1 hr relative to control",Other,17945398.0,
2194,412946,3,9,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as remaining activity at 10 uM relative to control,Other,19053751.0,
2195,413192,3,10,,103163840,3715,Active,7387730.0,9536.0,,,Inhibition of mPGES1 in human A549 cells assessed as inhibition of IL-1-beta-induced PGE2 formation at 10 uM by cell-intact assay,Other,19053751.0,
2196,414504,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Albino mouse assessed as inhibition of carrageenan-induced foot paw edema at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 2 hrs",Other,19272777.0,
2197,414507,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced inflammation in Albino mouse air ppouch model assessed as number of polymorphonuclear leukocytes infiltration at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs by air pouch test",Other,19272777.0,
2198,414771,7,6,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 by colorimetric assay,Other,19303782.0,
2199,414772,7,6,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 by colorimetric assay,Other,19303782.0,
2200,414773,6,2,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX2,Other,19303782.0,
2201,415882,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against brewer's yeast-induced hyperthermia in Wistar rat assessed as change in rectal temperature at 5 mg/kg, po after 30 mins",Other,18485539.0,
2202,415883,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against brewer's yeast-induced hyperthermia in Wistar rat assessed as change in rectal temperature at 5 mg/kg, po after 60 mins",Other,18485539.0,
2203,415884,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against brewer's yeast-induced hyperthermia in Wistar rat assessed as change in rectal temperature at 5 mg/kg, po after 90 mins",Other,18485539.0,
2204,415885,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against brewer's yeast-induced hyperthermia in Wistar rat assessed as change in rectal temperature at 5 mg/kg, po after 120 mins",Other,18485539.0,
2205,415886,3,3,,103163840,3715,Unspecified,,,,,"Antipyretic activity against brewer's yeast-induced hyperthermia in Wistar rat assessed as change in rectal temperature at 5 mg/kg, po after 150 mins",Other,18485539.0,
2206,416488,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition carrageenan-induced paw edema at 2 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs relative to control",Other,18579259.0,
2207,418086,3,5,,103163840,3715,Unspecified,,,,,"Toxicity in carrageenan treated Albino mouse stomach assessed as gastric ulcer at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs by hematoxilen eosine staining",Other,19272777.0,
2208,418091,3,4,,103163840,3715,Unspecified,,,,,"Toxicity in carrageenan treated Albino mouse liver assessed as cholestasis at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs by hematoxilen eosine staining",Other,19272777.0,
2209,419901,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcer index at 100 mg/kg, po",Other,19419878.0,
2210,420031,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema volume at 50 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 1 hr",Other,19027198.0,
2211,420032,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema volume at 50 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 2 hrs",Other,19027198.0,
2212,420033,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema volume at 50 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hrs",Other,19027198.0,
2213,420034,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema volume at 50 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hrs",Other,19027198.0,
2214,420035,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema volume at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 1 hr",Other,19027198.0,
2215,420036,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema volume at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 2 hrs",Other,19027198.0,
2216,420037,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema volume at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hrs",Other,19027198.0,
2217,420038,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema volume at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hrs",Other,19027198.0,
2218,420041,7,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced inflammation in albino rat air pouch model assessed as PGE2 level at 10 mg/kg, po administered 24 hrs before carrageenan challenge measured after 6 hrs",Other,19027198.0,
2219,420058,7,2,,103163840,3715,Active,,,0.04,IC50,Inhibition of COX2,Confirmatory,19427206.0,
2220,420059,11,1,,103163840,3715,Active,,,0.25,IC50,Inhibition of COX1,Confirmatory,19427206.0,
2221,420788,3,3,,103163840,3715,Unspecified,,,,,Ratio of IC50 for COX1 to IC50 for COX2,Other,19144452.0,
2222,425652,7,2,,103163840,3715,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
2223,425653,7,2,,103163840,3715,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
2224,426392,9,5,,103163840,3715,Active,124359.0,3576.0,0.05,IC50,Inhibition of CXCL8-induced chemotaxis in human polymorphonuclear leukocyte pretreated for 15 mins measured after 4 hrs by cell migration assay,Confirmatory,19560921.0,
2225,426393,3,3,,103163840,3715,Unspecified,,,,,Cytotoxicity against of human polymorphonuclear leukocytes assessed as cell viability by trypan blue dye exclusion assay,Other,19560921.0,
2226,426422,4,3,,103163840,3715,Inconclusive,,,,,Antioxidant activity against hydroxyl radical assessed as inhibition of formaldehyde production at 0.1 mM after 30 mins relative to DMSO,Other,19232783.0,
2227,426426,5,3,,103163840,3715,Inconclusive,,,,,Inhibition of soybean lipoxygenase assessed as conversion of sodium linoleate to 13-hydroperoxylinoleic acid at 0.1 mM,Other,19232783.0,
2228,426427,5,3,,103163840,3715,Unspecified,,,,,"In vivo antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip administered simultaneously with carrageenan measured after 3.5 hrs",Other,19232783.0,
2229,426478,3,4,,103163840,3715,Unspecified,,,,,Cytotoxicity against mouse L1.2 cells assessed as cell viability by trypan blue dye exclusion assay,Other,19560921.0,
2230,427305,8,1,,103163840,3715,Unspecified,,,,IC50,Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method,Confirmatory,19467877.0,
2231,427629,9,5,,103163840,3715,Active,754286265.0,443551.0,0.9,IC50,Inhibition of COX1 in ram seminal vesicle by enzyme immunoassay,Confirmatory,19481465.0,
2232,428388,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po treated for 30 mins measured after 1 hr of carrageenan challenge",Other,18722034.0,
2233,428389,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po treated for 30 mins measured after 2 hrs of carrageenan challenge",Other,18722034.0,
2234,428390,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po treated for 30 mins measured after 3 hrs of carrageenan challenge",Other,18722034.0,
2235,428391,3,3,,103163840,3715,Unspecified,,,,,"Gastrotoxicity in albino rat assessed as ulcer index at 100 mg/kg, po after 5 hrs",Other,18722034.0,
2236,428413,8,1,,103163840,3715,Unspecified,85701143.0,24565.0,,,Inhibition of MRP1/MRP2 in White Wistar rat jejunum assessed as permeability at 1 mM after 30 mins by HPLC analysis,Other,18752872.0,
2237,428414,8,1,,103163840,3715,Unspecified,85701143.0,24565.0,,,Inhibition of MRP1/MRP2 in White Wistar rat ileum assessed as permeability at 1 mM after 30 mins by HPLC analysis,Other,18752872.0,
2238,428415,8,1,,103163840,3715,Unspecified,85701143.0,24565.0,,,Inhibition of MRP1/MRP2 in White Wistar rat colon assessed as permeability at 1 mM after 30 mins by HPLC analysis,Other,18752872.0,
2239,428416,3,9,,103163840,3715,Unspecified,85701143.0,24565.0,,,Inhibition of MRP1/MRP2 in White Wistar rat jejunum assessed as increase in drug uptake at 1 mM after 30 mins by HPLC analysis,Other,18752872.0,
2240,428417,3,9,,103163840,3715,Unspecified,85701143.0,24565.0,,,Inhibition of MRP1/MRP2 in White Wistar rat ileum assessed as increase in drug uptake at 1 mM after 30 mins by HPLC analysis,Other,18752872.0,
2241,428418,3,9,,103163840,3715,Unspecified,85701143.0,24565.0,,,Inhibition of MRP1/MRP2 in White Wistar rat colon assessed as increase in drug uptake at 1 mM after 30 mins by HPLC analysis,Other,18752872.0,
2242,430042,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before carrageenan challenge measured after 6 hrs by plethysmometry analysis",Other,19481942.0,
2243,430048,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against bradykinin-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before bradykinin challenge measured after 15 mins by plethysmometry analysis",Other,19481942.0,
2244,430145,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against bradykinin-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before bradykinin challenge measured after 30 mins by plethysmometry analysis",Other,19481942.0,
2245,430146,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against bradykinin-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before bradykinin challenge measured after 60 mins by plethysmometry analysis",Other,19481942.0,
2246,430147,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against bradykinin-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before bradykinin challenge measured after 120 mins by plethysmometry analysis",Other,19481942.0,
2247,430148,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against bradykinin-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before bradykinin challenge measured after 240 mins by plethysmometry analysis",Other,19481942.0,
2248,430154,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before carrageenan challenge measured after 1 hr by plethysmometry analysis",Other,19481942.0,
2249,430155,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before carrageenan challenge measured after 2 hrs by plethysmometry analysis",Other,19481942.0,
2250,430156,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before carrageenan challenge measured after 4 hrs by plethysmometry analysis",Other,19481942.0,
2251,430157,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in mouse at 1 mg/kg, ip treated 30 mins before carrageenan challenge measured after 5 hrs by plethysmometry analysis",Other,19481942.0,
2252,431710,3,3,,103163840,3715,Active,,,,,"Antihyperalgesic effect in Freund's complete adjuvant-induced rat inflammatory pain model assessed as reversal of hyperalgesia at 30 mg/kg, sc",Other,19694468.0,
2253,432717,3,4,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Swiss albino mouse assessed as ulcerogenic effect at 100 mg/kg, po",Other,19535179.0,
2254,432723,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered before 60 mins of carrageenan-challenge measured after 90 mins",Other,19535179.0,
2255,432724,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered before 60 mins of carrageenan-challenge measured after 180 mins",Other,19535179.0,
2256,432725,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered before 60 mins of carrageenan-challenge measured after 270 mins",Other,19535179.0,
2257,432726,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered before 60 mins of carrageenan-challenge measured after 360 mins",Other,19535179.0,
2258,433912,3,3,,103163840,3715,Unspecified,,,,,Antinociceptive activity against acetic acid-induced writhing in sc dosed KM mouse for 30 mins relative to indomethacin,Other,19285756.0,
2259,434301,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Norwegian albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po after administered 60 mins prior to carrageenan-challenge measured after 1 hr",Other,19321237.0,
2260,434302,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Norwegian albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po after administered 60 mins prior to carrageenan-challenge measured after 3 hrs",Other,19321237.0,
2261,434303,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Norwegian albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po after administered 60 mins prior to carrageenan-challenge measured after 5 hrs",Other,19321237.0,
2262,434955,1,2,,56422212,3715,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
2263,434959,1,1,,85787264,3715,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
2264,434962,1,2,,56422212,3715,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
2265,434973,1,3,,856012,3715,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
2266,434989,1,1,,56422212,3715,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
2267,435003,1,3,,856012,3715,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
2268,435005,1,1,,56422212,3715,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
2269,435022,2,2,,856012,3715,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
2270,435030,1,2,,56422212,3715,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2271,435030,1,2,,56422212,3715,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2272,436175,3,5,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in human neutrophils assessed as respiratory burst inhibition at 1000 ug/ml by WST-1 assay,Other,19006373.0,
2273,436176,7,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production,Other,19006373.0,
2274,440888,4,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip after 3.5 hrs",Other,19781823.0,
2275,440889,3,3,,103163840,3715,Unspecified,,,,,"Toxicity in Fisher 344 rat assessed as mortality at 0.01 mmol/kg, ip administered daily once for 4 days measured after 24 hrs final post dose",Other,19781823.0,
2276,440890,3,3,,103163840,3715,Unspecified,,,,,"Toxicity in Fisher 344 rat assessed as gastrointestinal ulcer at 0.01 mmol/kg, ip administered daily once for 4 days measured after 24 hrs final post dose",Other,19781823.0,
2277,440891,3,3,,103163840,3715,Unspecified,,,,,"Toxicity in Fisher 344 rat assessed as body weight change per 100 g of animal at 0.01 mmol/kg, ip administered daily once for 4 days measured after 24 hrs final post dose",Other,19781823.0,
2278,440892,3,3,,103163840,3715,Unspecified,,,,,"Toxicity in Fisher 344 rat assessed as melena defecation at 0.01 mmol/kg, ip administered daily once for 4 days measured after 24 hrs final post dose",Other,19781823.0,
2279,442513,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/Kg, ip administered simultaneously with carrageenan measured after 3.5 hrs relative to control",Other,19939514.0,
2280,442514,11,5,,103163840,3715,Inconclusive,6225843.0,27306.0,,IC50,Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation,Confirmatory,19939518.0,
2281,442515,3,10,,103163840,3715,Unspecified,6225843.0,27306.0,,,Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation at 50 uM,Other,19939518.0,
2282,444050,7,1,,103163840,3715,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
2283,444051,6,2,,103163840,3715,Unspecified,,,,,Total clearance in human,Other,20070106.0,
2284,444052,6,2,,103163840,3715,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
2285,444053,6,2,,103163840,3715,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
2286,444054,6,1,,103163840,3715,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
2287,444055,3,3,,103163840,3715,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
2288,444056,3,3,,103163840,3715,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
2289,444057,3,3,,103163840,3715,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
2290,444058,6,2,,103163840,3715,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
2291,444874,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss mouse assessed as inhibition of acetic acid-induced writhing response at 10 mg/kg, po administered 1 hr before acetic acid challenge measured for 30 mins relative to control",Other,19913952.0,
2292,444875,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat assessed as inhibition of hind paw edema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hrs relative to control",Other,19913952.0,
2293,445753,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against arachidonic acid-induced ear edema in Balb/C mouse at 300 ug/ear administered topically 1 hr before arachidonic acid challenge measured after 60 mins,Other,19740655.0,
2294,446961,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in BALB/c mouse assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po after 90 mins",Other,19632747.0,
2295,446964,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in BALB/c mouse assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po after 360 mins",Other,19632747.0,
2296,446967,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in BALB/c mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po after 270 mins",Other,19632747.0,
2297,446970,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in BALB/c mouse assessed as inhibition of carrageenan-induced paw edema at 200 mg/kg, po after 180 mins",Other,19632747.0,
2298,447798,3,3,,103163840,3715,Active,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in mouse assessed as decrease in index of hind paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan challenge",Other,19524443.0,
2299,448016,6,2,,103163840,3715,Active,,,0.04,IC50,Inhibition of COX1-mediated PGH2 production by enzyme immunoassay,Confirmatory,19540763.0,
2300,448017,6,2,,103163840,3715,Active,,,0.6,IC50,Inhibition of COX2-mediated PGH2 production by enzyme immunoassay,Confirmatory,19540763.0,
2301,448127,3,3,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in mouse assessed as inhibition of acetic acid-induced abdominal constrictions at 100 umol/kg, po relative to untreated control",Other,19646868.0,
2302,448128,8,2,,103163840,3715,Unspecified,,,,,Antinociceptive activity in po dosed mouse assessed as inhibition of acetic acid-induced abdominal constrictions,Other,19646868.0,
2303,449531,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in albino mouse assessed as decrease in acetic acid-induced writhing at 10 mg/kg, po administered 1 hr prior to acetic acid challenge relative to control",Other,19628310.0,
2304,449538,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po after 1 hr relative to control",Other,19628310.0,
2305,449632,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po after 2 hrs relative to control",Other,19628310.0,
2306,449633,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po after 3 hrs relative to control",Other,19628310.0,
2307,449634,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po after 4 hrs relative to control",Other,19628310.0,
2308,449728,1,2,,56422212,3715,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
2309,449739,1,2,,856012,3715,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
2310,449762,1,2,,56422212,3715,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
2311,449763,1,3,,856012,3715,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
2312,449768,1,1,,856012,3715,Active,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
2313,452088,5,2,,103163840,3715,Inconclusive,,,,IC50,Inhibition of PDE1,Confirmatory,19744861.0,
2314,452089,4,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po treated 60 mins before carrageenan challenge measured after 90 mins",Other,19744861.0,
2315,452090,4,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po treated 60 mins before carrageenan challenge measured after 180 mins",Other,19744861.0,
2316,452091,4,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip treated 60 mins before carrageenan challenge measured after 90 mins",Other,19744861.0,
2317,452092,4,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip treated 60 mins before carrageenan challenge measured after 180 mins",Other,19744861.0,
2318,452093,3,3,,103163840,3715,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as gastrointestinal ulceration at 200 mg/kg, po once daily for 5 days",Other,19744861.0,
2319,453203,3,4,,103163840,3715,Unspecified,,,,,"Lipophilicity, log D of the compound",Other,19963379.0,
2320,453204,3,6,,103163840,3715,Unspecified,,,,,Permeability in human skin after 48 hrs by Franz cell permeability assay,Other,19963379.0,
2321,453622,4,8,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as residual enzyme activity at 10 uM relative to untreated control,Other,19884011.0,
2322,453623,4,8,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 assessed as residual enzyme activity at 10 uM relative to untreated control,Other,19884011.0,
2323,453641,3,6,,103163840,3715,Unspecified,,,,,Inhibition of COX1 in platelets assessed as inhibition of 12-HHT formation at 10 uM by RP-HPLC,Other,19884011.0,
2324,453646,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in CD1 mouse assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, ip administered 30 mins before carrageenan challenge relative to untreated control",Other,19884011.0,
2325,453648,4,3,,103163840,3715,Active,,,,,"Antiinflammatory activity in Wistar Han rat assessed as reduction in exudate volume at 5 mg/kg, ip administered 30 mins before carrageenan challenge",Other,19884011.0,
2326,453650,4,3,,103163840,3715,Active,,,,,"Antiinflammatory activity in Wistar Han rat assessed as reduction in inflammatory cell numbers at 5 mg/kg, ip administered 30 mins before carrageenan challenge",Other,19884011.0,
2327,454686,4,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Albino rat assessed as inhibition of carrageenan-induced paw edema at 10 umol/kg, ip",Other,19699644.0,
2328,455986,3,5,,103163840,3715,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
2329,456176,5,2,,103163840,3715,Active,,,45.51,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method,Confirmatory,19931461.0,
2330,456180,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction of COX2 protein expression at 50 uM after 24 hrs by Western blot analysis relative to control,Other,19931461.0,
2331,456181,3,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction of iNOS protein expression at 50 uM after 24 hrs by Western blot analysis relative to control,Other,19931461.0,
2332,460906,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar albino rat assessed as ulceration at 100 mg/kg/day, po administered twice daily for 3 days",Other,20138770.0,
2333,461316,4,8,,103163840,3715,Inactive,47117287.0,11343.0,,,Inhibition of human recombinant MGL at 100 uM,Other,20143779.0,
2334,462318,7,5,,103163840,3715,Active,548483.0,19225.0,0.068,IC50,Inhibition of mouse COX2,Confirmatory,20188577.0,
2335,463073,1,2,,856012,3715,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
2336,463075,1,1,,856012,3715,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
2337,463079,1,2,,56422212,3715,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
2338,463082,1,1,,56422212,3715,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
2339,463096,1,1,,50104238,3715,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
2340,463097,1,1,,50104238,3715,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
2341,463104,1,2,,856012,3715,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
2342,463106,1,2,,90340917,3715,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
2343,463111,1,1,,856012,3715,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
2344,463115,1,1,,856012,3715,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
2345,463141,1,2,,56422212,3715,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
2346,463165,1,1,,856012,3715,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
2347,463187,1,1,,856012,3715,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
2348,463189,1,1,,856012,3715,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
2349,463189,1,1,,53777798,3715,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
2350,463190,1,2,,856012,3715,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
2351,463193,1,1,,856012,3715,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
2352,463195,1,2,,856012,3715,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
2353,463210,1,2,,56422212,3715,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
2354,463212,1,1,,856012,3715,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
2355,463254,1,1,,856012,3715,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
2356,464323,5,2,,103163840,3715,Unspecified,,,50.0,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei after 48 hrs by luminescence assay,Confirmatory,20129783.0,
2357,464324,5,2,,103163840,3715,Unspecified,,,50.0,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay,Confirmatory,20129783.0,
2358,464325,5,2,,103163840,3715,Unspecified,,,50.0,IC50,Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay,Confirmatory,20129783.0,
2359,464326,5,2,,103163840,3715,Unspecified,,,50.0,IC50,Cytotoxicity against human Raji cells after 72 hrs by luminescence assay,Confirmatory,20129783.0,
2360,464327,5,2,,103163840,3715,Unspecified,,,50.0,IC50,Cytotoxicity against human BJ cells after 72 hrs by luminescence assay,Confirmatory,20129783.0,
2361,464498,4,3,,103163840,3715,Inconclusive,,,,,Inhibition of tubulin polymerization at 10 uM by fluorescence method,Other,20129783.0,
2362,464499,8,5,,103163840,3715,Active,754286265.0,443551.0,0.05,IC50,Inhibition of ovine COX1,Confirmatory,20129783.0,
2363,464500,8,5,,103163840,3715,Active,548483.0,19225.0,0.75,IC50,Inhibition of mouse COX2,Confirmatory,20129783.0,
2364,464501,4,1,,103163840,3715,Inconclusive,,,,,Half life in mouse plasma by UPLC-MS analysis,Other,20129783.0,
2365,464511,3,4,,103163840,3715,Unspecified,,,,,Selectivity ratio for IC50 for human BJ cells to IC50 for Trypanosoma brucei brucei,Other,20129783.0,
2366,464512,3,3,,103163840,3715,Unspecified,,,,,Selectivity for Trypanosoma brucei brucei over human HMEC,Other,20129783.0,
2367,464513,3,4,,103163840,3715,Unspecified,,,,,Selectivity ratio for IC50 for human BJ cells to IC50 for human HepG2 cells,Other,20129783.0,
2368,464514,3,4,,103163840,3715,Unspecified,,,,,Selectivity for human HepG2 cells over human HMEC,Other,20129783.0,
2369,464515,3,4,,103163840,3715,Unspecified,,,,,Selectivity ratio for IC50 for human BJ cells to IC50 for human HEK293 cells,Other,20129783.0,
2370,464516,3,4,,103163840,3715,Unspecified,,,,,Selectivity for human HEK293 cells over human HMEC,Other,20129783.0,
2371,464517,3,4,,103163840,3715,Unspecified,,,,,Selectivity ratio for IC50 for human BJ cells to IC50 for human Raji cells,Other,20129783.0,
2372,464518,3,4,,103163840,3715,Unspecified,,,,,Selectivity for human Raji cells over human HMEC,Other,20129783.0,
2373,464519,3,3,,103163840,3715,Unspecified,,,,,Half life in stimulated gastric fluid of pH 1.0,Other,20129783.0,
2374,467611,3,6,,103163840,3715,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
2375,467612,3,6,,103163840,3715,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
2376,467613,5,3,,103163840,3715,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
2377,469573,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema measured after 1 hr at 6 mg/kg, po administered 1 hr before carrageenan challenge",Other,19647903.0,
2378,469575,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema measured after 2 hrs at 6 mg/kg, po administered 1 hr before carrageenan challenge",Other,19647903.0,
2379,469577,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema measured after 3 hrs at 6 mg/kg, po administered 1 hr before carrageenan challenge",Other,19647903.0,
2380,469578,3,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing at 0.00001911 mol/kg, po administered 1 hr before acetic acid challenge measured after 25 mins",Other,19647903.0,
2381,475086,8,5,,103163840,3715,Active,754286265.0,443551.0,1.09,IC50,Inhibition of ram seminal vesicle COX1 assessed as PGE2 level by EIA,Confirmatory,20236826.0,
2382,475504,3,3,,103163840,3715,Inactive,,,,,Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
2383,475505,3,3,,103163840,3715,Inactive,,,,,Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
2384,476929,3,3,,103163840,3715,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
2385,477756,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 60 mins before carrageenan challenge measured after 90 mins",Other,20116903.0,
2386,477757,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 60 mins before carrageenan challenge measured after 180 mins",Other,20116903.0,
2387,477758,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 60 mins before carrageenan challenge measured after 270 mins",Other,20116903.0,
2388,477759,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 60 mins before carrageenan challenge measured after 360 mins",Other,20116903.0,
2389,478748,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced paw edema in po dosed rat administered 1 hr before carrageenan challenge assessed after 1 hr,Other,20153090.0,
2390,478749,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced paw edema in po dosed rat administered 1 hr before carrageenan challenge assessed after 2 hrs,Other,20153090.0,
2391,478750,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced paw edema in po dosed rat administered 1 hr before carrageenan challenge assessed after 3 hrs,Other,20153090.0,
2392,478751,3,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced paw edema in po dosed rat administered 1 hr before carrageenan challenge assessed after 4 hrs,Other,20153090.0,
2393,481237,6,2,,103163840,3715,Unspecified,,,,,Antiarthritic activity in po dosed BALB/c mouse collagen antibody induced arthritis model assessed as increase of arthritis score administered qd for 2 days after collagen antibody challenge measured after 2 days,Other,20399648.0,
2394,481238,3,3,,103163840,3715,Unspecified,,,,,Toxicity in po dosed BALB/c mouse collagen antibody induced arthritis model assessed as tolerated dose,Other,20399648.0,
2395,481239,3,3,,103163840,3715,Unspecified,,,,,Ratio of ED50 for BALB/c mouse collagen antibody induced arthritis model to tolerated dose for BALB/c mouse collagen antibody induced arthritis model,Other,20399648.0,
2396,481439,3,4,,103163840,3715,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
2397,481442,3,6,,103163840,3715,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
2398,481937,4,9,,103163840,3715,Inactive,296439301.0,4363.0,,,Inhibition of MRP1-mediated doxorubicin efflux in doxorubicin resistant human HepG2 cells at 10 to 100 uM by flow cytometry,Other,20455578.0,
2399,481938,4,9,,103163840,3715,Active,296439301.0,4363.0,,,Inhibition of MRP1-mediated doxorubicin efflux in doxorubicin resistant human HepG2 cells at 100 uM by flow cytometry,Other,20455578.0,
2400,482170,5,2,,103163840,3715,Unspecified,,,,,Thermodynamic solubility in sodium phosphate buffer of pH 7.4 by UV-reverse phase HPLC analysis,Other,20583844.0,
2401,482172,3,4,,103163840,3715,Unspecified,,,,,"Partition coefficient, log P at 5 mM by reverse phase HPLC analysis",Other,20583844.0,
2402,485270,1,1,,56422212,3715,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
2403,485272,1,1,,56422212,3715,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
2404,485273,2,1,,856012,3715,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
2405,485275,1,3,,56422212,3715,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
2406,485281,1,1,,856012,3715,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
2407,485281,1,1,,11111329,3715,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
2408,485290,1,1,,856012,3715,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2409,485290,1,1,,11111329,3715,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2410,485290,1,1,,11113361,3715,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2411,485290,1,1,,17389851,3715,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2412,485290,1,1,,26747086,3715,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2413,485290,1,1,,26751593,3715,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2414,485290,1,1,,50104238,3715,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2415,485294,1,1,,856012,3715,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
2416,485295,1,2,,90340917,3715,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
2417,485297,1,1,,856012,3715,Inactive,4759012.0,9367.0,6.3096,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
2418,485297,1,1,,90340917,3715,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
2419,485298,1,1,,856012,3715,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
2420,485298,1,1,,90340917,3715,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
2421,485313,1,2,,856012,3715,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
2422,485313,1,2,,90340917,3715,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
2423,485314,1,1,,856012,3715,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
2424,485314,1,1,,50104238,3715,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
2425,485317,1,2,,56422212,3715,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
2426,485341,1,1,,856012,3715,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
2427,485342,1,2,,90340917,3715,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
2428,485344,1,1,,856012,3715,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
2429,485345,1,2,,90340917,3715,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2430,485346,1,1,,856012,3715,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
2431,485346,1,1,,856012,3715,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
2432,485347,1,2,,856012,3715,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
2433,485349,1,1,,856012,3715,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
2434,485350,1,2,,92124045,3715,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
2435,485350,1,2,,92125110,3715,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
2436,485350,1,2,,99301013,3715,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
2437,485353,2,1,,856012,3715,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
2438,485358,1,1,,856012,3715,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
2439,485360,1,1,,856012,3715,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
2440,485364,1,1,,856012,3715,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
2441,485366,1,2,,90340917,3715,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2442,485367,1,2,,856012,3715,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
2443,485368,1,2,,90340917,3715,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
2444,485995,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 1 hr",Other,20137837.0,
2445,485996,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 2 hrs",Other,20137837.0,
2446,485997,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 3 hrs",Other,20137837.0,
2447,486180,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 4 hrs",Other,20137837.0,
2448,486185,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as ulcerogenic effect at 9 mg/kg, po after 7 hrs",Other,20137837.0,
2449,486706,3,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as reduction of carrageenan-induced paw edema at 50 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 hr by mercury displacement method relative to control",Other,20172630.0,
2450,486708,3,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Sprague-Dawley rat assessed as lengths of longest diameters of lesions at 20 mg/kg, po after 6 hrs",Other,20172630.0,
2451,487176,3,9,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of sheep COX1 assessed as PGE2 level at 50 uM by ELISA,Other,20207453.0,
2452,487177,3,9,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 assessed as PGE2 level at 50 uM by ELISA,Other,20207453.0,
2453,488194,8,5,,103163840,3715,Active,317373262.0,5742.0,0.2,IC50,Inhibition of COX1 in human whole blood,Confirmatory,20451397.0,
2454,488195,8,5,,103163840,3715,Active,3915797.0,5743.0,0.5,IC50,Inhibition of COX2 in human whole blood,Confirmatory,20451397.0,
2455,488196,3,3,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for COX2 in human whole blood to IC50 for COX1 in human whole blood,Other,20451397.0,
2456,488197,8,5,,103163840,3715,Inconclusive,126407.0,240.0,,IC50,Inhibition of 5-lipoxygenase in human whole blood assessed as inhibition of LTB4 production by HPLC method,Confirmatory,20451397.0,
2457,488198,8,5,,103163840,3715,Inconclusive,126407.0,240.0,,IC50,Inhibition of 5-lipoxygenase in human whole blood assessed as inhibition of 5-hydroxyeicosatetraenoic acid production by HPLC method,Confirmatory,20451397.0,
2458,488201,8,5,,103163840,3715,Active,317373262.0,5742.0,6.0,IC50,Inhibition of COX1 in human whole blood assessed as inhibition of 12-hydroxyheptadecatrienoic acid production by HPLC method,Confirmatory,20451397.0,
2459,488203,8,5,,103163840,3715,Active,3915797.0,5743.0,0.5,IC50,Inhibition of COX2 in human whole blood assessed as inhibition of 12-hydroxyheptadecatrienoic acid production by HPLC method,Confirmatory,20451397.0,
2460,488204,3,3,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for COX2-mediated 12-hydroxyheptadecatrienoic acid production in human whole blood to IC50 for COX1-mediated 12-hydroxyheptadecatrienoic acid production in human whole blood,Other,20451397.0,
2461,488745,1,4,,85231093,3715,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2462,488752,1,4,,85231093,3715,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2463,488772,1,1,,90340917,3715,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
2464,488773,1,2,,90340917,3715,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
2465,488806,1,2,,856012,3715,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
2466,488816,1,1,,90340917,3715,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
2467,488837,1,1,,856012,3715,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
2468,488837,1,1,,90340917,3715,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
2469,488839,1,1,,56422212,3715,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2470,488839,1,1,,56422212,3715,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2471,488847,1,3,,56422212,3715,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
2472,488862,1,1,,56422212,3715,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2473,488890,1,2,,56422212,3715,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
2474,488895,1,2,,56422212,3715,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2475,488896,1,1,,56422212,3715,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2476,488899,1,1,,56422212,3715,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2477,488922,1,2,,856012,3715,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
2478,488949,1,2,,85231093,3715,Inactive,41055989.0,54737.0,0.7943,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2479,488949,1,2,,90340917,3715,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2480,488953,1,1,,90340917,3715,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2481,488965,1,2,,56422212,3715,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2482,488966,1,1,,56422212,3715,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
2483,488975,1,2,,56422212,3715,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
2484,488977,1,2,,56422212,3715,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
2485,488978,1,1,,90340917,3715,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
2486,488979,1,1,,50104238,3715,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
2487,488980,1,1,,85231093,3715,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
2488,488981,1,1,,90340917,3715,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
2489,488982,1,1,,90340917,3715,Unspecified,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
2490,488983,1,1,,90340917,3715,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
2491,489030,2,1,,856012,3715,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
2492,489031,2,1,,856012,3715,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
2493,492143,5,2,,103163840,3715,Active,,,0.24,IC50,Antiinflammatory activity in NIH mouse assessed as inhibition of TPA-induced mouse ear edema measured per ear administered to right ear relative to untreated control,Confirmatory,20575572.0,
2494,492145,3,9,,103163840,3715,Unspecified,13432234.0,5468.0,,,Agonist activity at human PPARgamma expressed in Escherichia coli BL21 assessed as stimulation of binding between receptor and steroid receptor coactivator-1 at 320 uM by ELISA relative to untreated control,Other,20583750.0,
2495,492146,5,3,,103163840,3715,Unspecified,13432234.0,5468.0,,,Binding affinity to human PPARgamma expressed in Escherichia coli BL21 assessed as binding constant by fluorescence quenching assay,Other,20583750.0,
2496,492147,5,2,,103163840,3715,Unspecified,,,50.0,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,20583750.0,
2497,492148,5,2,,103163840,3715,Unspecified,,,100.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,20583750.0,
2498,492149,5,2,,103163840,3715,Unspecified,,,100.0,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,20583750.0,
2499,492150,5,2,,103163840,3715,Unspecified,,,100.0,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,20583750.0,
2500,492151,5,2,,103163840,3715,Unspecified,,,100.0,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,20583750.0,
2501,492158,5,3,,103163840,3715,Unspecified,,,250.0,IC50,Inhibition of compound 48/80-induced histamine release in Wister rat Peritoneal mast cells,Confirmatory,20586436.0,
2502,492302,3,4,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in Swiss mouse assessed as inhibition of acetic acid-induced abdominal constrictions at 100 umol/kg, po administered 40 mins before acetic acid challenge measured for 25 mins relative to control",Other,20598893.0,
2503,492305,3,4,,103163840,3715,Unspecified,,,,,"Analgesic activity against formalin-induced acute pain in Swiss mouse assessed inhibition of nociception at 100 umol/kg, po administered 40 mins before formalin challenge measured for 15 to 30 mins relative to control",Other,20598893.0,
2504,492314,3,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against zymosan A-induced peritonitis in Swiss mouse assessed as inhibition of granulocyte infiltration in to peritoneal cavity at 100 mg/kg, po administered 40 mins before zymosan A challenge measured after 6 hrs relative to control",Other,20598893.0,
2505,492315,3,4,,103163840,3715,Unspecified,,,,,"Antiedematogenic activity in Swiss mouse assessed as decrease of capsaicin-induced paw edema weight at 100 umol/kg, po administered 40 mins before capsaicin challenge measured after 30 mins relative to control",Other,20598893.0,
2506,492316,3,4,,103163840,3715,Unspecified,,,,,"Antiedematogenic activity in Swiss mouse assessed as inhibition of capsaicin-induced paw edema at 100 umol/kg, po administered 40 mins before capsaicin challenge measured after 30 mins relative to control",Other,20598893.0,
2507,492323,3,5,,103163840,3715,Inconclusive,,,,,Inhibition of Pgp expressed in mouse L5178Y cells at 1 uM relative to control,Other,20598550.0,
2508,492324,3,5,,103163840,3715,Inconclusive,,,,,Inhibition of Pgp expressed in mouse L5178Y cells at 10 uM relative to control,Other,20598550.0,
2509,492325,3,6,,103163840,3715,Unspecified,,,,,Inhibition of MRP1 expressed in human A2780 cells at 10 uM relative to control,Other,20598550.0,
2510,492326,3,6,,103163840,3715,Unspecified,,,,,Inhibition of MRP2 expressed in human A2780 cells at 10 uM relative to control,Other,20598550.0,
2511,492327,3,6,,103163840,3715,Inconclusive,,,,,Inhibition of BCRP expressed in human EPG-257RNOV cells at 0.1 uM relative to control,Other,20598550.0,
2512,492328,3,6,,103163840,3715,Inconclusive,,,,,Inhibition of BCRP expressed in human EPG-257RNOV cells at 1 uM relative to control,Other,20598550.0,
2513,492858,8,5,,103163840,3715,Active,3915797.0,5743.0,0.01,IC50,Inhibition of human recombinant COX2 after 5 mins,Confirmatory,20503989.0,
2514,492859,8,5,,103163840,3715,Active,754286265.0,443551.0,0.006,IC50,Inhibition of ovine COX1 after 5 mins,Confirmatory,20503989.0,
2515,492867,5,2,,103163840,3715,Active,,,25.0,IC50,Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA,Confirmatory,20503989.0,
2516,492947,1,1,,856012,3715,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2517,492953,1,1,,56422212,3715,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
2518,492956,1,1,,56422212,3715,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
2519,492967,1,2,,92125110,3715,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
2520,492967,1,2,,99301359,3715,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
2521,492972,1,1,,56422212,3715,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
2522,493005,1,1,,56422212,3715,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
2523,493008,1,1,,56422212,3715,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2524,493008,1,1,,56422212,3715,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2525,493008,1,1,,56422212,3715,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2526,493008,1,1,,56422212,3715,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2527,493011,1,1,,856012,3715,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
2528,493012,1,1,,856012,3715,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
2529,493014,1,1,,856012,3715,Inconclusive,,,7.0795,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2530,493027,1,2,,56422212,3715,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2531,493027,1,2,,56422212,3715,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2532,493033,1,2,,92124045,3715,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2533,493033,1,2,,92125110,3715,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2534,493033,1,2,,99301013,3715,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2535,493035,1,2,,56422212,3715,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2536,493035,1,2,,56422212,3715,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2537,493036,1,2,,856012,3715,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
2538,493056,1,1,,856012,3715,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
2539,493084,1,1,,856012,3715,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
2540,493087,1,1,,56422212,3715,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
2541,493091,1,1,,56422212,3715,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
2542,493098,1,1,,56422212,3715,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
2543,493106,1,1,,90340917,3715,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2544,493107,1,1,,90340917,3715,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2545,493127,1,1,,50104238,3715,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
2546,493131,1,1,,56422212,3715,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
2547,493140,1,1,,103914058,3715,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
2548,493153,1,1,,90340917,3715,Inconclusive,,4780.0,9.2,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2549,493153,1,1,,90340917,3715,Inconclusive,224028257.0,4780.0,9.2,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2550,493160,1,1,,56422212,3715,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
2551,493162,1,2,,99301359,3715,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
2552,493162,1,2,,99302533,3715,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
2553,493164,1,2,,90340917,3715,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2554,493164,1,2,,90340917,3715,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2555,493164,1,2,,90340917,3715,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2556,493187,1,2,,56422212,3715,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
2557,493189,1,1,,50104238,3715,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
2558,493244,1,1,,56422212,3715,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2559,493244,1,1,,56422212,3715,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2560,493244,1,1,,56422212,3715,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2561,493244,1,1,,56422212,3715,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2562,496817,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
2563,496818,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
2564,496819,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
2565,496820,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
2566,496821,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
2567,496823,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
2568,496824,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
2569,496825,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
2570,496826,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
2571,496827,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
2572,496828,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
2573,496829,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
2574,496830,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
2575,496831,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
2576,496832,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
2577,497005,4,2,,103163840,3715,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
2578,497222,2,3,,103163840,3715,Unspecified,,,,,"Toxicity in Wistar albino rat assessed as ulcerogenic activity at 300 mg/kg, po qd for 3 days",Other,20609589.0,
2579,499199,3,6,,103163840,3715,Active,,,,,Inhibition of COX1,Other,20684598.0,
2580,499200,3,6,,103163840,3715,Active,,,,,Inhibition of COX2,Other,20684598.0,
2581,500923,3,3,,103163840,3715,Active,,,,,Inhibition of COX2-mediated decrease in gata1 expression in heat-stimulated heterozygous transgenic zebrafish embryo assessed as restoration of gata1 level at 20 uM by in-situ hybridization analysis,Other,19172146.0,
2582,500926,3,3,,103163840,3715,Inactive,,,,,Inhibition of COX2-mediated decrease in gata1 expression in heterozygous transgenic zebrafish embryo assessed as restoration of gata1 level at 20 uM by in-situ hybridization analysis,Other,19172146.0,
2583,500928,3,3,,103163840,3715,Active,,,,,Inhibition of COX2 in heat-stimulated heterozygous transgenic zebrafish embryo assessed as MPO-positive granulocytic cell accumulation at 20 uM by in situ hybridization analysis,Other,19172146.0,
2584,500930,3,3,,103163840,3715,Inactive,,,,,Inhibition of COX2 in heterozygous transgenic zebrafish embryo assessed as MPO-positive granulocytic cell accumulation at 20 uM by in situ hybridization analysis,Other,19172146.0,
2585,500932,3,3,,103163840,3715,Inactive,,,,,Inhibition of COX2 in heat-stimulated heterozygous transgenic zebrafish embryo assessed as MPO-positive granulocytic cell accumulation at 20 uM by in situ hybridization analysis in presence of PGE2,Other,19172146.0,
2586,502271,3,7,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of sheep COX2 at 10 uM by enzyme immunoassay,Other,20692174.0,
2587,502272,3,8,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of sheep COX1 at 10 uM by enzyme immunoassay,Other,20692174.0,
2588,502273,7,5,,103163840,3715,Active,3914304.0,443460.0,0.537,IC50,Inhibition of sheep COX2 by enzyme immunoassay,Confirmatory,20692174.0,
2589,502274,7,5,,103163840,3715,Active,754286265.0,443551.0,0.069,IC50,Inhibition of sheep COX1 by enzyme immunoassay,Confirmatory,20692174.0,
2590,502275,2,3,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for sheep COX1 to IC50 for sheep COX2",Other,20692174.0,
2591,504326,1,2,,56422212,3715,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2592,504326,1,2,,56422212,3715,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2593,504327,1,1,,856012,3715,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2594,504327,1,1,,11111329,3715,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2595,504327,1,1,,90340917,3715,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2596,504329,1,1,,56422212,3715,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
2597,504332,1,1,,856012,3715,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2598,504332,1,1,,11111329,3715,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2599,504332,1,1,,50104238,3715,Inactive,168985070.0,,0.3981,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2600,504332,1,1,,90340917,3715,Inactive,168985070.0,,5.9728,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2601,504333,1,1,,856012,3715,Inconclusive,6683500.0,29994.0,100.0,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
2602,504339,1,1,,56422212,3715,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
2603,504357,1,1,,56422212,3715,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2604,504357,1,1,,56422212,3715,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2605,504364,1,1,,85231093,3715,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
2606,504406,1,1,,56422212,3715,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
2607,504408,2,1,,856012,3715,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
2608,504411,1,1,,56422212,3715,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
2609,504414,1,1,,56422212,3715,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2610,504414,1,1,,56422212,3715,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2611,504423,1,1,,56422212,3715,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2612,504441,1,1,,56422212,3715,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2613,504444,1,1,,56422212,3715,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
2614,504454,1,3,,56422212,3715,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
2615,504462,1,1,,56422212,3715,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
2616,504466,1,1,,856012,3715,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2617,504467,1,1,,856012,3715,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2618,504490,1,2,,56422212,3715,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
2619,504523,1,1,,56422212,3715,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2620,504523,1,1,,56422212,3715,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2621,504536,1,1,,90340917,3715,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
2622,504541,1,1,,856012,3715,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
2623,504547,1,1,,90340917,3715,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2624,504548,1,2,,90340917,3715,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
2625,504558,1,1,,56422212,3715,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2626,504577,2,2,,56422212,3715,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2627,504582,2,1,,56422212,3715,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2628,504594,1,1,,56422212,3715,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2629,504600,1,2,,856012,3715,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2630,504621,1,1,,56422212,3715,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2631,504634,1,1,,56422212,3715,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2632,504648,1,1,,56422212,3715,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
2633,504651,1,1,,856012,3715,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
2634,504652,1,1,,856012,3715,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
2635,504660,1,1,,856012,3715,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
2636,504690,1,3,,56422212,3715,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
2637,504692,2,2,,56422212,3715,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2638,504700,1,1,,56422212,3715,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2639,504700,1,1,,56422212,3715,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2640,504706,1,1,,856012,3715,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
2641,504707,1,1,,56422212,3715,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2642,504707,1,1,,56422212,3715,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2643,504720,1,1,,56422212,3715,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
2644,504734,1,1,,56422212,3715,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
2645,504766,2,1,,56422212,3715,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
2646,504770,1,2,,92124045,3715,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
2647,504775,1,1,,56422212,3715,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2648,504803,1,1,,56422212,3715,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
2649,504810,1,2,,856012,3715,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2650,504810,1,2,,90340917,3715,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2651,504812,1,2,,856012,3715,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2652,504812,1,2,,90340917,3715,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2653,504821,1,1,,85231093,3715,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
2654,504832,1,1,,856012,3715,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2655,504834,1,1,,856012,3715,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2656,504836,1,2,,90340917,3715,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
2657,504842,1,1,,856012,3715,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
2658,504845,1,1,,56422212,3715,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2659,504845,1,1,,90340917,3715,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2660,504847,1,1,,11111329,3715,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2661,504847,1,1,,56422212,3715,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2662,504847,1,1,,90340917,3715,Inconclusive,63054845.0,7421.0,89.1251,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2663,504858,1,1,,856012,3715,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Retest of Primary Hits,Screening,,
2664,504865,1,1,,11111329,3715,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2665,504865,1,1,,90340917,3715,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2666,504884,1,2,,56422212,3715,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2667,504891,1,1,,56422212,3715,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2668,504894,1,1,,56422212,3715,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2669,504937,1,2,,56422212,3715,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2670,509683,4,2,,103163840,3715,Unspecified,,,246.35,IC50,Antiinflammatory activity in human neutrophils assessed as inhibition of respiratory burst,Confirmatory,20576329.0,
2671,509685,4,2,,103163840,3715,Unspecified,,,1000.0,IC50,Antioxidant activity assessed as xanthin/xanthin oxidase superoxide scavengeing activity,Confirmatory,20576329.0,
2672,509686,7,2,,103163840,3715,Active,,,0.05,IC50,Inhibition of COX1,Confirmatory,20576329.0,
2673,509687,7,2,,103163840,3715,Active,,,0.67,IC50,Inhibition of COX2,Confirmatory,20576329.0,
2674,515501,2,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 10 mg/kg, po",Other,20731361.0,
2675,515503,2,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered prior to carrageenan challenge measured after 1 hrs post carrageenan challenge",Other,20731361.0,
2676,515504,2,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered prior to carrageenan challenge measured after 3 hrs post carrageenan challenge",Other,20731361.0,
2677,515505,2,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered prior to carrageenan challenge measured after 5 hrs post carrageenan challenge",Other,20731361.0,
2678,516449,7,5,,103163840,3715,Active,3914304.0,443460.0,5.7,IC50,Inhibition of ovine COX2 by enzyme immunoassay,Confirmatory,20727750.0,
2679,516452,1,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced rat paw edema at 4.2 mg/kg, po after 3 hrs",Other,20727750.0,
2680,521208,4,2,,103163840,3715,Inconclusive,,,,EC50,Antiproliferative activity against mouse neural precursor cells by MTT assay,Confirmatory,17417631.0,
2681,521209,4,3,,103163840,3715,Inconclusive,,,,EC50,Antiproliferative activity against mouse astrocyte cells by MTT assay,Confirmatory,17417631.0,
2682,521220,3,3,,103163840,3715,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2683,527190,4,2,,103163840,3715,Active,,,12.96,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay,Confirmatory,20879743.0,
2684,535924,2,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr before carrageenan challenge and measured 2 hrs post carrageenan challenge relative to untreated control",Other,20800934.0,
2685,535925,2,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr before carrageenan challenge and measured 4 hrs post carrageenan challenge relative to untreated control",Other,20800934.0,
2686,536095,2,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, ip administered 1 hrs before carrageenan challenge relative to untreated control",Other,20801553.0,
2687,536469,2,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced fisher 344 rat paw edema model assessed as reduction of paw volume at 50 mg/kg, ip after 3.5 hrs by plethysmometer",Other,20817324.0,
2688,536472,5,1,,103163840,3715,Unspecified,,,,,Acute toxicity in ip dosed albino mouse after 24 hrs,Other,20817324.0,
2689,536609,2,3,,103163840,3715,Unspecified,,,,,"Analgesic activity against heat induced nociception in Swiss albino mouse assessed as increase in latency at 100 mg/kg, po measured 60 mins post compound dose by hot plate method relative to pretreatment level",Other,20817329.0,
2690,536610,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of formaldehyde-induced paw edema at 100 mg/kg, po qd for 4 days administered 1 hr before formaldehyde challenge measured 2 hrs post formaldehyde challenge relative to untreated control",Other,20817329.0,
2691,537733,2,3,,103163840,3715,Inactive,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
2692,537734,5,2,,103163840,3715,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
2693,537735,2,3,,103163840,3715,Inactive,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
2694,537736,5,2,,103163840,3715,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
2695,540209,4,3,,103163840,3715,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2696,540210,4,3,,103163840,3715,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2697,540211,2,5,,103163840,3715,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2698,540212,4,3,,103163840,3715,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2699,540213,4,3,,103163840,3715,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2700,540214,4,3,,103163840,3715,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
2701,540215,3,2,,103163840,3715,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
2702,540216,4,3,,103163840,3715,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
2703,540217,4,3,,103163840,3715,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
2704,540218,4,3,,103163840,3715,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
2705,540219,4,3,,103163840,3715,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
2706,540220,4,3,,103163840,3715,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
2707,540221,4,3,,103163840,3715,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
2708,540230,2,5,,103163840,3715,Unspecified,,,,,Dose normalised AUC in rat after po administration,Other,16019946.0,
2709,540231,2,5,,103163840,3715,Unspecified,,,,,Dose normalised AUC in dog after po administration,Other,16019946.0,
2710,540232,2,5,,103163840,3715,Unspecified,,,,,Dose normalised AUC in monkey after po administration,Other,16019946.0,
2711,540233,2,5,,103163840,3715,Unspecified,,,,,Dose normalised AUC in human after po administration,Other,16019946.0,
2712,540253,1,1,,56422212,3715,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2713,540253,1,1,,56422212,3715,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2714,540253,1,1,,56422212,3715,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2715,540256,1,2,,856012,3715,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2716,540256,1,2,,50104238,3715,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2717,540256,1,2,,90340917,3715,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2718,540263,1,1,,56422212,3715,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2719,540263,1,1,,56422212,3715,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2720,540267,1,1,,56422212,3715,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2721,540275,1,1,,856012,3715,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2722,540276,1,2,,856012,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2723,540276,1,2,,11111328,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2724,540276,1,2,,11111329,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2725,540276,1,2,,11113361,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2726,540276,1,2,,17389851,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2727,540276,1,2,,26747086,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2728,540276,1,2,,26747087,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2729,540276,1,2,,26751593,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2730,540276,1,2,,50100255,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2731,540276,1,2,,50104238,3715,Inconclusive,420597.0,,0.0891,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2732,540276,1,2,,50104239,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2733,540276,1,2,,50126367,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2734,540276,1,2,,56422212,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2735,540276,1,2,,85231093,3715,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2736,540276,1,2,,90340917,3715,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2737,540277,1,1,,856012,3715,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2738,540295,1,1,,56422212,3715,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2739,540299,1,2,,92124045,3715,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2740,540299,1,2,,92125110,3715,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2741,540299,1,2,,99302533,3715,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2742,540303,1,1,,56422212,3715,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2743,540303,1,1,,56422212,3715,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2744,540303,1,1,,56422212,3715,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2745,540308,1,1,,56422212,3715,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2746,540317,1,1,,56422212,3715,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2747,540336,1,1,,56422212,3715,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2748,540336,1,1,,56422212,3715,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2749,540364,1,2,,56422212,3715,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2750,540370,1,3,,856012,3715,Inactive,6325022.0,855842.0,,,"Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin, Single Point, Cherry Pick 1",Other,,
2751,541261,2,5,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip administered simultaneously with carrageenan",Other,21049954.0,
2752,546254,7,5,,103163840,3715,Active,3915797.0,5743.0,35.2,IC50,Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell,Confirmatory,20974503.0,
2753,547625,3,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Sprague-Dawley rat assessed as reduction of cotton pellet-induced dry weight of granuloma measured after 7 days,Other,20970223.0,
2754,547626,2,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as reduction of carrageenan-induced paw edema at 10 umol/kg, sc administered 1 hr before carrageenan challenge measured after 4 hrs by plethysmometry",Other,20970223.0,
2755,547628,7,5,,103163840,3715,Active,3915797.0,5743.0,2.63,IC50,Inhibition of human recombinant COX2 after 45 mins,Confirmatory,20970223.0,
2756,547629,7,5,,103163840,3715,Active,317373262.0,5742.0,0.26,IC50,Inhibition of human platelets COX1 after 2 mins,Confirmatory,20970223.0,
2757,547630,2,3,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant COX2 to IC50 for human platelets COX1,Other,20970223.0,
2758,547631,2,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcerogenicity at 30 uM/kg, po bid for 3 days measured after 6 hrs of last post dose",Other,20970223.0,
2759,548101,2,9,,103163840,3715,Unspecified,75102135.0,,,,Inhibition of soybean lipoxygenase at 100 uM by UV spectrophotometry,Other,20888086.0,
2760,548103,2,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip measured 3.5 hrs after carrageenan challenge relative to control",Other,20888086.0,
2761,548963,2,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fisher rat assessed as inhibition of carrageenan-induced paw oedema at 0.01 mmol/kg, po measured after 3.5 hrs",Other,21041094.0,
2762,549588,2,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear edema at 0.3 umol administered topically per cm'2 of ear relative to control,Other,21167711.0,
2763,549589,2,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear edema at 0.1 umol administered topically per cm'2 of ear relative to control,Other,21167711.0,
2764,549590,3,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear edema per cm'2 administered topically,Other,21167711.0,
2765,549591,2,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear edema at 1 umol administered topically per cm'2 of ear relative to control,Other,21167711.0,
2766,549980,4,2,,103163840,3715,Active,,,0.24,IC50,Antiinflammatory activity in mouse assessed as TPA-induced mouse ear edema administered to right ear after 4 hrs,Confirmatory,20942442.0,
2767,551386,2,10,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 100 uM after 5 mins by microplate reader assay,Other,21144750.0,
2768,551387,2,10,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 100 uM after 5 mins by microplate reader assay,Other,21144750.0,
2769,551388,7,5,,103163840,3715,Active,754286265.0,443551.0,0.15,IC50,Inhibition of ovine COX1 after 5 mins by microplate reader assay,Confirmatory,21144750.0,
2770,551389,7,5,,103163840,3715,Active,3914304.0,443460.0,10.0,IC50,Inhibition of ovine COX2 after 5 mins by microplate reader assay,Confirmatory,21144750.0,
2771,552764,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against histamine-induced mouse edema model assessed as inflammation index 20 mg/kg, po (untreated control = 32.6+/-3.1%)",Other,21159508.0,
2772,552765,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against histamine-induced mouse edema model assessed as edema size 20 mg/kg, po (untreated control = 100%)",Other,21159508.0,
2773,552766,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against histamine-induced mouse edema model assessed as antiinflammatory effect 20 mg/kg, po (untreated control = 0%)",Other,21159508.0,
2774,567037,2,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw oedema at 0.01 mmol/kg, ip",Other,21106277.0,
2775,567091,2,6,,103163840,3715,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
2776,568008,7,5,,103163840,3715,Active,134039205.0,2739.0,24.0,Ki,Inhibition of human recombinant His-tagged glyoxalase 1 expressed in Escherichia coli BL21 (DE3) preincubated for 20 mins by Dixon plot analysis,Confirmatory,21237663.0,
2777,568009,7,2,,103163840,3715,Active,,,18.1,Ki,Inhibition of glyoxalase 1,Confirmatory,21237663.0,
2778,576612,7,5,,103163840,3715,Unspecified,7531135.0,3757.0,301.995,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
2779,577988,2,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in xylene-induced Kunming mouse ear edema model assessed as suppression of ear swelling at 100 mg/kg, po",Other,21288716.0,
2780,577992,2,4,,103163840,3715,Unspecified,,,,,"Cardiotoxicity in Kunming mouse assessed as pathological changes at 100 mg/kg, po after 12 days",Other,21288716.0,
2781,578766,7,1,,103163840,3715,Active,,,12.6,IC50,Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay,Confirmatory,21354800.0,
2782,579632,4,2,,103163840,3715,Active,,,38.3,IC50,Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry,Confirmatory,21316977.0,
2783,579633,4,2,,103163840,3715,Active,,,32.0,IC50,Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced elastase release,Confirmatory,21316977.0,
2784,580340,2,7,,103163840,3715,Unspecified,,,,,Inhibition of COX1 at 30 uM,Other,21345672.0,
2785,580341,2,7,,103163840,3715,Unspecified,,,,,Inhibition of COX2 at 30 uM,Other,21345672.0,
2786,580342,7,2,,103163840,3715,Active,,,0.18,IC50,Inhibition of COX1,Confirmatory,21345672.0,
2787,580344,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced mouse edema model assessed as ear thickness at 0.5 mg/ear (Rbv = 0.270 +/- 0.008 mm),Other,21345672.0,
2788,580345,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced mouse edema model assessed as reduction in ear edema at 0.5 mg/ear,Other,21345672.0,
2789,587233,2,10,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as PGE2 formation at 125 nM by LC-MS-MS analysis,Other,21261296.0,
2790,587235,2,10,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as PGE2 formation at 10 uM by LC-MS-MS analysis,Other,21261296.0,
2791,587448,7,5,,103163840,3715,Active,754286265.0,443551.0,0.13,IC50,Inhibition of ovine COX-1,Confirmatory,21280601.0,
2792,587449,7,5,,103163840,3715,Active,3915797.0,5743.0,6.9,IC50,Inhibition of human recombinant COX-2,Confirmatory,21280601.0,
2793,587450,1,5,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2",Other,21280601.0,
2794,587451,5,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed Sprague-Dawley rat assessed as inhibition of carrageenam-induced paw edema administered 1 hr before carrageenan challenge measured after 3 hrs by Plethysmometer,Other,21280601.0,
2795,587454,2,5,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in 12 fasting Sprague-Dawley rat assessed as ulcer index at 80 umol/kg, po measured after 6 hrs by magnifier lenses",Other,21280601.0,
2796,588209,2,3,,103163840,3715,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2797,588210,2,4,,103163840,3715,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2798,588211,2,3,,103163840,3715,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2799,588212,2,3,,103163840,3715,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2800,588213,2,3,,103163840,3715,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2801,588214,2,3,,103163840,3715,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2802,588215,2,3,,103163840,3715,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2803,588216,2,3,,103163840,3715,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2804,588217,2,3,,103163840,3715,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2805,588218,2,3,,103163840,3715,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2806,588219,2,3,,103163840,3715,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2807,588334,1,1,,56422212,3715,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2808,588335,1,1,,56422212,3715,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2809,588342,1,1,,856012,3715,Inconclusive,160794.0,,21.3313,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2810,588349,1,1,,90340917,3715,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2811,588352,1,2,,56422212,3715,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2812,588354,1,1,,56422212,3715,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2813,588358,1,2,,56422212,3715,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2814,588368,1,2,,856012,3715,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
2815,588378,1,1,,90340917,3715,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2816,588379,1,2,,124880450,3715,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
2817,588389,1,1,,856012,3715,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists:Counterscreen of Primary Hits,Other,,
2818,588391,1,1,,56422212,3715,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2819,588405,1,1,,56422212,3715,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2820,588413,1,2,,56422212,3715,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2821,588436,1,1,,56422212,3715,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2822,588453,1,1,,56422212,3715,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2823,588453,1,1,,85231093,3715,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2824,588453,1,1,,90340917,3715,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2825,588456,1,1,,56422212,3715,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2826,588456,1,1,,90340917,3715,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2827,588458,1,1,,56422212,3715,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2828,588459,1,2,,856012,3715,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
2829,588459,1,2,,856012,3715,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
2830,588459,1,2,,856012,3715,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
2831,588460,1,2,,856012,3715,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
2832,588460,1,2,,856012,3715,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
2833,588460,1,2,,856012,3715,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
2834,588461,1,2,,856012,3715,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
2835,588461,1,2,,856012,3715,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
2836,588461,1,2,,856012,3715,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
2837,588473,1,1,,56422212,3715,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2838,588473,1,1,,56422212,3715,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2839,588475,1,2,,56422212,3715,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2840,588475,1,2,,56422212,3715,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2841,588478,1,2,,124799842,3715,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2842,588489,1,1,,56422212,3715,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2843,588492,1,1,,56422212,3715,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2844,588493,1,2,,56422212,3715,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2845,588497,1,2,,56422212,3715,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2846,588497,1,2,,56422212,3715,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2847,588497,1,2,,56422212,3715,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2848,588499,1,3,,56422212,3715,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2849,588499,1,3,,56422212,3715,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2850,588499,1,3,,56422212,3715,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2851,588501,1,2,,56422212,3715,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2852,588501,1,2,,56422212,3715,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2853,588501,1,2,,56422212,3715,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2854,588506,1,2,,856012,3715,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
2855,588511,1,2,,56422212,3715,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2856,588513,1,1,,17389851,3715,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2857,588513,1,1,,50126367,3715,Inconclusive,348019627.0,2099.0,35.4813,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2858,588514,1,1,,17389851,3715,Inconclusive,348019627.0,2099.0,15.8489,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2859,588514,1,1,,50126367,3715,Inconclusive,348019627.0,2099.0,25.1189,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2860,588515,1,1,,17389851,3715,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2861,588515,1,1,,50126367,3715,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2862,588516,1,1,,17389851,3715,Inconclusive,124375976.0,367.0,3.1623,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2863,588516,1,1,,50126367,3715,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2864,588519,1,2,,92124045,3715,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2865,588519,1,2,,92125110,3715,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2866,588519,1,2,,99301013,3715,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2867,588519,1,2,,99302533,3715,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2868,588526,1,1,,17389851,3715,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2869,588526,1,1,,50126367,3715,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2870,588527,1,1,,17389851,3715,Inconclusive,325495553.0,9971.0,10.0,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2871,588527,1,1,,50126367,3715,Inconclusive,325495553.0,9971.0,12.5893,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2872,588532,1,1,,17389851,3715,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2873,588532,1,1,,50126367,3715,Inconclusive,311348376.0,2908.0,39.8107,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2874,588533,1,1,,17389851,3715,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2875,588533,1,1,,50126367,3715,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2876,588534,1,1,,17389851,3715,Inconclusive,216409690.0,5467.0,12.5893,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2877,588534,1,1,,50126367,3715,Inconclusive,216409690.0,5467.0,14.1254,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2878,588535,1,1,,17389851,3715,Inconclusive,216409690.0,5467.0,6.3096,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2879,588535,1,1,,50126367,3715,Inconclusive,216409690.0,5467.0,31.6228,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2880,588536,1,1,,17389851,3715,Inconclusive,216409692.0,5468.0,3.9811,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2881,588536,1,1,,50126367,3715,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2882,588537,1,1,,17389851,3715,Inconclusive,216409692.0,5468.0,31.6228,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2883,588537,1,1,,50126367,3715,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2884,588541,1,1,,17389851,3715,Inconclusive,216409708.0,7421.0,7.9433,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2885,588541,1,1,,50126367,3715,Inconclusive,216409708.0,7421.0,5.0119,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2886,588543,1,1,,17389851,3715,Inconclusive,216409708.0,7421.0,7.0795,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2887,588543,1,1,,50126367,3715,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2888,588544,1,1,,17389851,3715,Inconclusive,325495497.0,6256.0,14.1254,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2889,588544,1,1,,50126367,3715,Inconclusive,325495497.0,6256.0,28.1838,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2890,588545,1,1,,17389851,3715,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2891,588545,1,1,,50126367,3715,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2892,588546,1,1,,17389851,3715,Inconclusive,325495497.0,6256.0,28.1838,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2893,588546,1,1,,50126367,3715,Inconclusive,325495497.0,6256.0,14.1254,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2894,588547,1,1,,17389851,3715,Inconclusive,189491771.0,7068.0,50.1187,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2895,588547,1,1,,50126367,3715,Inconclusive,189491771.0,7068.0,12.5893,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2896,588549,1,1,,56422212,3715,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2897,588550,1,1,,856012,3715,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
2898,588579,1,1,,11111329,3715,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2899,588579,1,1,,56422212,3715,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2900,588579,1,1,,90340917,3715,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2901,588579,1,1,,124880450,3715,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2902,588579,1,1,,124880453,3715,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2903,588579,1,1,,124880455,3715,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2904,588579,1,1,,124880457,3715,Inactive,7705344.0,51426.0,7.5193,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2905,588590,1,1,,50104238,3715,Inconclusive,154350220.0,11201.0,63.0957,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2906,588590,1,1,,56422212,3715,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2907,588591,1,1,,50104238,3715,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2908,588591,1,1,,56422212,3715,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2909,588621,1,1,,56422212,3715,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2910,588627,1,1,,56422212,3715,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2911,588664,1,2,,56422212,3715,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2912,588664,1,2,,56422212,3715,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2913,588674,1,2,,56422212,3715,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2914,588675,1,1,,56422212,3715,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2915,588676,1,1,,56422212,3715,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2916,588685,1,1,,856012,3715,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
2917,588689,1,1,,56422212,3715,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2918,588692,2,1,,56422212,3715,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2919,588726,1,2,,56422212,3715,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2920,588727,1,1,,56422212,3715,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2921,588795,1,1,,56422212,3715,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2922,588795,1,1,,90340917,3715,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2923,588814,1,3,,56422212,3715,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2924,588819,1,4,,56422212,3715,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2925,588834,2,1,,17389851,3715,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2926,588834,2,1,,50104238,3715,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2927,588850,1,1,,56422212,3715,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2928,588852,1,3,,56422212,3715,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2929,588855,1,1,,56422212,3715,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2930,588856,1,1,,56422212,3715,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2931,591398,1,10,,103163840,3715,Unspecified,266649.0,18126.0,,,Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method relative to control,Other,21381754.0,
2932,591428,6,5,,103163840,3715,Active,266649.0,18126.0,48.89,IC50,Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis,Confirmatory,21381754.0,
2933,591429,6,5,,103163840,3715,Active,266649.0,18126.0,23.47,IC50,Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method,Confirmatory,21381754.0,
2934,591430,6,5,,103163840,3715,Active,548483.0,19225.0,15.37,IC50,Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA,Confirmatory,21381754.0,
2935,591431,3,2,,103163840,3715,Unspecified,,,100.0,IC50,Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay,Confirmatory,21381754.0,
2936,591432,3,2,,103163840,3715,Unspecified,,,100.0,IC50,Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay,Confirmatory,21381754.0,
2937,591438,2,4,,103163840,3715,Active,,,,,"Antiinflammatory activity against acetic acid-induced vascular permeability in ICR mouse assessed as evans blue peritoneal leakage at 10 mg/kg, ip administered 30 mins before acetic acid challenge measured after 50 mins",Other,21381754.0,
2938,591440,1,4,,103163840,3715,Active,,,,,"Antiarthritic activity in heat-killed mycobacterium tuberculosis-induced Lewis rat arthritis model assessed as decrease in arthritic score at 50 mg/kg, po QD for 28",Other,21381754.0,
2939,591625,1,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as appearance ulcer area of <1 mm diameter at 100 mg/kg, po administered as single dose after 6 hrs by Vernier caliper",Other,21284386.0,
2940,591626,1,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as appearance ulcer area of 1 to 3 mm diameter at 100 mg/kg, po administered as single dose after 6 hrs by Vernier caliper",Other,21284386.0,
2941,591627,1,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as appearance ulcer area of >3 mm diameter at 100 mg/kg, po administered as single dose after 6 hrs by Vernier caliper",Other,21284386.0,
2942,591628,1,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as ulcerogenic index at 100 mg/kg, po administered as single dose",Other,21284386.0,
2943,591629,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs by plethysmograph relative to control",Other,21284386.0,
2944,591630,1,3,,103163840,3715,Unspecified,,,,,"Partition coefficient, log P of the compound in n-octanol-phosphate buffer at pH 7.4 by HPLC analysis",Other,21284386.0,
2945,591631,1,3,,103163840,3715,Unspecified,,,,,"Partition coefficient, log P of the compound in 1-octanol-citric acid buffer at pH 3 by HPLC analysis",Other,21284386.0,
2946,591642,1,6,,103163840,3715,Unspecified,,,,,Metabolic stability in rat liver microsomes assessed as compound remaining at 5 mM after 30 mins by HPLC analysis,Other,21284386.0,
2947,591668,1,6,,103163840,3715,Unspecified,,,,,Metabolic stability in rat liver microsomes assessed as compound remaining at 5 mM after 60 mins by HPLC analysis,Other,21284386.0,
2948,591669,1,5,,103163840,3715,Unspecified,,,,,Metabolic stability in rat plasma assessed as compound remaining at 5 mM after 60 mins by HPLC analysis,Other,21284386.0,
2949,592681,1,4,,103163840,3715,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
2950,592741,1,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrate production at 10 uM treated 30 mins before LPS challenge measured after 24 hrs by Griess reagent method relative to control,Other,21405086.0,
2951,592742,1,4,,103163840,3715,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control,Other,21405086.0,
2952,592743,1,4,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrate production at 100 uM treated 30 mins before LPS challenge measured after 24 hrs by Griess reagent method relative to control,Other,21405086.0,
2953,592744,1,4,,103163840,3715,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 100 uM after 24 hrs by MTT assay relative to control,Other,21405086.0,
2954,592745,2,3,,103163840,3715,Unspecified,,,,,Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as reduction of amyloid beta (1 to 42) level at 1 uM after 24 hrs by ELISA relative to control,Other,21405086.0,
2955,592747,1,4,,103163840,3715,Unspecified,,,,,Antiamyloidogenic activity in mouse N2A cells transfected with human APP Swedish mutant assessed as reduction of amyloid beta (1 to 42) level at 100 uM after 24 hrs by ELISA relative to control,Other,21405086.0,
2956,592801,1,9,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX-1 at 100 uM after 2 mins by fluorescence assay,Other,21434686.0,
2957,592802,6,5,,103163840,3715,Active,3915797.0,5743.0,17.0,IC50,Inhibition of human recombinant COX-2 after 2 mins by fluorescence assay,Confirmatory,21434686.0,
2958,592803,5,5,,103163840,3715,Unspecified,67476665.0,2053.0,1.0,IC50,Inhibition of human recombinant soluble epoxide hydrolase after 10 mins by fluorescent-based assay,Confirmatory,21434686.0,
2959,595364,2,1,,103163840,3715,Unspecified,,,100.0,LD50,Cytotoxicity against human THP1 cells after 24 hrs by erythrosin B staining,Confirmatory,21319773.0,
2960,595367,1,4,,103163840,3715,Active,,,,,Antiinflammatory activity against human THP1 cells of assessed as inhibition of LPS-induced TNFalpha gene expression at 10 uM pretreated for 1 hr before LPS challenge measured after 2 to 10 hrs by RT-qPCR,Other,21319773.0,
2961,595370,6,5,,103163840,3715,Active,3915797.0,5743.0,1.9,IC50,Inhibition of human recombinant COX-2 assessed as PGE2 production from arachidonic acid after 20 mins enzyme immunoassay,Confirmatory,21319773.0,
2962,595372,1,4,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant COX2 to IC50 for ram seminal vesicle COX1,Other,21319773.0,
2963,595374,1,4,,103163840,3715,Active,,,,,Antiinflammatory activity against human THP1 cells assessed as inhibition of LPS-induced ZFP36 gene expression at 10 uM pretreated for 1 hr before LPS challenge measured after 2 hrs by RT-qPCR relative to control,Other,21319773.0,
2964,595375,1,4,,103163840,3715,Active,,,,,Antiinflammatory activity against human THP1 cells assessed as inhibition of LPS-induced NFKB p65 subunit translocation to nucleus at 10 uM pretreated for 1 hr before LPS challenge relative to control,Other,21319773.0,
2965,595393,6,5,,103163840,3715,Active,754286265.0,443551.0,0.3,IC50,Inhibition of ram seminal vesicle COX-1 assessed as PGE2 production from arachidonic acid after 20 mins enzyme immunoassay,Confirmatory,21319773.0,
2966,597265,1,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip administered simultaneously with carrageenan measured after 3.5 hrs relative to control",Other,21507662.0,
2967,598196,6,5,,103163840,3715,Active,754286265.0,443551.0,0.05,IC50,Inhibition of ram seminal vesicle COX1 assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis,Confirmatory,21524587.0,
2968,598197,6,5,,103163840,3715,Active,3915797.0,5743.0,0.75,IC50,Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis,Confirmatory,21524587.0,
2969,598198,1,3,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for human COX2 to IC50 for ram seminal vesicle COX1,Other,21524587.0,
2970,598525,1,3,,103163840,3715,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21601448.0,
2971,598526,1,3,,103163840,3715,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method",Other,21601448.0,
2972,598527,1,3,,103163840,3715,Unspecified,,,,,"1-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method",Other,21601448.0,
2973,599064,1,4,,103163840,3715,Unspecified,,,,,Plasma protein binding in human,Other,21601448.0,
2974,600514,2,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse assessed as inhibition of TPA-induced ear edema measured per ear,Other,19476340.0,
2975,602123,1,1,,56422212,3715,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2976,602141,1,1,,56422212,3715,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2977,602162,1,1,,56422212,3715,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2978,602163,1,1,,56422212,3715,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2979,602179,1,2,,56422212,3715,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2980,602229,1,1,,56422212,3715,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2981,602233,1,1,,56422212,3715,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2982,602244,1,2,,56422212,3715,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2983,602247,1,2,,56422212,3715,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2984,602248,1,2,,56422212,3715,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2985,602250,1,2,,56422212,3715,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2986,602252,1,1,,56422212,3715,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2987,602252,1,1,,56422212,3715,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2988,602261,1,1,,56422212,3715,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2989,602274,1,2,,56422212,3715,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2990,602276,1,1,,856012,3715,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
2991,602277,1,1,,856012,3715,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
2992,602281,1,1,,56422212,3715,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2993,602281,1,1,,56422212,3715,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2994,602310,1,2,,56422212,3715,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2995,602313,1,1,,56422212,3715,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2996,602314,1,2,,92124045,3715,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2997,602314,1,2,,92125110,3715,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2998,602314,1,2,,99301013,3715,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2999,602329,1,1,,56422212,3715,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3000,602332,1,1,,11111329,3715,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3001,602332,1,1,,56422212,3715,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3002,602332,1,1,,90340917,3715,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3003,602332,1,1,,124880450,3715,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3004,602332,1,1,,124880453,3715,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3005,602332,1,1,,124880455,3715,Inconclusive,168984549.0,,14.1254,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3006,602332,1,1,,124880457,3715,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3007,602332,1,1,,124880462,3715,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3008,602340,1,2,,56422212,3715,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
3009,602342,2,1,,56422212,3715,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3010,602346,1,1,,56422212,3715,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3011,602363,1,1,,56422212,3715,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
3012,602393,1,1,,56422212,3715,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3013,602396,1,2,,56422212,3715,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
3014,602399,1,2,,56422212,3715,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
3015,602405,1,1,,56422212,3715,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3016,602410,1,1,,56422212,3715,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
3017,602429,1,1,,56422212,3715,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
3018,602438,1,1,,56422212,3715,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
3019,602440,1,1,,56422212,3715,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
3020,602449,1,2,,56422212,3715,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
3021,602481,1,1,,56422212,3715,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3022,603857,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in carrageenan-induced Fischer-344 rat paw oedema at 0.01 mmol/kg, ip after 3.5 hrs",Other,21514701.0,
3023,604020,1,4,,103163840,3715,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3024,604021,3,1,,103163840,3715,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3025,604022,1,4,,103163840,3715,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3026,604023,1,3,,103163840,3715,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3027,604024,1,3,,103163840,3715,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
3028,604025,1,4,,103163840,3715,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3029,604026,1,4,,103163840,3715,Unspecified,,,,,Unbound CSF to plasma concentration ratio in human,Other,19764786.0,
3030,604299,6,5,,103163840,3715,Active,134039205.0,2739.0,24.4,Ki,Inhibition of human glyoxalase 1,Confirmatory,21689932.0,
3031,604522,1,3,,103163840,3715,Active,,,,,"Antinociceptive activity in rat assessed as suppression of carrageenan-induced nociception in right hind paw at 2 mg/kg, po measured after 1 hr",Other,21121633.0,
3032,604741,1,9,,103163840,3715,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
3033,604742,1,9,,103163840,3715,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
3034,604743,1,9,,103163840,3715,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
3035,604744,1,9,,103163840,3715,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
3036,604949,1,4,,103163840,3715,Unspecified,,,,,"Partition coefficient, log P of the compound by reverse phase HPLC analysis",Other,21067218.0,
3037,604955,3,1,,103163840,3715,Unspecified,,,,,"Drug level in C57Bl6 mouse plasma at 10 mg/kg, po after 1 hr by HPLC analysis",Other,21067218.0,
3038,604956,3,1,,103163840,3715,Unspecified,,,,,"Drug level in C57Bl6 mouse plasma at 10 mg/kg, po after 2 hrs by HPLC analysis",Other,21067218.0,
3039,611093,5,5,,103163840,3715,Unspecified,548475.0,19216.0,10.0,Ki,Displacement of [3H]-PGE2 from mouse EP1 receptor expressed in CHO cells after 20 mins by liquid scintillation counting,Confirmatory,21737285.0,
3040,611094,5,5,,103163840,3715,Unspecified,2495012.0,19217.0,10.0,Ki,Displacement of [3H]-PGE2 from mouse EP2 receptor expressed in CHO cells after 60 mins by liquid scintillation counting,Confirmatory,21737285.0,
3041,611095,5,5,,103163840,3715,Unspecified,266747.0,19218.0,10.0,Ki,Displacement of [3H]-PGE2 from mouse EP3 receptor expressed in CHO cells after 60 mins by liquid scintillation counting,Confirmatory,21737285.0,
3042,611096,5,5,,103163840,3715,Unspecified,417466.0,19219.0,10.0,Ki,Displacement of [3H]-PGE2 from mouse EP4 receptor expressed in CHO cells after 60 mins by liquid scintillation counting,Confirmatory,21737285.0,
3043,611097,5,5,,103163840,3715,Inconclusive,1172443.0,19220.0,,Ki,Displacement of [3H]-PGF2-alpha from mouse FP receptor expressed in CHO cells after 60 mins by liquid scintillation counting,Confirmatory,21737285.0,
3044,611098,4,5,,103163840,3715,Inconclusive,229463010.0,6915.0,,IC50,Displacement of [3H]-SQ29548 from human TP receptor expressed in CHO cells after 30 mins by liquid scintillation counting,Confirmatory,21737285.0,
3045,611099,5,5,,103163840,3715,Inconclusive,1172500.0,5739.0,,Ki,Displacement of [3H]-Iloprost from human IP receptor expressed in CHO cells after 30 mins by liquid scintillation counting,Confirmatory,21737285.0,
3046,611100,5,5,,103163840,3715,Unspecified,2495010.0,19214.0,10.0,Ki,Displacement of [3H]-PGD2 from mouse DP receptor expressed in CHO cells after 20 mins by liquid scintillation counting,Confirmatory,21737285.0,
3047,611101,2,6,,103163840,3715,Inconclusive,2495010.0,19214.0,,IC50,Antagonist activity at mouse DP receptor expressed in CHO cells assessed as inhibition of PGD2-induced cAMP accumulation after 10 mins by enzyme immunoassay in the presence of 0.1% BSA,Confirmatory,21737285.0,
3048,611506,1,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against Swiss mouse assessed as inhibition of 12-O-tetradecanoylphorbol acetate-induced ear edema at 1 mg/ear, topically administered measured after 4 hrs of 12-O-tetradecanoylphorbol acetate-challenge",Other,21608987.0,
3049,611507,1,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 30 mins prior to carrageenan challenge measured after 5 hrs",Other,21608987.0,
3050,611827,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po measured after 90 min by Plethysmograph",Other,21724403.0,
3051,611828,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po measured after 180 min by Plethysmograph",Other,21724403.0,
3052,611829,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po measured after 270 min by Plethysmograph",Other,21724403.0,
3053,611830,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po measured after 360 min by Plethysmograph",Other,21724403.0,
3054,611832,1,3,,103163840,3715,Unspecified,,,,,"Toxicity in albino Wistar rat assessed as ulcerogenic activity measuring gastric ulcer lesion index at 10 mg/kg, po once daily for four consecutive days",Other,21724403.0,
3055,611833,1,3,,103163840,3715,Unspecified,,,,,"Toxicity in albino Wistar rat assessed as ulcerogenic activity measuring gastric ulcer lesion index at 50 mg/kg, po once daily for four consecutive days",Other,21724403.0,
3056,612633,6,5,,103163840,3715,Active,317373262.0,5742.0,0.0338,IC50,Inhibition of human platelets COX1 assessed as PGE2 production using arachidonic acid as substrate preincubated for 15 mins measured after 15 mins by EIA,Confirmatory,21752640.0,
3057,614597,3,2,,103163840,3715,Active,,,25.0,IC50,Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA,Confirmatory,21873070.0,
3058,614601,6,5,,103163840,3715,Active,754286265.0,443551.0,0.006,IC50,Inhibition of ovine COX-1 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid by HPLC analysis,Confirmatory,21873070.0,
3059,614602,6,5,,103163840,3715,Active,3915797.0,5743.0,0.01,IC50,Inhibition of human recombinant COX-2 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid by HPLC analysis,Confirmatory,21873070.0,
3060,615922,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction of carrageenan-induced paw volume at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 0.5 hr relative to control",Other,21724303.0,
3061,615923,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction of carrageenan-induced paw volume at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 hr relative to control",Other,21724303.0,
3062,615924,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction of carrageenan-induced paw volume at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 2 hrs relative to control",Other,21724303.0,
3063,616299,3,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation,Other,21848266.0,
3064,616383,3,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release,Other,21848266.0,
3065,616386,1,4,,103163840,3715,Inactive,,,,,Antioxidant activity assessed DPPH scavenging activity at 500 uM,Other,21848266.0,
3066,616795,1,4,,103163840,3715,Active,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of capsaicin-induced ear edema at 300 umol/kg, po administered 1 hr before capsaicin challenge measured after 30 mins relative to control",Other,21766854.0,
3067,617128,3,2,,103163840,3715,Active,,,12.96,IC50,Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry,Confirmatory,21807513.0,
3068,617129,1,4,,103163840,3715,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells at 100 uM after 24 hrs by MTT assay,Other,21807513.0,
3069,618603,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 hr by plethysmograph",Other,21816516.0,
3070,618604,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 2 hrs by plethysmograph",Other,21816516.0,
3071,618605,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs by plethysmograph",Other,21816516.0,
3072,618606,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 4 hrs by plethysmograph",Other,21816516.0,
3073,618607,1,3,,103163840,3715,Unspecified,,,,,Analgesic activity in mouse assessed as inhibition of acetic acid-induced writhing administered 30 mins before acetic acid challenge measured after 30 mins relative to control,Other,21816516.0,
3074,620322,6,5,,103163840,3715,Active,317373262.0,5742.0,0.07,IC50,Inhibition of COX1-mediated 12-HHT production in human platelet after 5 mins by HPLC analysis,Confirmatory,21868137.0,
3075,621753,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse assessed as inhibition of TPA-induced mouse ear edema at 0.5 mg/ear administered relative to untreated control,Other,21865038.0,
3076,623639,1,4,,103163840,3715,Active,,,,,"Antinociceptive activity in mouse assessed as inhibition of acetic acid-induced abdominal constrictions at 10 mg/kg, ip administered 40 mins before acetic acid challenge measured for 30 mins",Other,21939182.0,
3077,623641,1,4,,103163840,3715,Active,,,,,"Antinociceptive activity against formalin-induced pain in mouse assessed as paw licking during early phase (0 to 10 mins) at 10 mg/kg, ip administered 40 mins before formalin challenge",Other,21939182.0,
3078,623644,1,4,,103163840,3715,Active,,,,,"Antinociceptive activity against formalin-induced pain in mouse assessed as paw licking during late phase (10 to 60 mins) at 10 mg/kg, ip administered 40 mins before formalin challenge",Other,21939182.0,
3079,623870,1,1,,56422212,3715,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3080,623870,1,1,,56422212,3715,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3081,623877,1,1,,56422212,3715,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
3082,623901,1,1,,56422212,3715,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
3083,624030,1,2,,124880462,3715,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
3084,624037,1,3,,56422212,3715,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
3085,624038,1,3,,56422212,3715,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
3086,624040,1,3,,56422212,3715,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
3087,624101,1,2,,85787264,3715,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3088,624125,1,4,,56422212,3715,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
3089,624126,1,3,,56422212,3715,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
3090,624127,1,2,,56422212,3715,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
3091,624137,1,1,,85787264,3715,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
3092,624146,1,1,,90340917,3715,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
3093,624147,1,1,,90340917,3715,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
3094,624148,1,2,,90340917,3715,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
3095,624149,1,1,,90340917,3715,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
3096,624151,1,1,,85787264,3715,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
3097,624156,1,1,,85787264,3715,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
3098,624168,1,1,,56422212,3715,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
3099,624169,1,1,,56422212,3715,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
3100,624170,1,1,,56422212,3715,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
3101,624170,1,1,,124880462,3715,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
3102,624171,1,1,,56422212,3715,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
3103,624172,1,1,,56422212,3715,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
3104,624172,1,1,,124880462,3715,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
3105,624173,1,3,,56422212,3715,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
3106,624173,1,3,,124880462,3715,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
3107,624178,1,1,,56422212,3715,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
3108,624202,1,1,,56422212,3715,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
3109,624204,1,2,,56422212,3715,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
3110,624246,1,1,,56422212,3715,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
3111,624256,1,2,,56422212,3715,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
3112,624260,1,1,,85787264,3715,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3113,624263,1,1,,56422212,3715,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
3114,624263,1,1,,56422212,3715,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
3115,624267,1,2,,56422212,3715,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
3116,624267,1,2,,56422212,3715,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
3117,624268,1,3,,56422212,3715,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
3118,624288,1,1,,56422212,3715,Inconclusive,52000961.0,2778.0,7.9433,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
3119,624296,1,1,,856012,3715,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
3120,624296,1,1,,56422212,3715,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
3121,624297,1,1,,856012,3715,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
3122,624297,1,1,,56422212,3715,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
3123,624304,1,2,,56422212,3715,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
3124,624330,1,2,,56422212,3715,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
3125,624349,1,2,,92124045,3715,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3126,624349,1,2,,92125110,3715,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3127,624349,1,2,,92307459,3715,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3128,624349,1,2,,92308955,3715,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3129,624349,1,2,,121362781,3715,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3130,624352,1,1,,56422212,3715,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
3131,624354,1,1,,56422212,3715,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
3132,624377,1,1,,56422212,3715,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
3133,624414,1,1,,56422212,3715,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
3134,624415,1,2,,56422212,3715,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
3135,624416,1,1,,56422212,3715,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
3136,624417,1,1,,56422212,3715,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
3137,624418,1,1,,56422212,3715,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
3138,624455,1,1,,90340917,3715,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
3139,624463,1,1,,56422212,3715,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
3140,624464,1,1,,56422212,3715,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
3141,624465,1,1,,56422212,3715,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
3142,624466,1,3,,56422212,3715,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
3143,624467,1,1,,56422212,3715,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
3144,624483,1,1,,56422212,3715,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
3145,624615,1,8,,103163840,3715,Unspecified,549155.0,7365.0,,,Specific activity of expressed human recombinant UGT2B10,Other,10836148.0,
3146,624618,3,2,,103163840,3715,Unspecified,6175083.0,7363.0,,,Specific activity of expressed human recombinant UGT2B4,Other,10836148.0,
3147,624619,3,2,,103163840,3715,Unspecified,136727.0,7364.0,,,Specific activity of expressed human recombinant UGT2B7,Other,10836148.0,
3148,624647,3,4,,103163840,3715,Unspecified,,,200.0,Ki,Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
3149,624700,1,9,,103163840,3715,Unspecified,6166033.0,266682.0,,,Mechanism based inhibition of rat cytochrome P450 CYP3A2,Other,16248836.0,
3150,625144,5,5,,103163840,3715,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
3151,625145,4,7,,103163840,3715,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
3152,625146,5,5,,103163840,3715,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
3153,625147,4,7,,103163840,3715,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3154,625148,4,7,,103163840,3715,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3155,625149,4,7,,103163840,3715,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3156,625150,5,5,,103163840,3715,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
3157,625151,4,7,,103163840,3715,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3158,625152,4,7,,103163840,3715,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3159,625153,4,7,,103163840,3715,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3160,625154,4,7,,103163840,3715,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3161,625155,4,7,,103163840,3715,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3162,625156,1,9,,103163840,3715,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
3163,625157,6,2,,103163840,3715,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
3164,625158,3,4,,103163840,3715,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
3165,625159,5,5,,103163840,3715,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
3166,625160,1,9,,103163840,3715,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
3167,625161,4,7,,103163840,3715,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
3168,625162,4,7,,103163840,3715,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3169,625163,4,7,,103163840,3715,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3170,625164,1,6,,103163840,3715,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
3171,625165,3,4,,103163840,3715,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3172,625166,3,4,,103163840,3715,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3173,625167,5,5,,103163840,3715,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
3174,625168,4,7,,103163840,3715,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
3175,625169,1,6,,103163840,3715,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
3176,625170,3,4,,103163840,3715,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
3177,625171,4,7,,103163840,3715,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
3178,625172,4,7,,103163840,3715,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
3179,625173,5,5,,103163840,3715,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
3180,625174,5,5,,103163840,3715,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
3181,625175,5,5,,103163840,3715,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
3182,625176,1,9,,103163840,3715,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
3183,625177,5,5,,103163840,3715,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3184,625178,5,5,,103163840,3715,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3185,625179,1,9,,103163840,3715,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
3186,625180,5,5,,103163840,3715,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3187,625181,5,5,,103163840,3715,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3188,625182,5,5,,103163840,3715,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3189,625183,5,5,,103163840,3715,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
3190,625184,5,5,,103163840,3715,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3191,625185,5,5,,103163840,3715,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3192,625186,5,5,,103163840,3715,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3193,625187,5,5,,103163840,3715,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3194,625188,1,9,,103163840,3715,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
3195,625189,1,7,,103163840,3715,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
3196,625190,4,5,,103163840,3715,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
3197,625191,4,7,,103163840,3715,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3198,625192,4,7,,103163840,3715,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
3199,625193,5,5,,103163840,3715,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
3200,625194,4,7,,103163840,3715,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
3201,625195,4,7,,103163840,3715,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
3202,625196,5,6,,103163840,3715,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
3203,625197,3,4,,103163840,3715,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
3204,625198,4,7,,103163840,3715,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3205,625199,4,7,,103163840,3715,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3206,625200,4,7,,103163840,3715,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3207,625201,4,7,,103163840,3715,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
3208,625202,4,7,,103163840,3715,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
3209,625203,4,7,,103163840,3715,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
3210,625204,4,7,,103163840,3715,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3211,625205,4,7,,103163840,3715,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
3212,625206,4,7,,103163840,3715,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3213,625207,4,7,,103163840,3715,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3214,625208,5,5,,103163840,3715,Active,1168407.0,24192.0,3.6310000000000002,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
3215,625209,4,7,,103163840,3715,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
3216,625210,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
3217,625211,1,6,,103163840,3715,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
3218,625212,3,4,,103163840,3715,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
3219,625213,4,7,,103163840,3715,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
3220,625214,1,9,,103163840,3715,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
3221,625215,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
3222,625216,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
3223,625217,4,7,,103163840,3715,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3224,625218,4,7,,103163840,3715,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
3225,625219,3,4,,103163840,3715,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
3226,625220,4,7,,103163840,3715,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
3227,625221,4,7,,103163840,3715,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3228,625222,4,7,,103163840,3715,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
3229,625223,4,7,,103163840,3715,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
3230,625224,3,4,,103163840,3715,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
3231,625225,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
3232,625226,4,7,,103163840,3715,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
3233,625227,4,7,,103163840,3715,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
3234,625228,4,7,,103163840,3715,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
3235,625229,5,5,,103163840,3715,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
3236,625230,1,6,,103163840,3715,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
3237,625231,4,7,,103163840,3715,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
3238,625232,1,9,,103163840,3715,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
3239,625233,4,7,,103163840,3715,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
3240,625234,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
3241,625235,4,7,,103163840,3715,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
3242,625236,5,5,,103163840,3715,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
3243,625237,4,7,,103163840,3715,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
3244,625238,4,7,,103163840,3715,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
3245,625239,4,7,,103163840,3715,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
3246,625240,1,9,,103163840,3715,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
3247,625241,4,7,,103163840,3715,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
3248,625242,4,7,,103163840,3715,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
3249,625243,5,5,,103163840,3715,Active,317373262.0,5742.0,0.015,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3250,625244,5,5,,103163840,3715,Active,3915797.0,5743.0,0.84,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3251,625245,5,5,,103163840,3715,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3252,625246,1,9,,103163840,3715,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
3253,625247,5,5,,103163840,3715,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3254,625248,5,5,,103163840,3715,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3255,625249,5,5,,103163840,3715,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3256,625250,5,5,,103163840,3715,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3257,625251,5,5,,103163840,3715,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
3258,625252,4,7,,103163840,3715,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
3259,625253,4,7,,103163840,3715,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3260,625254,4,7,,103163840,3715,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3261,625255,4,7,,103163840,3715,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3262,625256,4,7,,103163840,3715,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3263,625257,4,7,,103163840,3715,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
3264,625258,4,7,,103163840,3715,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3265,625259,4,7,,103163840,3715,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3266,625260,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
3267,625261,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
3268,625262,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
3269,625263,4,7,,103163840,3715,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
3270,625264,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
3271,625265,1,6,,103163840,3715,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
3272,625266,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
3273,625267,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
3274,625268,4,2,,103163840,3715,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3275,625268,4,2,,103163840,3715,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3276,625268,4,2,,103163840,3715,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3277,625268,4,2,,103163840,3715,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3278,625269,4,7,,103163840,3715,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
3279,625270,4,7,,103163840,3715,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
3280,625271,5,5,,103163840,3715,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
3281,625272,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
3282,625273,4,6,,103163840,3715,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
3283,625274,1,6,,103163840,3715,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
3284,625275,3,4,,103163840,3715,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
3285,625277,1,3,,103163840,3715,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
3286,625279,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
3287,625280,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
3288,625281,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
3289,625282,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
3290,625283,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
3291,625284,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
3292,625285,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
3293,625286,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
3294,625287,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
3295,625288,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
3296,625289,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
3297,625290,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
3298,625291,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
3299,625292,1,3,,103163840,3715,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
3300,633799,1,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in AKR mouse carrageenan-induced paw oedema inflammation model assessed as inhibition of carrageenan-induced right hind paw oedema at 0.1 mmol/kg, ip coadministered with carrageenan measured 3.5 hrs post carrageenan challenge relative to untreated control",Other,22119153.0,
3301,634855,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 30 mins prior to challenge measured after 1 hr relative to untreated control",Other,22137931.0,
3302,634932,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 30 mins prior to challenge measured after 2 hrs relative to untreated control",Other,22137931.0,
3303,634933,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 30 mins prior to challenge measured after 3 hrs relative to untreated control",Other,22137931.0,
3304,634934,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 30 mins prior to challenge measured after 4 hrs relative to untreated control",Other,22137931.0,
3305,634935,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 30 mins prior to challenge measured after 5 hrs relative to untreated control",Other,22137931.0,
3306,634938,1,3,,103163840,3715,Unspecified,,,,,"Gastric toxicity in albino rat assessed as ulcer index at 100 mg/kg, po after 5 hrs",Other,22137931.0,
3307,634939,1,3,,103163840,3715,Unspecified,,,,,"Gastric toxicity in albino rat assessed as loss of mucosal membrane at the area of ulceration at 100 mg/kg, po after 5 hrs by hematoxylin and eosin staining",Other,22137931.0,
3308,634940,1,3,,103163840,3715,Unspecified,,,,,"Gastric toxicity in albino rat assessed as degeneration of fundic gland at 100 mg/kg, po after 5 hrs by hematoxylin and eosin staining",Other,22137931.0,
3309,634941,1,3,,103163840,3715,Unspecified,,,,,"Gastric toxicity in albino rat assessed as capillary inflammatory cells appearance at 100 mg/kg, po after 5 hrs by hematoxylin and eosin staining",Other,22137931.0,
3310,634942,1,3,,103163840,3715,Unspecified,,,,,"Gastric toxicity in albino rat assessed as apoptotic glandular epithelial cells appearance at 100 mg/kg, po after 5 hrs by hematoxylin and eosin staining",Other,22137931.0,
3311,640116,1,5,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as decrease in carrageenan-induced serum TNFalpha level at 10 mg/kg, ip measured after 5 hrs",Other,22197135.0,
3312,640120,1,4,,103163840,3715,Unspecified,,,,,"Antioxidant activity in carrageenan-stimulated ICR mouse assessed as increase in CAT activity at 10 mg/kg, ip measured after 5 hrs",Other,22197135.0,
3313,640124,1,4,,103163840,3715,Unspecified,,,,,"Antioxidant activity in carrageenan-stimulated ICR mouse assessed as increase in SOD activity at 10 mg/kg, ip measured after 5 hrs",Other,22197135.0,
3314,640128,1,4,,103163840,3715,Unspecified,,,,,"Antioxidant activity in carrageenan-stimulated ICR mouse assessed as increase in GPx activity at 10 mg/kg, ip measured after 5 hrs",Other,22197135.0,
3315,640134,1,4,,103163840,3715,Unspecified,,,,,"Down regulation of COX-2 protein expression in carrageenan-stimulated ICR mouse at 10 mg/kg, ip measured after 5 hrs by Western blot analysis",Other,22197135.0,
3316,640135,1,4,,103163840,3715,Unspecified,,,,,"Down regulation of iNOS protein expression in carrageenan-stimulated ICR mouse at 10 mg/kg, ip measured after 5 hrs by Western blot analysis",Other,22197135.0,
3317,640222,1,4,,103163840,3715,Active,,,,,"Antiinflammatory activity in carrageenan-stimulated ICR mouse assessed as decrease in neutrophil number at 8 mg/kg, ip measured after 5 hrs",Other,22197135.0,
3318,640223,1,4,,103163840,3715,Active,,,,,"Antiinflammatory activity in carrageenan-stimulated ICR mouse assessed as reduction in iNOS immunoreactive cells at 8 mg/kg, ip measured after 5 hrs",Other,22197135.0,
3319,640224,1,4,,103163840,3715,Active,,,,,"Antiinflammatory activity in carrageenan-stimulated ICR mouse assessed as reduction in COX2 immunoreactive cells at 8 mg/kg, ip measured after 5 hrs",Other,22197135.0,
3320,640226,1,4,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced hind paw edema at 10 mg/kg, ip measured after 4 hrs",Other,22197135.0,
3321,640712,1,3,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in Swiss mouse assessed as inhibition of acetic acid induced writhing at 10 mg/kg, po measured every 5 mins for 45 mins",Other,22189137.0,
3322,640716,1,3,,103163840,3715,Unspecified,,,,,"Antiphlogistic activity in Wistar rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, po",Other,22189137.0,
3323,641287,1,4,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced hind paw edema at 10 mg/kg, ip",Other,22197135.0,
3324,641289,1,4,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as decrease in carrageenan-induced MDA level at 10 mg/kg, ip measured after 5 hrs",Other,22197135.0,
3325,641291,1,5,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as decrease in carrageenan-induced serum NO level at 10 mg/kg, ip measured after 5 hrs",Other,22197135.0,
3326,642874,1,6,,103163840,3715,Unspecified,,,,,Inhibition of COX1 at 100 uM,Other,24900317.0,
3327,642875,5,2,,103163840,3715,Active,,,0.01,IC50,Inhibition of COX1,Confirmatory,24900317.0,
3328,642876,1,6,,103163840,3715,Unspecified,,,,,Inhibition of COX2 at 100 uM,Other,24900317.0,
3329,642877,5,2,,103163840,3715,Active,,,18.0,IC50,Inhibition of COX2,Confirmatory,24900317.0,
3330,642879,1,5,,103163840,3715,Unspecified,,,,,Potentiation of doxorubicin-induced cytotoxicity against multidrug-resistant human T98G cells expressing MRP-1 at 50 uM pretreated for 2 hrs prior addition of doxorubicin measured after 3 days by crystal violet staining analysis,Other,24900317.0,
3331,642994,1,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as reduction in carrageenan-induced paw edema at 20 mg/kg, ip administered 30 mins before carrageenan challenge measured after 4 hrs by plethysmometer analysis",Other,22142423.0,
3332,644721,1,3,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant COX2 to IC50 for ram seminal vesicle COX1,Other,22305614.0,
3333,644804,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, po dosed 30 mins after carrageenan challenge measured after 5 hrs by plethysmograph analysis relative to control",Other,22318166.0,
3334,644806,1,3,,103163840,3715,Unspecified,,,,,"Ulcerogenicity in Wistar rat assessed as lesion score at 100 mg/kg, po after 6 hrs",Other,22318166.0,
3335,644807,3,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw oedema compound administered 30 mins after carrageenan challenge measured after 5 hrs by plethysmograph analysis,Other,22318166.0,
3336,645022,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 1 hr by plethysmometer relative to control",Other,22365409.0,
3337,645024,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 2 hrs by plethysmometer relative to control",Other,22365409.0,
3338,645026,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 3 hrs by plethysmometer relative to control",Other,22365409.0,
3339,645028,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 4 hrs by plethysmometer relative to control",Other,22365409.0,
3340,645030,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr before carrageenan challenge measured after 24 hrs by plethysmometer relative to control",Other,22365409.0,
3341,645031,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wister albino rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered 1 hr before carrageenan challenge measured after 4 hrs by plethysmometer relative to indomethacin",Other,22365409.0,
3342,647936,1,4,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 3 hrs by plethysmometer analysis",Other,22250858.0,
3343,647940,1,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced iNOS protein expression in paw at 10 mg/kg, ip administered 30 mins before carrageenan challenge by Western blotting relative to control",Other,22250858.0,
3344,647941,1,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced COX2 protein expression in paw at 10 mg/kg, ip administered 30 mins before carrageenan challenge by Western blotting relative to control",Other,22250858.0,
3345,647942,1,4,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced neutrophil infiltration in paw at 10 mg/kg, ip administered 30 mins before carrageenan challenge",Other,22250858.0,
3346,647947,1,5,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced decrease in CAT activity in liver at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs",Other,22250858.0,
3347,647948,1,5,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced decrease in SOD activity in liver at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs",Other,22250858.0,
3348,647949,1,5,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced decrease in GPx activity in liver at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs",Other,22250858.0,
3349,647950,1,5,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced TNFalpha level in paw serum at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs by ELISA",Other,22250858.0,
3350,647951,1,5,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced malondialdehyde level in paw serum at 10 mg/kg, ip administered 30 mins before carrageenan challenge measured after 5 hrs by TRARS method",Other,22250858.0,
3351,648861,5,5,,103163840,3715,Active,754286265.0,443551.0,0.1,IC50,Inhibition of ovine COX1,Confirmatory,22148253.0,
3352,648862,5,5,,103163840,3715,Active,3915797.0,5743.0,5.7,IC50,Inhibition of human recombinant COX2,Confirmatory,22148253.0,
3353,648868,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, po after 3 hrs relative to control",Other,22148253.0,
3354,648872,1,3,,103163840,3715,Unspecified,,,,,"Ulcerogenic effect in rat assessed as gastric ulcer overall length at 0.08 mmol/kg, po administered for 6 hrs",Other,22148253.0,
3355,649079,1,3,,103163840,3715,Inconclusive,,,,,"Analgesic activity in albino mouse assessed as inhibition of acetic acid-induced abdominal constriction at 100 umol/kg, po administered 1 hr before acetic acid challenge measured after 30 mins relative to control",Other,22356737.0,
3356,649080,1,3,,103163840,3715,Unspecified,,,,,"Analgesic activity in albino mouse assessed as inhibition of acetic acid-induced abdominal constriction at 100 umol/kg, po administered 1 hr before acetic acid challenge measured after 60 mins relative to control",Other,22356737.0,
3357,649083,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 umol/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs by plethysmometric analysis relative to control",Other,22356737.0,
3358,649089,1,8,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX-1 at 0.1 uM,Other,22356737.0,
3359,649092,1,8,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX-2 at 6 uM,Other,22356737.0,
3360,649269,5,5,,103163840,3715,Active,754286265.0,443551.0,0.13,IC50,Inhibition of ovine COX-1 by enzyme immuno assay,Confirmatory,22361134.0,
3361,649270,5,5,,103163840,3715,Active,3915797.0,5743.0,6.9,IC50,Inhibition of human recombinant COX-2 by enzyme immuno assay,Confirmatory,22361134.0,
3362,649271,1,5,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2",Other,22361134.0,
3363,649272,1,5,,103163840,3715,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,22361134.0,
3364,651548,1,1,,85787264,3715,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3365,651550,1,1,,56422212,3715,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
3366,651560,1,1,,56422212,3715,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
3367,651572,1,2,,56422212,3715,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
3368,651582,1,1,,56422212,3715,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
3369,651602,1,1,,56422212,3715,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3370,651602,1,1,,56422212,3715,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3371,651602,1,1,,56422212,3715,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3372,651610,2,1,,56422212,3715,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3373,651631,4,1,,144206660,3715,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3374,651631,4,1,,144208989,3715,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3375,651631,4,1,,144210586,3715,Inconclusive,269849759.0,7157.0,3.4376,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3376,651632,4,1,,144206660,3715,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3377,651632,4,1,,144208989,3715,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3378,651632,4,1,,144210586,3715,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3379,651633,4,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3380,651633,4,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3381,651633,4,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3382,651634,4,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3383,651634,4,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3384,651634,4,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3385,651635,1,3,,11111329,3715,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3386,651635,1,3,,56422212,3715,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3387,651635,1,3,,90340917,3715,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3388,651636,1,1,,56422212,3715,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
3389,651640,1,1,,56422212,3715,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
3390,651644,1,1,,56422212,3715,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
3391,651647,1,1,,56422212,3715,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
3392,651654,1,1,,56422212,3715,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3393,651658,1,1,,56422212,3715,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3394,651660,1,1,,56422212,3715,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3395,651661,2,1,,56422212,3715,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3396,651687,1,1,,56422212,3715,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3397,651699,1,1,,56422212,3715,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3398,651699,1,1,,56422212,3715,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3399,651702,1,2,,56422212,3715,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
3400,651704,2,1,,56422212,3715,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3401,651710,1,1,,56422212,3715,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3402,651711,2,1,,56422212,3715,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3403,651718,1,2,,56422212,3715,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
3404,651719,1,2,,56422212,3715,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
3405,651723,1,1,,56422212,3715,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
3406,651724,1,1,,56422212,3715,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
3407,651725,1,1,,56422212,3715,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
3408,651741,1,1,,17389851,3715,Inconclusive,20149576.0,4780.0,53.0804,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3409,651741,1,1,,124880458,3715,Inconclusive,20149576.0,4780.0,61.1306,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3410,651743,1,1,,17389851,3715,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
3411,651743,1,1,,50126367,3715,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
3412,651749,1,1,,17389851,3715,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
3413,651749,1,1,,50126367,3715,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
3414,651751,1,1,,17389851,3715,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
3415,651751,1,1,,50126367,3715,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
3416,651754,1,1,,17389851,3715,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
3417,651755,1,1,,17389851,3715,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
3418,651757,1,1,,17389851,3715,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
3419,651758,1,1,,17389851,3715,Inconclusive,186368.0,3576.0,66.8242,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
3420,651768,1,2,,56422212,3715,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
3421,651777,1,1,,17389851,3715,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
3422,651777,1,1,,50126367,3715,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
3423,651778,1,1,,17389851,3715,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
3424,651778,1,1,,50126367,3715,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
3425,651800,1,1,,56422212,3715,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
3426,651802,1,1,,17389851,3715,Inconclusive,49066040.0,6097.0,9.4392,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3427,651819,1,1,,56422212,3715,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
3428,651820,1,1,,856012,3715,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3429,651820,1,1,,56422212,3715,Inconclusive,,,35.4813,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3430,651821,2,4,,56422212,3715,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
3431,651828,1,2,,92308955,3715,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3432,651828,1,2,,121361649,3715,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3433,651838,1,1,,17389851,3715,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3434,651838,1,1,,50126367,3715,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3435,651838,1,1,1.0,17389851,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3436,651838,1,1,1.0,50126367,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3437,651838,1,1,2.0,17389851,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3438,651838,1,1,2.0,50126367,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3439,651838,1,1,3.0,17389851,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3440,651838,1,1,3.0,50126367,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3441,651838,1,1,4.0,17389851,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3442,651838,1,1,4.0,50126367,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3443,651838,1,1,5.0,17389851,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3444,651838,1,1,5.0,50126367,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3445,651838,1,1,6.0,17389851,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3446,651838,1,1,6.0,50126367,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3447,651838,1,1,7.0,17389851,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3448,651838,1,1,7.0,50126367,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3449,651838,1,1,8.0,17389851,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3450,651838,1,1,8.0,50126367,3715,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3451,651957,1,1,,56422212,3715,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
3452,651958,1,1,,56422212,3715,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
3453,651965,1,1,,56422212,3715,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
3454,651999,1,1,,56422212,3715,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
3455,652010,1,1,,56422212,3715,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
3456,652017,1,1,,56422212,3715,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
3457,652025,1,1,,56422212,3715,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
3458,652039,1,1,,56422212,3715,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
3459,652048,1,2,,56422212,3715,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3460,652048,1,2,,144206660,3715,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3461,652051,1,1,,56422212,3715,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3462,652051,1,1,,144206660,3715,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3463,652054,1,1,,56422212,3715,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
3464,652067,1,4,,56422212,3715,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
3465,652104,1,1,,56422212,3715,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
3466,652105,1,1,,56422212,3715,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
3467,652106,1,1,,56422212,3715,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3468,652106,1,1,,90340917,3715,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3469,652115,1,1,,56422212,3715,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
3470,652126,1,3,,56422212,3715,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
3471,652154,1,1,,56422212,3715,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3472,652162,2,1,,56422212,3715,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3473,652163,1,1,,56422212,3715,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3474,652197,1,1,,56422212,3715,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3475,652257,1,1,,56422212,3715,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
3476,653187,1,3,,103163840,3715,Unspecified,,,,,Toxicity in transgenic zebrafish larvae harboring Fli-1 gene assessed as maximum tolerated dosage after 24 hrs,Other,22000935.0,
3477,653188,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in transgenic zebrafish larvae harboring Fli-1 gene assessed as LPS-stimulated leukocyte migration to injury zone of tail transected larvae at 0.3 uM after 20 to 22 hrs by microscopy,Other,22000935.0,
3478,653310,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in transgenic zebrafish larvae harboring Fli-1 gene assessed as LPS-stimulated leukocyte migration to injury zone of tail transected larvae at 1 uM after 20 to 22 hrs by microscopy,Other,22000935.0,
3479,653311,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in transgenic zebrafish larvae harboring Fli-1 gene assessed as LPS-stimulated leukocyte migration to injury zone of tail transected larvae at 3 uM after 20 to 22 hrs by microscopy,Other,22000935.0,
3480,653312,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in transgenic zebrafish larvae harboring Fli-1 gene assessed as LPS-stimulated leukocyte migration to injury zone of tail transected larvae at 10 uM after 20 to 22 hrs by microscopy,Other,22000935.0,
3481,653313,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in transgenic zebrafish larvae harboring Fli-1 gene assessed as LPS-stimulated leukocyte migration to injury zone of tail transected larvae at 30 uM after 20 to 22 hrs by microscopy,Other,22000935.0,
3482,653314,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in transgenic zebrafish larvae harboring Fli-1 gene assessed as LPS-stimulated leukocyte migration to injury zone of tail transected larvae at 100 uM after 20 to 22 hrs by microscopy,Other,22000935.0,
3483,653321,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema in Swiss mouse assessed as inhibition of increase in ear weight at 0.5 mg/ear administered topically measured after 4 hrs relative to control,Other,22000935.0,
3484,653322,1,3,,103163840,3715,Unspecified,,,,,Inhibition of MPO activity in TPA-induced Swiss mouse ear tissue homogenates after 3 mins relative to control,Other,22000935.0,
3485,656843,2,2,,103163840,3715,Unspecified,,,271.212,IC50,Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay,Confirmatory,22437110.0,
3486,658413,1,7,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 10 uM by ELISA,Other,22450132.0,
3487,658414,1,7,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of recombinant human COX2 at 10 uM by ELISA,Other,22450132.0,
3488,664540,5,5,,103163840,3715,Unspecified,416877.0,1645.0,130.0,IC50,Inhibition of human recombinant GST-tagged AKR1C1 expressed in Escherichia coli using S-tetralol as substrate by fluorometry,Confirmatory,22506594.0,
3489,664541,5,5,,103163840,3715,Unspecified,20532374.0,1646.0,75.0,IC50,Inhibition of human recombinant AKR1C2 expressed in Escherichia coli using S-tetralol as substrate by fluorometry,Confirmatory,22506594.0,
3490,664542,5,5,,103163840,3715,Active,308153646.0,8644.0,4.1,IC50,Inhibition of human recombinant AKR1C3 expressed in Escherichia coli JM109 cells using S-tetralol as substrate by fluorometry,Confirmatory,22506594.0,
3491,664543,5,5,,103163840,3715,Unspecified,308153631.0,1109.0,54.0,IC50,Inhibition of human recombinant GST-tagged AKR1C4 expressed in Escherichia coli using S-tetralol as substrate by fluorometry,Confirmatory,22506594.0,
3492,666600,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 22 hrs by Griess method relative to untreated control,Other,22633833.0,
3493,666601,4,5,,103163840,3715,Active,266649.0,18126.0,20.0,IC50,Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay,Confirmatory,22633833.0,
3494,666602,2,2,,103163840,3715,Unspecified,,,80.0,IC50,Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS,Confirmatory,22633833.0,
3495,666603,2,2,,103163840,3715,Unspecified,,,80.0,IC50,Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS,Confirmatory,22633833.0,
3496,666604,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in ICR mouse assessed as decrease in carrageenan-induced paw edema at 10 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured at 4 hrs relative to vehicle treated control",Other,22633833.0,
3497,667602,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction of carrageenan-induced paw edema at 20 mg/kg, po measured after 2 hrs by plethysmometer",Other,22795833.0,
3498,667603,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction of carrageenan-induced paw edema at 20 mg/kg, po measured after 1 hr by plethysmometer",Other,22795833.0,
3499,667604,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction of carrageenan-induced paw edema at 20 mg/kg, po measured after 30 mins by plethysmometer",Other,22795833.0,
3500,667789,1,8,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as PGE2 formation at 1 uM by enzyme immunoassay,Other,22796043.0,
3501,667790,1,8,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of recombinant human COX2 assessed as PGE2 formation at 1 uM by enzyme immunoassay,Other,22796043.0,
3502,670254,1,2,,103163840,3715,Active,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip dosed 30 mins before carrageenan challenge measured before 6 hrs post carrageenan challenge",Other,22633122.0,
3503,670255,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip dosed 30 mins before carrageenan challenge measured at 24 hrs post carrageenan challenge",Other,22633122.0,
3504,671249,1,3,,103163840,3715,Active,,,,,Antiinflammatory activity in CD-1 mouse assessed as inhibition of TPA-induced ear edema at 0.1 to 1.0 uM applied topically 10 mins before compound challenge measured after 4 hrs,Other,22578169.0,
3505,673509,5,5,,103163840,3715,Active,166897622.0,282022.0,0.0041,IC50,Inhibition of bovine COX1 assessed as inhibition of calcium ionophore A23187-induced 12-hydroxyheptadecatrienoic acid formation by reverse-phase HPLC analysis,Confirmatory,22749420.0,
3506,673510,5,5,,103163840,3715,Active,3915797.0,5743.0,0.5,IC50,Inhibition of COX2 in human whole blood assessed as inhibition of LPS-induced PGE2 synthesis up to 24 hrs by radioimmunoassay,Confirmatory,22749420.0,
3507,673511,4,5,,103163840,3715,Inconclusive,75066909.0,,,IC50,Inhibition of bovine 5-LOX assessed as inhibition of calcium ionophore A23187-induced leukotriene B4 formation by reversed phase HPLC analysis,Confirmatory,22749420.0,
3508,674712,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po dosed 1 hr before carrageenan challenge measured 1 hr post carrageenan-induced inflammation",Other,22818041.0,
3509,674713,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po dosed 2 hrs before carrageenan challenge measured 1 hr post carrageenan-induced inflammation",Other,22818041.0,
3510,674714,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po dosed 3 hrs before carrageenan challenge measured 1 hr post carrageenan-induced inflammation",Other,22818041.0,
3511,674715,1,3,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 0.029 mmol/kg, po dosed 4 hrs before carrageenan challenge measured 1 hr post carrageenan-induced inflammation",Other,22818041.0,
3512,674721,1,4,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar albino rat assessed as incidence of stomach ulceration at 0.029 mmol/kg, po",Other,22818041.0,
3513,674722,1,3,,103163840,3715,Unspecified,,,,,Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing at 0.029 mmol/kg. po dosed 1 hr before acetic acid challenge and measured during 30 mins post acetic acid challenge,Other,22818041.0,
3514,674724,1,4,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar albino rat assessed as incidence of stomach ulceration at 0.029 mmol/kg, po followed by another two compound doses in second and third days measured on fourth day post dose by acute ulcerogenicity study",Other,22818041.0,
3515,674725,1,4,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar albino rat assessed as stomach ulcer index at 0.029 mmol/kg, po followed by another two compound doses in second and third days measured on fourth day post dose by acute ulcerogenicity study",Other,22818041.0,
3516,674726,1,3,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of inhibition of COX1 to inhibition of COX2 by Cayman's COX activity assay",Other,22818041.0,
3517,674727,1,6,,103163840,3715,Active,317373262.0,5742.0,,,Inhibition of COX1 by by Cayman's COX activity assay,Other,22818041.0,
3518,674728,1,6,,103163840,3715,Active,3915797.0,5743.0,,,Inhibition of COX2 by by Cayman's COX activity assay,Other,22818041.0,
3519,675016,1,2,,103163840,3715,Unspecified,,,,,Ulcerogenic activity in albino rat assessed as hyperemia at 300 mg/kg/day administered as equal doses at 0 and 12 hrs for three consecutive days measured at 6 hrs post last dose,Other,22835720.0,
3520,675140,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw edema at 10 mg/kg, po administered 60 mins before carrageenan challenge measured after 1 hr (Rvb = 59.2 +/- 6.4 mL)",Other,22846796.0,
3521,675141,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw edema at 10 mg/kg, po administered 60 mins before carrageenan challenge measured after 2 hr (Rvb = 89.4 +/- 7.3 mL)",Other,22846796.0,
3522,675142,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw edema at 10 mg/kg, po administered 60 mins before carrageenan challenge measured after 3 hr (Rvb = 96.2 +/- 2.5 mL)",Other,22846796.0,
3523,675143,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw edema at 10 mg/kg, po administered 60 mins before carrageenan challenge measured after 4 hr (Rvb = 91.2 +/- 2.3 mL)",Other,22846796.0,
3524,675144,1,2,,103163840,3715,Unspecified,,,,,"Analgesic activity in Albino rat assessed as reaction time at 10 mg/kg, po after 1 hr by Hot plate test",Other,22846796.0,
3525,675145,1,2,,103163840,3715,Unspecified,,,,,"Analgesic activity in Albino rat assessed as reaction time at 10 mg/kg, po after 2 hrs by Hot plate test",Other,22846796.0,
3526,675695,7,1,,103163840,3715,Active,317373262.0,5742.0,0.05,IC50,Inhibition of COX1,Confirmatory,22263894.0,
3527,675696,7,1,,103163840,3715,Active,3915797.0,5743.0,0.75,IC50,Inhibition of COX2,Confirmatory,22263894.0,
3528,677462,1,2,,103163840,3715,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,22521372.0,
3529,678053,1,3,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear edema model assessed as reduction in phorbol myristate acetate-induced edema at 3 mg/ear administered topically at right ear 1 hr before phorbol myristate acetate challenge and measured 24 hrs post dose,Other,22734800.0,
3530,678489,1,6,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX1 peroxidase activity assessed as formation of TMPD at 100 uM by colorimetric analysis,Other,22901385.0,
3531,678490,1,6,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 peroxidase activity assessed as formation of TMPD at 100 uM by colorimetric analysis,Other,22901385.0,
3532,678492,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in AKR mouse assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg dosed intradermally after 3.5 hrs relative to vehicle-treated control,Other,22901385.0,
3533,678712,1,8,,103163840,3715,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
3534,678713,1,8,,103163840,3715,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
3535,678714,1,8,,103163840,3715,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3536,678715,1,8,,103163840,3715,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3537,678716,1,8,,103163840,3715,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
3538,678717,1,8,,103163840,3715,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
3539,678721,1,5,,103163840,3715,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
3540,678722,1,5,,103163840,3715,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
3541,678787,3,6,,103163840,3715,Unspecified,81886651.0,29509.0,,IC50,TP_TRANSPORTER: inhibition of MTX uptake in Xenopus laevis oocytes,Confirmatory,11099697.0,
3542,678818,2,7,,103163840,3715,Unspecified,81871841.0,89776.0,0.366,Km,TP_TRANSPORTER: uptake in Oat2-expressing LLC PK1 cells,Confirmatory,,
3543,679385,1,8,,103163840,3715,Unspecified,74762955.0,9356.0,,,TP_TRANSPORTER: inhibition of p-amino hippurate uptake (Indomethacin:100 uM) in OAT1-expressing HeLa cells,Other,15716364.0,
3544,679408,1,8,,103163840,3715,Unspecified,269849624.0,368.0,,,TP_TRANSPORTER: inhibition of NEM-GS by Indomethacin at a concentration of 100uM in membrane vesicles from MRP6-expressing Sf9 cells,Other,11880368.0,
3545,679487,1,7,,103163840,3715,Unspecified,81886651.0,29509.0,,,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Other,10220563.0,
3546,679519,1,8,,103163840,3715,Unspecified,74762955.0,9356.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Indomethacin: 2000 uM) in Xenopus laevis oocytes",Other,9887087.0,
3547,679529,1,8,,103163840,3715,Unspecified,74762955.0,9356.0,,,TP_TRANSPORTER: inhibition of PAH uptake (Indomethacin: 200 uM) in OAT1-expressing HeLa cells,Other,9950961.0,
3548,679536,1,8,,103163840,3715,Unspecified,74762955.0,9356.0,,,"TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Indomethacin: 200 uM) in OAT1-expressing S2 cells",Other,11669456.0,
3549,679545,1,8,,103163840,3715,Unspecified,74762955.0,9356.0,,,"TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Indomethacin: 500 uM) in OAT1-expressing S2 cells",Other,12130730.0,
3550,679614,1,8,,103163840,3715,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Daunorubicin, LDS-751 and Rhodamine 123 efflux in NIH-3T3-G185 cells",Other,11716514.0,
3551,679815,1,8,,103163840,3715,Unspecified,3219824.0,25303.0,,,TP_TRANSPORTER: biliary excretion in SD rat,Other,10870987.0,
3552,679816,1,8,,103163840,3715,Unspecified,3219824.0,25303.0,,,TP_TRANSPORTER: biliary excretion in EHBR rat,Other,10870987.0,
3553,679945,2,7,,103163840,3715,Unspecified,27735248.0,80899.0,1000.0,Ki,TP_TRANSPORTER: inhibition of MTX uptake in OAT-K1-expressing LLC-PK1 cells,Confirmatory,9399974.0,
3554,680169,1,7,,103163840,3715,Unspecified,74734337.0,55867.0,,,"TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Indomethacin: 200 uM) in OAT4-expressing S2 cells",Other,12063169.0,
3555,680176,1,7,,103163840,3715,Unspecified,74734337.0,55867.0,,,"TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Indomethacin: 500 uM) in OAT4-expressing S2 cells",Other,12130730.0,
3556,680190,1,7,,103163840,3715,Unspecified,74734337.0,55867.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Indomethacin: 500 uM) in Xenopus laevis oocytes",Other,10660625.0,
3557,680415,1,7,,103163840,3715,Unspecified,74761045.0,,,,TP_TRANSPORTER: inhibition of glyburide accumulation by indomethacin at a concentration of 200uM in MRP3-expressing MDCK cells,Other,16460798.0,
3558,680473,1,8,,103163840,3715,Unspecified,1171883.0,50572.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.1 uM, Indomethacin: 1000 uM) in Oatp1-expressing LLC-PK1 cells",Other,11883641.0,
3559,680594,1,7,,103163840,3715,Unspecified,74761045.0,,,,TP_TRANSPORTER: inhibition of 5-carboxyfluorescein accumulation by indomethacin at a concentration of 200uM in MRP3-expressing MDCK cells,Other,16460798.0,
3560,680599,1,7,,103163840,3715,Unspecified,74761045.0,,,,"TP_TRANSPORTER: increase in Etoposide intracellular accumulation (Etoposide: 2 uM, Indomethacin: 500 uM) in MRP3-expressing fibroblast from kidney of mdr1a/1b and mrp1 (-/-) mouse",Other,11581266.0,
3561,680610,1,7,,103163840,3715,Unspecified,74762666.0,85320.0,,,TP_TRANSPORTER: inhibition of Estradiol-17beta-D-glucuronide uptake by Indomethacin at a concentration of 10 uM in membrane vesicle from MRP8-expressing LLC-PK1 cells,Other,15537867.0,
3562,680790,1,8,,103163840,3715,Unspecified,308153583.0,1244.0,,,TP_TRANSPORTER: inhibition of glyburide accumulation in MRP2-expressing MDCK cells,Other,16460798.0,
3563,680808,1,8,,103163840,3715,Unspecified,308153583.0,1244.0,,,TP_TRANSPORTER: inhibition of 5-carboxyfluorescein accumulation by indomethacin at a concentration of 200uM in MRP2-expressing MDCK cells,Other,16460798.0,
3564,680944,1,8,,103163840,3715,Unspecified,269849624.0,368.0,,,TP_TRANSPORTER: inhibition of NEM-GS in the presence of Indomethacin at a concentration of 100uM in membrane vesicles from MRP6-expressing Sf9 cells,Other,11880368.0,
3565,681023,1,8,,103163840,3715,Unspecified,81901833.0,18399.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 20 uM, Indomethacin: 1000 uM) in OAT-expressing COS-7 cells",Other,9880528.0,
3566,681036,1,7,,103163840,3715,Unspecified,74730587.0,9376.0,,,"TP_TRANSPORTER: inhibition of Ochratoxin A uptake (OTA: 1 uM, Indomethacin: 200 uM) in OAT3-expressing S2 cells",Other,11669456.0,
3567,681053,1,7,,103163840,3715,Unspecified,74730587.0,9376.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Indomethacin: 5 uM) in Xenopus laevis oocytes",Other,11306713.0,
3568,681104,1,8,,103163840,3715,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: inhibition of Glutathione efflux (Indomethacin: 400 uM) in MRP1-expressing MDCKII cells,Other,10917554.0,
3569,681108,1,8,,103163840,3715,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: inhibition of E217betaG in the presence of Indomethacin at a concentration of 50uM in membrane vesicles from MRP1-expressing Sf9 cells,Other,12835412.0,
3570,681118,1,8,,103163840,3715,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12954186.0,
3571,681136,1,8,,103163840,3715,Unspecified,27735248.0,80899.0,,,TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells,Other,10101033.0,
3572,681160,3,6,,103163840,3715,Unspecified,74762955.0,9356.0,3.0,IC50,TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells,Confirmatory,10991954.0,
3573,681168,2,7,,103163840,3715,Unspecified,124015184.0,19879.0,,Km,TP_TRANSPORTER: uptake in Oat3-expressing oocyte cells,Confirmatory,14762099.0,
3574,681340,3,6,,103163840,3715,Unspecified,81886651.0,29509.0,10.0,Ki,TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes,Confirmatory,10220563.0,
3575,681372,3,6,,103163840,3715,Unspecified,74730587.0,9376.0,5.95,Ki,TP_TRANSPORTER: inhibition of MTX uptake in OAT3-expressing S2 cells,Confirmatory,12130730.0,
3576,681379,1,8,,103163840,3715,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: inhibition of EGCG in MRP1-expressing MDCKII cells,Other,14511674.0,
3577,681417,1,7,,103163840,3715,Unspecified,81872813.0,83500.0,,,"TP_TRANSPORTER: inhibition of Homovanillic acid uptake (HVA: 0.2 uM, Indomethacin: 1000 uM) in Xenopus laevis oocytes",Other,12679720.0,
3578,681430,1,7,,103163840,3715,Unspecified,81872813.0,83500.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 40 uM, Indomethacin: 1000 uM) in Xenopus laevis oocytes",Other,10224140.0,
3579,681536,1,7,,103163840,3715,Unspecified,127792.0,24777.0,,,TP_TRANSPORTER: uptake in Ntcp-expressing COS-7 cells,Other,10870987.0,
3580,681851,1,8,,103163840,3715,Unspecified,3914190.0,170698.0,,,"TP_TRANSPORTER: inhibition of Digoxin uptake (Digoxin: 0.05 uM, Indomethacin: 1000 uM) in Oatp2-expressing LLC-PK1 cells",Other,11883641.0,
3581,681859,1,8,,103163840,3715,Unspecified,52783101.0,17250.0,,,TP_TRANSPORTER: inhibition of glyburide accumulation in the presence of indomethacin at a concentration of 200uM in MRP1-expressing HeLa cells,Other,16460798.0,
3582,681860,1,8,,103163840,3715,Unspecified,52783101.0,17250.0,,,TP_TRANSPORTER: inhibition of 5-carboxyfluorescein accumulation in the presence of indomethacin at a concentration of 200uM in MRP1-expressing HeLa cells,Other,16460798.0,
3583,681882,1,7,,103163840,3715,Unspecified,206729914.0,10257.0,,,TP_TRANSPORTER: inhibition of bimane-GS efflux in the presence of Indomethacin at a concentration of 50uM in MRP4-expressing HepG2 cells,Other,14643890.0,
3584,681928,1,7,,103163840,3715,Unspecified,206729914.0,10257.0,,,TP_TRANSPORTER: inhibition of E217betaG in the presence of Indomethacin at a concentration of 50uM in membrane vesicles from MRP4-expressing Sf9 cells,Other,12835412.0,
3585,682092,1,8,,103163840,3715,Unspecified,1171883.0,50572.0,,,TP_TRANSPORTER: uptake in Oatp1-expressing COS-7 cells,Other,10870987.0,
3586,682172,1,8,,103163840,3715,Unspecified,124015184.0,19879.0,,,TP_TRANSPORTER: inhibition of benzylpenicillin uptake by Indomethacin at a concentration of 1000uM in Oat3-expressing oocyte cells,Other,14762099.0,
3587,683092,5,5,,103163840,3715,Active,754286265.0,443551.0,0.68,IC50,Inhibition of ovine COX1 assessed as inhibition of PGF2alpha production from PGH2 by enzyme immuno assay,Confirmatory,23047224.0,
3588,683093,5,5,,103163840,3715,Active,3915797.0,5743.0,18.3,IC50,Inhibition of human recombinant COX2 assessed as inhibition of PGF2alpha production from PGH2 by enzyme immunoassay,Confirmatory,23047224.0,
3589,683094,1,2,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,23047224.0,
3590,683869,1,4,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip measured 3.5 hrs after carrageenan challenge",Other,22126405.0,
3591,684465,1,7,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of isolated ovine COX-1 at 10 uM by ELISA,Other,22959205.0,
3592,684466,1,7,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX-2 at 10 uM by ELISA,Other,22959205.0,
3593,684833,2,2,,103163840,3715,Unspecified,,,1052.0,IC50,Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,22940705.0,
3594,686940,1,1,,56422212,3715,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
3595,686964,1,1,,56422212,3715,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
3596,686970,1,2,,56422212,3715,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
3597,686971,1,2,,56422212,3715,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
3598,686977,2,1,,49698710,3715,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
3599,686978,1,1,,56422212,3715,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3600,686978,1,1,,124880450,3715,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3601,686978,1,1,,124880453,3715,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3602,686978,1,1,,144206660,3715,Inconclusive,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3603,686979,1,1,,56422212,3715,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3604,686979,1,1,,124880450,3715,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3605,686979,1,1,,124880453,3715,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3606,686979,1,1,,144206660,3715,Inconclusive,79154014.0,55775.0,33.4983,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3607,686992,2,1,,56422212,3715,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
3608,686996,1,1,,56422212,3715,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3609,687014,1,1,,56422212,3715,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
3610,687016,1,1,,56422212,3715,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
3611,687035,1,1,,163564646,3715,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3612,687037,1,3,,163564646,3715,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
3613,687240,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 40 mg/kg, po administered 1 hr prior to carrageenan challenge measured 1 hr post carrageenan challenge relative to control",Other,22981329.0,
3614,687241,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 40 mg/kg, po administered 1 hr prior to carrageenan challenge measured 2 hrs post carrageenan challenge relative to control",Other,22981329.0,
3615,687242,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 40 mg/kg, po administered 1 hr prior to carrageenan challenge measured 4 hrs post carrageenan challenge relative to control",Other,22981329.0,
3616,687437,1,2,,103163840,3715,Unspecified,,,,,Gastric toxicity in Swiss mouse assessed as inflammatory cell index at 10 mg/kg administered as single dose (Rvb = 0.2 +/- 0.2 inflammatory cell index),Other,21417376.0,
3617,687438,1,2,,103163840,3715,Unspecified,,,,,Gastric toxicity in Swiss mouse assessed as erosion index at 10 mg/kg administered as single dose (Rvb = 0 +/- 0 erosion index),Other,21417376.0,
3618,687439,1,2,,103163840,3715,Unspecified,,,,,Gastric toxicity in Swiss mouse assessed as edema index at 10 mg/kg administered as single dose (Rvb = 0.6 +/- 0.2 edema index),Other,21417376.0,
3619,687440,1,2,,103163840,3715,Unspecified,,,,,Gastric toxicity in Swiss mouse assessed as necrosis index at 10 mg/kg administered as single dose (Rvb = 0 +/- 0 necrosis index),Other,21417376.0,
3620,688451,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as inhibition of Croton oil-induced ear edema at 0.10 umol administered topically per cm'2 of ear measured after induction of dermatitis relative to untreated control,Other,21800856.0,
3621,688452,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as inhibition of Croton oil-induced ear edema at 0.30 umol administered topically per cm'2 of ear measured after induction of dermatitis relative to untreated control,Other,21800856.0,
3622,688453,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as inhibition of Croton oil-induced ear edema at 1 umol administered topically per cm'2 of ear measured after induction of dermatitis relative to untreated control,Other,21800856.0,
3623,688454,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as inhibition of Croton oil-induced ear edema administered topically per cm'2 of ear measured after induction of dermatitis relative to untreated control,Other,21800856.0,
3624,688457,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as inhibition of Croton oil-induced ear edema at 0.4 umol administered topically per cm'2 of ear measured 3 hrs after induction of dermatitis relative to untreated control,Other,21800856.0,
3625,688458,1,2,,103163840,3715,Inactive,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as inhibition of Croton oil-induced ear edema at 0.4 umol administered topically per cm'2 of ear measured 48 hrs after induction of dermatitis relative to untreated control,Other,21800856.0,
3626,688459,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as inhibition of Croton oil-induced ear edema at 0.4 umol administered topically per cm'2 of ear measured 6 hrs after induction of dermatitis relative to untreated control,Other,21800856.0,
3627,688462,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as reduction in AUC of of Croton oil-induced ear edema response at 0.4 umol administered topically per cm'2 of ear measured 48 hrs after induction of dermatitis relative to untreated control,Other,21800856.0,
3628,688464,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as reduction in leukocyte infiltration-based myeloperoxidase activity at 0.4 umol administered topically per cm'2 of ear measured 3 to 48 hrs post dermatitis induction relative to untreated control,Other,21800856.0,
3629,688466,1,2,,103163840,3715,Active,,,,,Antiinflammatory effect in CD1 mouse ear dermatitis model assessed as reduction in vascular changes at 0.4 umol administered topically per cm'2 of ear measured after 6 hrs post dermatitis induction relative to control,Other,21800856.0,
3630,688467,1,2,,103163840,3715,Active,,,,,Antiinflammatory effect in CD1 mouse ear dermatitis model assessed as reduction in cellular changes at 0.4 umol administered topically per cm'2 of ear measured after 6 hrs post dermatitis induction relative to control,Other,21800856.0,
3631,688468,1,2,,103163840,3715,Active,,,,,Antiinflammatory effect in CD1 mouse ear dermatitis model assessed as preservance of mast cell degranulation at 0.4 umol administered topically per cm'2 of ear measured after 6 hrs post dermatitis induction relative to control,Other,21800856.0,
3632,688469,1,2,,103163840,3715,Active,,,,,Antiinflammatory effect in CD1 mouse ear dermatitis model assessed as reduction in mast cell degranulation at 0.4 umol administered topically per cm'2 of ear measured after 6 hrs post dermatitis induction relative to control,Other,21800856.0,
3633,688470,1,2,,103163840,3715,Active,,,,,Antiinflammatory effect in CD1 mouse ear dermatitis model assessed as reduction in leukocyte infiltration-based myeloperoxidase at 0.4 umol administered topically per cm'2 of ear measured after 6 hrs post dermatitis induction relative to control,Other,21800856.0,
3634,688471,1,2,,103163840,3715,Inactive,,,,,Antiinflammatory effect in CD1 mouse ear dermatitis model assessed as dermal swelling at 0.4 umol administered topically per cm'2 of ear after 9 hrs of post dermatitis induction relative to control,Other,21800856.0,
3635,688617,4,5,,103163840,3715,Active,754286265.0,443551.0,2.1,IC50,Inhibition of ram seminal vesicle COX1 assessed as PGE2 production by enzyme immunoassay,Confirmatory,21800856.0,
3636,688624,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in CD1 mouse ear dermatitis model assessed as reduction in AUC of global leukocyte infiltration-based myeloperoxidase activity at 0.4 umol administered topically per cm'2 of ear measured 3 to 48 hrs post dermatitis induction relative to untreated control,Other,21800856.0,
3637,692103,4,1,,103163840,3715,Active,,,25.0,IC50,Inhibition of gamma secretase assessed as reduction in Abeta42 production,Confirmatory,21141968.0,
3638,693571,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan-challenge after 1 hr relative to vehicle-treated control",Other,23159805.0,
3639,693572,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan-challenge after 2 hrs relative to vehicle-treated control",Other,23159805.0,
3640,693573,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan-challenge after 3 hrs relative to vehicle-treated control",Other,23159805.0,
3641,693574,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan-challenge after 4 hrs relative to vehicle-treated control",Other,23159805.0,
3642,693575,1,2,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in Wistar albino rat assessed as ulcer index at 10 mg/kg, ip administered QD for 3 days",Other,23159805.0,
3643,693576,1,2,,103163840,3715,Unspecified,,,,,Analgesic activity in mouse assessed as inhibition of acetic-acid induced writhing at 10 mg/kg administered 15 mins prior to acetic acid-challenge measured for 15 mins relative to vehicle-treated control,Other,23159805.0,
3644,695143,4,5,,103163840,3715,Active,754286265.0,443551.0,0.0067,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate incubated for 1 min prior to substrate addition measured for 25 secs by TMPD-based chromogenic assay,Confirmatory,23010270.0,
3645,695144,4,5,,103163840,3715,Active,3915797.0,5743.0,0.048,IC50,Inhibition of human recombinant COX2 expressed in insect cells using arachidonic acid as substrate incubated for 1 min prior to substrate addition measured for 25 secs by TMPD-based chromogenic assay,Confirmatory,23010270.0,
3646,695145,1,2,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant COX2 to IC50 for ovine COX1,Other,23010270.0,
3647,698889,2,2,,103163840,3715,Unspecified,,,64.3,GI50,Growth inhibition of human NCI60 cells incubated for 48 hrs by SRB assay,Confirmatory,22734697.0,
3648,699539,1,7,,103163840,3715,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
3649,699540,1,7,,103163840,3715,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
3650,699541,1,7,,103163840,3715,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
3651,699542,2,7,,103163840,3715,Active,12643959.0,10599.0,,IC50,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting,Confirmatory,22541068.0,
3652,699543,2,7,,103163840,3715,Active,27734563.0,28234.0,,IC50,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting,Confirmatory,22541068.0,
3653,699544,2,7,,103163840,3715,Unspecified,313104012.0,11309.0,,IC50,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting,Confirmatory,22541068.0,
3654,700995,1,7,,103163840,3715,Unspecified,5921840.0,808251.0,,,Inhibition of ovine COX-1 mediated formation of 12-HHT from arachidonic acid assessed as remaining activity at 10 uM after 5 mins by HPLC analysis,Other,21591611.0,
3655,701948,3,1,,103163840,3715,Active,238054374.0,5243.0,32.0,IC50,Inhibition of human recombinant P-glycoprotein after 40 mins by Pgp-Glo assay,Confirmatory,22916727.0,
3656,701949,4,5,,103163840,3715,Active,3914304.0,443460.0,20.0,IC50,Inhibition of ovine COX2 by colorimetric assay,Confirmatory,22916727.0,
3657,701950,4,5,,103163840,3715,Active,754286265.0,443551.0,0.12,IC50,Inhibition of ovine COX1 by colorimetric assay,Confirmatory,22916727.0,
3658,701952,1,7,,103163840,3715,Unspecified,296439301.0,4363.0,,,Inhibition of human MRP1 in human T98G cells assessed as potentiation of doxorubicin induced cytotoxicity at 50 uM pre-incubated for 2 hrs before doxorubicin addition and measured 4 days after doxorubicin exposure by MTT assay relative to untreated control,Other,22916727.0,
3659,702430,4,5,,103163840,3715,Active,317373262.0,5742.0,0.044000000000000004,IC50,Inhibition of human platelet COX1 using arachidonic acid as substrate preincubated for 15 mins before arachidonic acid addition measured after 15 mins,Confirmatory,22652053.0,
3660,703399,4,5,,103163840,3715,Unspecified,308153631.0,1109.0,100.0,IC50,"Inhibition of human recombinant N-terminal His6-tagged AKR1C4 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis",Confirmatory,22877157.0,
3661,703400,4,5,,103163840,3715,Active,308153646.0,8644.0,0.73,IC50,"Inhibition of human recombinant N-terminal His6-tagged AKR1C3 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis",Confirmatory,22877157.0,
3662,703401,4,5,,103163840,3715,Unspecified,20532374.0,1646.0,100.0,IC50,"Inhibition of human recombinant N-terminal His6-tagged AKR1C2 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis",Confirmatory,22877157.0,
3663,703402,4,5,,103163840,3715,Unspecified,416877.0,1645.0,100.0,IC50,"Inhibition of human recombinant N-terminal His6-tagged AKR1C1 expressed in Escherichia coli BL21(DE3) cells using 8-Acetyl-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo[de]anthracen-10-one as substrate after 1 hr by fluorimetric analysis",Confirmatory,22877157.0,
3664,703403,1,2,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for AKR1C1 to IC50 for AKR1C3,Other,22877157.0,
3665,703404,3,2,,103163840,3715,Active,,,2.3,IC50,"Inhibition of AKR1C3 using 9,10-phenanthroquinone as substrate",Confirmatory,22877157.0,
3666,703405,1,2,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for AKR1C2 to IC50 for AKR1C3,Other,22877157.0,
3667,703840,4,5,,103163840,3715,Active,7387730.0,9536.0,40.6,IC50,Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis,Confirmatory,22992107.0,
3668,703842,1,7,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as inhibition of 12-HHT formation measuring remaining activity preincubated at 10 uM for 5 mins before arachidonic acid addition by HPLC analysis,Other,22992107.0,
3669,703844,3,5,,103163840,3715,Inactive,126407.0,240.0,,IC50,Inhibition of 5-lipoxygenase in A23187-stimulated human neutrophils assessed as inhibition of enzyme product formation by RP-HPLC analysis,Confirmatory,22992107.0,
3670,705365,2,6,,103163840,3715,Active,296439334.0,11251.0,0.389,EC50,Partial antagonist activity at CRTH2 in human eosinophils assessed as inhibition of PGD2-induced shape change by FACS analysis,Confirmatory,22224640.0,
3671,707114,1,2,,103163840,3715,Active,,,,,"Antihyperalgesic activity in carrageenan-induced mechanical hyperalgesia Swiss mouse model assessed as paw withdrawal latency at 5 mg/kg, ip administered 40 mins prior to challenge by electronic pressure-meter test",Other,22574649.0,
3672,707116,1,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Swiss mouse assessed as increase in stomach MPO activity at at 2.5 mg/kg, po for 7 days measured over 7 days relative to vehicle-treated control",Other,22574649.0,
3673,707118,1,2,,103163840,3715,Unspecified,,,,,"Hepatotoxicity in Swiss mouse assessed as change in plasma AST level at 2.5 mg/kg, po for 7 days measured over 7 days relative to vehicle-treated control",Other,22574649.0,
3674,707119,1,2,,103163840,3715,Unspecified,,,,,"Hepatotoxicity in Swiss mouse assessed as change in plasma ALT level at 2.5 mg/kg, po for 7 days measured over 7 days relative to vehicle-treated control",Other,22574649.0,
3675,707339,1,2,,103163840,3715,Active,,,,,"Antinociceptive activity in Swiss mouse assessed as inhibition of PBQ-induced writhing at 5 mg/kg, ip administered 30 mins prior to PBQ challenge",Other,22574649.0,
3676,707340,1,2,,103163840,3715,Active,,,,,"Antinociceptive activity in Swiss mouse assessed as inhibition of acetic acid-induced writhing at 5 mg/kg, ip administered 30 mins prior to acetic acid challenge",Other,22574649.0,
3677,717355,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po measured at 360 mins after carrageenan challenge by plethysmographic analysis",Other,23146282.0,
3678,717356,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po measured at 270 mins after carrageenan challenge by plethysmographic analysis",Other,23146282.0,
3679,717357,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po measured at 180 mins after carrageenan challenge by plethysmographic analysis",Other,23146282.0,
3680,717358,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po measured at 90 mins after carrageenan challenge by plethysmographic analysis",Other,23146282.0,
3681,720504,1,1,,56422212,3715,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
3682,720508,1,1,,56422212,3715,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3683,720509,1,1,,56422212,3715,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3684,720511,1,1,,56422212,3715,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
3685,720516,2,1,,144206660,3715,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3686,720516,2,1,,144208989,3715,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3687,720516,2,1,,144210586,3715,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3688,720532,1,1,,11111329,3715,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3689,720532,1,1,,124880450,3715,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3690,720532,1,1,,124880453,3715,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3691,720532,1,1,,124880455,3715,Inconclusive,420597.0,,19.9526,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3692,720532,1,1,,124880457,3715,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3693,720532,1,1,,144206660,3715,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3694,720533,1,1,,11111329,3715,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3695,720533,1,1,,124880450,3715,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3696,720533,1,1,,124880453,3715,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3697,720533,1,1,,124880455,3715,Inconclusive,,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3698,720533,1,1,,124880457,3715,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3699,720533,1,1,,144206660,3715,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3700,720538,1,2,,90340917,3715,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
3701,720542,1,2,,56422212,3715,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
3702,720543,1,1,,56422212,3715,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
3703,720551,1,2,,56422212,3715,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
3704,720552,2,1,,144206660,3715,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3705,720552,2,1,,144208989,3715,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3706,720552,2,1,,144210586,3715,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3707,720553,1,2,,56422212,3715,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
3708,720559,1,2,,90340917,3715,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
3709,720572,1,2,,90340917,3715,Inconclusive,3063388.0,5071.0,20.5962,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
3710,720573,1,2,,90340917,3715,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
3711,720579,2,1,,56422212,3715,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3712,720579,2,1,,124880453,3715,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3713,720580,1,1,,56422212,3715,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3714,720580,1,1,,124880453,3715,Inconclusive,222762.0,3707576.0,5.0119,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3715,720582,1,1,,56422212,3715,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
3716,720596,1,1,,56422212,3715,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
3717,720634,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3718,720634,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3719,720634,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3720,720635,2,1,,144206660,3715,Inconclusive,,,4.2163,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3721,720635,2,1,,144208989,3715,Inconclusive,,,10.9371,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3722,720635,2,1,,144210586,3715,Inconclusive,,,6.859,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3723,720636,1,1,,17389851,3715,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
3724,720636,1,1,,124880458,3715,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
3725,720637,2,1,,144206660,3715,Inconclusive,,,4.73079,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3726,720637,2,1,,144208989,3715,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3727,720637,2,1,,144210586,3715,Inconclusive,,,6.3522099999999995,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3728,720641,1,2,,92307459,3715,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3729,720641,1,2,,92308955,3715,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3730,720647,1,2,,56422212,3715,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
3731,720648,1,1,,56422212,3715,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
3732,720652,1,1,,17389851,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3733,720653,1,1,,17389851,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
3734,720653,1,1,,50126367,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
3735,720659,1,1,,17389851,3715,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
3736,720659,1,1,,50126367,3715,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
3737,720674,2,2,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3738,720674,2,2,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3739,720674,2,2,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3740,720675,2,2,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3741,720675,2,2,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3742,720675,2,2,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3743,720678,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3744,720678,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3745,720678,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3746,720679,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3747,720679,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3748,720679,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3749,720680,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3750,720680,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3751,720680,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3752,720681,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3753,720681,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3754,720681,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3755,720682,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3756,720682,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3757,720682,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3758,720683,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3759,720683,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3760,720683,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3761,720684,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3762,720684,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3763,720684,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3764,720685,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3765,720685,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3766,720685,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3767,720686,2,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3768,720686,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3769,720686,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3770,720687,2,2,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3771,720687,2,2,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3772,720687,2,2,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3773,720691,4,1,,144206660,3715,Inactive,311348376.0,2908.0,8.4852,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3774,720691,4,1,,144208989,3715,Inactive,311348376.0,2908.0,5.5277,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3775,720691,4,1,,144210586,3715,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3776,720692,3,1,,144206660,3715,Inconclusive,311348376.0,2908.0,1.8996,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3777,720692,3,1,,144208989,3715,Inconclusive,311348376.0,2908.0,8.7609,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3778,720692,3,1,,144210586,3715,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3779,720693,3,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3780,720693,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3781,720693,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3782,720700,1,4,,56422212,3715,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
3783,720702,1,1,,56422212,3715,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
3784,720704,1,4,,56422212,3715,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
3785,720707,1,2,,56422212,3715,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3786,720708,1,2,,56422212,3715,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
3787,720709,1,2,,56422212,3715,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3788,720711,1,2,,56422212,3715,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
3789,720717,1,3,,92124045,3715,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3790,720717,1,3,,92125110,3715,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3791,720717,1,3,,92307459,3715,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3792,720717,1,3,,92308955,3715,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3793,720717,1,3,,92310101,3715,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3794,720719,2,1,,144206660,3715,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3795,720719,2,1,,144208989,3715,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3796,720719,2,1,,144210586,3715,Inconclusive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3797,720725,2,1,,144206660,3715,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3798,720725,2,1,,144208989,3715,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3799,720725,2,1,,144210586,3715,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3800,721753,1,6,,103163840,3715,Unspecified,74731723.0,55244.0,,,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay,Other,23241029.0,
3801,721754,2,5,,103163840,3715,Unspecified,74731723.0,55244.0,500.0,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
3802,722039,1,3,,103163840,3715,Unspecified,,,100000.0,IC50,Cytotoxicity against human multiple myeloma cells,Confirmatory,23061607.0,
3803,722041,1,3,,103163840,3715,Unspecified,,,100000.0,IC50,Cytotoxicity against human MIAPaCa2 cells,Confirmatory,23061607.0,
3804,723695,1,6,,103163840,3715,Inactive,3915797.0,5743.0,,,Competitive inhibition of human recombinant COX2 assessed as inhibition of PGF2a production at 200 uM by enzyme immunoassay,Other,23219856.0,
3805,723697,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in AKR mouse assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip measured after 3.5 hrs of carrageenan-challenge",Other,23219856.0,
3806,723698,2,5,,103163840,3715,Inactive,754286265.0,443551.0,,IC50,Inhibition of ovine COX1 assessed as inhibition of PGF2a production by enzyme immunoassay,Confirmatory,23219856.0,
3807,723699,1,2,,103163840,3715,Inactive,,,,IC50,Inhibition of soybean lipoxygenase assessed as inhibition of sodium linolate conversion to 13-hydroperoxylinoleic acid after 4 mins by spectrophotometry,Confirmatory,23219856.0,
3808,724081,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced hind paw edema at 100 mg/kg, po administered 6 hrs before carrageenan-challenge measured after 1 hr",Other,23290048.0,
3809,724082,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced hind paw edema at 100 mg/kg, po administered 3 hrs before carrageenan-challenge measured after 1 hr",Other,23290048.0,
3810,724083,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced hind paw edema at 100 mg/kg, po administered 1 hr before carrageenan-challenge measured after 1 hr",Other,23290048.0,
3811,724084,1,6,,103163840,3715,Unspecified,3914304.0,443460.0,,,"Inhibition of ovine COX2 peroxidase activity assessed as appearance of oxidized N,N,N,N'-tetramethyl-p-phenylenediamine by colorimetric analysis relative to control",Other,23290048.0,
3812,724085,1,6,,103163840,3715,Unspecified,754286265.0,443551.0,,,"Inhibition of ovine COX1 peroxidase activity assessed as appearance of oxidized N,N,N,N'-tetramethyl-p-phenylenediamine by colorimetric analysis relative to control",Other,23290048.0,
3813,724352,1,2,,103163840,3715,Unspecified,,,,,"Toxicity against Fischer-344 rat up to 0.1 mmol/kg, ip",Other,23291118.0,
3814,724353,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fischer-344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip after 3.5 hrs relative to control",Other,23291118.0,
3815,729242,2,5,,103163840,3715,Active,1018618719.0,367.0,0.00014,EC50,Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay,Confirmatory,23432095.0,
3816,729243,1,6,,103163840,3715,Inactive,1018618719.0,367.0,,,Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 after 20 mins by luciferase reporter gene assay,Other,23432095.0,
3817,729244,1,6,,103163840,3715,Active,308153646.0,8644.0,,,"Inhibition of AKR1C3 (unknown origin)-mediated testosterone-17beta-glucuronide formation expressed in human LNCAP cells at 30 uM after 48 hrs in presence of 4-androstene-3,17-dione",Other,23432095.0,
3818,729248,1,2,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for mouse COX2,Other,23432095.0,
3819,729249,2,5,,103163840,3715,Active,548483.0,19225.0,0.2,IC50,Inhibition of wild type mouse COX2 by discontinuous radioactive TLC assay,Confirmatory,23432095.0,
3820,729250,2,5,,103163840,3715,Active,754286265.0,443551.0,0.05,IC50,Inhibition of ovine COX1 by discontinuous radioactive TLC assay,Confirmatory,23432095.0,
3821,729251,1,2,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for COX1 (unknown origin) to IC50 for human recombinant AKR1C3,Other,23432095.0,
3822,729252,2,5,,103163840,3715,Active,317373262.0,5742.0,0.02,IC50,"Inhibition of COX1 (unknown origin)-mediated oxidation of N,N,N,Ntetramethyl-1,4-phenylenediamine using arachidonic acid as substrate by colorimetric assay",Confirmatory,23432095.0,
3823,729257,1,2,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant AKR1C2 to IC50 for human recombinant AKR1C3,Other,23432095.0,
3824,729258,2,5,,103163840,3715,Active,308153646.0,8644.0,0.1,IC50,"Inhibition of human recombinant AKR1C3-mediated NADP+-dependent oxidation of S-(+)-1,2,3,4-tetrahydro-1-naphthol",Confirmatory,23432095.0,
3825,729259,2,5,,103163840,3715,Active,20532374.0,1646.0,36.53,IC50,"Inhibition of human recombinant AKR1C2-mediated NADP+-dependent oxidation of S-(+)-1,2,3,4-tetrahydro-1-naphthol",Confirmatory,23432095.0,
3826,732774,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 4 hrs by plethysmometer analysis",Other,23416192.0,
3827,732775,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs by plethysmometer analysis",Other,23416192.0,
3828,732776,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 2 hrs by plethysmometer analysis",Other,23416192.0,
3829,732777,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 1 hr by plethysmometer analysis",Other,23416192.0,
3830,736482,1,2,,103163840,3715,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of lambda-carrageenan-induced paw edema at 10 mg/kg, ip administered 2 hrs prior to carrageenan challenge measured after 2 to 18 hrs",Other,23357309.0,
3831,736887,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of acetic acid-induced vascular permeability by measuring Evan's blue dye leakage at 100 mg/kg, po administered 1 hr before acetic acid challenge measured after 30 mins",Other,23357629.0,
3832,736888,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw volume at 100 mg/kg, po measured after 6 hrs of carrageenan challenge (Rvb = 1.69 +/- 0.08 ml)",Other,23357629.0,
3833,736889,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw volume at 100 mg/kg, po measured after 1 hr of carrageenan challenge (Rvb = 0.94 +/- 0.05 ml)",Other,23357629.0,
3834,736890,1,6,,103163840,3715,Unspecified,3914304.0,443460.0,,,"Inhibition of ovine COX2 assessed as appearance of oxidized N,N,N,N'- tetramethyl-p-phenylenediamine at 100 uM",Other,23357629.0,
3835,736891,1,6,,103163840,3715,Unspecified,754286265.0,443551.0,,,"Inhibition of ovine COX1 assessed as appearance of oxidized N,N,N,N'- tetramethyl-p-phenylenediamine at 100 uM",Other,23357629.0,
3836,736892,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw volume at 100 mg/kg, po measured after 3 hrs of carrageenan challenge (Rvb = 1.17 +/- 0.1 ml)",Other,23357629.0,
3837,743012,3,1,,144206660,3715,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3838,743012,3,1,,144208989,3715,Inconclusive,,,10.9371,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3839,743012,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3840,743014,3,1,,144206660,3715,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3841,743014,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3842,743014,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3843,743015,3,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3844,743015,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3845,743015,3,1,,144210586,3715,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3846,743033,3,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3847,743033,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3848,743033,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3849,743035,2,1,,144206660,3715,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3850,743035,2,1,,144208989,3715,Inconclusive,124375976.0,367.0,34.8776,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3851,743035,2,1,,144210586,3715,Inconclusive,124375976.0,367.0,9.77,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3852,743036,2,1,,144206660,3715,Inconclusive,124375976.0,367.0,13.4481,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3853,743036,2,1,,144208989,3715,Inconclusive,124375976.0,367.0,19.6131,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3854,743036,2,1,,144210586,3715,Inconclusive,124375976.0,367.0,8.7076,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3855,743040,3,1,,144206660,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3856,743040,3,1,,144208989,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3857,743040,3,1,,144210586,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3858,743041,3,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3859,743041,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3860,743041,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3861,743042,3,1,,144206660,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3862,743042,3,1,,144208989,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3863,743042,3,1,,144210586,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3864,743053,2,1,,144206660,3715,Inconclusive,124375976.0,367.0,8.98795,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3865,743053,2,1,,144208989,3715,Inconclusive,124375976.0,367.0,14.0047,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3866,743053,2,1,,144210586,3715,Inconclusive,124375976.0,367.0,6.16448,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3867,743054,2,1,,144206660,3715,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3868,743054,2,1,,144208989,3715,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3869,743054,2,1,,144210586,3715,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3870,743063,2,1,,144206660,3715,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3871,743063,2,1,,144208989,3715,Inconclusive,124375976.0,367.0,43.9083,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3872,743063,2,1,,144210586,3715,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3873,743064,3,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3874,743064,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3875,743064,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3876,743065,3,1,,144206660,3715,Inconclusive,399498506.0,24831.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3877,743065,3,1,,144208989,3715,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3878,743065,3,1,,144210586,3715,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3879,743066,3,1,,144206660,3715,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3880,743066,3,1,,144208989,3715,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3881,743066,3,1,,144210586,3715,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3882,743067,2,1,,144206660,3715,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3883,743067,2,1,,144208989,3715,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3884,743067,2,1,,144210586,3715,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3885,743069,2,1,,144206660,3715,Inactive,348019627.0,2099.0,6.74,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3886,743069,2,1,,144208989,3715,Inactive,348019627.0,2099.0,6.959,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3887,743069,2,1,,144210586,3715,Inconclusive,348019627.0,2099.0,9.77,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3888,743074,2,1,,144206660,3715,Inconclusive,,,6.007000000000001,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3889,743074,2,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3890,743074,2,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3891,743075,2,1,,144206660,3715,Inactive,348019627.0,2099.0,3.0107,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3892,743075,2,1,,144208989,3715,Inactive,348019627.0,2099.0,0.8761,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3893,743075,2,1,,144210586,3715,Inactive,348019627.0,2099.0,6.9167,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3894,743077,2,1,,144206660,3715,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3895,743077,2,1,,144208989,3715,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3896,743077,2,1,,144210586,3715,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3897,743078,2,1,,144206660,3715,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3898,743078,2,1,,144208989,3715,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3899,743078,2,1,,144210586,3715,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3900,743079,3,1,,144206660,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3901,743079,3,1,,144208989,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3902,743079,3,1,,144210586,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3903,743080,3,1,,144206660,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3904,743080,3,1,,144208989,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3905,743080,3,1,,144210586,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3906,743081,3,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3907,743081,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3908,743081,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3909,743083,3,1,,144206660,3715,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3910,743083,3,1,,144208989,3715,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3911,743083,3,1,,144210586,3715,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3912,743084,3,1,,144206660,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3913,743084,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3914,743084,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3915,743085,3,1,,144206660,3715,Inconclusive,51095037.0,196.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3916,743085,3,1,,144208989,3715,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3917,743085,3,1,,144210586,3715,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3918,743086,3,1,,144206660,3715,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3919,743086,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3920,743086,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3921,743091,2,1,,144206660,3715,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3922,743091,2,1,,144208989,3715,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3923,743091,2,1,,144210586,3715,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3924,743094,3,1,,144206660,3715,Active,216409692.0,5468.0,7.5624,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3925,743094,3,1,,144208989,3715,Active,216409692.0,5468.0,1.9613,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3926,743094,3,1,,144210586,3715,Active,216409692.0,5468.0,2.7536,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3927,743122,2,1,,144206660,3715,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3928,743122,2,1,,144208989,3715,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3929,743122,2,1,,144210586,3715,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3930,743126,1,1,,56422212,3715,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3931,743139,2,1,,144206660,3715,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3932,743139,2,1,,144208989,3715,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3933,743139,2,1,,144210586,3715,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3934,743140,2,1,,144206660,3715,Active,216409692.0,5468.0,6.24205,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3935,743140,2,1,,144208989,3715,Active,216409692.0,5468.0,3.6242099999999997,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3936,743140,2,1,,144210586,3715,Active,216409692.0,5468.0,2.75357,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3937,743191,3,1,,144208989,3715,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3938,743191,3,1,,144210586,3715,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3939,743191,3,1,,170464705,3715,Inconclusive,216409692.0,5468.0,10.5901,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3940,743194,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3941,743194,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3942,743194,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3943,743199,2,1,,144208989,3715,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3944,743199,2,1,,144210586,3715,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3945,743199,2,1,,170464705,3715,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3946,743202,4,1,,144208989,3715,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3947,743202,4,1,,144210586,3715,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3948,743202,4,1,,170464705,3715,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3949,743203,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3950,743203,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3951,743203,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3952,743205,1,1,,90340917,3715,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3953,743205,1,1,,90340917,3715,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3954,743206,1,1,,90340917,3715,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3955,743206,1,1,,90340917,3715,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3956,743207,1,1,,90340917,3715,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3957,743207,1,1,,90340917,3715,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3958,743209,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3959,743209,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3960,743209,3,1,,170464705,3715,Inconclusive,,,0.0047,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3961,743210,4,1,,144208989,3715,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3962,743210,4,1,,144210586,3715,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3963,743210,4,1,,170464705,3715,Inconclusive,4504517.0,3315.0,33.4889,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3964,743211,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3965,743211,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3966,743211,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3967,743212,3,1,,144208989,3715,Inconclusive,216409690.0,5467.0,19.6131,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3968,743212,3,1,,144210586,3715,Inconclusive,216409690.0,5467.0,3.8895,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3969,743212,3,1,,170464705,3715,Inconclusive,216409690.0,5467.0,8.412,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3970,743213,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3971,743213,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3972,743213,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3973,743215,3,1,,144208989,3715,Inconclusive,216409690.0,5467.0,3.1085,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3974,743215,3,1,,144210586,3715,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3975,743215,3,1,,170464705,3715,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3976,743217,3,1,,144208989,3715,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3977,743217,3,1,,144210586,3715,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3978,743217,3,1,,170464705,3715,Inconclusive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3979,743218,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3980,743218,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3981,743218,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3982,743219,3,1,,144208989,3715,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3983,743219,3,1,,144210586,3715,Inconclusive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3984,743219,3,1,,170464705,3715,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3985,743220,3,1,,144208989,3715,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3986,743220,3,1,,144210586,3715,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3987,743220,3,1,,170464705,3715,Inconclusive,325495553.0,9971.0,29.846999999999998,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3988,743221,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3989,743221,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3990,743221,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3991,743222,3,1,,144208989,3715,Inconclusive,216409708.0,7421.0,3.1085,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3992,743222,3,1,,144210586,3715,Inconclusive,216409708.0,7421.0,1.9494,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3993,743222,3,1,,170464705,3715,Inconclusive,216409708.0,7421.0,18.8322,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3994,743223,3,1,,144208989,3715,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3995,743223,3,1,,144210586,3715,Inconclusive,216409708.0,7421.0,1.0962,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3996,743223,3,1,,170464705,3715,Inconclusive,216409708.0,7421.0,11.9856,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3997,743224,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3998,743224,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3999,743224,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4000,743225,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4001,743225,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4002,743225,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4003,743226,2,1,,144208989,3715,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4004,743226,2,1,,144210586,3715,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4005,743226,2,1,,170464705,3715,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4006,743227,2,1,,144208989,3715,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4007,743227,2,1,,144210586,3715,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4008,743227,2,1,,170464705,3715,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4009,743228,3,1,,144208989,3715,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
4010,743228,3,1,,144210586,3715,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
4011,743228,3,1,,170464705,3715,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
4012,743238,1,1,,56422212,3715,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
4013,743239,2,1,,144208989,3715,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4014,743239,2,1,,144210586,3715,Inconclusive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4015,743239,2,1,,170464705,3715,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4016,743240,2,1,,144208989,3715,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4017,743240,2,1,,144210586,3715,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4018,743240,2,1,,170464705,3715,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4019,743241,2,1,,144208989,3715,Inconclusive,216409708.0,7421.0,7.80812,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4020,743241,2,1,,144210586,3715,Inconclusive,216409708.0,7421.0,1.09622,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4021,743241,2,1,,170464705,3715,Inconclusive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4022,743242,2,1,,144208989,3715,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4023,743242,2,1,,144210586,3715,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4024,743242,2,1,,170464705,3715,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4025,743244,1,1,,90340917,3715,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
4026,743244,1,1,,144206660,3715,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
4027,743247,1,2,,56422212,3715,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
4028,743255,1,1,,56422212,3715,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
4029,743266,1,2,,56422212,3715,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
4030,743269,1,1,,56422212,3715,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
4031,743269,1,1,,56422212,3715,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
4032,743279,1,2,,56422212,3715,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
4033,743288,1,1,,17389851,3715,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
4034,743288,1,1,,50126367,3715,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
4035,743292,1,1,,17389851,3715,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
4036,743292,1,1,,50126367,3715,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
4037,743344,1,1,,174007200,3715,Inactive,,,4.2135,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
4038,743345,1,1,,174007200,3715,Inactive,,,0.0012,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
4039,743346,1,1,,174007200,3715,Inactive,,,4.2135,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
4040,743347,1,1,,174007200,3715,Inactive,,,5.3045,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
4041,743397,1,1,,56422212,3715,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
4042,743398,1,1,,56422212,3715,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
4043,745191,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 3 hrs relative to control",Other,23548704.0,
4044,745272,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio for COX1 (unknown origin) over COX2 (unknown origin),Other,23567953.0,
4045,745281,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Fisher 344 rat assessed as reduction of carrageenan-induced paw oedema at 0.01 mmol/kg, ip after 3.5 hrs",Other,23567956.0,
4046,746654,1,1,,103163840,3715,Unspecified,,,148.0,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method,Confirmatory,23566521.0,
4047,747923,1,5,,103163840,3715,Active,317373262.0,5742.0,,,Irreversible inhibition of COX-1 in human MDA-MB-231 cells assessed as inhibition of arachidonic acid-induced PGE2 formation at 100 uM incubated for 30 mins followed by compound washout measured 30 mins post arachidonic acid challenge by radioimmunoassay,Other,23651359.0,
4048,747925,1,5,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX-1 in human MDA-MB-231 cells assessed as inhibition of arachidonic acid-induced PGE2 formation at 100 uM incubated for 30 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay relative to vehicle-treated control,Other,23651359.0,
4049,747927,1,5,,103163840,3715,Active,317373262.0,5742.0,,,Irreversible inhibition of COX-1 in human THP1 cells assessed as inhibition of arachidonic acid-induced TXB2 formation at 100 uM incubated for 30 mins followed by compound washout measured 30 mins post arachidonic acid challenge by radioimmunoassay,Other,23651359.0,
4050,747928,1,5,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX-1 in human THP1 cells assessed as inhibition of arachidonic acid-induced TXB2 formation at 100 uM incubated for 30 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay relative to vehicle-treated control,Other,23651359.0,
4051,747930,1,5,,103163840,3715,Active,317373262.0,5742.0,,,Inhibition of COX-1 in human washed platelet assessed as inhibition of 0.5 uM arachidonic acid-induced TXB2 formation at 0.01 to 100 uM incubated for 25 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay,Other,23651359.0,
4052,747931,1,5,,103163840,3715,Active,317373262.0,5742.0,,,Inhibition of COX-1 in human washed platelet assessed as inhibition of 10 uM arachidonic acid-induced TXB2 formation at 0.01 to 100 uM incubated for 25 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay,Other,23651359.0,
4053,748506,2,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed Sprague-Dawley rat assessed as reduction of carrageenan-induced paw edema administered 1 hr measured after 2 hrs by plethysmometric analysis,Other,23687559.0,
4054,748508,1,5,,103163840,3715,Active,548483.0,19225.0,,,Binding affinity to wild type mouse COX2 expressed in insect cells using [1-14C]-arachidonic acid as substrate,Other,23687559.0,
4055,748509,2,3,,103163840,3715,Active,3915797.0,5743.0,1.5,Ki,Binding affinity to wild type human COX2 expressed in insect cells using [1-14C]-arachidonic acid as substrate,Confirmatory,23687559.0,
4056,748511,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for wild type mouse COX2 to IC50 for mouse COX2 V523I mutant,Other,23687559.0,
4057,748512,2,3,,103163840,3715,Active,3915797.0,5743.0,0.18,IC50,Inhibition of wild type human COX2 expressed in insect cells using [1-14C]-arachidonic acid as substrate incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Confirmatory,23687559.0,
4058,748513,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for wild type mouse COX2 to IC50 for mouse COX2 R120Q mutant,Other,23687559.0,
4059,748514,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for wild type mouse COX2 to IC50 for mouse COX2 S530A mutant,Other,23687559.0,
4060,748515,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for wild type mouse COX2 to IC50 for mouse COX2 V349L mutant,Other,23687559.0,
4061,748516,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for mouse COX2 V349A mutant to IC50 for wild type mouse COX2,Other,23687559.0,
4062,748517,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for wild type mouse COX2 to IC50 for mouse COX2 V349I mutant,Other,23687559.0,
4063,748518,1,1,,103163840,3715,Inactive,,,,,Inhibition of mouse COX2 Y355F mutant using [1-14C]-arachidonic acid as substrate up to 100 uM incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Other,23687559.0,
4064,748519,1,1,,103163840,3715,Inactive,,,,,Inhibition of mouse COX2 R120A mutant using [1-14C]-arachidonic acid as substrate up to 100 uM incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Other,23687559.0,
4065,748521,3,1,,103163840,3715,Active,,,0.475,IC50,Inhibition of mouse COX2 V523I mutant using [1-14C]-arachidonic acid as substrate incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Confirmatory,23687559.0,
4066,748522,3,1,,103163840,3715,Active,,,0.326,IC50,Inhibition of mouse COX2 R120Q mutant using [1-14C]-arachidonic acid as substrate incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Confirmatory,23687559.0,
4067,748523,1,1,,103163840,3715,Active,,,0.22,IC50,Inhibition of mouse COX2 S530A mutant using [1-14C]-arachidonic acid as substrate incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Confirmatory,23687559.0,
4068,748524,1,1,,103163840,3715,Active,,,1.34,IC50,Inhibition of mouse COX2 V349L mutant using [1-14C]-arachidonic acid as substrate incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Confirmatory,23687559.0,
4069,748525,3,1,,103163840,3715,Active,,,0.315,IC50,Inhibition of mouse COX2 V349I mutant using [1-14C]-arachidonic acid as substrate incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Confirmatory,23687559.0,
4070,748526,1,1,,103163840,3715,Active,,,0.071,IC50,Inhibition of mouse COX2 V349A mutant using [1-14C]-arachidonic acid as substrate incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Confirmatory,23687559.0,
4071,748527,4,2,,103163840,3715,Active,754286265.0,443551.0,0.027000000000000003,IC50,Inhibition of wild type ovine COX1 expressed in ram seminal vesicles using [1-14C]-arachidonic acid as substrate incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Confirmatory,23687559.0,
4072,748528,2,3,,103163840,3715,Active,548483.0,19225.0,0.127,IC50,Inhibition of wild type mouse COX2 expressed in insect cells using [1-14C]-arachidonic acid as substrate incubated for 17 mins at 25 degC followed by 3 mins at 37 degC prior to substrate addition measured after 30 secs by thin layer chromatographic analysis,Confirmatory,23687559.0,
4073,748529,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio for human COX1 over human COX2,Other,23687559.0,
4074,751099,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced neutrophil migration into peritoneal cavity at 10 mg/kg, ip administered 30 mins prior to carrageenan challenge measured after 4 hrs relative to carrageenan-treated control",Other,23734744.0,
4075,751100,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced total leukocytes migration into peritoneal cavity at 10 mg/kg, ip administered 30 mins prior to carrageenan challenge measured after 4 hrs relative to carrageenan-treated control",Other,23734744.0,
4076,751104,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss mouse assessed as reduction of carrageenan-induced paw myeloperoxidase activity measured per mg of tissue at 10 mg/kg, ip administered 30 mins prior to carrageenan challenge measured after 4 hrs (Rvb = 10.9 +/- 1.2 U)",Other,23734744.0,
4077,751105,1,1,,103163840,3715,Active,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of histamine-induced paw edema at 10 mg/kg, ip administered 30 mins prior to histamine challenge measured after 60 mins relative to untreated control",Other,23734744.0,
4078,751106,1,1,,103163840,3715,Active,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of bradykinin-induced paw edema at 10 mg/kg, ip administered 30 mins prior to bradykinin challenge measured after 60 mins in presence of captopril relative to untreated control",Other,23734744.0,
4079,751107,1,1,,103163840,3715,Active,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of serotonin-induced paw edema at 10 mg/kg, ip administered 30 mins prior to serotonin challenge measured after 4 hrs relative to untreated control",Other,23734744.0,
4080,751108,1,1,,103163840,3715,Active,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of dextran sulfate-induced paw edema at 10 mg/kg, ip administered 30 mins prior to dextran sulfate challenge measured after 4 hrs relative to untreated control",Other,23734744.0,
4081,751116,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip measured at 4 hrs by plethysmometric analysis relative to untreated control",Other,23734744.0,
4082,751120,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip measured at 3 hrs by plethysmometric analysis relative to untreated control",Other,23734744.0,
4083,751124,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip measured at 2 hrs by plethysmometric analysis relative to untreated control",Other,23734744.0,
4084,751128,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip measured at 1 hr by plethysmometric analysis relative to untreated control",Other,23734744.0,
4085,751153,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in Swiss mouse assessed as increase in myeloperoxidase activity in stomach at 2.5 mg/kg, ip for 7 days by spectrophotometric analysis",Other,23742617.0,
4086,751155,1,1,,103163840,3715,Unspecified,,,,,"Hepatotoxicity in Swiss mouse assessed as increase in plasma ALT level at 2.5 mg/kg, ip for 7 days",Other,23742617.0,
4087,751156,1,1,,103163840,3715,Unspecified,,,,,"Hepatotoxicity in Swiss mouse assessed as increase in plasma AST level at 2.5 mg/kg, ip for 7 days",Other,23742617.0,
4088,751214,1,1,,103163840,3715,Active,,,12.1,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay,Confirmatory,23755850.0,
4089,752636,1,1,,103163840,3715,Active,,,1.62,IC50,Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method,Confirmatory,23639653.0,
4090,753744,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as apoptotic glandular epithelial cells at 0.28 mmol/kg, po using haematoxylin and eosin staining by light microscopic analysis",Other,23665142.0,
4091,753745,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as severe atrophic gastritis and gland atrophy at 0.28 mmol/kg, po using haematoxylin and eosin staining by light microscopic analysis",Other,23665142.0,
4092,753746,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as acute inflammatory cell infiltrating its whole thickness and apparently destroying epithelial lining of gastric pits at 0.28 mmol/kg, po using haematoxylin and eosin staining by light microscopic analysis",Other,23665142.0,
4093,753747,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as acute inflammatory cell infiltrating its whole thickness and apparently destroying surface of epithelium at 0.28 mmol/kg, po using haematoxylin and eosin staining by light microscopic analysis",Other,23665142.0,
4094,753748,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as capillary vasodilatation associated with accumulation of edema fluid in lamina propria at 0.28 mmol/kg, po using haematoxylin and eosin staining by light microscopic analysis",Other,23665142.0,
4095,753749,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as decreased in thickness with marked loss of mucosal membrane at areas of ulceration at 0.28 mmol/kg, po using haematoxylin and eosin staining by light microscopic analysis",Other,23665142.0,
4096,753750,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcer index at 0.28 mmol/kg, po (Rvb = 0.60 +/- 0.05)",Other,23665142.0,
4097,753751,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po after 5 hrs relative to control",Other,23665142.0,
4098,753752,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po after 4 hrs relative to control",Other,23665142.0,
4099,753753,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po after 3 hrs relative to control",Other,23665142.0,
4100,753754,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po after 2 hrs relative to control",Other,23665142.0,
4101,753755,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po after 1 hr relative to control",Other,23665142.0,
4102,755466,1,1,,103163840,3715,Active,,,28.42,IC50,Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent,Confirmatory,23688954.0,
4103,755664,1,1,,103163840,3715,Active,,,,,Cytotoxicity against mouse BV2 cells assessed as maximum non-toxic concentration after 24 hrs by MTT assay,Other,23711917.0,
4104,757491,2,3,,103163840,3715,Active,3914304.0,443460.0,0.48,IC50,Inhibition of ovine COX2,Confirmatory,23693150.0,
4105,757493,2,3,,103163840,3715,Active,754286265.0,443551.0,0.063,IC50,Inhibition of ovine COX1,Confirmatory,23693150.0,
4106,757494,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as ulcerogenic index at 60 mg/kg, po after 6 hrs relative to control",Other,23693150.0,
4107,757495,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw oedema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 5 hrs by plethysmometer relative to control",Other,23693150.0,
4108,757496,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced hind paw oedema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs by plethysmometer relative to control",Other,23693150.0,
4109,759376,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Wistar rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured at 4 hrs by plethysmometeric analysis relative to control",Other,23787438.0,
4110,759377,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Wistar rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured at 3 hrs by plethysmometeric analysis relative to control",Other,23787438.0,
4111,759378,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Wistar rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured at 2 hrs by plethysmometeric analysis relative to control",Other,23787438.0,
4112,759379,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Wistar rat assessed as inhibition of carrageenan-induced paw oedema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured at 1 hr post carrageenan challenge by plethysmometeric analysis relative to control",Other,23787438.0,
4113,762999,1,5,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 assessed as PGF2alpha production by reduction of PGH2 with stannous chloride at 40 uM by enzyme immunoassay relative to control,Other,23914900.0,
4114,763000,1,5,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as PGF2alpha production by reduction of PGH2 with stannous chloride at 40 uM by enzyme immunoassay relative to control,Other,23914900.0,
4115,763515,2,3,,103163840,3715,Unspecified,3914304.0,443460.0,30.0,IC50,Inhibition of ovine COX2 using arachidonic acid as substrate assessed as production of PGF2alpha preincubated for 10 mins followed by substrate addition measured after 2 mins by EIA in presence of stannous chloride,Confirmatory,23769654.0,
4116,763516,2,3,,103163840,3715,Active,754286265.0,443551.0,0.18,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate assessed as production of PGF2alpha preincubated for 10 mins followed by substrate addition measured after 2 mins by EIA in presence of stannous chloride,Confirmatory,23769654.0,
4117,763517,1,5,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 using arachidonic acid as substrate assessed as production of PGF2alpha at 30 uM preincubated for 10 mins followed by substrate addition measured after 2 mins by EIA in presence of stannous chloride relative to control,Other,23769654.0,
4118,763518,1,5,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 using arachidonic acid as substrate assessed as production of PGF2alpha at 30 uM preincubated for 10 mins followed by substrate addition measured after 2 mins by EIA in presence of stannous chloride relative to control,Other,23769654.0,
4119,763523,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered 30 mins prior to carrageenan challenge measured at 4 hrs by plethysmometric analysis relative to control",Other,23769654.0,
4120,763524,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered 30 mins prior to carrageenan challenge measured at 3 hrs by plethysmometric analysis relative to control",Other,23769654.0,
4121,763525,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered 30 mins prior to carrageenan challenge measured at 2 hrs by plethysmometric analysis relative to control",Other,23769654.0,
4122,763526,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered 30 mins prior to carrageenan challenge measured at 1 hr by plethysmometric analysis relative to control",Other,23769654.0,
4123,763777,1,1,,103163840,3715,Unspecified,,,,,Antinociceptive activity in Swiss albino mouse assessed as inhibition of formalin-induced flinching at 5 mg/kg administered 30 mins prior to test measured for 10 to 30 mins relative to control,Other,23807113.0,
4124,763778,1,1,,103163840,3715,Unspecified,,,,,Antinociceptive activity in Swiss albino mouse assessed as inhibition of formalin-induced flinching at 5 mg/kg administered 30 mins prior to test measured up to 5 mins relative to control,Other,23807113.0,
4125,763779,1,1,,103163840,3715,Unspecified,,,,,Antinociceptive activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing at 5 mg/kg administered 30 mins prior to acetic acid-challenge measured for 30 mins relative to control,Other,23807113.0,
4126,763783,1,1,,103163840,3715,Unspecified,,,,,Neurotoxicity in Swiss albino mouse assessed as minimal motor impairment at 300 mg/kg after 4 hrs by rotarod test,Other,23807113.0,
4127,763784,1,1,,103163840,3715,Unspecified,,,,,Neurotoxicity in Swiss albino mouse assessed as minimal motor impairment at 300 mg/kg after 0.5 hrs by rotarod test,Other,23807113.0,
4128,767618,1,1,,103163840,3715,Unspecified,,,,,Antinociceptive activity in po dosed Albino-Swiss mouse assessed as acetic acid-induced abdominal writhing compound administered 30 mins prior challenge measured over 30 mins post acetic acid challenge,Other,23953687.0,
4129,774820,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered 1 hr before carrageenan challenge measured at 4 hrs relative to control",Other,23993677.0,
4130,774821,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered 1 hr before carrageenan challenge measured at 3 hrs relative to control",Other,23993677.0,
4131,774822,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered 1 hr before carrageenan challenge measured at 2 hrs relative to control",Other,23993677.0,
4132,774823,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, ip administered 1 hr before carrageenan challenge measured at 1 hr relative to control",Other,23993677.0,
4133,775267,1,1,,103163840,3715,Active,,,7.1,IC50,Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay,Confirmatory,24042007.0,
4134,781326,1,2,,103163840,3715,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
4135,781329,1,2,,103163840,3715,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by other workers,Other,24249037.0,
4136,781330,1,2,,103163840,3715,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
4137,873009,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/9,Other,,
4138,873010,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/9,Other,,
4139,873011,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/9,Other,,
4140,873012,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/9,Other,,
4141,873013,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/9,Other,,
4142,873014,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/9,Other,,
4143,873015,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/9,Other,,
4144,873016,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/9,Other,,
4145,873017,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/9,Other,,
4146,873018,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/10,Other,,
4147,873019,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/10,Other,,
4148,873041,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/6,Other,,
4149,873042,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/6,Other,,
4150,873043,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/6,Other,,
4151,873044,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/6,Other,,
4152,873045,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/6,Other,,
4153,873046,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/6,Other,,
4154,873047,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/6,Other,,
4155,873048,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/6,Other,,
4156,873049,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/6,Other,,
4157,873050,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/6,Other,,
4158,873051,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/6,Other,,
4159,873052,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/6,Other,,
4160,873053,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/6,Other,,
4161,873054,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/7,Other,,
4162,873055,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/7,Other,,
4163,873056,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/7,Other,,
4164,873057,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/7,Other,,
4165,873058,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/7,Other,,
4166,873059,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/7,Other,,
4167,873060,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/7,Other,,
4168,873061,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/7,Other,,
4169,873062,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/7,Other,,
4170,873063,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/7,Other,,
4171,873064,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/7,Other,,
4172,873065,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/7,Other,,
4173,873704,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/10,Other,,
4174,873705,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/10,Other,,
4175,873706,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/10,Other,,
4176,873707,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/10,Other,,
4177,873708,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/10,Other,,
4178,873709,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/10,Other,,
4179,873710,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/10,Other,,
4180,873711,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/10,Other,,
4181,873712,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/10,Other,,
4182,873713,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/10,Other,,
4183,873714,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/10,Other,,
4184,873715,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/10,Other,,
4185,873716,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/10,Other,,
4186,873717,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/10,Other,,
4187,873718,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/10,Other,,
4188,873719,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/10,Other,,
4189,873720,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/10,Other,,
4190,873721,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/10,Other,,
4191,873722,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/10,Other,,
4192,873723,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/11,Other,,
4193,873724,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/11,Other,,
4194,873725,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/11,Other,,
4195,873726,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/11,Other,,
4196,873727,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/11,Other,,
4197,873728,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/11,Other,,
4198,873729,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/11,Other,,
4199,873730,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/11,Other,,
4200,873731,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/11,Other,,
4201,873732,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/11,Other,,
4202,873733,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/11,Other,,
4203,873734,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/11,Other,,
4204,873735,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/11,Other,,
4205,873736,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/11,Other,,
4206,873737,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/11,Other,,
4207,873738,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/11,Other,,
4208,873739,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/11,Other,,
4209,873740,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/11,Other,,
4210,873750,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/7,Other,,
4211,873751,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/7,Other,,
4212,873752,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/7,Other,,
4213,873753,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/7,Other,,
4214,873754,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/7,Other,,
4215,873755,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/7,Other,,
4216,873756,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/7,Other,,
4217,873757,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/7,Other,,
4218,873758,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/7,Other,,
4219,873759,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/8,Other,,
4220,873760,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/8,Other,,
4221,873761,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/8,Other,,
4222,873762,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/8,Other,,
4223,873763,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/8,Other,,
4224,873764,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/8,Other,,
4225,873765,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/8,Other,,
4226,873766,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/8,Other,,
4227,873767,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/8,Other,,
4228,873768,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/8,Other,,
4229,873769,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/8,Other,,
4230,873770,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/8,Other,,
4231,873771,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/8,Other,,
4232,873772,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/8,Other,,
4233,873806,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/15,Other,,
4234,873807,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/15,Other,,
4235,873808,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/15,Other,,
4236,873809,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/15,Other,,
4237,873810,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/15,Other,,
4238,873811,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/15,Other,,
4239,873812,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/15,Other,,
4240,873813,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/15,Other,,
4241,873814,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/15,Other,,
4242,873815,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/15,Other,,
4243,873816,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/16,Other,,
4244,873817,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/16,Other,,
4245,873818,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/16,Other,,
4246,873819,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/16,Other,,
4247,873820,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/16,Other,,
4248,873821,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/16,Other,,
4249,873822,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/16,Other,,
4250,873823,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/16,Other,,
4251,873824,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/16,Other,,
4252,873825,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/16,Other,,
4253,873826,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/16,Other,,
4254,873827,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/16,Other,,
4255,873828,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/16,Other,,
4256,873829,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/16,Other,,
4257,873830,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/16,Other,,
4258,873831,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/16,Other,,
4259,873832,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/16,Other,,
4260,873833,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/16,Other,,
4261,873834,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/16,Other,,
4262,873835,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/16,Other,,
4263,873836,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/16,Other,,
4264,873837,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/5,Other,,
4265,873838,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/5,Other,,
4266,873839,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/5,Other,,
4267,873840,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/5,Other,,
4268,873886,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/12,Other,,
4269,874523,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/5,Other,,
4270,874524,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/5,Other,,
4271,874525,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/5,Other,,
4272,874526,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/5,Other,,
4273,874527,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/5,Other,,
4274,874528,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/5,Other,,
4275,874529,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/5,Other,,
4276,874530,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/5,Other,,
4277,874531,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/5,Other,,
4278,874532,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/5,Other,,
4279,874533,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/5,Other,,
4280,874534,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/5,Other,,
4281,874535,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/5,Other,,
4282,874568,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/12,Other,,
4283,874569,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/12,Other,,
4284,874570,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/12,Other,,
4285,874571,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/12,Other,,
4286,874572,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/12,Other,,
4287,874573,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/12,Other,,
4288,874574,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/12,Other,,
4289,874575,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/12,Other,,
4290,874576,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/12,Other,,
4291,874577,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/13,Other,,
4292,874578,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/13,Other,,
4293,874579,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/13,Other,,
4294,874580,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/13,Other,,
4295,874581,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/13,Other,,
4296,874582,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/13,Other,,
4297,874583,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/13,Other,,
4298,874584,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/13,Other,,
4299,874585,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/13,Other,,
4300,874586,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/13,Other,,
4301,874587,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/13,Other,,
4302,874588,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/13,Other,,
4303,874589,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/13,Other,,
4304,874590,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/13,Other,,
4305,874591,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/13,Other,,
4306,874592,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/13,Other,,
4307,874593,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/13,Other,,
4308,874594,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/13,Other,,
4309,874595,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/13,Other,,
4310,874596,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/13,Other,,
4311,874597,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/13,Other,,
4312,874598,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/14,Other,,
4313,874599,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/14,Other,,
4314,874600,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/14,Other,,
4315,874601,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/14,Other,,
4316,874602,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/14,Other,,
4317,874603,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/14,Other,,
4318,874604,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/14,Other,,
4319,874605,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/14,Other,,
4320,874606,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/14,Other,,
4321,874607,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/14,Other,,
4322,874608,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/14,Other,,
4323,874609,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/14,Other,,
4324,874610,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/14,Other,,
4325,874611,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/14,Other,,
4326,874612,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/14,Other,,
4327,875295,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/14,Other,,
4328,875928,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/11,Other,,
4329,875929,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/11,Other,,
4330,875930,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/11,Other,,
4331,875960,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/8,Other,,
4332,875961,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/8,Other,,
4333,875962,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/8,Other,,
4334,875963,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/8,Other,,
4335,875964,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/8,Other,,
4336,875965,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/8,Other,,
4337,875966,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/8,Other,,
4338,875967,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/9,Other,,
4339,875968,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/9,Other,,
4340,875969,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/9,Other,,
4341,875970,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/9,Other,,
4342,875971,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/9,Other,,
4343,875972,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/9,Other,,
4344,875973,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/9,Other,,
4345,875974,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/9,Other,,
4346,875975,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/9,Other,,
4347,875976,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/9,Other,,
4348,876614,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/12,Other,,
4349,876615,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/12,Other,,
4350,876616,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/12,Other,,
4351,876617,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/12,Other,,
4352,876618,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/12,Other,,
4353,876619,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/12,Other,,
4354,876620,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/12,Other,,
4355,876621,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/12,Other,,
4356,876622,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/12,Other,,
4357,876623,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/12,Other,,
4358,876624,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/12,Other,,
4359,876625,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/12,Other,,
4360,876626,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/12,Other,,
4361,876627,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/12,Other,,
4362,876628,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/12,Other,,
4363,876629,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/12,Other,,
4364,876630,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/12,Other,,
4365,876631,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/12,Other,,
4366,876632,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/12,Other,,
4367,876633,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/12,Other,,
4368,876634,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/12,Other,,
4369,876635,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/13,Other,,
4370,876636,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/13,Other,,
4371,876637,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/13,Other,,
4372,876638,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/13,Other,,
4373,876639,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/13,Other,,
4374,876640,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/13,Other,,
4375,876641,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/13,Other,,
4376,876642,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/13,Other,,
4377,876643,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/13,Other,,
4378,876644,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/13,Other,,
4379,876645,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/13,Other,,
4380,876646,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/13,Other,,
4381,876647,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/13,Other,,
4382,876648,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/13,Other,,
4383,876649,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/13,Other,,
4384,876650,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/13,Other,,
4385,876651,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/13,Other,,
4386,876652,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/13,Other,,
4387,876653,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/13,Other,,
4388,876654,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/13,Other,,
4389,876655,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/13,Other,,
4390,876656,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/14,Other,,
4391,876657,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/14,Other,,
4392,876658,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/14,Other,,
4393,876660,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/9,Other,,
4394,876661,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/9,Other,,
4395,876662,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/9,Other,,
4396,876663,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/9,Other,,
4397,876664,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/9,Other,,
4398,876665,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/9,Other,,
4399,876666,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/9,Other,,
4400,876667,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/9,Other,,
4401,876668,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/9,Other,,
4402,876669,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/9,Other,,
4403,876670,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/9,Other,,
4404,876671,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/10,Other,,
4405,876672,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/10,Other,,
4406,876673,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/10,Other,,
4407,876674,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/10,Other,,
4408,876675,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/10,Other,,
4409,876676,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/10,Other,,
4410,876677,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/10,Other,,
4411,876678,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/10,Other,,
4412,876679,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/10,Other,,
4413,876680,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/10,Other,,
4414,876681,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/10,Other,,
4415,876682,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/10,Other,,
4416,876683,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/10,Other,,
4417,876684,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/10,Other,,
4418,876685,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/10,Other,,
4419,876686,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/10,Other,,
4420,876687,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/10,Other,,
4421,876688,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/10,Other,,
4422,876689,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/10,Other,,
4423,876690,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/10,Other,,
4424,876724,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/5,Other,,
4425,876725,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/5,Other,,
4426,876726,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/5,Other,,
4427,876727,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/5,Other,,
4428,876728,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/6,Other,,
4429,876729,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/6,Other,,
4430,876730,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/6,Other,,
4431,876731,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/6,Other,,
4432,876732,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/6,Other,,
4433,876733,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/6,Other,,
4434,876734,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/6,Other,,
4435,876735,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/6,Other,,
4436,876736,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/6,Other,,
4437,876737,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/6,Other,,
4438,876738,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/6,Other,,
4439,876739,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/6,Other,,
4440,876740,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/6,Other,,
4441,876741,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/6,Other,,
4442,876742,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/6,Other,,
4443,876743,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/6,Other,,
4444,876744,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/6,Other,,
4445,876745,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/6,Other,,
4446,876746,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/6,Other,,
4447,876747,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/6,Other,,
4448,876748,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/6,Other,,
4449,876749,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/7,Other,,
4450,877433,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/7,Other,,
4451,877434,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/7,Other,,
4452,877435,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/7,Other,,
4453,877436,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/7,Other,,
4454,877437,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/7,Other,,
4455,877438,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/7,Other,,
4456,877439,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/7,Other,,
4457,877440,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/7,Other,,
4458,877441,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/7,Other,,
4459,877442,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/7,Other,,
4460,877443,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/7,Other,,
4461,877444,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/7,Other,,
4462,877445,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/7,Other,,
4463,877446,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/7,Other,,
4464,877447,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/7,Other,,
4465,877448,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/7,Other,,
4466,877449,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/7,Other,,
4467,877450,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/7,Other,,
4468,877451,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/7,Other,,
4469,877452,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/7,Other,,
4470,877453,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/8,Other,,
4471,877486,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/14,Other,,
4472,877487,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/14,Other,,
4473,877488,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/14,Other,,
4474,877489,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/14,Other,,
4475,877490,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/14,Other,,
4476,877491,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/15,Other,,
4477,877492,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/15,Other,,
4478,877493,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/15,Other,,
4479,877494,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/15,Other,,
4480,877495,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/15,Other,,
4481,877496,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/15,Other,,
4482,877497,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/15,Other,,
4483,877498,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/15,Other,,
4484,877499,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/15,Other,,
4485,877500,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/15,Other,,
4486,877501,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/15,Other,,
4487,877502,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/15,Other,,
4488,877503,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/15,Other,,
4489,877504,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/15,Other,,
4490,877505,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/15,Other,,
4491,877506,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/15,Other,,
4492,877507,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/15,Other,,
4493,877508,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/15,Other,,
4494,877509,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/15,Other,,
4495,877510,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/15,Other,,
4496,877511,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/15,Other,,
4497,877512,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/16,Other,,
4498,877513,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/16,Other,,
4499,877514,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/16,Other,,
4500,877515,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/16,Other,,
4501,877516,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/16,Other,,
4502,877517,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/16,Other,,
4503,877518,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/16,Other,,
4504,877519,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/16,Other,,
4505,877520,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/16,Other,,
4506,877521,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/16,Other,,
4507,877522,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/16,Other,,
4508,877523,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/16,Other,,
4509,878204,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/16,Other,,
4510,878205,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/16,Other,,
4511,878206,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/16,Other,,
4512,878207,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/16,Other,,
4513,878208,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/16,Other,,
4514,878209,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/16,Other,,
4515,878210,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/16,Other,,
4516,878211,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/16,Other,,
4517,878212,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/16,Other,,
4518,878768,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/5,Other,,
4519,878769,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/5,Other,,
4520,878770,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/5,Other,,
4521,878771,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/5,Other,,
4522,878772,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/5,Other,,
4523,878773,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/5,Other,,
4524,878774,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/5,Other,,
4525,878775,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/5,Other,,
4526,878776,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/5,Other,,
4527,878777,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/5,Other,,
4528,878778,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/5,Other,,
4529,878779,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/5,Other,,
4530,878780,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/5,Other,,
4531,878781,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/5,Other,,
4532,878782,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/5,Other,,
4533,878783,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/5,Other,,
4534,878784,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/5,Other,,
4535,878785,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/5,Other,,
4536,878786,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/5,Other,,
4537,878787,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/5,Other,,
4538,878788,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/5,Other,,
4539,878789,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/6,Other,,
4540,878790,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/6,Other,,
4541,878791,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/6,Other,,
4542,878792,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/6,Other,,
4543,878793,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/6,Other,,
4544,878794,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/6,Other,,
4545,878795,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/6,Other,,
4546,878879,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/10,Other,,
4547,878880,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/11,Other,,
4548,878881,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/11,Other,,
4549,878882,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/11,Other,,
4550,878883,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/11,Other,,
4551,878884,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/11,Other,,
4552,878885,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/11,Other,,
4553,878886,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/11,Other,,
4554,879480,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/6,Other,,
4555,879481,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/6,Other,,
4556,879482,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/6,Other,,
4557,879483,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/6,Other,,
4558,879484,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/6,Other,,
4559,879485,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/6,Other,,
4560,879486,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/6,Other,,
4561,879487,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/6,Other,,
4562,879488,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/6,Other,,
4563,879489,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/6,Other,,
4564,879490,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/6,Other,,
4565,879491,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/6,Other,,
4566,879492,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/6,Other,,
4567,879493,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/6,Other,,
4568,879494,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/7,Other,,
4569,879495,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/7,Other,,
4570,879496,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/7,Other,,
4571,879497,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/7,Other,,
4572,879498,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/7,Other,,
4573,879499,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/7,Other,,
4574,879532,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/14,Other,,
4575,879533,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/14,Other,,
4576,879534,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/14,Other,,
4577,879535,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/14,Other,,
4578,879536,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/14,Other,,
4579,879537,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/14,Other,,
4580,879538,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/14,Other,,
4581,879539,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/14,Other,,
4582,879540,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/14,Other,,
4583,879541,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/14,Other,,
4584,879542,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/14,Other,,
4585,879543,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/14,Other,,
4586,879544,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/14,Other,,
4587,879545,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/14,Other,,
4588,879546,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/14,Other,,
4589,879547,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/14,Other,,
4590,879548,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/14,Other,,
4591,879549,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/14,Other,,
4592,879550,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/15,Other,,
4593,879551,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/15,Other,,
4594,879552,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/15,Other,,
4595,879553,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/15,Other,,
4596,879554,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/15,Other,,
4597,879555,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/15,Other,,
4598,879556,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/15,Other,,
4599,879557,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/15,Other,,
4600,879558,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/15,Other,,
4601,879559,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/15,Other,,
4602,879560,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/15,Other,,
4603,879561,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/15,Other,,
4604,879562,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/15,Other,,
4605,879563,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/15,Other,,
4606,879564,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/15,Other,,
4607,879565,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/15,Other,,
4608,879566,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/15,Other,,
4609,879567,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/15,Other,,
4610,879568,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/15,Other,,
4611,879569,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/15,Other,,
4612,879570,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/15,Other,,
4613,879571,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/16,Other,,
4614,879572,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/11,Other,,
4615,879573,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/11,Other,,
4616,879574,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/11,Other,,
4617,879575,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/11,Other,,
4618,879576,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/11,Other,,
4619,879577,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/11,Other,,
4620,879578,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/11,Other,,
4621,879579,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/11,Other,,
4622,879580,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/11,Other,,
4623,879581,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/11,Other,,
4624,879582,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/11,Other,,
4625,879583,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/11,Other,,
4626,879584,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/11,Other,,
4627,879585,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/11,Other,,
4628,879586,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/12,Other,,
4629,879587,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/12,Other,,
4630,879588,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/12,Other,,
4631,879589,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/12,Other,,
4632,879590,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/12,Other,,
4633,879591,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/12,Other,,
4634,879592,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/12,Other,,
4635,879593,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/12,Other,,
4636,879594,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/12,Other,,
4637,879595,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/12,Other,,
4638,879596,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/12,Other,,
4639,879597,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/12,Other,,
4640,879598,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/12,Other,,
4641,879599,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/12,Other,,
4642,879600,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/12,Other,,
4643,879601,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/12,Other,,
4644,879602,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/12,Other,,
4645,879603,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/12,Other,,
4646,879604,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/12,Other,,
4647,879605,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/12,Other,,
4648,879606,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/12,Other,,
4649,879607,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/13,Other,,
4650,879608,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/13,Other,,
4651,879609,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/13,Other,,
4652,879610,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/13,Other,,
4653,879611,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/13,Other,,
4654,879644,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/8,Other,,
4655,879645,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/8,Other,,
4656,879646,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/8,Other,,
4657,879647,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/8,Other,,
4658,879648,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/8,Other,,
4659,879649,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/8,Other,,
4660,879650,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/8,Other,,
4661,879651,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/8,Other,,
4662,879652,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/8,Other,,
4663,879653,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/8,Other,,
4664,879654,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/8,Other,,
4665,879655,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/8,Other,,
4666,879656,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/8,Other,,
4667,879657,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/8,Other,,
4668,879658,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/8,Other,,
4669,879659,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/8,Other,,
4670,879660,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/8,Other,,
4671,879661,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/8,Other,,
4672,880253,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/16,Other,,
4673,880254,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/16,Other,,
4674,880255,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/16,Other,,
4675,880256,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/16,Other,,
4676,880257,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/16,Other,,
4677,880258,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/16,Other,,
4678,880259,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/16,Other,,
4679,880260,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/16,Other,,
4680,880343,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/8,Other,,
4681,880344,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/8,Other,,
4682,880345,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/9,Other,,
4683,880346,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/9,Other,,
4684,880347,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/9,Other,,
4685,880348,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/9,Other,,
4686,880349,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/9,Other,,
4687,880350,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/9,Other,,
4688,880351,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/9,Other,,
4689,880352,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/9,Other,,
4690,880353,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/9,Other,,
4691,880354,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/9,Other,,
4692,880355,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/9,Other,,
4693,880356,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/9,Other,,
4694,880357,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/9,Other,,
4695,880358,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/9,Other,,
4696,880359,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/9,Other,,
4697,880360,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/9,Other,,
4698,880361,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/9,Other,,
4699,880362,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/9,Other,,
4700,880363,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/9,Other,,
4701,880364,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/9,Other,,
4702,880365,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/9,Other,,
4703,880366,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/10,Other,,
4704,880367,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/10,Other,,
4705,880368,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/10,Other,,
4706,880369,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/10,Other,,
4707,880370,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/10,Other,,
4708,880371,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/10,Other,,
4709,881688,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/7,Other,,
4710,881689,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/7,Other,,
4711,881690,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/7,Other,,
4712,881691,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/7,Other,,
4713,881692,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/7,Other,,
4714,881693,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/7,Other,,
4715,881694,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/7,Other,,
4716,881695,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/7,Other,,
4717,881696,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/7,Other,,
4718,881697,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/7,Other,,
4719,881698,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/7,Other,,
4720,881699,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/7,Other,,
4721,881700,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/7,Other,,
4722,881701,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/7,Other,,
4723,881702,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/7,Other,,
4724,881703,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/8,Other,,
4725,881704,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/8,Other,,
4726,881705,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/8,Other,,
4727,881706,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/8,Other,,
4728,881707,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/8,Other,,
4729,881739,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/5,Other,,
4730,881740,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/5,Other,,
4731,881741,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/5,Other,,
4732,881742,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/5,Other,,
4733,881743,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/5,Other,,
4734,881744,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/5,Other,,
4735,881745,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/5,Other,,
4736,881746,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/5,Other,,
4737,881747,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/5,Other,,
4738,881748,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/5,Other,,
4739,881749,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/5,Other,,
4740,881750,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/5,Other,,
4741,881751,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/5,Other,,
4742,881752,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/5,Other,,
4743,881753,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/5,Other,,
4744,882391,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/8,Other,,
4745,882392,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/8,Other,,
4746,882393,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/8,Other,,
4747,882394,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/8,Other,,
4748,882395,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/8,Other,,
4749,882396,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/8,Other,,
4750,882397,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/8,Other,,
4751,882398,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/8,Other,,
4752,882399,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/8,Other,,
4753,882400,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/8,Other,,
4754,882401,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/8,Other,,
4755,882402,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/8,Other,,
4756,882403,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/8,Other,,
4757,882404,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/8,Other,,
4758,882405,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/8,Other,,
4759,882406,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/8,Other,,
4760,882407,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 631/9,Other,,
4761,882408,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 631/9,Other,,
4762,882409,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 631/9,Other,,
4763,882410,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 631/9,Other,,
4764,882411,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 631/9,Other,,
4765,882412,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 631/9,Other,,
4766,882413,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 631/9,Other,,
4767,882414,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 631/9,Other,,
4768,882415,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 631/9,Other,,
4769,882416,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/9,Other,,
4770,882417,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/9,Other,,
4771,882418,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/9,Other,,
4772,882437,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/5,Other,,
4773,882438,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/5,Other,,
4774,882439,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/5,Other,,
4775,882440,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/5,Other,,
4776,882441,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/5,Other,,
4777,882442,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/5,Other,,
4778,882443,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/6,Other,,
4779,882444,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/6,Other,,
4780,882445,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/6,Other,,
4781,882446,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/6,Other,,
4782,882447,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/6,Other,,
4783,882448,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/6,Other,,
4784,882449,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/6,Other,,
4785,882450,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/6,Other,,
4786,882451,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 631/16,Other,,
4787,882452,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 631/16,Other,,
4788,882453,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 631/16,Other,,
4789,882454,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 631/16,Other,,
4790,882455,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 631/16,Other,,
4791,882456,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 631/16,Other,,
4792,882457,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 631/16,Other,,
4793,882458,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 631/16,Other,,
4794,882459,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 631/16,Other,,
4795,882460,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 631/16,Other,,
4796,882461,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 631/16,Other,,
4797,882462,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 631/16,Other,,
4798,882485,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/13,Other,,
4799,882486,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/13,Other,,
4800,882487,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/13,Other,,
4801,882488,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/13,Other,,
4802,882489,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/13,Other,,
4803,882490,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/13,Other,,
4804,882491,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/13,Other,,
4805,882492,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/13,Other,,
4806,882493,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/13,Other,,
4807,882494,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/13,Other,,
4808,882495,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/13,Other,,
4809,882496,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/13,Other,,
4810,882497,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/13,Other,,
4811,882498,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/13,Other,,
4812,882499,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/13,Other,,
4813,882500,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/13,Other,,
4814,882501,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/14,Other,,
4815,882502,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/14,Other,,
4816,882503,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/14,Other,,
4817,882504,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/14,Other,,
4818,882505,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/14,Other,,
4819,882506,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/14,Other,,
4820,882507,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/14,Other,,
4821,882508,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/14,Other,,
4822,882509,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/14,Other,,
4823,882510,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/14,Other,,
4824,882511,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/14,Other,,
4825,882512,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 112/14,Other,,
4826,882513,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 112/14,Other,,
4827,882514,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 112/14,Other,,
4828,882515,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 112/14,Other,,
4829,882516,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 112/14,Other,,
4830,882517,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 112/14,Other,,
4831,882518,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 112/14,Other,,
4832,882519,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 112/14,Other,,
4833,882520,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 112/14,Other,,
4834,882521,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 112/14,Other,,
4835,882522,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 112/15,Other,,
4836,882523,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 112/15,Other,,
4837,882524,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 112/15,Other,,
4838,882525,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 112/15,Other,,
4839,882526,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 112/15,Other,,
4840,882527,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 112/15,Other,,
4841,882528,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 112/15,Other,,
4842,882565,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/10,Other,,
4843,882566,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/10,Other,,
4844,882567,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/10,Other,,
4845,882568,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/10,Other,,
4846,882569,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/10,Other,,
4847,882570,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/10,Other,,
4848,882571,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/10,Other,,
4849,882572,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/10,Other,,
4850,882573,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/10,Other,,
4851,883210,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 112/15,Other,,
4852,883211,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 112/15,Other,,
4853,883212,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 112/15,Other,,
4854,883213,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 112/15,Other,,
4855,883255,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/10,Other,,
4856,883256,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/10,Other,,
4857,883257,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/10,Other,,
4858,883258,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/10,Other,,
4859,883259,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/10,Other,,
4860,883260,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/10,Other,,
4861,883261,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/11,Other,,
4862,883262,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/11,Other,,
4863,883263,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/11,Other,,
4864,883264,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/11,Other,,
4865,883265,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/11,Other,,
4866,883266,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/11,Other,,
4867,883267,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/11,Other,,
4868,883268,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/11,Other,,
4869,883269,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/11,Other,,
4870,883270,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/11,Other,,
4871,883271,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/11,Other,,
4872,883272,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 113/11,Other,,
4873,883273,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 113/11,Other,,
4874,883274,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 113/11,Other,,
4875,883275,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 113/11,Other,,
4876,883276,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 113/11,Other,,
4877,883277,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 113/11,Other,,
4878,883278,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 113/11,Other,,
4879,883279,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 113/11,Other,,
4880,883280,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 113/11,Other,,
4881,883281,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 113/11,Other,,
4882,883282,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 113/12,Other,,
4883,883283,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 113/12,Other,,
4884,883284,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 113/12,Other,,
4885,883285,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 113/12,Other,,
4886,883286,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 113/12,Other,,
4887,883287,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 113/12,Other,,
4888,883288,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 113/12,Other,,
4889,883289,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 113/12,Other,,
4890,883290,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 113/12,Other,,
4891,883291,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 113/12,Other,,
4892,883292,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 113/12,Other,,
4893,929027,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011204,Other,,
4894,929028,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011204,Other,,
4895,929029,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011204,Other,,
4896,929030,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011204,Other,,
4897,929031,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011204,Other,,
4898,929032,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011204,Other,,
4899,929033,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011204,Other,,
4900,929034,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011204,Other,,
4901,929035,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011204,Other,,
4902,929036,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011204,Other,,
4903,929037,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011204,Other,,
4904,929038,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011204,Other,,
4905,929039,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011204,Other,,
4906,929040,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011204,Other,,
4907,929041,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011204",Other,,
4908,929042,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011204,Other,,
4909,929043,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011204,Other,,
4910,929044,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011204,Other,,
4911,929045,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011204,Other,,
4912,930510,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
4913,930511,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
4914,930512,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
4915,930513,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
4916,930514,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
4917,930515,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
4918,932531,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
4919,932532,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
4920,932533,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
4921,932534,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
4922,932535,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
4923,932536,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
4924,932537,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
4925,932538,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
4926,932539,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
4927,932554,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
4928,932555,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
4929,932556,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
4930,932557,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
4931,932558,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
4932,932559,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
4933,932560,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
4934,933190,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
4935,933191,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
4936,933192,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
4937,933193,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
4938,933194,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
4939,933195,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
4940,933196,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
4941,933197,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
4942,933198,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
4943,933199,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
4944,933200,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
4945,933201,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
4946,934861,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
4947,934862,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
4948,935492,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
4949,935493,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
4950,935494,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
4951,935495,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
4952,935496,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
4953,935497,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
4954,935498,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
4955,935499,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
4956,935500,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
4957,935501,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
4958,935502,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
4959,935503,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
4960,935504,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
4961,935505,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
4962,935506,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
4963,935507,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
4964,935508,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
4965,938508,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
4966,938509,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
4967,938510,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
4968,938511,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
4969,938707,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: XXB040712,Other,,
4970,938708,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: XXB040712,Other,,
4971,938709,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: XXB040712,Other,,
4972,938710,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: XXB040712,Other,,
4973,938711,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: XXB040712,Other,,
4974,938712,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: XXB040712,Other,,
4975,938713,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: XXB040712,Other,,
4976,938714,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: XXB040712,Other,,
4977,938715,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: XXB040712,Other,,
4978,938716,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: XXB040712,Other,,
4979,938717,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: XXB040712,Other,,
4980,938718,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: XXB040712,Other,,
4981,938719,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: XXB040712,Other,,
4982,938720,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: XXB040712,Other,,
4983,938721,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: XXB040712,Other,,
4984,939352,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: XXB040712,Other,,
4985,941305,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011009,Other,,
4986,941306,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011009,Other,,
4987,941307,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011009,Other,,
4988,941308,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011009,Other,,
4989,941309,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011009,Other,,
4990,941310,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011009,Other,,
4991,941311,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011009,Other,,
4992,941312,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011009",Other,,
4993,941313,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011009,Other,,
4994,941314,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011009,Other,,
4995,941315,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011009,Other,,
4996,941316,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011009,Other,,
4997,941317,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011009,Other,,
4998,941318,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011009,Other,,
4999,941319,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011009,Other,,
5000,941320,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011009,Other,,
5001,941951,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011009,Other,,
5002,941952,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011009,Other,,
5003,943972,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011009,Other,,
5004,946882,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011204,Other,,
5005,946883,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011204",Other,,
5006,946884,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011204,Other,,
5007,946885,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011204,Other,,
5008,946886,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011204,Other,,
5009,946887,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011204,Other,,
5010,946888,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011204,Other,,
5011,946889,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011204,Other,,
5012,946890,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011204,Other,,
5013,946891,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011204,Other,,
5014,946892,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011204,Other,,
5015,946893,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011204,Other,,
5016,946894,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011204,Other,,
5017,946895,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011204,Other,,
5018,946896,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011204,Other,,
5019,946897,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011204,Other,,
5020,946898,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011204,Other,,
5021,946899,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011204,Other,,
5022,946900,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011204,Other,,
5023,952392,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
5024,952393,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
5025,952394,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
5026,952395,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
5027,952396,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
5028,952397,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
5029,952398,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
5030,952399,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
5031,952400,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
5032,952401,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
5033,952402,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
5034,952403,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
5035,952404,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
5036,952405,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
5037,952406,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
5038,952407,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
5039,952408,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
5040,952409,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
5041,952410,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
5042,957393,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: XXB040712,Other,,
5043,957394,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: XXB040712,Other,,
5044,959260,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: XXB040712,Other,,
5045,959261,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: XXB040712,Other,,
5046,959262,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: XXB040712,Other,,
5047,959263,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: XXB040712,Other,,
5048,959264,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: XXB040712,Other,,
5049,959265,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: XXB040712,Other,,
5050,959266,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: XXB040712,Other,,
5051,959267,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: XXB040712,Other,,
5052,959268,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: XXB040712,Other,,
5053,959269,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: XXB040712,Other,,
5054,959270,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: XXB040712,Other,,
5055,959271,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: XXB040712,Other,,
5056,959272,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: XXB040712,Other,,
5057,963883,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011204,Other,,
5058,963884,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011204,Other,,
5059,963885,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011204,Other,,
5060,963886,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011204,Other,,
5061,963887,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011204,Other,,
5062,963888,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011204,Other,,
5063,964083,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011204,Other,,
5064,965412,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011204,Other,,
5065,965413,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011204,Other,,
5066,965414,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011204,Other,,
5067,965415,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011204,Other,,
5068,965416,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011204,Other,,
5069,965417,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011204,Other,,
5070,965418,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011204,Other,,
5071,965419,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011204,Other,,
5072,965420,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011204,Other,,
5073,965421,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011204,Other,,
5074,965422,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011204,Other,,
5075,965423,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011204,Other,,
5076,965424,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011204,Other,,
5077,965425,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011204,Other,,
5078,965426,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011204,Other,,
5079,965427,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011204,Other,,
5080,965685,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011204,Other,,
5081,965686,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011204,Other,,
5082,965687,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011204,Other,,
5083,965688,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011204,Other,,
5084,965689,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011204,Other,,
5085,965690,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011204,Other,,
5086,965691,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011204,Other,,
5087,965692,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011204,Other,,
5088,965693,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011204,Other,,
5089,965694,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011204,Other,,
5090,965695,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011204,Other,,
5091,965696,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011204,Other,,
5092,965697,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011204,Other,,
5093,965861,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011204,Other,,
5094,965862,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011204,Other,,
5095,967881,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
5096,967882,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
5097,967883,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
5098,967884,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
5099,967885,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
5100,967886,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
5101,967887,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
5102,967888,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
5103,967889,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
5104,967890,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
5105,967891,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
5106,967892,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
5107,967893,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
5108,968524,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
5109,968525,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
5110,968526,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
5111,968866,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
5112,968867,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
5113,968868,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
5114,968869,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
5115,968870,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
5116,968871,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
5117,968872,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
5118,968873,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
5119,968874,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
5120,968875,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
5121,968876,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
5122,968877,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
5123,968878,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
5124,968879,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
5125,968880,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
5126,968881,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
5127,968882,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
5128,968883,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
5129,968884,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
5130,971565,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011009,Other,,
5131,971566,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011009,Other,,
5132,971567,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011009,Other,,
5133,971568,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011009,Other,,
5134,971569,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011009,Other,,
5135,971570,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
5136,971571,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
5137,971572,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011009,Other,,
5138,971573,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011009,Other,,
5139,971574,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011009,Other,,
5140,971575,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011009,Other,,
5141,971576,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011009,Other,,
5142,971577,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
5143,971578,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011009,Other,,
5144,971579,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011009,Other,,
5145,971580,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011009,Other,,
5146,971581,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011009,Other,,
5147,971582,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011009,Other,,
5148,971583,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011009,Other,,
5149,976570,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011009,Other,,
5150,976571,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011009,Other,,
5151,976572,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011009,Other,,
5152,977599,1,1,,103163840,3715,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
5153,977602,1,2,,103163840,3715,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
5154,977608,3,1,,46393715,3715,Active,67464376.0,,1000.0,IC50,Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,Other,15854652.0,
5155,977610,3,1,,208013925,3715,Active,,,18.0,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,23857942.0,
5156,996768,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011204",Other,,
5157,996769,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011204",Other,,
5158,996770,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011204",Other,,
5159,996771,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011204,Other,,
5160,996772,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011204",Other,,
5161,996773,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5162,996774,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5163,996775,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5164,996776,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011204",Other,,
5165,996777,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011204",Other,,
5166,996778,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011204,Other,,
5167,996779,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5168,996780,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011204",Other,,
5169,996781,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011204",Other,,
5170,996782,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011204",Other,,
5171,996783,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011204",Other,,
5172,996784,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5173,996785,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5174,996786,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011204",Other,,
5175,996787,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011204",Other,,
5176,996788,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011204",Other,,
5177,996902,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5178,996903,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011009",Other,,
5179,996904,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011009,Other,,
5180,996905,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5181,997371,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011204",Other,,
5182,997372,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011204",Other,,
5183,997373,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011204",Other,,
5184,997374,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011204",Other,,
5185,997375,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011204",Other,,
5186,997376,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011204,Other,,
5187,997377,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5188,997378,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011204",Other,,
5189,997379,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011204",Other,,
5190,997380,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011204",Other,,
5191,997381,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011204,Other,,
5192,997382,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5193,997383,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011204",Other,,
5194,997384,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5195,997385,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5196,997386,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5197,997387,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011204",Other,,
5198,997388,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011204",Other,,
5199,997389,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011204,Other,,
5200,997390,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5201,997391,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011204",Other,,
5202,997489,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011009",Other,,
5203,997490,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011009",Other,,
5204,997491,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011009",Other,,
5205,997492,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5206,997493,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5207,997494,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011009",Other,,
5208,997495,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011009",Other,,
5209,997496,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011009",Other,,
5210,997497,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011009",Other,,
5211,997498,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011009",Other,,
5212,997499,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011009",Other,,
5213,997500,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011009",Other,,
5214,997501,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011009",Other,,
5215,997502,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011009",Other,,
5216,997503,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011009,Other,,
5217,997504,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5218,997505,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011009",Other,,
5219,997506,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011009",Other,,
5220,997507,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011009",Other,,
5221,997508,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011009,Other,,
5222,997509,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5223,997510,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011009",Other,,
5224,997511,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5225,997512,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5226,997513,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5227,997514,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011009",Other,,
5228,997515,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011009",Other,,
5229,997516,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011009,Other,,
5230,997517,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5231,997518,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011009",Other,,
5232,997519,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011009",Other,,
5233,997520,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011009",Other,,
5234,997521,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5235,997522,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011009",Other,,
5236,997523,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011009",Other,,
5237,997524,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011009",Other,,
5238,997525,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011009",Other,,
5239,999251,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011204",Other,,
5240,999252,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011204",Other,,
5241,999253,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5242,999254,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5243,999255,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011204",Other,,
5244,999256,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011204",Other,,
5245,999257,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011204",Other,,
5246,999258,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011204",Other,,
5247,999259,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011204,Other,,
5248,999260,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011204",Other,,
5249,999261,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011204,Other,,
5250,999262,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011204",Other,,
5251,999263,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5252,999264,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011204",Other,,
5253,999265,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011204",Other,,
5254,999847,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5255,999848,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011204",Other,,
5256,999849,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5257,999850,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011204",Other,,
5258,999851,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011204",Other,,
5259,999852,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011204",Other,,
5260,999853,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011204,Other,,
5261,999854,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5262,999855,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5263,999856,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5264,999857,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5265,999858,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5266,999859,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5267,999860,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011204",Other,,
5268,999861,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5269,999862,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5270,999863,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011204",Other,,
5271,999864,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5272,999865,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011204",Other,,
5273,999866,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011204",Other,,
5274,999867,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011204",Other,,
5275,999868,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011204,Other,,
5276,999869,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011204,Other,,
5277,999870,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011204",Other,,
5278,999871,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5279,999872,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5280,999965,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Epithelial Atrophy; Study_ID: S011009,Other,,
5281,999966,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011009,Other,,
5282,999967,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011009",Other,,
5283,999968,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011009,Other,,
5284,999969,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011009",Other,,
5285,999970,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5286,999971,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011009",Other,,
5287,999972,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011009",Other,,
5288,999973,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5289,999974,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011009",Other,,
5290,999975,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5291,999976,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011009",Other,,
5292,999977,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011009",Other,,
5293,999978,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5294,999979,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011009",Other,,
5295,999980,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011009,Other,,
5296,999981,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5297,999982,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5298,999983,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5299,999984,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5300,999985,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5301,999986,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5302,999987,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011009",Other,,
5303,999988,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5304,999989,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5305,999990,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011009",Other,,
5306,999991,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5307,999992,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011009",Other,,
5308,999993,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011009",Other,,
5309,999994,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011009",Other,,
5310,999995,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011009,Other,,
5311,999996,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011009,Other,,
5312,999997,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011009",Other,,
5313,999998,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5314,999999,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5315,1000000,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011009",Other,,
5316,1000001,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011009",Other,,
5317,1000002,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011009",Other,,
5318,1000582,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011009",Other,,
5319,1000583,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011009",Other,,
5320,1001671,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011009,Other,,
5321,1001672,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011009",Other,,
5322,1001673,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5323,1001674,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5324,1001675,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011009",Other,,
5325,1001676,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011009,Other,,
5326,1001677,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5327,1001678,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011009",Other,,
5328,1001679,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011009",Other,,
5329,1001680,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011009",Other,,
5330,1001681,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011009",Other,,
5331,1001682,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5332,1001683,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5333,1001684,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011009",Other,,
5334,1001685,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011009",Other,,
5335,1001686,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011009",Other,,
5336,1001687,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011009",Other,,
5337,1001688,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011009",Other,,
5338,1001689,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011009",Other,,
5339,1001690,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Villus Tip Fusion; Study_ID: S011009,Other,,
5340,1001691,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011009",Other,,
5341,1001692,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011009",Other,,
5342,1001693,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011009,Other,,
5343,1001694,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5344,1001695,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011009",Other,,
5345,1001696,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011009",Other,,
5346,1001697,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011009",Other,,
5347,1001698,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Peritonitis; Study_ID: S011009,Other,,
5348,1001699,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011009,Other,,
5349,1001700,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5350,1001701,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011009",Other,,
5351,1001702,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5352,1001732,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011204",Other,,
5353,1001733,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011204",Other,,
5354,1001734,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011204",Other,,
5355,1001735,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011204",Other,,
5356,1001736,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011204",Other,,
5357,1001737,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011204,Other,,
5358,1001738,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011204",Other,,
5359,1001739,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5360,1001740,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5361,1001741,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5362,1002283,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5363,1002284,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5364,1002285,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5365,1002286,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011009",Other,,
5366,1002287,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011009",Other,,
5367,1002288,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011204,Other,,
5368,1002289,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5369,1002290,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011204",Other,,
5370,1002291,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011204",Other,,
5371,1002321,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011204",Other,,
5372,1002322,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011204,Other,,
5373,1002323,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5374,1002324,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011204",Other,,
5375,1002325,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011204",Other,,
5376,1002326,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011204",Other,,
5377,1002327,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011204",Other,,
5378,1002328,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011204",Other,,
5379,1002329,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5380,1002330,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5381,1002331,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011204",Other,,
5382,1002332,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011204",Other,,
5383,1002333,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011204",Other,,
5384,1002334,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011204",Other,,
5385,1002335,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011204",Other,,
5386,1002336,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011204",Other,,
5387,1002337,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011204",Other,,
5388,1002338,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011204",Other,,
5389,1002339,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011204,Other,,
5390,1002340,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5391,1002341,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011204",Other,,
5392,1002342,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011204",Other,,
5393,1002343,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011204,Other,,
5394,1002344,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5395,1002345,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011204",Other,,
5396,1002346,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5397,1002347,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5398,1002348,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5399,1002349,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011204",Other,,
5400,1002350,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011204",Other,,
5401,1002414,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011009,Other,,
5402,1002415,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5403,1002416,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011009",Other,,
5404,1002417,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011009",Other,,
5405,1002418,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011009",Other,,
5406,1002419,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5407,1002420,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5408,1002421,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011009",Other,,
5409,1002422,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011009",Other,,
5410,1002423,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011009",Other,,
5411,1002424,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011009",Other,,
5412,1002425,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011009,Other,,
5413,1002426,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011009",Other,,
5414,1004163,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5415,1004164,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011204",Other,,
5416,1004165,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011204",Other,,
5417,1004166,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011204",Other,,
5418,1004167,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011204",Other,,
5419,1004168,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011204,Other,,
5420,1004169,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011204",Other,,
5421,1004170,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011204,Other,,
5422,1004171,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011204",Other,,
5423,1004172,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5424,1004173,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011204",Other,,
5425,1004174,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011204",Other,,
5426,1004175,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5427,1004176,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011204",Other,,
5428,1004177,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5429,1004178,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011204",Other,,
5430,1004179,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011204",Other,,
5431,1004180,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5432,1004181,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011204",Other,,
5433,1004182,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011204,Other,,
5434,1004183,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5435,1004184,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5436,1004185,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5437,1004186,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5438,1004187,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5439,1004188,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5440,1004298,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011009,Other,,
5441,1004299,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011009",Other,,
5442,1004300,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5443,1004301,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011009",Other,,
5444,1004302,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011009",Other,,
5445,1004303,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5446,1004304,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011009",Other,,
5447,1004305,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5448,1004770,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011204",Other,,
5449,1004771,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5450,1004772,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5451,1004773,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011204",Other,,
5452,1004774,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5453,1004775,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011204",Other,,
5454,1004776,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011204",Other,,
5455,1004777,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011204",Other,,
5456,1004778,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011204,Other,,
5457,1004779,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011204,Other,,
5458,1004780,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011204",Other,,
5459,1004781,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5460,1004782,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5461,1004783,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011204",Other,,
5462,1004784,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011204",Other,,
5463,1004887,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011009",Other,,
5464,1004888,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011009",Other,,
5465,1004889,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5466,1004890,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5467,1004891,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011009",Other,,
5468,1004892,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011009,Other,,
5469,1004893,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5470,1004894,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5471,1004895,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5472,1004896,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5473,1004897,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5474,1004898,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5475,1004899,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011009",Other,,
5476,1004900,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5477,1004901,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5478,1004902,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011009",Other,,
5479,1004903,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5480,1004904,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011009",Other,,
5481,1004905,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011009",Other,,
5482,1004906,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011009",Other,,
5483,1004907,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011009,Other,,
5484,1004908,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011009,Other,,
5485,1004909,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011009",Other,,
5486,1004910,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011009",Other,,
5487,1004911,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011009",Other,,
5488,1004912,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011009",Other,,
5489,1004913,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011009",Other,,
5490,1004914,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011009",Other,,
5491,1004915,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011009,Other,,
5492,1004916,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011009",Other,,
5493,1004917,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5494,1004918,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5495,1005432,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011009",Other,,
5496,1005433,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011009",Other,,
5497,1005434,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5498,1005435,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5499,1005436,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011009",Other,,
5500,1005437,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011009",Other,,
5501,1005438,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011009",Other,,
5502,1005439,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011009",Other,,
5503,1005440,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011009,Other,,
5504,1005441,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011009",Other,,
5505,1005442,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011009,Other,,
5506,1005443,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011009",Other,,
5507,1005444,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5508,1005445,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011009",Other,,
5509,1005446,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011009",Other,,
5510,1005447,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5511,1005448,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011009",Other,,
5512,1005449,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5513,1005450,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011009",Other,,
5514,1005451,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011009",Other,,
5515,1005452,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5516,1005453,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011009",Other,,
5517,1005454,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011009,Other,,
5518,1005455,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5519,1005456,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5520,1005457,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5521,1005458,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5522,1005459,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5523,1005460,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5524,1005461,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011009",Other,,
5525,1005462,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5526,1005463,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5527,1005464,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011009",Other,,
5528,1005465,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5529,1005466,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011009",Other,,
5530,1005467,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011009",Other,,
5531,1006050,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011009",Other,,
5532,1006051,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011009,Other,,
5533,1006052,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011009,Other,,
5534,1006053,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011009",Other,,
5535,1007887,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011009,Other,,
5536,1007888,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5537,1007889,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011009",Other,,
5538,1007890,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011009",Other,,
5539,1007891,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011009",Other,,
5540,1007912,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5541,1007913,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011009",Other,,
5542,1007914,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011009",Other,,
5543,1007915,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011009",Other,,
5544,1007916,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011009",Other,,
5545,1007917,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011009",Other,,
5546,1007918,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011009,Other,,
5547,1007919,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011009",Other,,
5548,1007920,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5549,1007921,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5550,1007922,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5551,1007923,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011009",Other,,
5552,1007924,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011009,Other,,
5553,1007925,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5554,1007926,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011009",Other,,
5555,1007927,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011009",Other,,
5556,1007928,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011009",Other,,
5557,1007929,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011009",Other,,
5558,1007930,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5559,1007931,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5560,1007932,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011009",Other,,
5561,1007933,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011009",Other,,
5562,1007934,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011009",Other,,
5563,1007935,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011009",Other,,
5564,1007936,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011009",Other,,
5565,1007937,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011009",Other,,
5566,1007938,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011009",Other,,
5567,1007939,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011009",Other,,
5568,1007940,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011009,Other,,
5569,1007941,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5570,1007942,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011009",Other,,
5571,1007943,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011009",Other,,
5572,1008528,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011009",Other,,
5573,1008529,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011009,Other,,
5574,1008530,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5575,1008531,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011009",Other,,
5576,1008532,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5577,1008533,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5578,1008534,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5579,1008535,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011009",Other,,
5580,1008536,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011009",Other,,
5581,1009760,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5582,1009761,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011009",Other,,
5583,1009762,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011009",Other,,
5584,1009763,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011009",Other,,
5585,1009764,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011009",Other,,
5586,1009765,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011009",Other,,
5587,1009766,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011009,Other,,
5588,1009767,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011009",Other,,
5589,1010349,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011009,Other,,
5590,1010350,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011009",Other,,
5591,1010351,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5592,1010352,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011009",Other,,
5593,1010353,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011009",Other,,
5594,1010354,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011009",Other,,
5595,1010355,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5596,1010356,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011009",Other,,
5597,1010357,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011009",Other,,
5598,1010358,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5599,1010359,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011009",Other,,
5600,1010360,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011009,Other,,
5601,1010361,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5602,1010362,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5603,1010363,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5604,1010364,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5605,1010365,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5606,1010366,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5607,1010367,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011009",Other,,
5608,1010368,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5609,1010369,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5610,1010370,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011009",Other,,
5611,1010371,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5612,1010372,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011009",Other,,
5613,1010373,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011009",Other,,
5614,1010374,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011009",Other,,
5615,1010375,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011009,Other,,
5616,1010376,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011009,Other,,
5617,1010377,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011009",Other,,
5618,1010378,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5619,1010379,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5620,1010380,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011009",Other,,
5621,1010381,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011009",Other,,
5622,1012250,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011009",Other,,
5623,1012251,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011009",Other,,
5624,1012833,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011009",Other,,
5625,1012834,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011009,Other,,
5626,1012835,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5627,1012836,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5628,1012837,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5629,1012838,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011009",Other,,
5630,1012839,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011009,Other,,
5631,1012840,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5632,1012841,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5633,1012842,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011009",Other,,
5634,1012843,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011009",Other,,
5635,1012844,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011009",Other,,
5636,1012845,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011009",Other,,
5637,1012846,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5638,1012847,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5639,1012848,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011009",Other,,
5640,1012849,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011009",Other,,
5641,1012850,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011009",Other,,
5642,1012851,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011009",Other,,
5643,1012852,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011009",Other,,
5644,1012853,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011009",Other,,
5645,1012854,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011009",Other,,
5646,1012855,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011009",Other,,
5647,1012856,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011009,Other,,
5648,1012857,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5649,1012858,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011009",Other,,
5650,1012859,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011009",Other,,
5651,1012860,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011009",Other,,
5652,1012861,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011009,Other,,
5653,1012862,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5654,1012863,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011009",Other,,
5655,1012864,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5656,1012865,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5657,1012866,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5658,1012867,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011009",Other,,
5659,1012868,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011009",Other,,
5660,1012869,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011009,Other,,
5661,1012870,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5662,1012871,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011009",Other,,
5663,1017735,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011009,Other,,
5664,1017736,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5665,1017737,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011009",Other,,
5666,1019607,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011009",Other,,
5667,1019608,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011009",Other,,
5668,1019609,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5669,1019610,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011009",Other,,
5670,1019611,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011009",Other,,
5671,1019612,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011009",Other,,
5672,1019613,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011009",Other,,
5673,1019614,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011009,Other,,
5674,1019615,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011009",Other,,
5675,1019616,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011009,Other,,
5676,1019617,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011009",Other,,
5677,1019618,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5678,1019619,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011009",Other,,
5679,1019620,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011009",Other,,
5680,1019621,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5681,1019622,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011009",Other,,
5682,1019623,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5683,1019624,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011009",Other,,
5684,1019625,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011009",Other,,
5685,1019626,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5686,1019627,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011009",Other,,
5687,1019628,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011009,Other,,
5688,1019629,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5689,1019630,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5690,1019631,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5691,1019632,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5692,1019633,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5693,1019634,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5694,1020219,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011009",Other,,
5695,1020220,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5696,1020221,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011009",Other,,
5697,1020222,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5698,1020223,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011009",Other,,
5699,1020224,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011009",Other,,
5700,1020225,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011009",Other,,
5701,1020226,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011009,Other,,
5702,1020227,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011009,Other,,
5703,1020228,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011009",Other,,
5704,1020229,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5705,1020230,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5706,1022098,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011009",Other,,
5707,1022099,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011009",Other,,
5708,1022100,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011009",Other,,
5709,1022101,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011009",Other,,
5710,1022102,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011009",Other,,
5711,1022103,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011009,Other,,
5712,1022104,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011009",Other,,
5713,1022105,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5714,1022106,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5715,1022107,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011009",Other,,
5716,1022108,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011009,Other,,
5717,1022109,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011009",Other,,
5718,1022110,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011009",Other,,
5719,1022111,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011009",Other,,
5720,1022112,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011009",Other,,
5721,1022113,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011009",Other,,
5722,1022114,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011009",Other,,
5723,1022115,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5724,1022116,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011009",Other,,
5725,1022117,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011009",Other,,
5726,1022118,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011009",Other,,
5727,1022119,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011009",Other,,
5728,1022120,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011009",Other,,
5729,1022121,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011009",Other,,
5730,1022705,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011009",Other,,
5731,1022706,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011009",Other,,
5732,1022707,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011009",Other,,
5733,1022708,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011009,Other,,
5734,1022709,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011009",Other,,
5735,1022710,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011009",Other,,
5736,1022711,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011009",Other,,
5737,1022712,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011009",Other,,
5738,1022713,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011009,Other,,
5739,1022714,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5740,1022715,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011009",Other,,
5741,1022716,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011009",Other,,
5742,1022717,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011009",Other,,
5743,1022718,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5744,1022719,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011009",Other,,
5745,1022720,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011009",Other,,
5746,1022721,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011009",Other,,
5747,1028265,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011204,Other,,
5748,1028266,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5749,1030138,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011204",Other,,
5750,1030139,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011204",Other,,
5751,1030140,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5752,1030141,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011204",Other,,
5753,1030142,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011204",Other,,
5754,1030143,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011204",Other,,
5755,1030144,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011204",Other,,
5756,1030145,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011204,Other,,
5757,1030146,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011204",Other,,
5758,1030147,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011204,Other,,
5759,1030148,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011204",Other,,
5760,1030149,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5761,1030150,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011204",Other,,
5762,1030442,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011204,Other,,
5763,1030443,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5764,1030444,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011204",Other,,
5765,1030445,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011204",Other,,
5766,1030446,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011204",Other,,
5767,1030447,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5768,1030448,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5769,1030449,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011204",Other,,
5770,1030450,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011204",Other,,
5771,1030451,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011204",Other,,
5772,1030452,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011204",Other,,
5773,1030453,1,4,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Nuclear Proliferation; Study_ID: S011204",Other,,
5774,1030454,1,4,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: S011204",Other,,
5775,1030455,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011204,Other,,
5776,1030456,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011204",Other,,
5777,1030457,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011204,Other,,
5778,1030458,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5779,1030459,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011204",Other,,
5780,1030460,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011204",Other,,
5781,1030461,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011204",Other,,
5782,1030734,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011204",Other,,
5783,1030735,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5784,1030736,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011204",Other,,
5785,1030737,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5786,1030738,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011204",Other,,
5787,1030739,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011204",Other,,
5788,1030740,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5789,1030741,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011204",Other,,
5790,1030742,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011204,Other,,
5791,1030743,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5792,1030744,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5793,1030745,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5794,1030746,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5795,1030747,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5796,1030748,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011204",Other,,
5797,1030749,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5798,1030750,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5799,1030751,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011204",Other,,
5800,1030752,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5801,1030753,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011204",Other,,
5802,1030754,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011204",Other,,
5803,1030755,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011204",Other,,
5804,1030756,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011204,Other,,
5805,1030757,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011204,Other,,
5806,1030758,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011204",Other,,
5807,1030759,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011204",Other,,
5808,1030760,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5809,1031045,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5810,1032629,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5811,1032630,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011204",Other,,
5812,1032631,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011204",Other,,
5813,1032632,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011204",Other,,
5814,1032633,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011204",Other,,
5815,1032634,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011204",Other,,
5816,1032635,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011204,Other,,
5817,1032636,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011204",Other,,
5818,1032915,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011204",Other,,
5819,1032916,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011204",Other,,
5820,1032917,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011204",Other,,
5821,1032918,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011204,Other,,
5822,1032919,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5823,1032920,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5824,1032921,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5825,1032922,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5826,1032923,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5827,1032924,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5828,1032925,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011204",Other,,
5829,1032926,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5830,1032927,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011204",Other,,
5831,1032928,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011204",Other,,
5832,1032929,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5833,1032930,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011204",Other,,
5834,1032931,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011204",Other,,
5835,1032932,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011204",Other,,
5836,1032933,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011204,Other,,
5837,1032934,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011204,Other,,
5838,1032935,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011204",Other,,
5839,1032936,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5840,1032937,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5841,1032938,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5842,1032939,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011204",Other,,
5843,1032940,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011204",Other,,
5844,1032941,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011204",Other,,
5845,1032942,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011204",Other,,
5846,1032943,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011204",Other,,
5847,1032944,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011204,Other,,
5848,1032945,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011204",Other,,
5849,1032946,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5850,1032947,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5851,1032948,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011204",Other,,
5852,1033221,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5853,1033222,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5854,1033223,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5855,1033224,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5856,1033225,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011204",Other,,
5857,1033226,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011204,Other,,
5858,1033227,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5859,1033228,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011204",Other,,
5860,1033229,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011204",Other,,
5861,1033230,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011204",Other,,
5862,1033231,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011204",Other,,
5863,1033232,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5864,1033233,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5865,1033234,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011204",Other,,
5866,1033235,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011204",Other,,
5867,1033236,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011204",Other,,
5868,1033237,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011204",Other,,
5869,1033238,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011204",Other,,
5870,1033239,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011204",Other,,
5871,1033240,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011204",Other,,
5872,1033241,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011204",Other,,
5873,1033242,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011204,Other,,
5874,1033243,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5875,1033244,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011204",Other,,
5876,1033245,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011204",Other,,
5877,1033246,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011204",Other,,
5878,1033247,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011204,Other,,
5879,1033248,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5880,1033249,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011204",Other,,
5881,1033250,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5882,1033251,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5883,1033252,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5884,1033253,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011204",Other,,
5885,1033531,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011204,Other,,
5886,1033532,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5887,1033533,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011204",Other,,
5888,1033534,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011204",Other,,
5889,1033535,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011204",Other,,
5890,1033536,1,4,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: S011204",Other,,
5891,1034631,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011204",Other,,
5892,1034632,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011204",Other,,
5893,1034633,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011204",Other,,
5894,1034634,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011204",Other,,
5895,1034635,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011204",Other,,
5896,1034636,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011204",Other,,
5897,1034637,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011204",Other,,
5898,1034638,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011204",Other,,
5899,1034639,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011204",Other,,
5900,1034640,1,4,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: S011204",Other,,
5901,1034641,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011204",Other,,
5902,1034642,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011204",Other,,
5903,1034643,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011204",Other,,
5904,1034644,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011204,Other,,
5905,1034645,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011204",Other,,
5906,1034646,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011204",Other,,
5907,1034647,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011204",Other,,
5908,1034648,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011204",Other,,
5909,1034649,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011204",Other,,
5910,1034650,1,3,,103163840,3715,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011204,Other,,
5911,1034651,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5912,1034652,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011204",Other,,
5913,1034653,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011204",Other,,
5914,1034654,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5915,1034655,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011204",Other,,
5916,1034932,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011204",Other,,
5917,1035237,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011204",Other,,
5918,1035238,1,3,,103163840,3715,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M3; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011204",Other,,
5919,1049945,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/15,Other,,
5920,1049946,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/15,Other,,
5921,1049947,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/15,Other,,
5922,1049948,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/15,Other,,
5923,1049949,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/16,Other,,
5924,1049950,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/16,Other,,
5925,1049951,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/16,Other,,
5926,1049952,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/16,Other,,
5927,1049953,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/16,Other,,
5928,1049954,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/5,Other,,
5929,1049955,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/5,Other,,
5930,1049956,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/5,Other,,
5931,1049957,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/5,Other,,
5932,1049958,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/5,Other,,
5933,1049959,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/6,Other,,
5934,1049960,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/6,Other,,
5935,1049961,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/6,Other,,
5936,1049962,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/6,Other,,
5937,1049963,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/6,Other,,
5938,1049964,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/7,Other,,
5939,1049965,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/7,Other,,
5940,1049966,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/7,Other,,
5941,1049967,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/7,Other,,
5942,1049968,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/7,Other,,
5943,1049969,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/8,Other,,
5944,1049970,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/8,Other,,
5945,1049971,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/8,Other,,
5946,1049972,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/8,Other,,
5947,1049973,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/8,Other,,
5948,1049974,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/9,Other,,
5949,1049975,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/9,Other,,
5950,1049976,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/9,Other,,
5951,1049977,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/9,Other,,
5952,1049978,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/9,Other,,
5953,1049979,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/10,Other,,
5954,1049980,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/10,Other,,
5955,1049981,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/10,Other,,
5956,1049982,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/10,Other,,
5957,1049983,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/10,Other,,
5958,1050195,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/11,Other,,
5959,1050196,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/11,Other,,
5960,1050197,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/11,Other,,
5961,1050198,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/11,Other,,
5962,1050199,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/12,Other,,
5963,1050200,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/12,Other,,
5964,1050201,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/12,Other,,
5965,1050202,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/11,Other,,
5966,1050966,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/5,Other,,
5967,1050967,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/5,Other,,
5968,1051190,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/5,Other,,
5969,1051191,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/5,Other,,
5970,1051192,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/5,Other,,
5971,1051193,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/6,Other,,
5972,1051194,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/6,Other,,
5973,1051195,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/6,Other,,
5974,1051196,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/6,Other,,
5975,1051197,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/6,Other,,
5976,1051198,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/7,Other,,
5977,1051199,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/7,Other,,
5978,1051200,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/7,Other,,
5979,1051201,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/7,Other,,
5980,1051202,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/7,Other,,
5981,1051203,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/8,Other,,
5982,1051204,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/8,Other,,
5983,1051205,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/8,Other,,
5984,1051698,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/12,Other,,
5985,1051699,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/12,Other,,
5986,1051700,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/13,Other,,
5987,1051701,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/13,Other,,
5988,1051702,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/13,Other,,
5989,1051703,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/13,Other,,
5990,1051704,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/13,Other,,
5991,1051705,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/14,Other,,
5992,1051706,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/14,Other,,
5993,1051707,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/14,Other,,
5994,1051708,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/14,Other,,
5995,1051917,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/14,Other,,
5996,1051918,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/15,Other,,
5997,1051919,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/15,Other,,
5998,1051920,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/15,Other,,
5999,1051921,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/15,Other,,
6000,1051922,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/15,Other,,
6001,1051923,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 631/16,Other,,
6002,1051924,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 631/16,Other,,
6003,1051925,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 631/16,Other,,
6004,1051926,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 631/16,Other,,
6005,1051927,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 631/16,Other,,
6006,1051974,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/6,Other,,
6007,1051975,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/6,Other,,
6008,1051976,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/6,Other,,
6009,1051977,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/6,Other,,
6010,1051978,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/6,Other,,
6011,1051979,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/7,Other,,
6012,1051980,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/7,Other,,
6013,1051981,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/7,Other,,
6014,1051982,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/7,Other,,
6015,1051983,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/7,Other,,
6016,1051984,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/8,Other,,
6017,1051985,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/8,Other,,
6018,1051986,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/8,Other,,
6019,1051987,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/8,Other,,
6020,1051988,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/8,Other,,
6021,1051989,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/9,Other,,
6022,1051990,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/9,Other,,
6023,1051991,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/9,Other,,
6024,1051992,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/9,Other,,
6025,1051993,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/9,Other,,
6026,1051994,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/10,Other,,
6027,1051995,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/10,Other,,
6028,1051996,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/10,Other,,
6029,1051997,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/10,Other,,
6030,1052221,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/10,Other,,
6031,1052222,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/11,Other,,
6032,1052223,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/11,Other,,
6033,1052224,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/11,Other,,
6034,1052225,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/11,Other,,
6035,1052226,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/11,Other,,
6036,1052227,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/12,Other,,
6037,1052228,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/12,Other,,
6038,1052229,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/12,Other,,
6039,1052230,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/12,Other,,
6040,1052231,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/12,Other,,
6041,1052232,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/13,Other,,
6042,1052233,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/13,Other,,
6043,1052234,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/13,Other,,
6044,1052235,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/13,Other,,
6045,1052236,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/13,Other,,
6046,1052237,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/14,Other,,
6047,1052238,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/14,Other,,
6048,1052239,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/14,Other,,
6049,1052240,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/14,Other,,
6050,1052241,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/14,Other,,
6051,1052242,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/15,Other,,
6052,1052736,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/8,Other,,
6053,1052737,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/8,Other,,
6054,1052738,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/9,Other,,
6055,1052981,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/9,Other,,
6056,1052982,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/9,Other,,
6057,1052983,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/9,Other,,
6058,1052984,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/9,Other,,
6059,1052985,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/10,Other,,
6060,1052986,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/10,Other,,
6061,1052987,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/10,Other,,
6062,1052988,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/10,Other,,
6063,1052989,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/10,Other,,
6064,1052990,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/11,Other,,
6065,1052991,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/11,Other,,
6066,1052992,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/11,Other,,
6067,1052993,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/11,Other,,
6068,1052994,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/11,Other,,
6069,1052995,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/12,Other,,
6070,1052996,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/12,Other,,
6071,1052997,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/12,Other,,
6072,1052998,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/12,Other,,
6073,1052999,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/12,Other,,
6074,1053000,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/13,Other,,
6075,1053001,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/13,Other,,
6076,1053002,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/13,Other,,
6077,1053003,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/13,Other,,
6078,1053004,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/13,Other,,
6079,1053005,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/14,Other,,
6080,1053006,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/14,Other,,
6081,1053007,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/14,Other,,
6082,1053008,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/14,Other,,
6083,1053009,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/14,Other,,
6084,1053010,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/15,Other,,
6085,1053011,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/15,Other,,
6086,1053012,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/15,Other,,
6087,1053013,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/15,Other,,
6088,1053014,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/15,Other,,
6089,1053015,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 112/16,Other,,
6090,1053016,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 112/16,Other,,
6091,1053017,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 112/16,Other,,
6092,1053018,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 112/16,Other,,
6093,1053019,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 112/16,Other,,
6094,1053020,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 113/5,Other,,
6095,1053021,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 113/5,Other,,
6096,1053022,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 113/5,Other,,
6097,1053023,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 113/5,Other,,
6098,1053024,1,2,,103163840,3715,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 113/5,Other,,
6099,1053175,2,1,,178127330,3715,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
6100,1053197,1,1,,56422212,3715,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
6101,1055537,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 4 hrs by plethysmometer",Other,24177361.0,
6102,1055538,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs by plethysmometer",Other,24177361.0,
6103,1055539,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 2 hrs by plethysmometer",Other,24177361.0,
6104,1055540,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as reduction in carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 1 hr by plethysmometer",Other,24177361.0,
6105,1055825,1,2,,103163840,3715,Unspecified,,,,,"Ulcerogenicity in albino Wistar rat assessed as gastric muscular layer damage at 0.15 mmol/kg, po by hematoxylin and eosin staining-based assay",Other,24211633.0,
6106,1055826,1,2,,103163840,3715,Unspecified,,,,,"Ulcerogenicity in albino Wistar rat assessed as gastric deep mucosal damage at 0.15 mmol/kg, po by hematoxylin and eosin staining-based assay",Other,24211633.0,
6107,1055827,1,2,,103163840,3715,Unspecified,,,,,"Ulcerogenicity in albino Wistar rat assessed as gastric superficial mucosal damage at 0.15 mmol/kg, po by hematoxylin and eosin staining-based assay",Other,24211633.0,
6108,1055828,1,2,,103163840,3715,Unspecified,,,,,"Ulcerogenicity in albino Wistar rat assessed as gastric surface epithelial damage at 0.15 mmol/kg, po by hematoxylin and eosin staining-based assay",Other,24211633.0,
6109,1055829,1,2,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in albino Wistar rat assessed as thermal-stimulus induced tail flick latency at 0.05 mmol/kg, po after 120 mins (Rvb = 2.38 +/- 0.11 mins)",Other,24211633.0,
6110,1055830,1,2,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in albino Wistar rat assessed as thermal-stimulus induced tail flick latency at 0.05 mmol/kg, po after 60 mins (Rvb = 2.54 +/- 0.05 mins)",Other,24211633.0,
6111,1055831,1,2,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in albino Wistar rat assessed as thermal-stimulus induced tail flick latency at 0.05 mmol/kg, po after 30 mins (Rvb = 2.22 +/- 0.20 mins)",Other,24211633.0,
6112,1055832,1,2,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in mouse assessed as inhibition of acetic acid-induced writhing at 0.05 mmol/kg, po administered 30 mins prior to acetic acid-challenge measured after 20 mins relative to control",Other,24211633.0,
6113,1055833,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in macrophages (unknown origin) assessed as inhibition of TNF-alpha secretion incubated for 2 hrs by ELISA relative to control,Other,24211633.0,
6114,1055835,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Wistar rat assessed as inhibition of carrageenan-induced hind paw edema at 0.05 mmol/kg, po administered 1 hr prior to carrageenan challenge measured after 5 hrs by plethysmometric analysis relative to control",Other,24211633.0,
6115,1055836,1,2,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino Wistar rat assessed as inhibition of carrageenan-induced hind paw edema at 0.05 mmol/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hrs by plethysmometric analysis relative to control",Other,24211633.0,
6116,1057592,1,4,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 using arachidonic acid as substrate at 10 uM incubated 5 mins prior to substrate addition measured after 5 mins by HPLC analysis,Other,24171493.0,
6117,1057593,1,4,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 using arachidonic acid as substrate at 10 uM incubated 5 mins prior to substrate addition measured after 5 mins by HPLC analysis,Other,24171493.0,
6118,1060436,1,2,,103163840,3715,Active,,,29.6,IC50,Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method,Confirmatory,24268542.0,
6119,1060437,1,1,,103163840,3715,Inconclusive,,,,,"Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for human KB-3-1 cells",Other,24268542.0,
6120,1060438,1,1,,103163840,3715,Inconclusive,,,,IC50,Cytotoxicity against human KB-3-1 cells assessed as cell survival after 24 hrs by MTT assay,Confirmatory,24268542.0,
6121,1060439,1,2,,103163840,3715,Unspecified,,,100.0,IC50,Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay,Confirmatory,24268542.0,
6122,1061772,1,1,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,24332492.0,
6123,1061773,2,3,,103163840,3715,Active,754286265.0,443551.0,0.08,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate incubated for 10 mins prior to substrate addition measured after 2 mins by spectrophotometry,Confirmatory,24332492.0,
6124,1061774,2,3,,103163840,3715,Active,3915797.0,5743.0,0.96,IC50,Inhibition of human recombinant COX2 using arachidonic acid as substrate incubated for 10 mins prior to substrate addition measured after 2 mins by spectrophotometry,Confirmatory,24332492.0,
6125,1062918,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan-challenge measured after 1 hr relative to control",Other,24308998.0,
6126,1062919,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan-challenge measured after 2 hrs relative to control",Other,24308998.0,
6127,1062920,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan-challenge measured after 3 hrs relative to control",Other,24308998.0,
6128,1062921,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan-challenge measured after 4 hrs relative to control",Other,24308998.0,
6129,1062922,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan-challenge measured after 5 hrs relative to control",Other,24308998.0,
6130,1062923,1,1,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in albino rat carrageenan-induced paw edema model assessed as ulcer index at 0.28 mmol/kg, po (Rvb = 0.60 +/- 0.05)",Other,24308998.0,
6131,1062924,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat carrageenan-induced paw edema model assessed as decrease in thickness of gastric mucosa with marked loss of mucosal membrane at areas of ulceration at 0.28 mmol/kg, po by hematoxylin and eosin staining-based light microscopic analysis",Other,24308998.0,
6132,1062925,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat carrageenan-induced paw edema model assessed as capillary vasodilatation of lamina propria associated with accumulation of edema fluid at 0.28 mmol/kg, po by hematoxylin and eosin staining-based light microscopic analysis",Other,24308998.0,
6133,1062926,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat carrageenan-induced paw edema model assessed as acute inflammatory cell infiltrating its whole thickness at 0.28 mmol/kg, po by hematoxylin and eosin staining-based light microscopic analysis",Other,24308998.0,
6134,1062927,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat carrageenan-induced paw edema model assessed as destruction of surface epithelium and epithelial lining of gastric pits at 0.28 mmol/kg, po by hematoxylin and eosin staining-based light microscopic analysis",Other,24308998.0,
6135,1062928,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat carrageenan-induced paw edema model assessed as severe atrophic gastritis and gland atrophy at 0.28 mmol/kg, po by hematoxylin and eosin staining-based light microscopic analysis",Other,24308998.0,
6136,1062929,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in albino rat carrageenan-induced paw edema model assessed as apoptotic glandular epithelial cells at 0.28 mmol/kg, po by hematoxylin and eosin staining-based light microscopic analysis",Other,24308998.0,
6137,1063316,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 release at 10 uM treated 2 hrs before LPS challenge measured by ELISA,Other,24333613.0,
6138,1063317,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha release at 10 uM treated 2 hrs before LPS challenge measured by ELISA,Other,24333613.0,
6139,1063318,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 release at 10 uM treated 2 hrs before LPS challenge measured after 24 hrs by ELISA (Rvb = 45.1 +/- 5.6 pg/ml),Other,24333613.0,
6140,1063319,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 release at 10 uM treated 2 hrs before LPS challenge measured after 12 hrs by ELISA (Rvb = 13.9 +/- 2.6 pg/ml),Other,24333613.0,
6141,1063320,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 release at 10 uM treated 2 hrs before LPS challenge measured after 6 hrs by ELISA (Rvb = 7.2 +/- 0.9 pg/ml),Other,24333613.0,
6142,1063321,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha release at 10 uM treated 2 hrs before LPS challenge measured after 24 hrs by ELISA (Rvb = 38.3 +/- 3.3 pg/ml),Other,24333613.0,
6143,1063322,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha release at 10 uM treated 2 hrs before LPS challenge measured after 12 hrs by ELISA (Rvb = 11.8 +/- 1.2 pg/ml),Other,24333613.0,
6144,1063323,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha release at 10 uM treated 2 hrs before LPS challenge measured after 6 hrs by ELISA (Rvb = 5.9 +/- 0.5 pg/ml),Other,24333613.0,
6145,1063325,1,2,,103163840,3715,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay relative to control,Other,24333613.0,
6146,1063326,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release at 10 uM treated 2 hrs before LPS challenge measured after 48 hrs by Griess assay relative to control,Other,24333613.0,
6147,1063660,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as change in carrageenan-induced hind paw thickness at 5 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 1 hr (Rvb = 1.84 +/- 0.41 mm)",Other,24361187.0,
6148,1063661,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as change in carrageenan-induced hind paw thickness at 5 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 2 hrs (Rvb = 1.86 +/- 0.38 mm)",Other,24361187.0,
6149,1063662,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as change in carrageenan-induced hind paw thickness at 5 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 3 hrs (Rvb = 1.78 +/- 0.39 mm)",Other,24361187.0,
6150,1063665,1,1,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in Swiss albino mouse assessed as licking time in primary neurogenic period at 5 mg/kg, ip administered 30 mins prior to formalin-challenge (Rvb = 80 +/- 19 seconds)",Other,24361187.0,
6151,1063668,1,1,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in Swiss albino mouse assessed as licking time in secondary inflammatory period at 5 mg/kg, ip administered 30 mins prior to formalin-challenge (Rvb = 217 +/- 68.5 seconds)",Other,24361187.0,
6152,1067405,1,4,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 50 uM by peroxidase activity-based colorimetric assay,Other,24531199.0,
6153,1067406,2,3,,103163840,3715,Active,3914304.0,443460.0,4.2,IC50,Inhibition of ovine COX2 by peroxidase activity-based colorimetric assay,Confirmatory,24531199.0,
6154,1067407,2,3,,103163840,3715,Active,754286265.0,443551.0,0.099,IC50,Inhibition of ovine COX1 by peroxidase activity-based colorimetric assay,Confirmatory,24531199.0,
6155,1067408,1,4,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 50 uM by peroxidase activity-based colorimetric assay,Other,24531199.0,
6156,1079931,1,1,,103163840,3715,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
6157,1079932,1,1,,103163840,3715,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
6158,1079933,1,1,,103163840,3715,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
6159,1079934,1,1,,103163840,3715,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
6160,1079935,1,1,,103163840,3715,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
6161,1079936,1,1,,103163840,3715,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
6162,1079937,1,1,,103163840,3715,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
6163,1079938,1,1,,103163840,3715,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
6164,1079939,1,1,,103163840,3715,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
6165,1079940,1,1,,103163840,3715,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
6166,1079941,1,1,,103163840,3715,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
6167,1079942,1,1,,103163840,3715,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
6168,1079943,1,1,,103163840,3715,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
6169,1079944,1,1,,103163840,3715,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
6170,1079945,1,1,,103163840,3715,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
6171,1079946,1,1,,103163840,3715,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
6172,1079947,1,1,,103163840,3715,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
6173,1079948,1,1,,103163840,3715,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
6174,1079949,1,1,,103163840,3715,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
6175,1083253,1,2,,103163840,3715,Unspecified,,,,,"Induction of lipid peroxidation in fasted Rattus norvegicus Wistar (rat) assessed as malondialdehyde level per 100 mg gastric mucosal tissue at 60 mg/kg, po measured after 17 hr by thiobarbuteric acid method",Other,,
6176,1083254,1,2,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in fasted Rattus norvegicus Wistar (rat) assessed as ulcer index at 60 mg/kg, po measured after 17 hr",Other,,
6177,1083256,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min prior to carrageenan-induced measured after 3 hr relative to control",Other,,
6178,1083257,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min prior to carrageenan-induced measured after 2 hr relative to control",Other,,
6179,1083473,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hr",Other,,
6180,1084020,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in in Mus musculus BALB/c (mouse) assessed as behavioral changes at 50 to 200 mg/kg, po after 72 hr",Other,,
6181,1084021,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in in Mus musculus BALB/c (mouse) assessed as mortality at 50 to 200 mg/kg, po after 72 hr",Other,,
6182,1084024,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus BALB/c (mouse) assessed as inhibition of carrageenan-induced paw swelling at 10 mg/kg, po administered 1 hr followed by carrageenan challenge measured at 360 min relative to control",Other,,
6183,1084028,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus BALB/c (mouse) assessed as inhibition of carrageenan-induced paw swelling at 10 mg/kg, po administered 1 hr followed by carrageenan challenge measured at 270 min relative to control",Other,,
6184,1084032,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus BALB/c (mouse) assessed as inhibition of carrageenan-induced paw swelling at 10 mg/kg, po administered 1 hr followed by carrageenan challenge measured at 180 min relative to control",Other,,
6185,1084036,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus BALB/c (mouse) assessed as inhibition of carrageenan-induced paw swelling at 10 mg/kg, po administered 1 hr followed by carrageenan challenge measured at 90 min relative to control",Other,,
6186,1084293,1,2,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus Wistar (rat) assessed as ulcer index at 20 mg/kg, po measured after 17 hr",Other,,
6187,1084296,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity against Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip measured 4 hr after carrageenan challenge by plethysmometer",Other,,
6188,1084298,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity against Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip measured 3 hr after carrageenan challenge by plethysmometer",Other,,
6189,1084580,1,4,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of Ovis aries (sheep) COX2 at 5 uM by colorimetric analysis,Other,,
6190,1084581,1,4,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of Ovis aries (sheep) COX1 at 0.1 uM by colorimetric analysis,Other,,
6191,1084595,1,3,,103163840,3715,Unspecified,,,,,"Antiulcerogenic activity in fasted Rattus norvegicus Sprague-Dawley (rat) stomach assessed as ulcer index at 48 mg/kg, po after 8 hr (Rvb = 0.23 +/- 0.09)",Other,,
6192,1084603,1,2,,103163840,3715,Unspecified,,,,,"Analgesic activity in Rattus norvegicus Sprague-Dawley (rat) assessed as inhibition of acetic acid-induced abdominal writhing at 10 mg/kg, po measured for 20 min relative to vehicle-treated control",Other,,
6193,1084611,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Sprague-Dawley (rat) assessed as increase in carrageenan-induced paw edema at 12 mg/kg, po measured at 4 hr by plethysmometer (Rvb = 81.58 +/- 0.63 %)",Other,,
6194,1084618,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Sprague-Dawley (rat) assessed as increase in carrageenan-induced paw edema at 12 mg/kg, po measured at 2 hr by plethysmometer (Rvb = 64.73 +/- 0.72 %)",Other,,
6195,1085484,1,4,,103163840,3715,Unspecified,3914304.0,443460.0,,,"Inhibition of Ovis aries (sheep) COX-2 assessed as appearance of oxidized N,N,N',N'-tetramethyl-p-phenylenediamine at 20 uM by colorimetric analysis",Other,,
6196,1085485,1,4,,103163840,3715,Unspecified,754286265.0,443551.0,,,"Inhibition of Ovis aries (sheep) COX-1 assessed as appearance of oxidized N,N,N',N'-tetramethyl-p-phenylenediamine at 20 uM by colorimetric analysis",Other,,
6197,1085486,1,2,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in Rattus norvegicus Sprague-Dawley (rat) assessed as ulcer index at 10 mg/kg, po after 8 hr",Other,,
6198,1085487,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Sprague-Dawley (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po after 1.5 to 3 hr relative to control",Other,,
6199,1086016,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 4 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 4 hr by plethysmometric analysis relative to control",Other,,
6200,1086017,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 4 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 3 hr by plethysmometric analysis relative to control",Other,,
6201,1086018,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 4 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 2 hr by plethysmometric analysis relative to control",Other,,
6202,1086019,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 4 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 1 hr by plethysmometric analysis relative to control",Other,,
6203,1086254,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as inhibition of carageenaan-induced paw edema at 10 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 3 hr relative to control",Other,,
6204,1086341,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered for 30 min prior to carrageenan challenge measured at 4 hr relative to control",Other,,
6205,1086342,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered for 30 min prior to carrageenan challenge measured at 3 hr relative to control",Other,,
6206,1086343,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered for 30 min prior to carrageenan challenge measured at 2 hr relative to control",Other,,
6207,1086344,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered for 30 min prior to carrageenan challenge measured at 1 hr relative to control",Other,,
6208,1086395,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr prior tocarrageenan-challenge measured after 3 hr relative to control",Other,,
6209,1086501,1,3,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in Rattus norvegicus Wistar (rat) stomach at 5 mg/kg, po relative to vehicle-treated control",Other,,
6210,1086502,1,2,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus Wistar (rat) duodenum assessed as appearance of redness at 5 mg/kg, po relative to vehicle-treated control",Other,,
6211,1086503,1,3,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus Wistar (rat) stomach assessed as appearance of redness at 5 mg/kg, po relative to vehicle-treated control",Other,,
6212,1086508,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as mortality at 5 mg/kg, po administered for 7 days measured on day 8",Other,,
6213,1086509,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as cotton pellet-induced final granuloma weight at 5 mg/kg, po administered for 7 days measured on day 8 (Rvb = 110.3 +/- 8.7 mg)",Other,,
6214,1086510,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema administered for 1 hr followed by carrageenan challenge measured at 4 hr relative to control,Other,,
6215,1086511,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema administered for 1 hr followed by carrageenan challenge measured at 3 hr relative to control,Other,,
6216,1086512,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema administered for 1 hr followed by carrageenan challenge measured at 2 hr relative to control,Other,,
6217,1086513,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema administered for 1 hr followed by carrageenan challenge measured at 1 hr relative to control,Other,,
6218,1086517,2,3,,103163840,3715,Active,317373262.0,5742.0,0.253,Kd,Binding affinity to COX1 (unknown origin),Confirmatory,,
6219,1086518,2,3,,103163840,3715,Active,3915797.0,5743.0,0.092,Kd,Binding affinity to COX2 (unknown origin),Confirmatory,,
6220,1086519,2,3,,103163840,3715,Active,317373262.0,5742.0,0.1,IC50,Inhibition of COX1 (unknown origin),Confirmatory,,
6221,1086520,2,3,,103163840,3715,Active,3915797.0,5743.0,1.17,IC50,Inhibition of COX2 (unknown origin),Confirmatory,,
6222,1086899,1,3,,103163840,3715,Unspecified,,,,,Ulcerogenicity in Rattus norvegicus Sprague-Dawley (rat) stomach assessed as appearance of cone shape gastric mucosa layer at 50 mg/kg administered via intragastrically after 6 hr by hematoxylin and eosin staining relative to untreated control,Other,,
6223,1086900,1,3,,103163840,3715,Unspecified,,,,,Ulcerogenicity in Rattus norvegicus Sprague-Dawley (rat) stomach assessed as decrease in gastric mucosa layer thickness at 50 mg/kg administered via intragastrically after 6 hr by hematoxylin and eosin staining relative to untreated control,Other,,
6224,1086901,1,3,,103163840,3715,Unspecified,,,,,Ulcerogenicity in Rattus norvegicus Sprague-Dawley (rat) stomach assessed as ulcer score at 50 mg/kg administered via intragastrically after 6 hr by hematoxylin and eosin staining,Other,,
6225,1086913,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered for 30 min prior to carrageenan challenge measured at 4 hr relative to control",Other,,
6226,1086914,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered for 30 min prior to carrageenan challenge measured at 3 hr relative to control",Other,,
6227,1086915,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered for 30 min prior to carrageenan challenge measured at 2 hr relative to control",Other,,
6228,1086916,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered for 30 min prior to carrageenan challenge measured at 1 hr relative to control",Other,,
6229,1086924,1,3,,103163840,3715,Unspecified,,,,,"Antioxidant activity in Rattus norvegicus Wistar albino (rat) stomach assessed as decrease in malondialdehyde content measured per 100 mg of tissue at 30 mg/kg, po after 60 min by spectrophotometric analysis (Rvb = 3.86 +/- 0.19 nmol)",Other,,
6230,1086925,1,3,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in Rattus norvegicus Wistar albino (rat) stomach assessed as ulcer index at 30 mg/kg, po measured after 17 hr relative to control",Other,,
6231,1086926,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced hind paw edema at 10 mg/kg, po measured at 3 hr relative to control",Other,,
6232,1086928,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced hind paw edema at 10 mg/kg, po measured at 4 hr relative to control",Other,,
6233,1087280,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 min prior to carrageenan challenge measured at 4 hr relative to control",Other,,
6234,1087306,1,2,,103163840,3715,Unspecified,,,,,"Ulcerogenicity in Rattus norvegicus albino (rat) at 9 mg/kg/day, po qd for 3 successive days",Other,,
6235,1087309,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema in Rattus norvegicus albino (rat) at 10 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 1 to 4 hr post challenge relative to control",Other,,
6236,1087310,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema in Rattus norvegicus albino (rat) assessed as paw thickness at 10 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 4 hr post challenge",Other,,
6237,1087311,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema in Rattus norvegicus albino (rat) assessed as paw thickness at 10 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 3 hr post challenge",Other,,
6238,1087312,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema in Rattus norvegicus albino (rat) assessed as paw thickness at 10 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 2 hr post challenge",Other,,
6239,1087313,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity carrageenan-induced paw edema in Rattus norvegicus albino (rat) assessed as paw thickness at 10 mg/kg, ip administered 1 hr prior to carrageenan-induced measured 1 hr post challenge",Other,,
6240,1093247,2,3,,103163840,3715,Unspecified,3915797.0,5743.0,25704.0,IC50,Inhibition of COX2 (unknown origin) expressed in CHO cells,Confirmatory,,
6241,1093826,1,2,,103163840,3715,Unspecified,,,,,"Analgesic activity in Mus musculus (mouse) assessed as inhibition of acetic acid-induced writhing at 15 mg/kg, po administered 1 hr prior to acetic acid challenge measured at 5 to 20 min relative to control",Other,,
6242,1093827,1,3,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in 36 hr fasting Rattus norvegicus Sprague-Dawley (rat) stomach assessed as ulcer index at 25 mg/kg, po measured after 4 hr",Other,,
6243,1093828,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Sprague-Dawley (rat) assessed as inhibition of carrageenan-induced paw edema at 3 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 3 hr by plethysmometric analysis relative to control",Other,,
6244,1094688,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 min before carrageenan challenge measured after 24 hr",Other,,
6245,1094689,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 min before carrageenan challenge measured after 4 hr",Other,,
6246,1094690,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 min before carrageenan challenge measured after 3 hr",Other,,
6247,1094691,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 min before carrageenan challenge measured after 2 hr",Other,,
6248,1094692,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 min before carrageenan challenge measured after 1 hr",Other,,
6249,1094693,1,2,,103163840,3715,Unspecified,,,,,"Analgesic activity in Mus musculus (mouse) assessed as paw withdrawal latency time at 10 mg/kg, ip after 30 min",Other,,
6250,1094733,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Swiss albino (mouse) assessed as inhibition of carrageenan-induced edema at 10 mg/kg, po pretreated 60 min before carrageenan-challenge measured after 360 min",Other,,
6251,1094734,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Swiss albino (mouse) assessed as inhibition of carrageenan-induced edema at 10 mg/kg, po pretreated 60 min before carrageenan-challenge measured after 270 min",Other,,
6252,1094735,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Swiss albino (mouse) assessed as inhibition of carrageenan-induced edema at 10 mg/kg, po pretreated 60 min before carrageenan-challenge measured after 180 min",Other,,
6253,1094736,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Swiss albino (mouse) assessed as inhibition of carrageenan-induced edema at 10 mg/kg, po pretreated 60 min before carrageenan-challenge measured after 90 min",Other,,
6254,1094757,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar albino (rat) assessed as mortality at 139.6 umol/kg, po",Other,,
6255,1094758,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar albino (rat) assessed as mortality at 69.8 umol/kg, po",Other,,
6256,1094773,1,2,,103163840,3715,Unspecified,,,,,"Inhibition of hyaluronidase-induced capillary permeability in albino Oryctolagus cuniculus (rabbit) assessed as area of subcutaneous spreading of trypan blue at 27.9 umol/kg, po pretreated 1 hr prior to mixture of hyaluronidase and trypan blue challenge measured after 30 min (Rvb = 498.8 mm'2)",Other,,
6257,1094774,1,2,,103163840,3715,Unspecified,,,,,"Inhibition of hyaluronidase-induced capillary permeability in albino Oryctolagus cuniculus (rabbit) assessed as area of subcutaneous spreading of trypan blue at 27.9 umol/kg, po pretreated 1 hr prior to mixture of hyaluronidase and trypan blue challenge measured after 5 min (Rvb = 288.5 mm'2)",Other,,
6258,1094775,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 69.8 X 10'2 umol/kg, po administered 1 hr prior to carrageenan challenge through oral gavage measured measured 4 hr after carrageenan treatment by plethysmometer",Other,,
6259,1094776,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 69.8 X 10'2 umol/kg, po administered 1 hr prior to carrageenan challenge through oral gavage measured measured 2 hr after carrageenan treatment by plethysmometer",Other,,
6260,1094777,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 69.8 X 10'2 umol/kg, po administered 1 hr prior to carrageenan challenge through oral gavage measured measured 1 hr after carrageenan treatment by plethysmometer",Other,,
6261,1094787,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 69.8 X 10'2 umol/kg, po administered 1 hr prior to carrageenan challenge through oral gavage measured measured 3 hr after carrageenan treatment by plethysmometer",Other,,
6262,1094964,1,2,,103163840,3715,Unspecified,,,,,"Antioxidant activity in Rattus norvegicus Wistar (rat) assessed as malondialdehyde content in gastric mucosa at 105 mg/kg, po after 17 hr by UV spectrophotometric analysis (Rvb = 3.23 +/- 0.05 nmol)",Other,,
6263,1094966,1,3,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in Rattus norvegicus Wistar (rat) stomach assessed as severity index at 105 mg/kg, po after 17 hr relative to control",Other,,
6264,1094968,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 35 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hr by plethysmometric analysis relative to control",Other,,
6265,1094970,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 35 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hr by plethysmometric analysis relative to control",Other,,
6266,1095017,1,2,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus albino (rat) assessed as incidence of gastric ulceration at 0.9 mg/100 g body weight, po qd",Other,,
6267,1095018,1,2,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus albino (rat) assessed as ulcer index at 0.9 mg/100 g body weight, po qd",Other,,
6268,1095663,1,2,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus Sprague-Dawley (rat) assessed as ulcer index at 48 mg/kg, po measured after 8 hr (Rvb = 0.2 +/- 0.06 No_unit)",Other,,
6269,1095666,1,2,,103163840,3715,Unspecified,,,,,"Analgesic activity in Rattus norvegicus Sprague-Dawley (rat) assessed as inhibition of acetic acid-induced writhing at 10 mg/kg, po measured during 20 min period beginning 3 min after acetic acid challenge",Other,,
6270,1095671,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced paw edema Rattus norvegicus Sprague-Dawley (rat) model assessed as increase in paw volume at 12 mg/kg, po measured after 4 hr",Other,,
6271,1095672,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced paw edema Rattus norvegicus Sprague-Dawley (rat) model assessed as increase in paw volume at 12 mg/kg, po measured after 2 hr",Other,,
6272,1096892,1,2,,103163840,3715,Unspecified,,,,,"Toxicity inRattus norvegicus albino (rat) assessed as ulcerogenicity at 100 mg/kg, po measured after 1 hr",Other,,
6273,1096893,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 3 hr prior challenge measured after 1 hr post challenge",Other,,
6274,1096894,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 2 hr prior challenge measured after 1 hr post challenge",Other,,
6275,1096895,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr prior challenge measured after 1 hr post challenge",Other,,
6276,1096937,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as GPx activity per gram of Hb at 600 mg/kg, po for 10 days (Rvb =179.16 +/- 10.45 U/g Hb)",Other,,
6277,1096938,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as SOD activity per gram of Hb at 600 mg/kg, po for 10 days (Rvb = 12.7 +/- 2.08 U/g Hb)",Other,,
6278,1096939,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as GSH activity at 600 mg/kg, po for 10 days (Rvb = 59.57 +/- 5.10 %)",Other,,
6279,1096940,1,3,,103163840,3715,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as serum TBARS level at 600 mg/kg, po for 10 days (Rvb = 4.35 +/- 0.86 U/l)",Other,,
6280,1096941,1,3,,103163840,3715,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as serum LDH level at 600 mg/kg, po for 10 days (Rvb = 217.84 +/- 13.36 U/l)",Other,,
6281,1096942,1,3,,103163840,3715,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as serum gamma-glutamyl transferase level at 600 mg/kg, po for 10 days (Rvb = 4.43 +/- 0.31 U/l)",Other,,
6282,1096943,1,3,,103163840,3715,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as serum ALP level at 600 mg/kg, po for 10 days (Rvb = 31.63 +/- 3.73 U/l)",Other,,
6283,1096944,1,3,,103163840,3715,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as serum SGPT level at 600 mg/kg, po for 10 days (Rvb = 35.82 +/- 5.26 U/l)",Other,,
6284,1096945,1,3,,103163840,3715,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as serum SGOT level at 600 mg/kg, po for 10 days (Rvb = 9.74 +/- 1.73 U/l)",Other,,
6285,1096980,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus albino (mouse) assessed as inhibition of formalin-induced paw swelling at 60 mg/kg, po administered 30 min prior formalin challenge measured after 120 min post challenge (Rvb = 9.83 +/- 0.071 mm/min)",Other,,
6286,1096981,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus albino (mouse) assessed as inhibition of formalin-induced paw swelling at 60 mg/kg, po administered 30 min prior formalin challenge measured after 90 min post challenge (Rvb = 9.5 +/- 0.04 mm/min)",Other,,
6287,1096982,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus albino (mouse) assessed as inhibition of formalin-induced paw swelling at 60 mg/kg, po administered 30 min prior formalin challenge measured after 60 min post challenge (Rvb = 9.73 +/- 0.06 mm/min)",Other,,
6288,1096983,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus albino (mouse) assessed as inhibition of formalin-induced paw swelling at 60 mg/kg, po administered 30 min prior formalin challenge measured after 30 min post challenge (Rvb = 9.46 +/- 0.035 mm/min)",Other,,
6289,1096999,1,2,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus (rat) assessed as incidence of melena at 84 umol/kg, sc qd for 4 days",Other,,
6290,1097000,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in rat assessed as body weight change per 100 gram body weight at 84 umol/kg, sc qd for 4 days",Other,,
6291,1097001,1,2,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus (rat) assessed as perforating ulcers at 84 umol/kg, sc qd for 4 days",Other,,
6292,1097002,1,2,,103163840,3715,Unspecified,,,,,"Toxicity in Rattus norvegicus (rat) assessed as mortality at 84 umol/kg, sc qd for 4 days",Other,,
6293,1097010,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Balb-C Mus musculus (mouse) assessed as inhibition of FCA-induced paw oedema at 0.15 mmol/kg, ip administered 5 min before FCA challenge measured after 3 hr relative to control",Other,,
6294,1097092,1,2,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in Rattus norvegicus Wistar (rat) assessed as length of lesion at 10 mg/kg, po after 6 hr (Rvb = 0 mm)",Other,,
6295,1097094,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in po dosed Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema administered 30 min post carrageenan challenge measured at 5 hr,Other,,
6296,1097099,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 min post carrageenan challenge measured at 5 hr relative to control",Other,,
6297,1097319,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as protection against carrageenan-induced paw edema at 50 mg/kg after 3 hr,Other,,
6298,1097320,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as protection against carrageenan-induced paw edema at 50 mg/kg after 2 hr,Other,,
6299,1097321,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as protection against carrageenan-induced paw edema at 50 mg/kg after 90 min,Other,,
6300,1097322,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as protection against carrageenan-induced paw edema at 50 mg/kg after 60 min,Other,,
6301,1097323,1,2,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as protection against carrageenan-induced paw edema at 50 mg/kg after 30 min,Other,,
6302,1106036,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as reduction of cotton pellet-induced dry weight of granuloma at 5 mg/kg, po measured after 7 days relative to control",Other,,
6303,1106039,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as reduction of carrageenan-induced paw edema at 5 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hr by mercury plethysmographic analysis relative to control",Other,,
6304,1106242,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced Mus musculus Swiss albino (mouse) paw edema model assessed as inhibition of paw edema at 10 mg/kg, sc administered 30 min prior to carrageenan injection measured after 360 min",Other,,
6305,1106244,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced Mus musculus Swiss albino (mouse) paw edema model assessed as inhibition of paw edema at 10 mg/kg, sc administered 30 min prior to carrageenan injection measured after 270 min",Other,,
6306,1106246,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced Mus musculus Swiss albino (mouse) paw edema model assessed as inhibition of paw edema at 10 mg/kg, sc administered 30 min prior to carrageenan injection measured after 180 min",Other,,
6307,1106248,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced Mus musculus Swiss albino (mouse) paw edema model assessed as inhibition of paw edema at 10 mg/kg, sc administered 30 min prior to carrageenan injection measured after 90 min",Other,,
6308,1106250,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced Mus musculus Swiss albino (mouse) paw edema model assessed as paw swelling at 10 mg/kg, sc administered 30 min prior to carrageenan injection measured after 360 min (Rvb = 77.0 +/-3.0 x10'-2 mm)",Other,,
6309,1106252,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced Mus musculus Swiss albino (mouse) paw edema model assessed as paw swelling at 10 mg/kg, sc administered 30 min prior to carrageenan injection measured after 270 min (Rvb = 75.0 +/-3.0 x10'-2 mm)",Other,,
6310,1106254,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced Mus musculus Swiss albino (mouse) paw edema model assessed as paw swelling at 10 mg/kg, sc administered 30 min prior to carrageenan injection measured after 180 min (Rvb = 51.0 +/-3.0 x10'-2 mm)",Other,,
6311,1106256,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in carrageenan-induced Mus musculus Swiss albino (mouse) paw edema model assessed as paw swelling at 10 mg/kg, sc administered 30 min prior to carrageenan injection measured after 90 min (Rvb = 38.0 +/-2.0 x10'-2 mm)",Other,,
6312,1106466,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity against Rattus norvegicus Albino Sprague-Dawley (rat) assessed as inhibition of carrageenan-induced paw edema at 18 mg/kg, ip administered 30 min prior to carrageenan injection measured after 1 hr by plethysmometer analysis",Other,,
6313,1114136,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 60 min prior to crrageenan-challenge measured at 360 min relative to control",Other,,
6314,1114137,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 60 min prior to crrageenan-challenge measured at 270 min relative to control",Other,,
6315,1114138,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 60 min prior to crrageenan-challenge measured at 180 min relative to control",Other,,
6316,1114139,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 60 min prior to crrageenan-challenge measured at 90 min relative to control",Other,,
6317,1114844,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 min prior to carrageenan-challenge measured after 5 hr relative to control",Other,,
6318,1114847,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 3 hr relative to control",Other,,
6319,1116322,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of cotton pellet-induced granuloma formation at 10 mg/kg, po administered QD for 5 days measured at 1 hr post-last dose relative to control",Other,,
6320,1116323,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 30 min prior to carrageenan-challenge measured after 5 hr relative to control",Other,,
6321,1116777,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 5 hr by mercury displacement technique",Other,,
6322,1116779,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 2 hr by mercury displacement technique",Other,,
6323,1116781,1,2,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 1 hr by mercury displacement technique",Other,,
6324,1117298,1,2,,170464705,3715,Inactive,,,22.3872,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
6325,1117304,1,2,,170464705,3715,Inactive,,,2.8184,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
6326,1117305,1,2,,170464705,3715,Inactive,,,1.7783,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
6327,1117310,1,1,,170464705,3715,Inactive,,,22.3872,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
6328,1117312,1,1,,170464705,3715,Inactive,,,1.7782799999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
6329,1117314,1,1,,170464705,3715,Inactive,,,2.81838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
6330,1117319,1,2,,856012,3715,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
6331,1117319,1,2,,856012,3715,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
6332,1117326,1,1,,170464705,3715,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
6333,1117329,1,1,,170464705,3715,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
6334,1117336,1,1,,170464705,3715,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
6335,1117340,1,1,,170464705,3715,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
6336,1117341,1,1,,170464705,3715,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
6337,1117342,1,1,,170464705,3715,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
6338,1117343,1,1,,170464705,3715,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
6339,1117346,1,1,,170464705,3715,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
6340,1123070,1,1,,103163840,3715,Unspecified,,,,,Inhibition of cyclooxygenase activity in bovine seminal vesicles assessed as arachodonic acid dependent formation of adenochrome from L-epinephrine at 20 uM,Other,109614.0,
6341,1123739,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 3 mg/kg, po preincubated for 1 hr followed by carrageenan challenge relative to control",Other,423183.0,
6342,1123740,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema preincubated for 1 hr followed by carrageenan challenge relative to control,Other,423183.0,
6343,1123741,1,1,,103163840,3715,Unspecified,,,,,Antiarthritic activity in po dosed rat assessed as reduction of adjuvant-induced foot volume administered as qd for 14 days starting on day 14 after adjuvant inoculation measured on day 28,Other,423183.0,
6344,1123742,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing,Other,423183.0,
6345,1123743,1,1,,103163840,3715,Unspecified,,,,,Ulcerogenic activity in po dosed rat assessed as induction of lesions in gastric mucosa measured after 24 hrs,Other,423183.0,
6346,1125124,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 1 hr relative to control",Other,24631895.0,
6347,1125125,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 2 hrs relative to control",Other,24631895.0,
6348,1125126,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs relative to control",Other,24631895.0,
6349,1125127,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 4 hrs relative to control",Other,24631895.0,
6350,1125128,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins before carrageenan challenge measured after 5 hrs relative to control",Other,24631895.0,
6351,1125129,1,1,,103163840,3715,Unspecified,,,,,"Ulcerogenic effect in albino rat assessed as ulcer index at 0.28 mmol/kg, po",Other,24631895.0,
6352,1125132,1,1,,103163840,3715,Unspecified,,,,,"Ulcerogenic effect in albino rat assessed as loss of mucosal membrane using hematoxylin and eosin staining at 0.28 mmol/kg, po by light microscopic analysis",Other,24631895.0,
6353,1125133,1,1,,103163840,3715,Unspecified,,,,,"Ulcerogenic effect in albino rat assessed as capillary inflammatory cells using hematoxylin and eosin staining at 0.28 mmol/kg, po by light microscopic analysis",Other,24631895.0,
6354,1125134,1,1,,103163840,3715,Unspecified,,,,,"Ulcerogenic effect in albino rat assessed as apoptotic glandular epithelial cells using hematoxylin and eosin staining at 0.28 mmol/kg, po by light microscopic analysis",Other,24631895.0,
6355,1125137,1,3,,103163840,3715,Active,754286265.0,443551.0,0.6,IC50,Inhibition of ovine COX1 assessed as prostaglandin F2alpha level,Confirmatory,24631895.0,
6356,1125138,1,3,,103163840,3715,Active,3915797.0,5743.0,18.5,IC50,Inhibition of human recombinant COX2 assessed as prostaglandin F2alpha level,Confirmatory,24631895.0,
6357,1125139,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio IC50 for ovine COX1 to IC50 for human recombinant COX2,Other,24631895.0,
6358,1125893,1,1,,103163840,3715,Active,,,16.67,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method,Confirmatory,24660966.0,
6359,1128712,1,1,,103163840,3715,Inconclusive,,,,IC50,Antioxidant activity in rat liver microsome membrane assessed as inhibition of lipid peroxidation after 45 mins by TBARS-based spectrophotometric assay,Confirmatory,24568631.0,
6360,1128714,1,2,,103163840,3715,Inconclusive,,,,IC50,Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins,Confirmatory,24568631.0,
6361,1128731,1,3,,103163840,3715,Inconclusive,399484.0,29580.0,,IC50,Inhibition of squalene synthase in rat liver microsomes assessed as decrease in conversion of [3H]FPP to squalene,Confirmatory,24568631.0,
6362,1128732,1,3,,103163840,3715,Unspecified,166897622.0,282022.0,,,Inhibition of bovine COX-1 assessed as PGF2-alpha formation using arachidonic acid as substrate at 20 uM by enzyme immunoassay,Other,24568631.0,
6363,1128733,1,3,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX-2 assessed as PGF2-alpha formation using arachidonic acid as substrate at 20 uM by enzyme immunoassay,Other,24568631.0,
6364,1128736,1,1,,103163840,3715,Unspecified,,,,,"In vivo antiinflammatory activity in mouse assessed as decrease in carrageenan-induced paw edema at 0.30 mmol/kg, ip administered immediately after carrageenan injection measured after 3.5 hrs",Other,24568631.0,
6365,1128737,1,1,,103163840,3715,Inconclusive,,,,,"In vivo antidyslipidemic activity against Triton WR 1339-induced hyperlipidemic Wistar rat model assessed as decrease in total cholesterol level in plasma at 56 umol/kg, ip administered as single dose 1 hr after Triton WR 1339 challenge measured after 24 hrs",Other,24568631.0,
6366,1128738,1,1,,103163840,3715,Inconclusive,,,,,"In vivo antidyslipidemic activity against Triton WR 1339-induced hyperlipidemic Wistar rat model assessed as decrease in LDL-cholesterol level in plasma at 56 umol/kg, ip administered as single dose 1 hr after Triton WR 1339 challenge measured after 24 hrs",Other,24568631.0,
6367,1128739,1,1,,103163840,3715,Inconclusive,,,,,"In vivo antidyslipidemic activity against Triton WR 1339-induced hyperlipidemic Wistar rat model assessed as decrease in triglyceride level in plasma at 56 umol/kg, ip administered as single dose 1 hr after Triton WR 1339 challenge measured after 24 hrs",Other,24568631.0,
6368,1129361,1,1,,103163840,3715,Unspecified,,,,,Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis,Other,24601604.0,
6369,1131122,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against adjuvant-induced arthritis rat model assessed as inhibition of swelling at 2 mg/kg, po measured on day 14 (Rvb = 0%)",Other,533886.0,
6370,1131123,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against adjuvant-induced arthritis rat model assessed as inhibition of swelling at 1 mg/kg, po measured on day 14 (Rvb = 0%)",Other,533886.0,
6371,1131124,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against adjuvant-induced arthritis rat model assessed as inhibition of swelling at 0.5 mg/kg, po measured on day 14 (Rvb = 0%)",Other,533886.0,
6372,1131128,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against adjuvant-induced arthritis rat model assessed as inhibition of swelling at 2 mg/kg, po measured on day 21 (Rvb = 0%)",Other,533886.0,
6373,1131129,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against adjuvant-induced arthritis rat model assessed as inhibition of swelling at 1 mg/kg, po measured on day 21 (Rvb = 0%)",Other,533886.0,
6374,1131130,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against adjuvant-induced arthritis rat model assessed as inhibition of swelling at 0.5 mg/kg, po measured on day 21 (Rvb = 0%)",Other,533886.0,
6375,1131301,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against rat adjuvant arthritis model assessed as reduction of swelling in non-injected foot at 1 mg/kg, po administered for 16 days",Other,536992.0,
6376,1132865,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed Donryu rat assessed as inhibition of carrageenan-induced paw edema,Other,671462.0,
6377,1133358,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in po dosed CF-1 mouse assessed as reduction in phenylquinone-induced writhing responses administered 15 mins prior to phenylquinone challenge,Other,722756.0,
6378,1133360,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity against po dosed yeast-induced inflammed foot Sprague-Dawley rat model assessed as increase in pain threshold in inflamed paw measured after 2 hrs,Other,722756.0,
6379,1133922,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema,Other,845879.0,
6380,1133923,1,1,,103163840,3715,Unspecified,,,,,Gastrointestinal toxicity in po dosed rat assessed as induction of gastric irritation,Other,845879.0,
6381,1133924,1,1,,103163840,3715,Unspecified,,,,,"Therapeutic index, ratio of ID50 for po dosed rat to ED50 for po dosed rat",Other,845879.0,
6382,1134012,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in depilated albino guinea pig assessed as suppression of UV radiation-induced skin erythema compound administered via gavage measured 2 hrs after UV irradiation exposure,Other,850248.0,
6383,1134827,1,1,,103163840,3715,Unspecified,,,,,Acute toxicity in po dosed mouse,Other,102794.0,
6384,1134828,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced foot edema,Other,102794.0,
6385,1134829,1,1,,103163840,3715,Unspecified,,,,,Antiarthritic activity in rat assessed as reduction in adjuvant-induced arthritic pain,Other,102794.0,
6386,1134830,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in rat assessed as dose required to give 50% inhibition of weight increment per ear,Other,102794.0,
6387,1134831,1,3,,103163840,3715,Unspecified,7387730.0,9536.0,,,Inhibition of prostaglandin synthetase (unknown origin),Other,102794.0,
6388,1134895,1,1,,103163840,3715,Active,,,1.0,IC50,Inhibition of prostaglandin synthetase (unknown origin) using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition,Confirmatory,114655.0,
6389,1134897,1,2,,103163840,3715,Unspecified,,,,,Inhibition of PGF2-alpha formation in ip dosed rat serum after 1 hr by radioimmunoassay,Other,114655.0,
6390,1134898,1,2,,103163840,3715,Unspecified,,,,,Inhibition of PGF2-alpha formation in po dosed rat serum after 1 hr by radioimmunoassay,Other,114655.0,
6391,1134899,1,1,,103163840,3715,Active,,,2.8,IC50,Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins,Confirmatory,114655.0,
6392,1134900,1,1,,103163840,3715,Active,,,0.1,IC50,Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins,Confirmatory,114655.0,
6393,1134901,3,1,,103163840,3715,Active,,,3.2,IC50,Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins,Confirmatory,114655.0,
6394,1134902,1,1,,103163840,3715,Unspecified,,,,,Inhibition of arachidonic acid-induced diarrhea in po dosed mouse treated for 1 hr prior to arachidonic acid-challenge measured after 30 mins,Other,114655.0,
6395,1134903,1,1,,103163840,3715,Unspecified,,,,,Toxicity in po dosed rat assessed as gastric ulcer incidence after 4 hrs,Other,114655.0,
6396,1135112,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in rabbit assessed as inhibition of edema at 200 ug per site by reversed passive arthus test,Other,140243.0,
6397,1136193,1,1,,103163840,3715,Unspecified,,,,,"Toxicity in dog assessed as gastrointestinal intolerance at 10 to 30 mg/kg, po administered as single dose",Other,309946.0,
6398,1136203,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in po dosed rat assessed as inhibition of yeast-induced inflammatory pain,Other,309947.0,
6399,1136204,1,1,,103163840,3715,Unspecified,,,,,Antipyretic activity in po dosed rat,Other,309947.0,
6400,1136205,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in po dosed dog knee joint pain model,Other,309947.0,
6401,1136206,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in po dosed rat assessed as inhibition of adjuvant-induced arthritis pain,Other,309947.0,
6402,1136207,1,1,,103163840,3715,Unspecified,,,,,Inhibition of PG synthase (unknown origin),Other,309947.0,
6403,1136209,1,1,,103163840,3715,Unspecified,,,,,Toxicity in po dosed rat assessed as intestinal perforating ulcer,Other,309947.0,
6404,1136211,1,1,,103163840,3715,Unspecified,,,,,Toxicity in po dosed rat assessed as gastric hemorrhage,Other,309947.0,
6405,1136444,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 12 mg/kg, sc administered post-challenge measured at 3 hrs post compound treatment relative to vehicle-treated control",Other,314983.0,
6406,1136449,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 12 mg/kg, sc administered post-challenge measured at 5 hrs post compound treatment relative to vehicle-treated control",Other,314983.0,
6407,1136451,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in CF1 mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 3 hrs and 30 mins prior to carrageenan-challenge measured after 3 hrs (Rvb = 0%)",Other,316462.0,
6408,1136452,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in CF1 mouse assessed as increase in foot weight at 10 mg/kg, ip administered 3 hrs and 30 mins prior to carrageenan-challenge measured after 3 hrs (Rvb = 97 +/- 10 mg)",Other,316462.0,
6409,1136456,1,1,,103163840,3715,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as host survival on day 7 at 20 mg/kg, ip qd for 2 weeks",Other,316462.0,
6410,1136457,1,1,,103163840,3715,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as tumor growth inhibition at 20 mg/kg, ip qd for 2 weeks (Rvb = 100%)",Other,316462.0,
6411,1136458,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in CF1 mouse assessed as increase in foot weight at 20 mg/kg, ip administered 3 hrs and 30 mins prior to carrageenan-challenge measured after 3 hrs (Rvb = 97 +/- 10 mg)",Other,316462.0,
6412,1136459,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in CF1 mouse assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, ip administered 3 hrs and 30 mins prior to carrageenan-challenge measured after 3 hrs (Rvb = 0%)",Other,316462.0,
6413,1139284,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat paw edema model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 4 hrs relative to vehicle-treated control",Other,24689881.0,
6414,1139290,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in ICR mouse ear edema model assessed as inhibition of TPA-induced ear edema at 20 mg/kg, po administered 30 mins prior to TPA challenge measured after 4 hrs relative to vehicle-treated control",Other,24689881.0,
6415,1139565,1,3,,103163840,3715,Active,754286265.0,443551.0,,,Inhibition of ovine COX1 using arachidonic acid at 10 uM after 5 mins by HPLC analysis,Other,24697244.0,
6416,1139566,1,3,,103163840,3715,Active,3915797.0,5743.0,,,Inhibition of human COX-2 using arachidonic acid at 10 uM after 5 mins by HPLC analysis,Other,24697244.0,
6417,1141756,1,3,,103163840,3715,Active,754286265.0,443551.0,0.18,IC50,Inhibition of ovine COX1 using arachidonic acid as substrate preincubated for 10 mins before substrate addition measured after 5 mins by EIA,Confirmatory,24763362.0,
6418,1141757,1,3,,103163840,3715,Unspecified,3914304.0,443460.0,30.0,IC50,Inhibition of ovine COX2 using arachidonic acid as substrate preincubated for 10 mins before substrate addition measured after 5 mins by EIA,Confirmatory,24763362.0,
6419,1141758,1,1,,103163840,3715,Inconclusive,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,24763362.0,
6420,1143904,1,3,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of purified ovine COX1 assessed as residual activity preincubated at 10 uM for 5 mins by HPLC analysis,Other,24871899.0,
6421,1145133,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of adjuvant-induced arthritis administered for 9 days into foot pad 14 days after adjuvant challenge measured on day 22 by mercury displacement analysis,Other,1255663.0,
6422,1145137,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenin-induced paw edema,Other,1255663.0,
6423,1145138,1,1,,103163840,3715,Unspecified,,,,,Gastrointestinal toxicity in 8 hrs starved po dosed Charles River rat assessed as ulcerogenic effect after 18 hrs,Other,1255663.0,
6424,1145139,1,1,,103163840,3715,Unspecified,,,,,"Therapeutic index, ratio of UD50 for 8 hrs starved po dosed Charles River rat to ED50 for rat assessed as inhibition of adjuvant-induced arthritis",Other,1255663.0,
6425,1149349,1,1,,103163840,3715,Unspecified,,,,,Therapeutic ratio of ID50 for ulcerogenicity in Wistar rat to ED50 for antiinflammatory activity against Mycobacterium butyricum adjuvant-induced polyarthritis in Lewis albino rat adjuvant treated paw,Other,833828.0,
6426,1149350,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw edema administered 1 hr prior to carrageenan challenge measured 3 hrs post-carrageenan injection,Other,833828.0,
6427,1149352,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in po dosed CD-1 mouse assessed as inhibition of phenylquinone-induced writhing administered prior to phenylquinone challenge measured 5 mins after phenylquinone injection,Other,833828.0,
6428,1149353,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against Mycobacterium butyricum adjuvant-induced polyarthritis in po dosed Lewis albino rat assessed as decrease in adjuvant treated paw edema administered daily for 21 days prior to adjuvant injection,Other,833828.0,
6429,1149354,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against Mycobacterium butyricum adjuvant-induced polyarthritis in po dosed Lewis albino rat assessed as decrease in non-injected paw edema administered daily for 21 days prior to adjuvant injection,Other,833828.0,
6430,1149355,1,1,,103163840,3715,Unspecified,,,,,Ulcerogenicity in po dosed Wistar rat assessed as induction of gastric irritation,Other,833828.0,
6431,1149356,1,1,,103163840,3715,Unspecified,,,,,Therapeutic ratio of ID50 for ulcerogenicity in Wistar rat to ED50 for antiinflammatory activity against Mycobacterium butyricum adjuvant-induced polyarthritis in Lewis albino rat non-injected paw,Other,833828.0,
6432,1149802,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced edema measured as increase in foot volume at 5 mg/kg, po administered 1 hr prior challenge measured 3 hrs after carrageenin injection (Rvb = 187.6 %)",Other,903922.0,
6433,1149805,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced edema measured as increase in foot volume at 5 mg/kg, po administered 1 hr prior challenge measured 7 hrs after carrageenin injection (Rvb = 178.8 %)",Other,903922.0,
6434,1150001,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw edema administered 1 hr prior to carrageenan challenge measured after 3 hrs of carrageenan challenge,Other,915913.0,
6435,1150252,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema,Other,940112.0,
6436,1150257,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat with acute phase of inflammation assessed as inhibition of adjuvant-carrageenan-induced paw edema at 2 mg/kg, po relative to control",Other,940112.0,
6437,1150259,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat with prolonged phase of inflammation assessed as inhibition of adjuvant-carrageenan-induced paw edema at 2 mg/kg, po relative to control",Other,940112.0,
6438,1150262,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 0.5 mg/kg, po administered for 14 days prior to adjuvant challenge relative to control",Other,940112.0,
6439,1150267,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 0.5 mg/kg, po administered for 14 days followed by adjuvant challenge relative to control",Other,940112.0,
6440,1150270,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing,Other,940112.0,
6441,1150271,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in carrageenan-treated po dosed rat assessed as concentration required to double pain index of control,Other,940112.0,
6442,1150274,1,1,,103163840,3715,Unspecified,,,,,Toxicity in po dosed rat assessed as induction of gastric lesion,Other,940112.0,
6443,1150275,1,1,,103163840,3715,Unspecified,,,,,Acute toxicity in po dosed rat after 7 days,Other,940112.0,
6444,1150596,1,1,,103163840,3715,Unspecified,,,,,Chronic antiinflammatory activity against adjuvant-induced arthritis in po dosed rat assessed as decrease in volume of paw administered for 9 days starting 14 days after adjuvant injection and continued until day 22 by therapeutic test,Other,950647.0,
6445,1151354,1,1,,103163840,3715,Active,,,1.25,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay,Confirmatory,24806310.0,
6446,1153375,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema measured as paw thickness at 0.03 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hrs (Rvb = 1.260 +/- 0.172 mm)",Other,24835630.0,
6447,1153376,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.03 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 4 hrs relative to control",Other,24835630.0,
6448,1153377,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema measured as paw thickness at 0.03 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 6 hrs (Rvb = 1.081 +/- 0.257 mm)",Other,24835630.0,
6449,1153378,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 0.03 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 6 hrs relative to control",Other,24835630.0,
6450,1153381,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in rat assessed as inhibition of acetic acid-induced writhing at 0.03 mM/kg,Other,24835630.0,
6451,1153382,1,1,,103163840,3715,Unspecified,,,,,Analgesic activity in rat assessed as inhibition of acetic acid-induced writhing measured as potency at 0.03 mM/kg,Other,24835630.0,
6452,1153843,1,3,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX-1 using arachidonic acid as substrate assessed as residual activity at 10 uM preincubated for 5 mins followed by substrate addition measured after 5 mins by HPLC analysis relative to control,Other,24844534.0,
6453,1153844,1,3,,103163840,3715,Inconclusive,3915797.0,5743.0,,,Inhibition of human recombinant COX-2 using arachidonic acid as substrate assessed as residual activity at 10 uM preincubated for 5 mins followed by substrate addition measured after 5 mins by HPLC analysis relative to control,Other,24844534.0,
6454,1155578,1,3,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX1-mediated PGE2 production in human platelets assessed as residual activity by measuring formation of 12-HHT from arachidonic acid preincubated at 10 uM for 5 mins measured after 5 mins by RP-HPLC analysis relative to control,Other,24920381.0,
6455,1155580,1,3,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of purified ovine COX-1 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid preincubated at 10 uM for 5 mins before substrate addition measured after 5 mins by HPLC analysis relative to control,Other,24920381.0,
6456,1155581,1,3,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of purified human COX-2 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid preincubated at 10 uM for 5 mins before substrate addition measured after 5 mins by HPLC analysis relative to control,Other,24920381.0,
6457,1155582,1,3,,103163840,3715,Inconclusive,125987838.0,239.0,,,Inhibition of 12-LO in human neutrophils assessed as residual activity relative to control,Other,24920381.0,
6458,1155584,1,3,,103163840,3715,Inconclusive,126396.0,246.0,,,Inhibition of 15-LO in human neutrophils assessed as residual activity relative to control,Other,24920381.0,
6459,1155597,1,3,,103163840,3715,Active,317373262.0,5742.0,1.2,IC50,Inhibition of COX1-mediated PGF2alpha formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis,Confirmatory,24920381.0,
6460,1155598,1,3,,103163840,3715,Active,317373262.0,5742.0,1.2,IC50,Inhibition of COX1-mediated PGD2 formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis,Confirmatory,24920381.0,
6461,1155600,1,3,,103163840,3715,Active,3915797.0,5743.0,1.2,IC50,Inhibition of COX2-mediated PGF2alpha formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis,Confirmatory,24920381.0,
6462,1155601,1,3,,103163840,3715,Active,3915797.0,5743.0,1.2,IC50,Inhibition of COX2-mediated PGD2 formation in LPS-stimulated human monocytes preincubated for 15 mins before arachidonic acid substrate addition measured after 30 mins by UPLC-MS/MS analysis,Confirmatory,24920381.0,
6463,1156826,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 1 hr relative to control",Other,24983538.0,
6464,1156827,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 2 hrs relative to control",Other,24983538.0,
6465,1156828,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs relative to control",Other,24983538.0,
6466,1156829,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 4 hrs relative to control",Other,24983538.0,
6467,1156830,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 5 hrs relative to control",Other,24983538.0,
6468,1156831,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against albino rat assessed as inhibition of carrageenan-induced paw edema at 0.28 mmol/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs relative to indomethacin",Other,24983538.0,
6469,1156833,1,1,,103163840,3715,Unspecified,,,,,"Gastric toxicity in rat assessed as ulcer index at 0.28 mmol/kg, po",Other,24983538.0,
6470,1157959,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against CD1 mouse ear edema model assessed as reduction of TPA-induced ear edema measured per ear administered topically 10 mins prior to TPA challenge measured after 4 hrs,Other,24842703.0,
6471,1157960,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against TPA-induced CD1 mouse ear edema model assessed as neutrophil infiltration by measuring myeloperoxidase content at 1 umol/ear administered topically 10 mins prior to TPA challenge measured after 4 hrs relative to control,Other,24842703.0,
6472,1159509,1,1,,144208989,3715,Inconclusive,119626539.0,4790.0,31.0847,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
6473,1159509,1,1,,144210586,3715,Inconclusive,119626539.0,4790.0,48.9662,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
6474,1159509,1,1,,170464705,3715,Inconclusive,119626539.0,4790.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
6475,1159515,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
6476,1159515,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
6477,1159515,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
6478,1159516,1,1,,144208989,3715,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
6479,1159516,1,1,,144210586,3715,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
6480,1159516,1,1,,170464705,3715,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
6481,1159517,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
6482,1159517,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
6483,1159517,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
6484,1159518,1,1,,144208989,3715,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
6485,1159518,1,1,,144210586,3715,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
6486,1159518,1,1,,170464705,3715,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
6487,1159519,1,1,,144208989,3715,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
6488,1159519,1,1,,144210586,3715,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
6489,1159519,1,1,,170464705,3715,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
6490,1159520,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
6491,1159520,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
6492,1159520,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
6493,1159521,1,1,,144208989,3715,Inconclusive,15928672.0,19885.0,34.5861,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
6494,1159521,1,1,,144210586,3715,Inconclusive,15928672.0,19885.0,48.5577,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
6495,1159521,1,1,,170464705,3715,Inconclusive,15928672.0,19885.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
6496,1159523,1,1,,144208989,3715,Inconclusive,15928672.0,19885.0,27.4727,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
6497,1159523,1,1,,144210586,3715,Inconclusive,15928672.0,19885.0,27.305999999999997,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
6498,1159523,1,1,,170464705,3715,Inconclusive,15928672.0,19885.0,33.4915,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
6499,1159524,1,1,,56422212,3715,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
6500,1159524,1,1,,124880450,3715,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
6501,1159524,1,1,,124880453,3715,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
6502,1159525,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
6503,1159525,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
6504,1159525,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
6505,1159526,1,1,,144208989,3715,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
6506,1159526,1,1,,144210586,3715,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
6507,1159526,1,1,,170464705,3715,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
6508,1159527,1,1,,144208989,3715,Inconclusive,325495497.0,6256.0,19.6131,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
6509,1159527,1,1,,144210586,3715,Inconclusive,325495497.0,6256.0,6.9167,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
6510,1159527,1,1,,170464705,3715,Inconclusive,325495497.0,6256.0,15.089,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
6511,1159528,1,1,,144208989,3715,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
6512,1159528,1,1,,144210586,3715,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
6513,1159528,1,1,,170464705,3715,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
6514,1159529,1,1,,144208989,3715,Inconclusive,,,27.7043,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
6515,1159529,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
6516,1159529,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
6517,1159531,1,1,,144208989,3715,Inconclusive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
6518,1159531,1,1,,144210586,3715,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
6519,1159531,1,1,,170464705,3715,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
6520,1159550,3,1,,252402250,3715,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
6521,1159551,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
6522,1159551,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
6523,1159551,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
6524,1159552,1,1,,144208989,3715,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
6525,1159552,1,1,,144210586,3715,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
6526,1159552,1,1,,170464705,3715,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
6527,1159553,2,1,,144208989,3715,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
6528,1159553,2,1,,144210586,3715,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
6529,1159553,2,1,,170464705,3715,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
6530,1159555,1,1,,144208989,3715,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
6531,1159555,1,1,,144210586,3715,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
6532,1159555,1,1,,170464705,3715,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
6533,1159580,2,1,,268734583,3715,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
6534,1159580,2,1,,273002863,3715,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
6535,1159583,2,1,,178127330,3715,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
6536,1159606,1,1,,56422212,3715,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
6537,1159607,2,1,,312309715,3715,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
6538,1159614,1,2,,170464705,3715,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
6539,1159620,1,1,,103163840,3715,Active,,,,,Summary of drug indications.,Other,,
6540,1162913,1,2,,103163840,3715,Unspecified,,,,,"Acute gastrolesivity in Wistar rat assessed as stomach lesions at 10 mg/kg, po measured after 5 hrs",Other,25194932.0,
6541,1164048,1,2,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 assessed as reduction in PGF2alpha formation at 10 uM incubated for 18 hrs by enzyme immunoassay,Other,25219899.0,
6542,1164049,1,2,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 assessed as reduction in PGF2alpha formation at 10 uM incubated for 18 hrs by enzyme immunoassay,Other,25219899.0,
6543,1164050,1,2,,103163840,3715,Active,754286265.0,443551.0,0.18,IC50,Inhibition of ovine COX1 assessed as reduction in PGF2alpha formation incubated for 18 hrs by enzyme immunoassay,Confirmatory,25219899.0,
6544,1164051,1,2,,103163840,3715,Inconclusive,3914304.0,443460.0,,IC50,Inhibition of ovine COX2 assessed as reduction in PGF2alpha formation incubated for 18 hrs by enzyme immunoassay,Confirmatory,25219899.0,
6545,1164052,1,1,,103163840,3715,Inconclusive,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,25219899.0,
6546,1165101,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse assessed as reduction in PMA-induced ear edema at 3 mg/ear administered topically relative to control,Other,25240256.0,
6547,1171107,1,1,,103163840,3715,Unspecified,,,,,"Hepatotoxicity in Swiss mouse assessed as plasma AST level at 2.5 mg/kg, po daily for 7 days",Other,25394199.0,
6548,1171108,1,1,,103163840,3715,Unspecified,,,,,"Hepatotoxicity in Swiss mouse assessed as plasma ALT level at 2.5 mg/kg, po daily for 7 days",Other,25394199.0,
6549,1171110,1,1,,103163840,3715,Unspecified,,,,,"Toxicity in Swiss mouse assessed as gastric MPO activity at 2.5 mg/kg, po daily for 7 days",Other,25394199.0,
6550,1171120,1,1,,103163840,3715,Active,,,,,"Antinociceptive activity in Swiss Webster mouse assessed as inhibition of acetic acid-induced abdominal constrictions at 10 mg/kg, ip dosed 40 mins before acetic acid injection",Other,25396337.0,
6551,1171126,1,1,,103163840,3715,Active,,,,,"Antinociceptive activity in Swiss Webster mouse assessed as inhibition of formalin-induced late phase pain response at 10 mg/kg, ip dosed 40 mins before formalin injection",Other,25396337.0,
6552,1172776,1,1,,103163840,3715,Active,,,1.25,IC50,Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production,Confirmatory,25442320.0,
6553,1172862,1,2,,103163840,3715,Active,754286265.0,443551.0,9.0,IC50,Inhibition of ovine COX1,Confirmatory,25444084.0,
6554,1172863,1,2,,103163840,3715,Active,3914304.0,443460.0,3.1,IC50,Inhibition of ovine COX2,Confirmatory,25444084.0,
6555,1172864,1,1,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,25444084.0,
6556,1174276,1,2,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 using arachidonic acid substrate incubated for 5 mins by colorimetry,Other,25462246.0,
6557,1174277,1,2,,103163840,3715,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 using arachidonic acid substrate incubated for 5 mins by colorimetry,Other,25462246.0,
6558,1174279,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Sprague-Dawley rat model of LPS-induced sepsis assessed as ALT level at 5 mg/kg/day dosed through gastric intubation for 6 days (Rvb = 70.3 +/- 7.9 U/L),Other,25462246.0,
6559,1174280,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Sprague-Dawley rat model of LPS-induced sepsis assessed as AST level at 5 mg/kg/day dosed through gastric intubation for 6 days (Rvb = 148.9 +/- 41.3 U/L),Other,25462246.0,
6560,1174281,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Sprague-Dawley rat model of LPS-induced sepsis assessed as hsCRP level at 5 mg/kg/day dosed through gastric intubation for 6 days (Rvb = 1.9 +/- 0.3 mg/L),Other,25462246.0,
6561,1174282,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Sprague-Dawley rat model of LPS-induced sepsis assessed as MPO level at 5 mg/kg/day dosed through gastric intubation for 6 days (Rvb = 4.2 +/- 1.8 mg/L),Other,25462246.0,
6562,1174283,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Sprague-Dawley rat model of LPS-induced sepsis assessed as nitric oxide level at 5 mg/kg/day dosed through gastric intubation for 6 days by cadmium reduction method (Rvb = 28.6 +/- 2.4 umol/L),Other,25462246.0,
6563,1174284,1,2,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in Sprague-Dawley rat model of LPS-induced sepsis assessed as serum MDA level at 5 mg/kg/day dosed through gastric intubation for 6 days (Rvb = 4.7 +/- 2.8 mg/L),Other,25462246.0,
6564,1174765,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as ulcer index at 150 umol/kg, po administered for 3 days measured on day 4 (Rvb = 0.33 +/-0.20)",Other,25462274.0,
6565,1174766,1,1,,103163840,3715,Unspecified,,,,,"Antioxidant activity in Wistar rat assessed as catalase level measured per mg of protein at 150 umol/kg, po administered for 3 days measured on day 4 (Rvb = 22.14 +/- 1.19 umol)",Other,25462274.0,
6566,1174767,1,1,,103163840,3715,Unspecified,,,,,"Antioxidant activity in Wistar rat assessed as thiobarbituric acid reactive substance level measured per mg of protein at 150 umol/kg, po administered for 3 days measured on day 4 (Rvb = 3.72 +/- 00.23 nmol)",Other,25462274.0,
6567,1174768,1,1,,103163840,3715,Unspecified,,,,,"Antioxidant activity in Wistar rat assessed as GSH level measured per 100 mg of protein at 150 umol/kg, po administered for 3 days measured on day 4 (Rvb = 184.10 +/- 4.19 umol)",Other,25462274.0,
6568,1175391,1,2,,103163840,3715,Unspecified,296452849.0,7442.0,,,Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 250 uM after 30 mins by Fluo-4 AM fluorescence assay,Other,25467164.0,
6569,1175392,1,2,,103163840,3715,Unspecified,296452849.0,7442.0,,,Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 50 uM after 30 mins by Fluo-4 AM fluorescence assay,Other,25467164.0,
6570,1177981,1,2,,103163840,3715,Unspecified,317373262.0,5742.0,,,Binding affinity to COX-1 (unknown origin) by ESI mass spectrometry,Other,24631898.0,
6571,1177984,1,2,,103163840,3715,Active,754286265.0,443551.0,0.08,IC50,Inhibition of ovine COX-1 assessed as decrease in prostaglandin production using arachidonic acid as substrate incubated with enzyme for 10 mins prior to substrate challenge by enzyme immunoassay,Confirmatory,24631898.0,
6572,1177989,1,2,,103163840,3715,Active,3915797.0,5743.0,0.96,IC50,Inhibition of human recombinant COX-2 assessed as decrease in prostaglandin production using arachidonic acid as substrate incubated with enzyme for 10 mins prior to substrate challenge by enzyme immunoassay,Confirmatory,24631898.0,
6573,1177990,1,1,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2",Other,24631898.0,
6574,1177996,1,2,,103163840,3715,Unspecified,3915797.0,5743.0,,,Binding affinity to COX-2 (unknown origin) by ESI mass spectrometry,Other,24631898.0,
6575,1178534,1,1,,103163840,3715,Active,,,,,"Antinociceptive activity in Complete Freund's adjuvant-induced inflammatory pain CD rat model assessed as mechanical hypersensitivity measured as weight bearing capacity at 30 mg/kg, po measured up to 15 mins relative to control",Other,24863744.0,
6576,1178536,1,1,,103163840,3715,Unspecified,,,,,"Antinociceptive activity in Complete Freund's adjuvant-induced inflammatory pain CD rat model assessed as time required for maximal effect at 30 mg/kg, po relative to control",Other,24863744.0,
6577,1178538,1,1,,103163840,3715,Active,,,,,"Antinociceptive activity in Complete Freund's adjuvant-induced inflammatory pain CD rat model assessed as mechanical hypersensitivity measured as weight bearing capacity at 30 mg/kg, po measured after 15 to 120 mins relative to control",Other,24863744.0,
6578,1178540,1,1,,103163840,3715,Unspecified,,,,,"Toxicity in Complete Freund's adjuvant-induced inflammatory pain CD rat model assessed as sedation at 30 mg/kg, po measured at 2 hrs post dose",Other,24863744.0,
6579,1178548,1,1,,103163840,3715,Unspecified,,,,,"Cmax in CD rat at 27 mg/kg, iv",Other,24863744.0,
6580,1178549,1,2,,103163840,3715,Unspecified,,,,,"AUC (0 to t) in CD rat at 27 mg/kg, iv",Other,24863744.0,
6581,1178550,1,2,,103163840,3715,Unspecified,,,,,"AUC (0 to infinity) in CD rat at 27 mg/kg, iv",Other,24863744.0,
6582,1178551,1,1,,103163840,3715,Unspecified,,,,,"Tmax in CD rat at 27 mg/kg, iv",Other,24863744.0,
6583,1178552,1,1,,103163840,3715,Unspecified,,,,,"Half life in CD rat at 27 mg/kg, iv",Other,24863744.0,
6584,1178553,1,1,,103163840,3715,Unspecified,,,,,"Elimination rate constant in CD rat at 27 mg/kg, iv",Other,24863744.0,
6585,1180074,1,2,,103163840,3715,Active,754286265.0,443551.0,0.21,IC50,Inhibition of ovine COX1 using arachidonic acid substrate assessed as PGE2 production ELISA method after 2 mins,Confirmatory,24938495.0,
6586,1180075,1,2,,103163840,3715,Active,3915797.0,5743.0,3.24,IC50,Inhibition of human recombinant COX2 using arachidonic acid substrate assessed as PGE2 production ELISA method after 2 mins,Confirmatory,24938495.0,
6587,1180665,1,1,,103163840,3715,Active,,,3.9,IC50,Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma plus LPS-induced NO production,Confirmatory,24960143.0,
6588,1181043,1,1,,103163840,3715,Active,,,15.8,IC50,Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay,Confirmatory,24963714.0,
6589,1181044,1,1,,103163840,3715,Active,,,18.7,IC50,Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA,Confirmatory,24963714.0,
6590,1181953,1,1,,103163840,3715,Unspecified,,,,,Apparent permeability in human Caco2 cells,Other,24984938.0,
6591,1183331,1,2,,103163840,3715,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 using fluorometric substrate at 100 uM by fluorescent inhibitor screening assay,Other,25016374.0,
6592,1183335,1,2,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of human recombinant COX2 using fluorometric substrate at 10 mM by fluorescent inhibitor screening assay,Other,25016374.0,
6593,1183359,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as reduction in carrageenan-induced inflamed paw volume at 3.7 mg/kg, ip relative to untreated control",Other,25016374.0,
6594,1187257,1,1,,103163840,3715,Active,,,,,"Anti-inflammatory activity in Wistar rat model of carrageenan-induced edema assessed as reduction in right hind paw thickness at 1 mg/kg, po dosed 1 hour before carrageenan injection measured 3 hrs post carrageenan challenge by digital plethysmometry",Other,25113875.0,
6595,1188643,1,1,,103163840,3715,Active,,,28.56,IC50,Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs,Confirmatory,25140384.0,
6596,1192206,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema male Wistar albino rat assessed as edema volume at 10 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 1 hr (Rvb = 1.11 +/- 0.12 mL)",Other,25702850.0,
6597,1192207,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema male Wistar albino rat assessed as edema volume at 10 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 2 hrs (Rvb = 1.21 +/- 0.16 mL)",Other,25702850.0,
6598,1192209,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema male Wistar albino rat assessed as edema volume at 10 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 3 hrs (Rvb = 1.73 +/- 0.09 mL)",Other,25702850.0,
6599,1192211,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema male Wistar albino rat assessed as edema volume at 10 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 4 hrs (Rvb = 1.88 +/- 0.20 mL)",Other,25702850.0,
6600,1192213,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema male Wistar albino rat at 10 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 1 hr relative to control",Other,25702850.0,
6601,1192215,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema male Wistar albino rat at 10 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 2 hrs relative to control",Other,25702850.0,
6602,1192217,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema male Wistar albino rat at 10 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 3 hrs relative to control",Other,25702850.0,
6603,1192219,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema male Wistar albino rat at 10 mg/kg, ip administered 30 mins prior to carrageenan-challenge measured after 4 hrs relative to control",Other,25702850.0,
6604,1193492,1,1,,103163840,3715,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method",Other,25740159.0,
6605,1193493,1,1,,103163840,3715,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
6606,1193494,1,1,,103163840,3715,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
6607,1193495,1,1,,103163840,3715,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
6608,1193496,1,1,,103163840,3715,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method",Other,25740159.0,
6609,1193497,1,1,,103163840,3715,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method",Other,25740159.0,
6610,1193498,1,1,,103163840,3715,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method",Other,25740159.0,
6611,1193499,1,1,,103163840,3715,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method",Other,25740159.0,
6612,1193500,1,1,,103163840,3715,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound",Other,25740159.0,
6613,1193882,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema administered 30 mins prior to carrageenan challenge measured after 1 hr relative to control,Other,25765910.0,
6614,1193883,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema administered 30 mins prior to carrageenan challenge measured after 2 hrs relative to control,Other,25765910.0,
6615,1193884,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema administered 30 mins prior to carrageenan challenge measured after 3 hrs relative to control,Other,25765910.0,
6616,1194323,1,1,,103163840,3715,Inactive,,,,,Induction of SCL expression in human HaCaT cells at 5 uM by qRT-PCR analysis relative to control,Other,25801150.0,
6617,1195043,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in CD-1 mouse ear edema model assessed as reduction in TPA-induced edema size at 2 mg/ear, topically administered 30 mins prior to TPA-challenge measured after 6 hrs relative to control",Other,25863493.0,
6618,1195044,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in CD-1 mouse ear edema model assessed as reduction in TPA-induced edema size at 8 mg/kg, po administered 30 mins prior to TPA-challenge for every 48 hrs for 10 days relative to vehicle treated control",Other,25863493.0,
6619,1195045,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in po dosed CD-1 mouse ear edema model assessed as reduction in TPA-induced edema size administered 30 mins prior to TPA-challenge for every 48 hrs for 10 days relative to vehicle treated control,Other,25863493.0,
6620,1195146,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as latancy of withdrawing tail at 50 mg/kg, po measured after 2 hrs by tail flick test relative to control",Other,25868745.0,
6621,1195147,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as latancy of withdrawing tail at 100 mg/kg, po measured after 2 hrs by tail flick test relative to control",Other,25868745.0,
6622,1195148,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as time of licking paws at 50 mg/kg, po measured after 2 hrs by tail flick test relative to control",Other,25868745.0,
6623,1195149,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as time of licking paws at 100 mg/kg, po measured after 2 hrs by tail flick test relative to control",Other,25868745.0,
6624,1195150,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 2 hrs relative to control",Other,25868745.0,
6625,1195151,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Swiss albino mouse assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 2 hrs relative to control",Other,25868745.0,
6626,1195152,1,2,,103163840,3715,Active,754286265.0,443551.0,0.65,IC50,Inhibition of ovine recombinant COX-1 using PGH2 as substrate incubated for 10 mins prior to arachidonic acid addition measured after 2 mins by EIA,Confirmatory,25868745.0,
6627,1195153,1,2,,103163840,3715,Active,3915797.0,5743.0,29.6,IC50,Inhibition of human recombinant COX-2 using PGH2 as substrate incubated for 10 mins prior to arachidonic acid addition measured after 2 mins by EIA,Confirmatory,25868745.0,
6628,1195154,1,1,,103163840,3715,Unspecified,,,,,Selectivity ratio of IC50 for ovine recombinant COX-1 to IC50 for human recombinant COX-2,Other,25868745.0,
6629,1195155,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Swiss albino mouse assessed as ulcer index at 50 mg/kg, po measured after 2 hrs",Other,25868745.0,
6630,1195156,1,1,,103163840,3715,Unspecified,,,,,"Gastrointestinal toxicity in Swiss albino mouse assessed as ulcer index at 100 mg/kg, po measured after 2 hrs",Other,25868745.0,
6631,1195160,1,1,,103163840,3715,Unspecified,,,,,"Acute toxicity in Swiss albino mouse assessed as mortality at 50 mg/kg, po after 12 hrs",Other,25868745.0,
6632,1196196,1,1,,103163840,3715,Active,,,40.3,IC50,Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method,Confirmatory,25555141.0,
6633,1196198,1,1,,103163840,3715,Unspecified,,,80.0,IC50,Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay,Confirmatory,25555141.0,
6634,1196199,1,1,,103163840,3715,Unspecified,,,80.0,IC50,Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay,Confirmatory,25555141.0,
6635,1196212,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in ICR mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins before carrageenan challenge measured after 2 hrs",Other,25555141.0,
6636,1198256,1,1,,103163840,3715,Inactive,,,,,Antiproliferative activity against human U373MG cells assessed as effect on cell number at 1 nM to 10 uM incubated for 1 to 6 days by trypan blue dye exclusion dye based inverted microscopy,Other,25666913.0,
6637,1198262,1,1,,103163840,3715,Inconclusive,,,,IC50,Antiproliferative activity against human U373MG cells assessed reduction in cell number at 10 uM incubated for 6 days by trypan blue dye exclusion dye based inverted microscopy,Confirmatory,25666913.0,
6638,1199377,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in male Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured at 2 hrs of carrageenan treatment",Other,25522819.0,
6639,1199378,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in male Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr prior to carrageenan challenge measured at 3 hrs of carrageenan treatment",Other,25522819.0,
6640,1199379,1,1,,103163840,3715,Unspecified,,,,,Potency ratio of compound to Indomethacin for inhibition of carrageenan-induced paw edema in po dosed male Wistar rat,Other,25522819.0,
6641,1199383,1,2,,103163840,3715,Unspecified,,,,,"Acute ulcerogenicity in male Wistar rat assessed as severity index measured as ulcer in stomach at 10 mg/kg, po after 17 hrs with normal diet",Other,25522819.0,
6642,1199384,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as maximal possible effect on nociception measured as time of licking forepaws or jump response at 10 mg/kg, po after 3 hrs of treatment by Eddys hot plate method",Other,25522819.0,
6643,1199386,1,1,,103163840,3715,Unspecified,,,,,"Acute ulcerogenicity in male Wistar rat assessed as lipid peroxidation measured as malondialdehyde level per 100 mg of gastric tissue at to 10 mg/kg, po",Other,25522819.0,
6644,1199420,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw volume at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hrs (Rvb = 1.68 +/- 0.029 ml)",Other,25596479.0,
6645,1199421,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw volume at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 5 hrs (Rvb = 1.70 +/- 0.020 ml)",Other,25596479.0,
6646,1199422,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw volume at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 3 hrs relative to vehicle-treated control",Other,25596479.0,
6647,1199423,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw volume at 20 mg/kg, po administered 1 hr prior to carrageenan challenge measured after 5 hrs relative to vehicle-treated control",Other,25596479.0,
6648,1199424,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha level at 20 uM after 24 hrs by ELISA relative to untreated control,Other,25596479.0,
6649,1199425,1,1,,103163840,3715,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 20 uM after 24 hrs by MTT assay,Other,25596479.0,
6650,1199426,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss Albino acetic acid-induced writhing mouse model assessed as number of writhes at 20 mg/kg, po administered 30 mins before to acetic acid challenge measured for 10 mins (Rvb = 92.8 +/- 1.49 No_unit)",Other,25596479.0,
6651,1199427,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss Albino acetic acid-induced writhing mouse model assessed as protection at 20 mg/kg, po administered 30 mins before to acetic acid challenge measured for 10 mins",Other,25596479.0,
6652,1199428,1,1,,103163840,3715,Unspecified,,,,,"Ulcerogenic effect in Albino Wistar rat assessed as damage in gastric mucosa at 60 mg, po after 5 hrs",Other,25596479.0,
6653,1199429,1,1,,103163840,3715,Active,,,,,Inhibition of carrageenan-induced TNFalpha expression in paw tissue (unknown origin) by immunohistochemistry,Other,25596479.0,
6654,1199430,1,1,,103163840,3715,Active,,,,,Inhibition of carrageenan-induced NFkappaB expression in paw tissue (unknown origin) by immunohistochemistry,Other,25596479.0,
6655,1199431,1,1,,103163840,3715,Active,,,,,Inhibition of carrageenan-induced COX-2 expression in paw tissue (unknown origin) by immunohistochemistry,Other,25596479.0,
6656,1202782,1,1,,103163840,3715,Active,,,0.297,IC50,Anti-inflammatory activity in CD1 mouse model of TPA-induced ear edema assessed as inhibition of ear edema at 0.1 to 1 umol/ear applied to right ear 10 mins after TPA-stimulation and measured 4 hrs post compound dose,Confirmatory,25634541.0,
6657,1203973,1,1,,103163840,3715,Unspecified,,,,,Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 10 uM pre-incubated for 2 hrs before LPS stimulation for 18 hrs by Griess reagent based colorimetric method,Other,25881822.0,
6658,1203974,1,2,,103163840,3715,Active,266649.0,18126.0,4.5,IC50,Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry,Confirmatory,25881822.0,
6659,1203975,1,1,,103163840,3715,Active,,,9.2,IC50,Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay,Confirmatory,25881822.0,
6660,1203976,1,1,,103163840,3715,Active,,,10.7,IC50,Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay,Confirmatory,25881822.0,
6661,1203979,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in ICR mouse model of carrageenan-induced edema assessed as inhibition of paw thickness at 10 mg/kg, ip",Other,25881822.0,
6662,1204221,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr prior to carrageenan challenge measured at 1 hr relative to control",Other,25937011.0,
6663,1204223,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr prior to carrageenan challenge measured at 2 hrs relative to control",Other,25937011.0,
6664,1204225,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr prior to carrageenan challenge measured at 3 hrs relative to control",Other,25937011.0,
6665,1204227,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr prior to carrageenan challenge measured at 4 hrs relative to control",Other,25937011.0,
6666,1204229,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 1 hr prior to carrageenan challenge measured at 24 hrs relative to control",Other,25937011.0,
6667,1204235,1,1,,103163840,3715,Unspecified,,,,,"Ulcerogenic activity in Wistar rat assessed as ulcer index at 10 mg/kg, po administered 3 days relative to control",Other,25937011.0,
6668,1204915,1,1,,103163840,3715,Active,,,6.3,IC50,Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs,Confirmatory,25621853.0,
6669,1209581,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
6670,1209582,1,1,,103163840,3715,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
6671,1209583,1,1,,103163840,3715,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
6672,1209585,1,1,,103163840,3715,Active,,,,,Drug uptake in Sprague-Dawley rat brain slices in presence of 50 nM of monensin,Other,21149540.0,
6673,1209592,1,1,,103163840,3715,Unspecified,,,,,"Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
6674,1213540,1,1,,103163840,3715,Unspecified,,,,,Retention time of the compound by LC-MS/MS method,Other,22451699.0,
6675,1217704,1,2,,103163840,3715,Unspecified,117144.0,1544.0,,,Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
6676,1217705,1,2,,103163840,3715,Unspecified,117205.0,1555.0,,,Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
6677,1217706,1,2,,103163840,3715,Unspecified,6686268.0,1559.0,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
6678,1217707,1,2,,103163840,3715,Unspecified,60416369.0,1557.0,,,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system,Other,21467212.0,
6679,1217708,1,2,,103163840,3715,Unspecified,84028191.0,1565.0,,,Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
6680,1217709,1,2,,103163840,3715,Unspecified,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
6681,1217710,1,2,,103163840,3715,Unspecified,,,,,Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting,Other,21467212.0,
6682,1217711,1,2,,103163840,3715,Unspecified,,,,,Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
6683,1217712,1,2,,103163840,3715,Unspecified,117225.0,1558.0,,,Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
6684,1217727,1,2,,103163840,3715,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
6685,1217728,1,1,,103163840,3715,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay,Other,21467212.0,
6686,1217729,1,1,,103163840,3715,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation,Other,21467212.0,
6687,1220237,1,1,,103163840,3715,Unspecified,,,,,Unbound fraction during UGT-mediated glucuronidation in human intestinal microsomes,Other,22685216.0,
6688,1220238,1,1,,103163840,3715,Unspecified,,,,,Intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance,Other,22685216.0,
6689,1220239,1,1,,103163840,3715,Unspecified,,,,,Unbound intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance,Other,22685216.0,
6690,1220240,1,1,,103163840,3715,Inconclusive,,,,,Unbound fraction during CYP4500-mediated metabolism in human intestinal microsomes,Other,22685216.0,
6691,1220241,1,1,,103163840,3715,Unspecified,,,,,Intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance,Other,22685216.0,
6692,1220242,1,1,,103163840,3715,Unspecified,,,,,Unbound intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance,Other,22685216.0,
6693,1220248,1,2,,103163840,3715,Unspecified,29839451.0,54600.0,,,Activity of human UGT1A9 expressed in insect cells assessed as reduction in compound level after 30 mins,Other,22685216.0,
6694,1220255,1,1,,103163840,3715,Unspecified,,,,,Apparent permeability by PAMPA method,Other,22685216.0,
6695,1220256,1,1,,103163840,3715,Unspecified,,,,,Total clearance in human,Other,22685216.0,
6696,1220257,1,2,,103163840,3715,Unspecified,,,,,Ratio of drug level in blood to plasma in human,Other,22685216.0,
6697,1220258,1,1,,103163840,3715,Unspecified,,,,,Renal clearance in human,Other,22685216.0,
6698,1220259,1,1,,103163840,3715,Unspecified,,,,,Oral absorption in human,Other,22685216.0,
6699,1220554,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
6700,1220555,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
6701,1220556,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
6702,1220557,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
6703,1220558,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
6704,1220559,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
6705,1220560,1,1,,103163840,3715,Unspecified,,,,,Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
6706,1220783,1,1,,103163840,3715,Unspecified,,,,,Drug metabolism in human assessed as glucuronide concentration in bile and urine,Other,21282406.0,
6707,1220784,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in mouse plasma by ultracentrifugation method,Other,21282406.0,
6708,1220785,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in rat plasma by ultracentrifugation method,Other,21282406.0,
6709,1220786,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in monkey plasma by ultracentrifugation method,Other,21282406.0,
6710,1220787,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in dog plasma by ultracentrifugation method,Other,21282406.0,
6711,1220788,1,2,,103163840,3715,Unspecified,,,,,Fraction unbound in human plasma by ultracentrifugation method,Other,21282406.0,
6712,1220789,1,2,,103163840,3715,Unspecified,,,,,Ratio of drug level in blood to plasma in mouse,Other,21282406.0,
6713,1220790,1,2,,103163840,3715,Unspecified,,,,,Ratio of drug level in blood to plasma in rat,Other,21282406.0,
6714,1220791,1,2,,103163840,3715,Unspecified,,,,,Ratio of drug level in blood to plasma in monkey,Other,21282406.0,
6715,1220792,1,2,,103163840,3715,Unspecified,,,,,Ratio of drug level in blood to plasma in dog,Other,21282406.0,
6716,1220793,1,2,,103163840,3715,Unspecified,,,,,Ratio of drug level in blood to plasma in human,Other,21282406.0,
6717,1220794,1,1,,103163840,3715,Unspecified,,,,,Plasma clearance in human,Other,21282406.0,
6718,1220795,1,1,,103163840,3715,Unspecified,,,,,Plasma clearance in po dosed human,Other,21282406.0,
6719,1220796,1,1,,103163840,3715,Unspecified,,,,,"Drug metabolism in bile duct-cannulated rat assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
6720,1220797,1,1,,103163840,3715,Unspecified,,,,,Volume of distribution at steady state in human,Other,21282406.0,
6721,1220798,1,1,,103163840,3715,Unspecified,,,,,Half life in human,Other,21282406.0,
6722,1220799,1,1,,103163840,3715,Unspecified,,,,,"Drug metabolism in gallbladder-cannulated mouse assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
6723,1220800,1,1,,103163840,3715,Unspecified,,,,,"Drug metabolism in bile duct-cannulated monkey assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
6724,1220801,1,1,,103163840,3715,Unspecified,,,,,"Drug metabolism in bile duct-cannulated dog assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
6725,1221821,1,1,,103163840,3715,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay,Other,20926620.0,
6726,1224818,1,1,,312344817,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
6727,1224819,1,1,,312344817,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
6728,1224820,1,1,,312344817,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
6729,1224821,1,1,,312344817,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
6730,1224822,1,1,,312344817,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
6731,1224823,1,1,,312344817,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
6732,1224824,1,1,,174007200,3715,Inactive,,,0.0047,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
6733,1224825,1,1,,174007200,3715,Inactive,,,37.2212,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
6734,1224834,3,1,,144208989,3715,Inconclusive,,,48.8542,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
6735,1224834,3,1,,144210586,3715,Inconclusive,,,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
6736,1224834,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
6737,1224835,1,1,,144208989,3715,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
6738,1224835,1,1,,144210586,3715,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
6739,1224835,1,1,,170464705,3715,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
6740,1224836,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
6741,1224836,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
6742,1224836,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
6743,1224837,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
6744,1224837,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
6745,1224837,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
6746,1224838,1,1,,144208989,3715,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
6747,1224838,1,1,,144210586,3715,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
6748,1224838,1,1,,170464705,3715,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
6749,1224839,1,1,,144208989,3715,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
6750,1224839,1,1,,144210586,3715,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
6751,1224839,1,1,,170464705,3715,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
6752,1224840,3,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
6753,1224840,3,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
6754,1224840,3,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
6755,1224841,3,1,,144208989,3715,Active,325495545.0,2101.0,30.8249,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
6756,1224841,3,1,,144210586,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
6757,1224841,3,1,,170464705,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
6758,1224842,3,1,,144208989,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
6759,1224842,3,1,,144210586,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
6760,1224842,3,1,,170464705,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
6761,1224843,1,1,,144208989,3715,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
6762,1224843,1,1,,144210586,3715,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
6763,1224843,1,1,,170464705,3715,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
6764,1224844,1,1,,144208989,3715,Inconclusive,,,55.2773,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
6765,1224844,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
6766,1224844,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
6767,1224845,1,1,,144208989,3715,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
6768,1224845,1,1,,144210586,3715,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
6769,1224845,1,1,,170464705,3715,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
6770,1224846,1,1,,144208989,3715,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
6771,1224846,1,1,,144210586,3715,Inconclusive,11995455.0,3091.0,24.5412,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
6772,1224846,1,1,,170464705,3715,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
6773,1224847,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
6774,1224847,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
6775,1224847,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
6776,1224848,3,1,,144208989,3715,Active,325495545.0,2101.0,30.8249,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
6777,1224848,3,1,,144210586,3715,Inconclusive,325495545.0,2101.0,34.3762,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
6778,1224848,3,1,,170464705,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
6779,1224849,3,1,,144208989,3715,Inactive,325495545.0,2101.0,30.8249,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
6780,1224849,3,1,,144210586,3715,Inactive,325495545.0,2101.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
6781,1224849,3,1,,170464705,3715,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
6782,1224857,2,1,,170464705,3715,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
6783,1224857,2,1,,174007200,3715,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
6784,1224857,2,1,,312344817,3715,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
6785,1224859,2,1,,90340917,3715,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
6786,1224859,2,1,,170464705,3715,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
6787,1224859,2,1,,174007200,3715,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
6788,1224863,1,1,,176484153,3715,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
6789,1224863,1,1,,176484675,3715,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
6790,1224863,1,1,,316920367,3715,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
6791,1224864,1,2,,316933599,3715,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
6792,1224865,1,2,,56422212,3715,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
6793,1224867,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
6794,1224867,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
6795,1224867,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
6796,1224868,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
6797,1224868,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
6798,1224868,1,1,,170464705,3715,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
6799,1224869,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
6800,1224869,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
6801,1224869,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
6802,1224870,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
6803,1224870,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
6804,1224870,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
6805,1224871,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
6806,1224871,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
6807,1224871,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
6808,1224872,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
6809,1224872,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
6810,1224872,1,1,,170464705,3715,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
6811,1224873,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
6812,1224873,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
6813,1224873,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
6814,1224874,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
6815,1224874,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
6816,1224874,1,1,,170464705,3715,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
6817,1224875,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
6818,1224875,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
6819,1224875,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
6820,1224876,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
6821,1224876,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
6822,1224876,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
6823,1224877,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
6824,1224877,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
6825,1224877,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
6826,1224878,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
6827,1224878,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
6828,1224878,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
6829,1224879,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
6830,1224879,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
6831,1224879,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
6832,1224880,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
6833,1224880,1,1,,144210586,3715,Inconclusive,,,43.6412,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
6834,1224880,1,1,,170464705,3715,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
6835,1224881,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
6836,1224881,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
6837,1224881,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
6838,1224882,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
6839,1224882,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
6840,1224882,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
6841,1224883,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
6842,1224883,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
6843,1224883,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
6844,1224884,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
6845,1224884,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
6846,1224884,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
6847,1224885,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
6848,1224885,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
6849,1224885,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
6850,1224886,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
6851,1224886,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
6852,1224886,1,1,,170464705,3715,Inconclusive,,,10.6822,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
6853,1224887,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
6854,1224887,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
6855,1224887,1,1,,170464705,3715,Inconclusive,,,13.4481,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
6856,1224888,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
6857,1224888,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
6858,1224888,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
6859,1224889,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
6860,1224889,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
6861,1224889,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
6862,1224890,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
6863,1224890,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
6864,1224890,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
6865,1224892,1,1,,144208989,3715,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
6866,1224892,1,1,,144210586,3715,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
6867,1224892,1,1,,170464705,3715,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
6868,1224893,1,1,,144208989,3715,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
6869,1224893,1,1,,144210586,3715,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
6870,1224893,1,1,,170464705,3715,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
6871,1224894,1,1,,144208989,3715,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
6872,1224894,1,1,,144210586,3715,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
6873,1224894,1,1,,170464705,3715,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
6874,1224895,1,1,,144208989,3715,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
6875,1224895,1,1,,144210586,3715,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
6876,1224895,1,1,,170464705,3715,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
6877,1224896,1,1,,144208989,3715,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
6878,1224896,1,1,,144210586,3715,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
6879,1224896,1,1,,170464705,3715,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
6880,1224905,2,1,,92308955,3715,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
6881,1224905,2,1,,92308955,3715,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
6882,1224905,2,1,,121361649,3715,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
6883,1224905,2,1,,121361649,3715,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
6884,1224905,2,1,,252566551,3715,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
6885,1224905,2,1,,252566551,3715,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
6886,1226814,1,1,,103163840,3715,Active,754286265.0,443551.0,0.08,IC50,Inhibition of ovine COX-1 assessed as PGF2alpha formation using arachidonic acid as substrate pretreated with compound for 20 mins prior to substrate addition by spectrophotometric analysis,Confirmatory,25956953.0,
6887,1226815,1,1,,103163840,3715,Active,3915797.0,5743.0,0.96,IC50,Inhibition of human recombinant COX-2 assessed as PGF2 alpha formation using arachidonic acid as substrate pretreated with compound for 20 mins prior to substrate addition by spectrophotometric analysis,Confirmatory,25956953.0,
6888,1226816,1,1,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to human recombinant COX-2",Other,25956953.0,
6889,1228147,1,1,,103163840,3715,Active,,,14.1,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay,Confirmatory,25821895.0,
6890,1228720,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 3.1 uM after 24 hrs by Griess assay relative to control,Other,25945867.0,
6891,1228721,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 6.3 uM after 24 hrs by Griess assay relative to control,Other,25945867.0,
6892,1228722,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 12.5 uM after 24 hrs by Griess assay relative to control,Other,25945867.0,
6893,1228723,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 25 uM after 24 hrs by Griess assay relative to control,Other,25945867.0,
6894,1228724,1,1,,103163840,3715,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 50 uM after 24 hrs by Griess assay relative to control,Other,25945867.0,
6895,1228725,1,1,,103163840,3715,Active,,,42.6,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay,Confirmatory,25945867.0,
6896,1229623,1,1,,103163840,3715,Active,,,42.6,IC50,Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay,Confirmatory,26024020.0,
6897,1232306,1,1,,103163840,3715,Unspecified,,,,,Dissociation constant of the compound,Other,25799158.0,
6898,1232307,1,1,,103163840,3715,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,25799158.0,
6899,1232308,1,1,,103163840,3715,Unspecified,,,,,"Distribution coefficient, log D of the compound",Other,25799158.0,
6900,1232309,1,1,,103163840,3715,Unspecified,,,,,Unbound fraction in human plasma,Other,25799158.0,
6901,1232310,1,1,,103163840,3715,Unspecified,,,,,Volume of distribution at steady state in human,Other,25799158.0,
6902,1232311,1,1,,103163840,3715,Unspecified,,,,,Unbound volume of distribution at steady state in human,Other,25799158.0,
6903,1233393,1,1,,103163840,3715,Unspecified,,,,,"Gastroprotective activity in Swiss albino mouse model of HCl/EtOH-induced lesion assessed as gastric lesion index at 10 mg/kg, po dosed 50 mins before HCl/EtOH challenge and measured 1 hr post HCl/EtOH challenge (Rvb = 42 +/- 1.9 mm)",Other,26009162.0,
6904,1236801,1,1,,103163840,3715,Active,,,,,"Antinociceptive activity in ip dosed Swiss mouse assessed as inhibition of acetic acid-induced writhing response at 3 mg/kg, ip administered 30 mins prior to acetic acid challenge measured for 20 mins relative to vehicle-treated control",Other,25975638.0,
6905,1237266,1,1,,103163840,3715,Active,3915797.0,5743.0,1.2,IC50,Inhibition of COX2 (unknown origin),Confirmatory,26048794.0,
6906,1237267,1,1,,103163840,3715,Active,317373262.0,5742.0,12.5,IC50,Inhibition of COX1 (unknown origin),Confirmatory,26048794.0,
6907,1237663,1,1,,103163840,3715,Unspecified,,,,,"Anti-nociceptive activity in Swiss mouse assessed as reduction in paw licking response during inflammatory phase at 10 umol/kg, ip dosed 40 mins before formalin injection",Other,26116178.0,
6908,1237664,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Swiss mouse assessed as inhibition of zymosan-induced peritonitis by measuring reduction in leukocyte migration at 10 umol/kg, ip administered 30 min before the zymosan injection",Other,26116178.0,
6909,1241807,1,1,,103163840,3715,Unspecified,,,,,In-vitro antiinflammatory activity assessed as inhibition of denaturation of bovine serum albumin at 10 mg,Other,26117820.0,
6910,1241817,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat model of acute inflammation assessed as inhibition of carrageenan-induced paw oedema dosed at 10 mg/kg, po dosed 1 hr before carrageenan injection and measured 1 hr after carrageenan injection",Other,26117820.0,
6911,1241819,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat model of acute inflammation assessed as inhibition of carrageenan-induced paw oedema dosed at 10 mg/kg, po dosed 1 hr before carrageenan injection and measured 2 hrs after carrageenan injection",Other,26117820.0,
6912,1241821,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat model of acute inflammation assessed as inhibition of carrageenan-induced paw oedema dosed at 10 mg/kg, po dosed 1 hr before carrageenan injection and measured 3 hrs after carrageenan injection",Other,26117820.0,
6913,1241823,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat model of acute inflammation assessed as inhibition of carrageenan-induced paw oedema dosed at 10 mg/kg, po dosed 1 hr before carrageenan injection and measured 4 hrs after carrageenan injection",Other,26117820.0,
6914,1241825,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat model of acute inflammation assessed as inhibition of carrageenan-induced paw oedema dosed at 10 mg/kg, po dosed 1 hr before carrageenan injection and measured 5 hrs after carrageenan injection",Other,26117820.0,
6915,1241827,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat model of acute inflammation assessed as inhibition of carrageenan-induced paw oedema dosed at 10 mg/kg, po dosed 1 hr before carrageenan injection and measured 6 hrs after carrageenan injection",Other,26117820.0,
6916,1241830,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat assessed as inhibition of arachidonic acid-induced paw edema at 10 mg/kg, po dosed 30 mins before arachidonic acid injection and measured 1 hr after arachidonic acid injection",Other,26117820.0,
6917,1241832,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat model of sub-chronic inflammation assessed as inhibition of cotton pellet-induced granuloma by measuring weight of granulation at 10 mg/kg, po QD for seven consecutive days from day of cotton pellet insertion (94.13 +/- 8.1 mg)",Other,26117820.0,
6918,1241834,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as inhibition of right hind paw swelling at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 3",Other,26117820.0,
6919,1241836,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as inhibition of right hind paw swelling at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 6",Other,26117820.0,
6920,1241838,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as inhibition of right hind paw swelling at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 9",Other,26117820.0,
6921,1241840,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as inhibition of right hind paw swelling at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 12",Other,26117820.0,
6922,1241842,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as inhibition of right hind paw swelling at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 15",Other,26117820.0,
6923,1241844,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as inhibition of right hind paw swelling at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 18",Other,26117820.0,
6924,1241846,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as inhibition of right hind paw swelling at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21",Other,26117820.0,
6925,1241848,1,1,,103163840,3715,Unspecified,,,,,"Gastro-intestinal toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as ulcer index at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21",Other,26117820.0,
6926,1241851,1,1,,103163840,3715,Unspecified,,,,,"Gastro-intestinal toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as histological changes at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 by hematoxylin and eosin staining based microscopy",Other,26117820.0,
6927,1241852,1,1,,103163840,3715,Unspecified,,,,,"Hepato-toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as SGOT level at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 (Rvb = 92.48 +/- 7.8 U/mL)",Other,26117820.0,
6928,1241854,1,1,,103163840,3715,Unspecified,,,,,"Hepato-toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as SGPT level at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 (Rvb = 34.23 +/- 2.5 U/mL)",Other,26117820.0,
6929,1241856,1,1,,103163840,3715,Unspecified,,,,,"Hepato-toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as alkaline phosphatase level at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 (Rvb = 17.82 +/- 1.2 U)",Other,26117820.0,
6930,1241858,1,1,,103163840,3715,Unspecified,,,,,"Renal toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as total protein level at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 (Rvb = 1.78 +/- 0.11 g/dL)",Other,26117820.0,
6931,1241860,1,1,,103163840,3715,Unspecified,,,,,"Renal toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as total albumin level at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 (Rvb = 1.77 +/- 0.12 g/dL)",Other,26117820.0,
6932,1241862,1,1,,103163840,3715,Unspecified,,,,,"Renal toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as creatinine level at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 (Rvb = 0.62 +/- 0.049 mg/dL)",Other,26117820.0,
6933,1241864,1,1,,103163840,3715,Unspecified,,,,,"Renal toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as blood urea nitrogen level at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 (Rvb = 23.48 +/- 1.8 mg/dL)",Other,26117820.0,
6934,1241868,1,1,,103163840,3715,Unspecified,,,,,"Hepato-toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as histological changes at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 by hematoxylin and eosin staining based microscopy",Other,26117820.0,
6935,1241869,1,1,,103163840,3715,Unspecified,,,,,"Renal toxicity in rat Freund's adjuvant induced arthritis model of chronic inflammation assessed as assessed as histological changes at 10 mg/kg, po dosed after 14 days from day of adjuvant injection until day 21 and measured on day 21 by hematoxylin and eosin staining based microscopy",Other,26117820.0,
6936,1241870,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as reduction in number of writhing episodes at 10 mg/kg, po measured 30 mins following acetic acid injection",Other,26117820.0,
6937,1241872,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as reduction in formalin-induced paw licking by measuring time spent on licking during phase-1 at 10 mg/kg, po dosed 1 hr before formalin challenge and measured 30 mins after formalin injection",Other,26117820.0,
6938,1241874,1,1,,103163840,3715,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as reduction in formalin-induced paw licking by measuring time spent on licking during phase-2 at 10 mg/kg, po dosed 1 hr before formalin challenge and measured 30 mins after formalin injection",Other,26117820.0,
6939,1241876,1,1,,103163840,3715,Active,754286265.0,443551.0,3.74,IC50,Inhibition of ovine COX1 by oxidized TMPD detection based colorimetric assay,Confirmatory,26117820.0,
6940,1241877,1,1,,103163840,3715,Active,3914304.0,443460.0,3.93,IC50,Inhibition of ovine COX2 by oxidized TMPD detection based colorimetric assay,Confirmatory,26117820.0,
6941,1241878,1,1,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,26117820.0,
6942,1241879,1,1,,103163840,3715,Active,3914304.0,443460.0,9.86,Ki,Competitive inhibition of ovine COX2 using arachidonic acid substrate by Ellman's spectrophotometric assay based Lineweaver-Burk double reciprocal plot,Confirmatory,26117820.0,
6943,1242111,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 1 hr by plethysmometric analysis relative to control",Other,26160113.0,
6944,1242112,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 2 hrs by plethysmometric analysis relative to control",Other,26160113.0,
6945,1242113,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs by plethysmometric analysis relative to control",Other,26160113.0,
6946,1242114,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 4 hrs by plethysmometric analysis relative to control",Other,26160113.0,
6947,1243713,1,1,,103163840,3715,Active,,,35.7,IC50,Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay,Confirmatory,26348503.0,
6948,1244193,1,1,,103163840,3715,Unspecified,3914292.0,24693.0,,,Inhibition of rat seminal vesicles COX-1 using arachidonic acid as substrate at 50 ug/ml preincubated for 5 mins followed by substrate addition after 20 mins by competitive PGE2 EIA method,Other,26197159.0,
6949,1244194,1,1,,103163840,3715,Inconclusive,3914304.0,443460.0,,,Inhibition of sheep placental cotyledons COX-2 using arachidonic acid as substrate at 50 ug/ml preincubated for 5 mins followed by substrate addition after 20 mins by competitive PGE2 EIA method,Other,26197159.0,
6950,1248669,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in mouse model of histamine-induced paw edema assessed as inhibition of inflammation at 50 mg/kg, ip dosed 1 hr before histamine injection",Other,,
6951,1248670,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in mouse model of histamine-induced paw edema assessed as inhibition of inflammation at 20 mg/kg, po dosed 1 hr before histamine injection",Other,,
6952,1248671,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in mouse model of histamine-induced paw edema assessed as inhibition of inflammation at 50 mg/kg, ip dosed 1 hr before histamine injection relative to 50 mg/kg, ip indomethacin",Other,,
6953,1251036,1,1,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX1 (unknown origin) assessed as PGH2 production at 10 uM by measuring PGH2alpha level by enzyme immunoassay,Other,26351040.0,
6954,1251037,1,1,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX1 (unknown origin) assessed as PGH2 production at 35 uM by measuring PGH2alpha level by enzyme immunoassay,Other,26351040.0,
6955,1251038,1,1,,103163840,3715,Unspecified,317373262.0,5742.0,,,Inhibition of COX1 (unknown origin) assessed as PGH2 production at 100 uM by measuring PGH2alpha level by enzyme immunoassay,Other,26351040.0,
6956,1251039,1,1,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 (unknown origin) assessed as PGH2 production at 10 uM by measuring PGH2alpha level by enzyme immunoassay,Other,26351040.0,
6957,1251040,1,1,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 (unknown origin) assessed as PGH2 production at 35 uM by measuring PGH2alpha level by enzyme immunoassay,Other,26351040.0,
6958,1251041,1,1,,103163840,3715,Unspecified,3915797.0,5743.0,,,Inhibition of COX2 (unknown origin) assessed as PGH2 production at 100 uM by measuring PGH2alpha level by enzyme immunoassay,Other,26351040.0,
6959,1253839,1,1,,103163840,3715,Active,754286265.0,443551.0,0.79,IC50,Inhibition of ovine COX-1 using arachidonic acid after 5 mins by colorimetric method,Confirmatory,26455657.0,
6960,1253840,1,1,,103163840,3715,Active,3914304.0,443460.0,11.8,IC50,Inhibition of ovine COX-2 using arachidonic acid after 5 mins by colorimetric method,Confirmatory,26455657.0,
6961,1253841,1,1,,103163840,3715,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for ovine COX-2",Other,26455657.0,
6962,1254089,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, ip administered 30 mins before xylene challenge relative to control",Other,26490095.0,
6963,1254090,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, po administered 1 hr before xylene challenge relative to control",Other,26490095.0,
6964,1254091,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, po administered 2 hrs before xylene challenge relative to control",Other,26490095.0,
6965,1254092,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, po administered 3 hrs before xylene challenge relative to control",Other,26490095.0,
6966,1254093,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, po administered 4 hrs before xylene challenge relative to control",Other,26490095.0,
6967,1254094,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, po administered 5 hrs before xylene challenge relative to control",Other,26490095.0,
6968,1254095,1,1,,103163840,3715,Inactive,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, po administered 24 hrs before xylene challenge relative to control",Other,26490095.0,
6969,1254096,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 25 mg/kg, po administered 3 hrs before xylene challenge relative to control",Other,26490095.0,
6970,1254097,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 12.5 mg/kg, po administered 3 hrs before xylene challenge relative to control",Other,26490095.0,
6971,1256770,1,1,,103163840,3715,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw oedema at 0.15 mmol/kg, ip administered 5 mins before carrageenan challenge measured after 3.5 hrs",Other,26494261.0,
6972,1257023,1,1,,103163840,3715,Unspecified,,,,,"Anti-inflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip after 3.5 hrs",Other,26515039.0,
6973,1259241,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
6974,1259241,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
6975,1259241,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
6976,1259242,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
6977,1259242,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
6978,1259242,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
6979,1259243,1,1,,144208989,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
6980,1259243,1,1,,144210586,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
6981,1259243,1,1,,170464705,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
6982,1259244,1,1,,144208989,3715,Inconclusive,348019627.0,2099.0,27.4727,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
6983,1259244,1,1,,144210586,3715,Inconclusive,348019627.0,2099.0,2.7306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
6984,1259244,1,1,,170464705,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
6985,1259247,1,1,,144208989,3715,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
6986,1259247,1,1,,144210586,3715,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
6987,1259247,1,1,,170464705,3715,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
6988,1259248,1,1,,144208989,3715,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
6989,1259248,1,1,,144210586,3715,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
6990,1259248,1,1,,170464705,3715,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
6991,1259252,1,1,,174007200,3715,Active,169655958.0,,14.818,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
6992,1259253,1,1,,174007200,3715,Inconclusive,169655958.0,,26.3506,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
6993,1259255,1,1,,174007200,3715,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
6994,1259256,1,1,,174007200,3715,Inconclusive,169655958.0,,5.2576,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
6995,1259309,1,1,,178127330,3715,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
6996,1259310,1,1,,332876391,3715,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
6997,1259310,1,1,,332876459,3715,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
6998,1259310,1,1,,332876508,3715,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
6999,1259310,1,1,,332876675,3715,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
7000,1259311,1,1,,178127330,3715,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
7001,1259313,1,1,,56422212,3715,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
7002,1259318,1,1,,56422212,3715,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
7003,1259325,1,2,,336954198,3715,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
7004,1259344,1,1,,144206660,3715,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
7005,1259354,1,1,,348446665,3715,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
7006,1259364,1,1,,144208989,3715,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
7007,1259364,1,1,,144210586,3715,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
7008,1259364,1,1,,170464705,3715,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
7009,1259365,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
7010,1259365,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
7011,1259365,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
7012,1259366,1,1,,144208989,3715,Inconclusive,,,61.5038,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
7013,1259366,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
7014,1259366,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
7015,1259367,1,1,,144208989,3715,Inconclusive,,,54.8153,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
7016,1259367,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
7017,1259367,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
7018,1259368,1,1,,144208989,3715,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
7019,1259368,1,1,,144210586,3715,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
7020,1259368,1,1,,170464705,3715,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
7021,1259369,1,1,,144208989,3715,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
7022,1259369,1,1,,144210586,3715,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
7023,1259369,1,1,,170464705,3715,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
7024,1259370,2,2,,124638004,3715,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
7025,1259370,2,2,,124638004,3715,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
7026,1259370,2,2,,124638004,3715,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
7027,1259377,1,1,,144208989,3715,Inconclusive,54288833.0,2100.0,30.8249,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
7028,1259377,1,1,,144210586,3715,Inconclusive,54288833.0,2100.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
7029,1259377,1,1,,170464705,3715,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
7030,1259378,1,1,,144208989,3715,Inconclusive,54288833.0,2100.0,30.8249,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
7031,1259378,1,1,,144210586,3715,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
7032,1259378,1,1,,170464705,3715,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
7033,1259379,1,1,,144208989,3715,Inconclusive,,,69.0083,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
7034,1259379,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
7035,1259379,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
7036,1259380,1,1,,144208989,3715,Inconclusive,,,30.8249,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
7037,1259380,1,1,,144210586,3715,Inconclusive,,,13.6854,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
7038,1259380,1,1,,170464705,3715,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
7039,1259381,1,1,,144208989,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
7040,1259381,1,1,,144210586,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
7041,1259381,1,1,,170464705,3715,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
7042,1259382,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
7043,1259382,1,1,,144210586,3715,Inconclusive,,,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
7044,1259382,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
7045,1259383,1,1,,144208989,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
7046,1259383,1,1,,144210586,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
7047,1259383,1,1,,170464705,3715,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
7048,1259384,1,1,,144208989,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
7049,1259384,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
7050,1259384,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
7051,1259385,1,1,,144208989,3715,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
7052,1259385,1,1,,144210586,3715,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
7053,1259385,1,1,,170464705,3715,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
7054,1259386,1,1,,144208989,3715,Inconclusive,,,69.0083,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
7055,1259386,1,1,,144210586,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
7056,1259386,1,1,,170464705,3715,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
7057,1259387,1,1,,144208989,3715,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
7058,1259387,1,1,,144210586,3715,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
7059,1259387,1,1,,170464705,3715,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
7060,1259388,1,1,,144208989,3715,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
7061,1259388,1,1,,144210586,3715,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
7062,1259388,1,1,,170464705,3715,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
7063,1259389,1,1,,124638004,3715,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
7064,1259390,1,1,,144208989,3715,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
7065,1259390,1,1,,144210586,3715,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
7066,1259390,1,1,,170464705,3715,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
7067,1259391,1,1,,144208989,3715,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
7068,1259391,1,1,,144210586,3715,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
7069,1259391,1,1,,170464705,3715,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
7070,1259392,1,1,,144208989,3715,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
7071,1259392,1,1,,144210586,3715,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
7072,1259392,1,1,,170464705,3715,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
7073,1259393,1,1,,144208989,3715,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
7074,1259393,1,1,,144210586,3715,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
7075,1259393,1,1,,170464705,3715,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
7076,1259394,1,1,,144208989,3715,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
7077,1259394,1,1,,144210586,3715,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
7078,1259394,1,1,,170464705,3715,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
7079,1259395,1,1,,144208989,3715,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
7080,1259395,1,1,,144210586,3715,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
7081,1259395,1,1,,170464705,3715,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
7082,1259396,1,1,,144208989,3715,Active,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
7083,1259396,1,1,,144210586,3715,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
7084,1259396,1,1,,170464705,3715,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
7085,1259400,1,1,,170464705,3715,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
7086,1259401,1,1,,144208989,3715,Active,325495545.0,2101.0,34.5861,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
7087,1259401,1,1,,144210586,3715,Inconclusive,325495545.0,2101.0,43.2771,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
7088,1259401,1,1,,170464705,3715,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
7089,1259402,1,1,,144208989,3715,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
7090,1259402,1,1,,144210586,3715,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
7091,1259402,1,1,,170464705,3715,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
7092,1259403,1,1,,144208989,3715,Active,325495545.0,2101.0,33.284,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
7093,1259403,1,1,,144210586,3715,Active,325495545.0,2101.0,48.5577,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
7094,1259403,1,1,,170464705,3715,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
7095,1259404,1,1,,144208989,3715,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
7096,1259404,1,1,,144210586,3715,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
7097,1259404,1,1,,170464705,3715,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
7098,1259407,1,1,,363901452,3715,Active,,,,,CCRIS mutagenicity studies,Other,,
7099,1259408,1,1,,363894807,3715,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
7100,1259409,1,1,,363901452,3715,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
7101,1259410,1,1,,363901452,3715,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
7102,1259415,1,1,,56422212,3715,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
7103,1259416,1,2,,56422212,3715,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
7104,1259416,1,2,,340080069,3715,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
7105,1259416,1,2,,375174803,3715,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
7106,1259416,1,2,,375179041,3715,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
7107,1259421,1,1,,340080069,3715,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
7108,1259421,1,1,,375174803,3715,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
7109,1259423,1,2,,354793699,3715,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
7110,1259423,1,2,,354802580,3715,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
7111,1259423,1,2,,354915143,3715,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
7112,1259423,1,2,,354936455,3715,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
